<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://embryology.med.unsw.edu.au/embryology/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Z3290379</id>
	<title>Embryology - User contributions [en-gb]</title>
	<link rel="self" type="application/atom+xml" href="https://embryology.med.unsw.edu.au/embryology/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Z3290379"/>
	<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Special:Contributions/Z3290379"/>
	<updated>2026-11-20T03:58:41Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.39.10</generator>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=79677</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=79677"/>
		<updated>2011-10-27T02:08:45Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Individual Assessments */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:11, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:06, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:04, 20 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 10===&lt;br /&gt;
&lt;br /&gt;
'''Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.'''&lt;br /&gt;
&lt;br /&gt;
Radiation is an environmental teratogen that can lead to hearing loss. &lt;br /&gt;
&lt;br /&gt;
'''Identify 3 factors that contribute to poor neonatal drainage of the middle ear'''&lt;br /&gt;
&lt;br /&gt;
In neonates, the Eustachian tube has not yet fully developed and thus has features that contribute to poor drainage of the middle ear, which can lead to infections. These include the length of the tube, which is much shorter than those in adults, the angle of the tube, which is almost horizontal – thus inhibiting proper drainage and in addition, only one muscle controls it’s movement. &lt;br /&gt;
&lt;br /&gt;
'''Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)'''&lt;br /&gt;
&lt;br /&gt;
Tietz albinism-deafness syndrome - due to a mutation on 3p14-p13 on the MITF gene. [http://omim.org/entry/103500?search=congenital%20hearing%20loss&amp;amp;highlight=congenital%20loss%20hearing Tietz Syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 11===&lt;br /&gt;
&lt;br /&gt;
''' Name the components that give rise to the interatrial septum and the passages that connect the right and left atria.'''&lt;br /&gt;
&lt;br /&gt;
The right and left atrium are separated by a membranous tissue that is derived from the roof of atria called the septum primum. During the 5th-6th week of development, septum secundum is derived from septum primum to allow blood to flow from the right to the left atrium. The septum secundum does not completely completely partition between the left and right atria, giving rise to the foramen ovale. &lt;br /&gt;
&lt;br /&gt;
''' Identify the cardiac defects that arise through abnormal development of the outflow tract. '''&lt;br /&gt;
&lt;br /&gt;
Right-left ventricular outflow tract obstruction&lt;br /&gt;
&lt;br /&gt;
Truncus and Conus Arteriosus&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot&lt;br /&gt;
&lt;br /&gt;
Hypoplastic left heart&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 12===&lt;br /&gt;
&lt;br /&gt;
'''Give examples of 3 systems that continue to develop postnatally'''&lt;br /&gt;
&lt;br /&gt;
Immune&lt;br /&gt;
&lt;br /&gt;
Neural&lt;br /&gt;
&lt;br /&gt;
Cardiovascular&lt;br /&gt;
&lt;br /&gt;
'''Identify the abnormalities detected by the Guthrie Test and link to one abnormality listed in OMIM'''&lt;br /&gt;
&lt;br /&gt;
Immune, cardiovascular neural&lt;br /&gt;
&lt;br /&gt;
Phenylketonuria (PKU) &lt;br /&gt;
&lt;br /&gt;
Biotinidase Deficiency &lt;br /&gt;
&lt;br /&gt;
Congenital Adrenal Hyperplasia (CAH)&lt;br /&gt;
 &lt;br /&gt;
Congenital Hypothyroidism (CH) &lt;br /&gt;
&lt;br /&gt;
Congenital Toxoplasmosis &lt;br /&gt;
&lt;br /&gt;
Cystic Fibrosis (CF) &lt;br /&gt;
&lt;br /&gt;
Galactosemia (GAL)&lt;br /&gt;
 &lt;br /&gt;
Homocystinuria &lt;br /&gt;
&lt;br /&gt;
Maple Syrup Urine Disease (MSUD)[http://omim.org/entry/248600 OMIM MSUD]&lt;br /&gt;
&lt;br /&gt;
Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)&lt;br /&gt;
&lt;br /&gt;
Toxoplasma gondii IgM antibodies&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=78811</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=78811"/>
		<updated>2011-10-20T01:49:12Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Lab 11 */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:11, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:06, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:04, 20 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 10===&lt;br /&gt;
&lt;br /&gt;
'''Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.'''&lt;br /&gt;
&lt;br /&gt;
Radiation is an environmental teratogen that can lead to hearing loss. &lt;br /&gt;
&lt;br /&gt;
'''Identify 3 factors that contribute to poor neonatal drainage of the middle ear'''&lt;br /&gt;
&lt;br /&gt;
In neonates, the Eustachian tube has not yet fully developed and thus has features that contribute to poor drainage of the middle ear, which can lead to infections. These include the length of the tube, which is much shorter than those in adults, the angle of the tube, which is almost horizontal – thus inhibiting proper drainage and in addition, only one muscle controls it’s movement. &lt;br /&gt;
&lt;br /&gt;
'''Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)'''&lt;br /&gt;
&lt;br /&gt;
Tietz albinism-deafness syndrome - due to a mutation on 3p14-p13 on the MITF gene. [http://omim.org/entry/103500?search=congenital%20hearing%20loss&amp;amp;highlight=congenital%20loss%20hearing Tietz Syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 11===&lt;br /&gt;
&lt;br /&gt;
''' Name the components that give rise to the interatrial septum and the passages that connect the right and left atria.'''&lt;br /&gt;
&lt;br /&gt;
The right and left atrium are separated by a membranous tissue that is derived from the roof of atria called the septum primum. During the 5th-6th week of development, septum secundum is derived from septum primum to allow blood to flow from the right to the left atrium. The septum secundum does not completely completely partition between the left and right atria, giving rise to the foramen ovale. &lt;br /&gt;
&lt;br /&gt;
''' Identify the cardiac defects that arise through abnormal development of the outflow tract. '''&lt;br /&gt;
&lt;br /&gt;
Right-left ventricular outflow tract obstruction&lt;br /&gt;
&lt;br /&gt;
Truncus and Conus Arteriosus&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot&lt;br /&gt;
&lt;br /&gt;
Hypoplastic left heart&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=78809</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=78809"/>
		<updated>2011-10-20T01:48:30Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Individual Assessments */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:11, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:06, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:04, 20 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 10===&lt;br /&gt;
&lt;br /&gt;
'''Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.'''&lt;br /&gt;
&lt;br /&gt;
Radiation is an environmental teratogen that can lead to hearing loss. &lt;br /&gt;
&lt;br /&gt;
'''Identify 3 factors that contribute to poor neonatal drainage of the middle ear'''&lt;br /&gt;
&lt;br /&gt;
In neonates, the Eustachian tube has not yet fully developed and thus has features that contribute to poor drainage of the middle ear, which can lead to infections. These include the length of the tube, which is much shorter than those in adults, the angle of the tube, which is almost horizontal – thus inhibiting proper drainage and in addition, only one muscle controls it’s movement. &lt;br /&gt;
&lt;br /&gt;
'''Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)'''&lt;br /&gt;
&lt;br /&gt;
Tietz albinism-deafness syndrome - due to a mutation on 3p14-p13 on the MITF gene. [http://omim.org/entry/103500?search=congenital%20hearing%20loss&amp;amp;highlight=congenital%20loss%20hearing Tietz Syndrome]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 11===&lt;br /&gt;
&lt;br /&gt;
''' Name the components that give rise to the interatrial septum and the passages that connect the right and left atria.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Identify the cardiac defects that arise through abnormal development of the outflow tract. '''&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=78787</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=78787"/>
		<updated>2011-10-20T01:04:46Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Lab Attendance */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:11, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:06, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:04, 20 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 10===&lt;br /&gt;
&lt;br /&gt;
'''Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.'''&lt;br /&gt;
&lt;br /&gt;
Radiation is an environmental teratogen that can lead to hearing loss. &lt;br /&gt;
&lt;br /&gt;
'''Identify 3 factors that contribute to poor neonatal drainage of the middle ear'''&lt;br /&gt;
&lt;br /&gt;
In neonates, the Eustachian tube has not yet fully developed and thus has features that contribute to poor drainage of the middle ear, which can lead to infections. These include the length of the tube, which is much shorter than those in adults, the angle of the tube, which is almost horizontal – thus inhibiting proper drainage and in addition, only one muscle controls it’s movement. &lt;br /&gt;
&lt;br /&gt;
'''Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)'''&lt;br /&gt;
&lt;br /&gt;
Tietz albinism-deafness syndrome - due to a mutation on 3p14-p13 on the MITF gene. [http://omim.org/entry/103500?search=congenital%20hearing%20loss&amp;amp;highlight=congenital%20loss%20hearing Tietz Syndrome]&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=77770</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=77770"/>
		<updated>2011-10-13T01:06:22Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Lab Attendance */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:11, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:06, 13 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 10===&lt;br /&gt;
&lt;br /&gt;
'''Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.'''&lt;br /&gt;
&lt;br /&gt;
Radiation is an environmental teratogen that can lead to hearing loss. &lt;br /&gt;
&lt;br /&gt;
'''Identify 3 factors that contribute to poor neonatal drainage of the middle ear'''&lt;br /&gt;
&lt;br /&gt;
In neonates, the Eustachian tube has not yet fully developed and thus has features that contribute to poor drainage of the middle ear, which can lead to infections. These include the length of the tube, which is much shorter than those in adults, the angle of the tube, which is almost horizontal – thus inhibiting proper drainage and in addition, only one muscle controls it’s movement. &lt;br /&gt;
&lt;br /&gt;
'''Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)'''&lt;br /&gt;
&lt;br /&gt;
Tietz albinism-deafness syndrome - due to a mutation on 3p14-p13 on the MITF gene. [http://omim.org/entry/103500?search=congenital%20hearing%20loss&amp;amp;highlight=congenital%20loss%20hearing Tietz Syndrome]&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=76952</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=76952"/>
		<updated>2011-10-12T00:20:07Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Lab 10 */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:11, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 10===&lt;br /&gt;
&lt;br /&gt;
'''Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.'''&lt;br /&gt;
&lt;br /&gt;
Radiation is an environmental teratogen that can lead to hearing loss. &lt;br /&gt;
&lt;br /&gt;
'''Identify 3 factors that contribute to poor neonatal drainage of the middle ear'''&lt;br /&gt;
&lt;br /&gt;
In neonates, the Eustachian tube has not yet fully developed and thus has features that contribute to poor drainage of the middle ear, which can lead to infections. These include the length of the tube, which is much shorter than those in adults, the angle of the tube, which is almost horizontal – thus inhibiting proper drainage and in addition, only one muscle controls it’s movement. &lt;br /&gt;
&lt;br /&gt;
'''Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)'''&lt;br /&gt;
&lt;br /&gt;
Tietz albinism-deafness syndrome - due to a mutation on 3p14-p13 on the MITF gene. [http://omim.org/entry/103500?search=congenital%20hearing%20loss&amp;amp;highlight=congenital%20loss%20hearing Tietz Syndrome]&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=76951</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=76951"/>
		<updated>2011-10-12T00:19:04Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Lab 10 */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:11, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 10===&lt;br /&gt;
&lt;br /&gt;
'''Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.'''&lt;br /&gt;
&lt;br /&gt;
Radiation is an environmental teratogen that can lead to hearing loss. &lt;br /&gt;
&lt;br /&gt;
'''Identify 3 factors that contribute to poor neonatal drainage of the middle ear'''&lt;br /&gt;
&lt;br /&gt;
In neonates, the Eustachian tube has not yet fully developed and thus has features that contribute to poor drainage of the middle ear, which can lead to infections. These include the length of the tube, which is much shorter than those in adults, the angle of the tube, which is almost horizontal – thus inhibiting proper drainage and in addition, only one muscle controls it’s movement. &lt;br /&gt;
&lt;br /&gt;
'''Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)'''&lt;br /&gt;
&lt;br /&gt;
Tietz albinism-deafness syndrome - due to a mutation on 3p14-p13 on the MITF gene.&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=76950</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=76950"/>
		<updated>2011-10-12T00:12:29Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:11, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 10===&lt;br /&gt;
&lt;br /&gt;
'''Besides fetal alcohol syndrome, identify another environmental teratogen that can lead to hearing loss.'''&lt;br /&gt;
&lt;br /&gt;
Radiation is an environmental teratogen that can lead to hearing loss. &lt;br /&gt;
&lt;br /&gt;
'''Identify 3 factors that contribute to poor neonatal drainage of the middle ear'''&lt;br /&gt;
&lt;br /&gt;
In neonates, the Eustachian tube has not yet fully developed and thus has features that contribute to poor drainage of the middle ear, which can lead to infections. These include the length of the tube, which is much shorter than those in adults, the angle of the tube, which is almost horizontal – thus inhibiting proper drainage and in addition, only one muscle controls it’s movement. &lt;br /&gt;
&lt;br /&gt;
'''Identify 1 genetic abnormality that affects hearing development and link to the OMIM record. (Your individual abnormality should be different from all other students)'''&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_4&amp;diff=76566</id>
		<title>Talk:2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_4&amp;diff=76566"/>
		<updated>2011-10-10T03:44:56Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Post-Peer review discussion */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[2011_Group_Project_4|'''Group 4''']]: [[User:z3389806]] | [[User:z3290270]] | [[User:z3290379]] | [[User:z3290558]]&lt;br /&gt;
&lt;br /&gt;
{{2011GroupDiscussionMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Page Edits 30 Sep'''&lt;br /&gt;
&amp;lt;gallery&amp;gt;&lt;br /&gt;
File:2011_Project_Group_4_edits.jpg|Project Page&lt;br /&gt;
File:2011_Project_Group_1-11_edits.jpg|All Groups (1-11) Project&lt;br /&gt;
File:2011_Talk_Group_4_edits.jpg|Discussion Page&lt;br /&gt;
File:2011 Talk Group 1-11 edits.jpg|All Groups (1-11) Discussion&lt;br /&gt;
&amp;lt;/gallery&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== Post-Peer review discussion ==&lt;br /&gt;
&lt;br /&gt;
Good job girls- page is looking good! Sharalyn, thanks for fixing the references and glossary. See you all on thursday&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 14:44, 10 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Thanks for that Nur, one problem, reference 1 and 63 are citing the same reference. Would you be able to fix that? :)&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 07:00, 10 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey girls, I've done the linkage for the glossary. So if you wanna add new words to the glossary, refer to the words that are already linked for the format kay? If you aren't able to do it, do tell me and i will fix it up. Have a great weekend! :)&lt;br /&gt;
--Nur Sharalyn Abdullah 12:14, 9 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Yup, I've fixed the references all up (:&lt;br /&gt;
--Nur Sharalyn Abdullah 13:15, 7 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys, good job on the intro image I really like it. Also, Nur are you still okay with fixing the references? :)&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 00:20, 2 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys, I made our facebook page public because Mark said he needs to be able to access the page to show that we have had substantial discussion amongst the group.&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 11:19, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Also, Mark said we can delete the comments he made on the page from previous weeks so that's gone. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 11:20, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Peer Review==&lt;br /&gt;
&lt;br /&gt;
Group 4: &lt;br /&gt;
Truly amazing work on this page. The balance between the images and text is phenomenal. It seems quite simple but easy to read well referenced. &lt;br /&gt;
I like how you used tables to illustrate the epidemiology &lt;br /&gt;
Nicely drawn images in Genetics Section. &lt;br /&gt;
I really don’t see many things wrong with the page… It is well done.. the tables and images all speak up for the quality of the page. However, pay closer attention to the references because some of them are repeated or empty when you look at the list. &lt;br /&gt;
Great work. &lt;br /&gt;
--[[User:Z3284061|z3284061]] 11:55, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
* Overall the project is good&lt;br /&gt;
* An image could be good in the introduction&lt;br /&gt;
* History and Timeline are good&lt;br /&gt;
* In the History section it might be useful to have the years in bold&lt;br /&gt;
* Well researched&lt;br /&gt;
* Image for &amp;quot;Role in Transciption inhibition&amp;quot; needs to be fixed&lt;br /&gt;
* Good table in treatment&lt;br /&gt;
* Image in Pathogenesis needs copyright info&lt;br /&gt;
* Good use of text/tables/images&lt;br /&gt;
--[[User:Z3292953|z3292953]] 11:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''''Huntington’s Disease (Group 4) Peer Review:'''''&lt;br /&gt;
&lt;br /&gt;
Introduction: Good content. Possibly include a picture to get the reader interested from the beginning. &lt;br /&gt;
&lt;br /&gt;
History: Great section! Many references which shows you have done your research. Possibly make the dates bold so that they stand out more. Good use of quote. Image needs to be referenced properly and lacks a student template. &lt;br /&gt;
&lt;br /&gt;
Epidemiology: Extensive! Great use of tables and explanation of the tables! Well done. &lt;br /&gt;
&lt;br /&gt;
Genetics: Great detail in this section. Images are well drawn and relevant to the information. Remember to include a student template in these images. &lt;br /&gt;
&lt;br /&gt;
Molecular Mechanisms and Pathogenesis: Great use of subheadings to organize the text. Image is good, just try to format the reference better and once again, include the student template. &lt;br /&gt;
&lt;br /&gt;
Clinical Manifestations: Image is slightly too small as a thumbnail. Good information, however, I think this section would benefit with a table to help better organize the information.&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests: Very extensive section. Good use of images, however maybe their placement needs to be more thought out. Also, delete the subheading for the video as this is irrelevant. Great use of video- stimulates the viewer! &lt;br /&gt;
&lt;br /&gt;
Treatment: Table is very extensive and well done. This section is impressive! Images need to have a student template and correct referencing. &lt;br /&gt;
&lt;br /&gt;
Current/ Future Research: Good information in this section. Image on right needs a label at the bottom. &lt;br /&gt;
&lt;br /&gt;
Glossary: Heading needs to be to the left – it is slightly distorted by the image above it. &lt;br /&gt;
Extensive glossary. &lt;br /&gt;
&lt;br /&gt;
References: Well done, a lot of research has been done. &lt;br /&gt;
&lt;br /&gt;
Overall, impressive page! --[[User:Z3290808|z3290808]] 10:43, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Huntingtons – Group 4&lt;br /&gt;
&lt;br /&gt;
*	This page looks very good and highly detailed. Some of the images do not have correct referencing information and could also contain a little more of a description. &lt;br /&gt;
*	Excellent use of referencing. This seems highly detailed and looks like a lot of work has been done to get the page to this standard. &lt;br /&gt;
*	Some formatting issues such as the image in future research and in diagnostic tests headings. &lt;br /&gt;
*	Video of Huntington’s patient doesn’t need such a big heading, ruins the flow of the page in my opinion. &lt;br /&gt;
*	Timeline could give a bit more information, and the importance of these events explained better. &lt;br /&gt;
*	Overall was very good work of a high standard&lt;br /&gt;
--[[User:Z3288196|Z3288196]] 10:41, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 4:&lt;br /&gt;
&lt;br /&gt;
Glossary and reference take up half the page because the glossary has terms which should probably be explained in the text instead of being an item in the glossary. The references section should also be checked, for example 56, 57,60, 69 all reference Zuccato, C, 2009. There is an excessive amount of references. Not every sentence needs to be referenced. &lt;br /&gt;
&lt;br /&gt;
Title “video of Huntington’s disease patient” should probably go as a subheading not a heading coz then all of the information that should be refering to diagnostic test becomes a subheading of the video. But its a good idea to have the links to videos for extra information.&lt;br /&gt;
&lt;br /&gt;
Apart from that, good assignment. Good use of pictures and written text. And tables.&lt;br /&gt;
&lt;br /&gt;
z3332178 =]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Peer review:&lt;br /&gt;
&lt;br /&gt;
*intro is a bit wordy e.g polyglutamate&lt;br /&gt;
*history: indent the quotes, maybe italcis too. timeline can be bolded to make it more readable.&lt;br /&gt;
*epidemiology: could have verbose words simplified and explained (the ones that are not in the glossary)&lt;br /&gt;
*genetics could have a picture about where the gene is located abnd also be simplified into tables. &lt;br /&gt;
*the picture in pathogenesis could have alot less writing or have it simplified, spaced and bolded.&lt;br /&gt;
*clinical manifestations is well written and succinct&lt;br /&gt;
*picture in diagnosis could be explained better so we can see the link to HD&lt;br /&gt;
*expand glossary and recheck the references&lt;br /&gt;
--[[User:Z3291423|Jasjit Walia]] 10:14, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4 peer review'''&lt;br /&gt;
&lt;br /&gt;
History: I love the idea of the quote. Is 'On Chorea' a book, article or report? Clarifying this would be nice.&lt;br /&gt;
&lt;br /&gt;
Epidemiology: I like how you have elaborate on table one. I found the paragraph on Warby et al paper hard to understand. I think it may become easier to understand if you linked terminologies (like HTT and Halotypes) to the glossary, even if a particular terminology has been linked before in other sections because some readers might be just reading your section.&lt;br /&gt;
&lt;br /&gt;
Clinical manifestations: It was an interesting read. :) But one suggestion ( this is what I got suggested for my section and I thought it was a good idea) is to enlarge the image so that the writing can be seen clearly. I understand that you may think that readers can click on it and see the enlarged picture but some readers may not be bothered and would prefer being able to read it on the main page. Plus, you have unlimited space and with a large image the webpage may look more interesting.&lt;br /&gt;
&lt;br /&gt;
Treatment: In the clinical manifestation, the symptoms are divided into three classes: motor, cognitive and behaviour. It may be more consistant if you reorganise the classes of medication so that it falls into the three classes described in clinical manifestation. I know, this may sound like a huge task, if so, why don't you just ask the clinical manifestation person to change their classes to two, motor and psychiatric.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289301|z3289301]] 09:44, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Peer Assessment'''&lt;br /&gt;
*Good introduction: concise and easy to understand. It might be a good idea to hyperlink some words in this section with the glossary. &lt;br /&gt;
*History and time line; well written and researched. I really like how you inserted one the original quotes in the text. I suggest you putting the timeline into a table so it looks better. &lt;br /&gt;
*Epidemiology; Good use of tables to summarize the figures/numbers. The placement of the tables between paragraphs also break up the text nicely. &lt;br /&gt;
*I strongly suggest hyperlinking words to the glossary. Makes the page more user friendly.&lt;br /&gt;
*Small typo in &amp;quot;Hungtingtin&amp;quot; title in the genetics section, but that's just a minor fix up. The section was well written. Good us of student drawn images to explain the concepts. I like how the genetics was sub-sectioned into the normal and diseased parts, makes it easier to understand.  &lt;br /&gt;
*Other sections were also well done. Maybe include a table in the 'clinical manifestations' section. Also I'm not sure if this is beyond the scope of the course but have they been able to link the five specific features of this disease to specific genetic abnormalities or pathways that happens due to this disease? What causes these features? (This is just out of my curiosity). &lt;br /&gt;
*Maybe it would look neater if the &amp;quot;imaging&amp;quot; heading was also placed on the most left hand side of the page so it aligns with other headings such as 'neuropathy'. It seems a bit messy atm. Same goes for genetic testing and prenatal diagnosis. &lt;br /&gt;
*Excellent table in the treatment section. Is there a specific reason only the actions of 'Tetrabenazine' was explained below the table? if so, what are the reasons?&lt;br /&gt;
*Overall, good job :)&lt;br /&gt;
--[[User:Z3291622|z3291622]] 09:19, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Peer evaluation'''&lt;br /&gt;
&lt;br /&gt;
*The introduction is very informative and actually introduced most of the subheadings that will be discussed in the page. The downfall of this introduction is the failure to introduce all of the sections of and proof-reading this section it is fine. &lt;br /&gt;
*The history of the disease is very well-done. The quick description or beginning of the history combined with the timeline is utilised well. Only improvement that would make it better is making the dates stand out by putting it I bold or something. &lt;br /&gt;
*I can find no fault in the epidemiology. It is the best one I have seen so far. You have described the demography of the disease and the statistics of other mutations. The tables were used appropriately as well, and the fact that it was described straight after the table is perfect. &lt;br /&gt;
*I like the genetics section of the page. It made sense and easy to understand. The diagrams are all relevant to the page section. Only criticism I can say is the description of the gene could probably be organised in a much simpler or better fashion, like a table, rather than just one whole sentence. Also I don’t know if it is typo or if that’s how you actually spell it, but I would just like to mention “Huntingtin gene”. &lt;br /&gt;
*The pathogenesis section is very informative of the disease. Unfortunately it is very disjointed. One idea was introduced after the other and they did not really connect properly. I think as the reader I am looking for some sort of direction that leads Huntington’s, like a step by step thing. &lt;br /&gt;
*I am assuming that the clinical manifestation is not yet finished, so I won’t say anything else other than change the positioning of the image to the other side because it breaks the page and it does not aid in getting the information across to your readers. &lt;br /&gt;
*The diagnostic test is a bit of a disappointment. I’m pretty sure that since it is a genetic disease there is some form of genetic testing that doctors can use to diagnose the onset of the disease, unless the etiology is still under debate and not sure of, and from what I have read from your page so far it is pretty definite that mutation in a particular gene is already implicated in the disease. So I think this section could probably do a lot more research and work. &lt;br /&gt;
*The video… section of your page is pointless, why isn’t this in the diagnostic section?? I think synthesizing both section is needed, as this section alone is pointless.   &lt;br /&gt;
*The really like the table in the treatment section it is a a very good summary. If you could add the actual effect of each drugs to the patient, it would make this table better than what it actually is. The tetrabenzaine part is a bit out of place. If you are elaborating on the entire active chemical ingredients, I believe this is a good idea. &lt;br /&gt;
*I like the current and future research section of the page, as it informs the reader that the page is current and well informed about the recent endeavors on the disease. The only let down is that there is not a single research on finding a cure for the disease or looking for other treatments, which I think is one of the most popular topic on this disease. If you could add this in this section it would make this area much better. You could even add it in the treatment section. &lt;br /&gt;
*Not really a big fan of the glossary, but it is good idea anyway.&lt;br /&gt;
--[[User:Z3290841|z3290841]] 10:23, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
*Very clear introduction, seems well researched and easy to understand&lt;br /&gt;
*History – good structure, my only suggestion is to put the timeline into a table and to highlight or bold the years mentioned, it’d look sweet as then.&lt;br /&gt;
*I like the tables in epidemiology, same colour structure could be used for the timeline under history maybe?&lt;br /&gt;
*Genetics – quite possibly the best heading on this page, I’m sure other people have mentioned this but ‘Huntington Gene’ the sub-heading is spelt wrong. Great incorporation of the student drawn image, this heading is very clear and easy to follow.&lt;br /&gt;
*Image under ‘Molecular Mechanisms &amp;amp; Pathogenesis’ is a bit big in my opinion, maybe consider reformatting it so the text is not broken up so suddenly.&lt;br /&gt;
*Image under ‘Clinical Manifestations’ could be better placed on the right hand side of the page so that there is continuity on the page, same with the other images under ‘Video of Huntington's disease patient’ and ‘Treatment’ and ‘Current/Future Research’&lt;br /&gt;
*Overall a well detailed page that is easy to understand and clear in its aims.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 06:59, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Peer Review'''&lt;br /&gt;
&lt;br /&gt;
•	Great sub-heading structure, and the overall flow of the page is neat.  Although, it would appear more orderly if all images were on &lt;br /&gt;
the right hand side of the page, in alignment with the text (it looks messy otherwise).&lt;br /&gt;
&lt;br /&gt;
•	The introduction is very clear and to the point, I think a picture which portrays the abnormality would  look good here.&lt;br /&gt;
&lt;br /&gt;
•	History is done really well, I loved the quote and the picture of George Huntington. The only thing in this section would be to make &lt;br /&gt;
the dates bold or possibly even use a table.&lt;br /&gt;
&lt;br /&gt;
•	Nice use of tables in epidemiology, they make the information easy to read and easily accessible. &lt;br /&gt;
&lt;br /&gt;
•	Well described genetics component and nice incorporation of the student drawn image. I’m not sure if there’s a need to break down &lt;br /&gt;
Huntington (misspelt as ‘Huntingtin’ in the heading) gene into more headings. &lt;br /&gt;
&lt;br /&gt;
•	Molecular mechanisms and pathogenesis is done well. I actually think the image is a good size, as its side-by-side to the text and clearly explains what most of the text is about.&lt;br /&gt;
&lt;br /&gt;
•	I think a table would be helpful in clinical manifestations. Also, the image would look better larger and on the right hand side of the page. &lt;br /&gt;
&lt;br /&gt;
•	Treatment section was a little overwhelming. Too much detail in the table, possibly?&lt;br /&gt;
	&lt;br /&gt;
•	Good glossary and a vast range of references, good work thus far!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289829|z3289829]] 02:42, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Peer Review'''&lt;br /&gt;
* Introduction does well in that it briefly addresses each of the facets of the topic that follow.&lt;br /&gt;
* Relevance of each historical point in the timeline is not adequately explained.&lt;br /&gt;
* Use of the table to show epidemiology is very nicely set up. &lt;br /&gt;
* Epidemiology is very much at the level required, delving into specific research details.&lt;br /&gt;
* You misspelled &amp;quot;Huntington&amp;quot; in &amp;quot;Huntingtin Gene&amp;quot;. Really?&lt;br /&gt;
* Image error in the Molecular Mechanisms section. Remaining picture is very comprehensive though.&lt;br /&gt;
* Could potentially use more references in the Molecular Mechanisms section; otherwise decently referenced.&lt;br /&gt;
* The Diagnostic tests aren't actually mentioned, only their significance is outlined.&lt;br /&gt;
* &amp;quot;Neuropathology&amp;quot; section is not properly titled - it seems to be a subset of the Video section (which, incidentally, can probably be moved within Clinical Manifestations)&lt;br /&gt;
* Medication table is very nicely set out.&lt;br /&gt;
* Picture in Current/Future research (mouse/person/etc) seems irrelevant, and is not actually explained.&lt;br /&gt;
* Glossary is thorough&lt;br /&gt;
--[[User:Z3290689|z3290689]] 00:46, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Peer Review for Group 4'''&lt;br /&gt;
&lt;br /&gt;
*Introduction is informative but not catchy. You need the reader to feel eager to read on the rest of the page.&lt;br /&gt;
*I like the way the history has a portrait and how there is a blue box around the quote. Maybe In the timeline you should bold the dates so it looks better on the page.&lt;br /&gt;
*Information found in the epidemiology is great, and the use of tables is very good. Just wanted to let yous know that whenever I read HD I always remember High Definition, a little distraction to my reading. Just wanted to make that point.&lt;br /&gt;
*Information in the HTT &amp;amp; normal functions section seems a bit disjointed and doesn’t seem to flow well.&lt;br /&gt;
*The HTT and Huntington’s disease section showed be reformatted so it is one nice flowing informative paragraph.&lt;br /&gt;
*Image found in the molecular mechanisms and pathogenesis section doesn’t show. Please fix it or remove the thumb altogether. However included information in this section is informative&lt;br /&gt;
*In clinical manifestations, it would be really good if you could describe how the clinical manifestations are brought about at a neurological level.&lt;br /&gt;
*It’s not necessary to have a large subheading for’ Video of Huntington's disease patient’&lt;br /&gt;
*Diagnostics has lots of info so formatting it so it’s spread out will be good.&lt;br /&gt;
*The image of Amniocentesis seems not to have the copyright clearance for it to be modified. Please fix it.&lt;br /&gt;
*Table in the treatments section is cool and massive, try to make it a bit smaller?&lt;br /&gt;
*I believe if the tetrabenzine information should come first then the massive medications table it would make the treatments part look and flow better.&lt;br /&gt;
*Current and future research section has information that very informative and portrays a good view on the current research arena for HD. However I don’t understand the relevance of having the brain scans in this section. Maybe have another section as a glossary which you could use for all other miscellaneous pictures.&lt;br /&gt;
*Some parts of the referencing include multiple referencing, just fix that up it will make it much better&lt;br /&gt;
*Overall, page is really well constructed, put a lot of work in and I’m impressed. Good word to picture ratio thus makes the page to be wanted to be read. Good work people of group 4.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291317|Z3291317]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
Introduction: Introduction is alright but could be more detailed.&lt;br /&gt;
&lt;br /&gt;
History: This section is good but the timeline would be better with more information/ more detailed explanation of the points already there.&lt;br /&gt;
&lt;br /&gt;
Epidemiology: This section seems too concerned with the occurrence of the HD. I think this section could use some more general &lt;br /&gt;
epidemiological information as well.&lt;br /&gt;
&lt;br /&gt;
Genetics: This section is explained clearly and done quite well. The pictures need to be bigger though.&lt;br /&gt;
&lt;br /&gt;
Pathogenesis: This section is good. The image could be a tiny bit bigger and would be better if it had a caption explaining the different parts of the diagram.&lt;br /&gt;
&lt;br /&gt;
Clinical manifestations: This section could be longer/more detailed. You could explain some of the symptoms. Eg.what is chorea? Also, the picture is good but needs to be much bigger.&lt;br /&gt;
&lt;br /&gt;
Diagnosis: This section doesn’t seem to actually explain how HD is diagnosed. Where is the diagnosis? Also, the picture is good but needs a more detailed caption.&lt;br /&gt;
&lt;br /&gt;
Treatment: This table is not very nice to read and seems a bit complicated. I think it would work better simplified and put into paragraphs.&lt;br /&gt;
&lt;br /&gt;
Future research: Good pictures and text. I think the images need more explaining. Eg. where is the caudate located in the brain. Maybe arrows could show this.&lt;br /&gt;
--[[User:Z3291324|z3291324]] 23:21, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4:'''&lt;br /&gt;
&lt;br /&gt;
•Formatting of the page seems well done, I like the inclusion of the quote in the history section, maybe put the timeline into a table as this would make it more visually appealing&lt;br /&gt;
&lt;br /&gt;
•The file Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg, does not have the correct copyright information for the student drawn images&lt;br /&gt;
&lt;br /&gt;
•I like the inclusion of the video, but am not sure about the subheading choice for this section. Does the video need its own separate heading?&lt;br /&gt;
&lt;br /&gt;
•Good balance of text and images&lt;br /&gt;
&lt;br /&gt;
•A couple of the references seem to be missing some of the information, but you have a large number of references so it looks like a lot of research has gone into this, good work so far.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332183|z3332183]] 21:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4: Peer Assessment'''&lt;br /&gt;
* Your page has a good balance of text, images and tables&lt;br /&gt;
* I like that your introduction is brief and to the point&lt;br /&gt;
* You history section is the best one have seen so far, it looks good and it easy to read&lt;br /&gt;
* The image in the pathogenesis has no copyright information&lt;br /&gt;
* In clinical manifestations are quite important I think and your section seems a little weak in comparison to the rest&lt;br /&gt;
* Treatment: I'm sure the table was a lot of work but it is quite complex ad all the drug names make me a bid dizzy. May be you can shorten it to the most relevant?&lt;br /&gt;
*Overall the page has a good content and it's fun to read. The diagrams and drawings are great --z3279511 17:09, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''GROUP 4: Huntington's Disease'''&lt;br /&gt;
*Intro has good summary of the disease, however the first paragraph is a little too technical, could you maybe simplify it a little so you don't lose the reader right at the start (reference 5 is missing though)&lt;br /&gt;
*History is succinct and summarised well, i like the quote included, could you have gone a little further with the timeline? (maybe include some of the more recent developments), maybe the timeline could be better formatted in a table&lt;br /&gt;
*Good info from a variety of sources in epidemiology, good use of tables, I like how prevalence has been compared and how the table is explained (one little thing: could you maybe find more statistics for Australia?)&lt;br /&gt;
*Inheritance image needs student template added and maybe made a little bigger so detail can be seen&lt;br /&gt;
*Genetics section is informative but could use an image of the gene maybe&lt;br /&gt;
*Molecular Mechanisms &amp;amp; Pathogenesis section is well researched and good summary is provided. I like how key words have been highlighted. images need fixing (more descriptive legend is needed for the first image and what happened to the second image?&lt;br /&gt;
*I don't think you need to explain what the disease is again in the clinical manifestation segment (don't want to sound repetitive), image in this section isn't very clear, I feel that this section is a tad incomplete-maybe some expansion is needed e.g. classes 2 and 3 could be expanded on more &lt;br /&gt;
*I feel that diagnosis section could go further up? This section is very informative, but could be summarised a little more Some of the images in this section need better explaining, good balance of text and images in this section&lt;br /&gt;
*good use of table in treatment section, however more info could be provided as to how these drugs help the disorder &lt;br /&gt;
*Current/Future Research is very up to date, images here again need more description&lt;br /&gt;
&lt;br /&gt;
Overall:&lt;br /&gt;
*it is evident that this project has been extensively researched&lt;br /&gt;
*good use of subheadings and headings&lt;br /&gt;
*maybe include the acronyms in the glossary and it would be good if glossary words were linked to text&lt;br /&gt;
*make sure all images include the student template required and legends of some images need to be expanded (more info on what the image is about)&lt;br /&gt;
*fix repetitive sentences&lt;br /&gt;
*good balance of images and text, good use of tables&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 15:27, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Peer Assessment Group 4'''&lt;br /&gt;
&lt;br /&gt;
*Second sentence of intro is WAY too detailed for the intro, it means very little as the disease has not yet been explained to us and is too technical – OR, keep it but explain it in a more general way. &lt;br /&gt;
*What do you mean by familially or sporadical development? Define what you mean by this (intro)&lt;br /&gt;
*Timeline – events need to be explained. E.g. Venezuela Project – what is this? Why is it significant? (this is needed for most of the history entries)&lt;br /&gt;
*HTT and normal functions – can you explain what some of the processes are? E.g. dynactin complex, clathrin-mediated endocytosis are?&lt;br /&gt;
*Calcium signalling in pathogenesis – maybe explain why the calcium signalling pathway is important?&lt;br /&gt;
*The video file – make sure you write a little para about it. It has a new headings – shouldn’t it be a subheading?&lt;br /&gt;
*The paragraph of ‘Imaging’ in diagnostic tests needs to be pushed so its under the pics from neuropathology&lt;br /&gt;
*Tetrabenazine – I think have an intro sentence about it to highlight that this is the most commonly used one, as you only discuss it in depth (as a drug treatment) – unless you are going to add in explanations of other drugs?&lt;br /&gt;
*In Current/future research, refer to the pics on the RHS if they are relevant, otherwise I think they need to go somewhere else&lt;br /&gt;
*Overall comment: its good, lots of research, but even as someone who has a background in bio, we still don’t know everything about everything, so I think as you go, explain some of the more complicated processes so you can really understand what is going on. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332824|z3332824]] 11:48, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 4: Huntington’s Disease&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Peer Review'''&lt;br /&gt;
* Good introduction, history seems adequate - although the timeline stops at 2002? Is there anything after this?&lt;br /&gt;
* Nice table for epidemiology; although some terms require explaining&lt;br /&gt;
* Excellent student-drawn diagrams and genetics section with a good balance between the text, bullet points and images. One image has been removed so be sure that that is re-uploaded!&lt;br /&gt;
* Video section: Formatting is a bit of a pain to read when the left hand margin keeps shifting with the images being placed here. Fix this please so that it is easier to track the page with our eyes.&lt;br /&gt;
* Treatment section is overwhelming, whilst some might have said that it looks great (and it really does), to suddenly be hit with such a huge table is exhausting. Perhaps shorten this section by mentioning that there is only treatment available for the symptoms, list them, and then link to an image containing the table in its entirety.&lt;br /&gt;
* Current/Future research section seems a bit short. &lt;br /&gt;
* Overall, it looks like an excellent project that has had a lot of thought put into it. Well done guys :)&lt;br /&gt;
--[[User:Z3288827|Leonard Tiong]] 10:25, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Initial thoughts, was wow! Clearly immense time and effort was put into this! Loved the structure of the headings and sub-headings. &lt;br /&gt;
*Introduction: Top notch, just needs an image to complete it.&lt;br /&gt;
*History: Nice use of the quote box, this section was done very well, except BOLD the years. Personally, I would have liked it more if the timeline itself was in a coloured table, no biggie. &lt;br /&gt;
*Epidemiology: Add “(Australia)” After Tasmania? Or just listing countries would be better? Overall, nicely done.&lt;br /&gt;
*Genetics: “Inheritance” part feels a little too short. Preferred if the image had black text over a white background. Everything else was great!&lt;br /&gt;
*Molecular Mechanisms &amp;amp; Pathogenesis: The space between the purple words and commas could be removed. The purple colour, made me think they were hyperlinks, maybe chose either to bold or colour the words, as having both is a bit much.&lt;br /&gt;
*Clinical Manifestations: The features would look better in a table, in my opinion. I like the image, very nice indeed! Good summary.&lt;br /&gt;
*Diagnostic Tests: Done well, though compared to the rest of the webpage, it looks very insignificant. I suggest adding more information!&lt;br /&gt;
*Video: Fix the formatting please!&lt;br /&gt;
*Treatment: Nice table, informative. The “Tetrabenzine” section, the text needs some formatting, sentences are cut off to the next line for some reason, to be honest Medications and Therapies seem to be most important part, so they should maybe be expanded on? &lt;br /&gt;
*Glossary: Looks good, just a few full stops missing!&lt;br /&gt;
--[[User:Z3332327|Lisa Xiao]] 01:24, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
*Very good introduction&lt;br /&gt;
&lt;br /&gt;
*History: looks very nice, but the layout of the quote disrupts the page. I think it would be better to use bold letters, good idea though. &lt;br /&gt;
&lt;br /&gt;
*Epidemiology: nice section, useful tables&lt;br /&gt;
&lt;br /&gt;
*Genetics: good detailed content and drawings&lt;br /&gt;
&lt;br /&gt;
*Pathogenesis: do not bold words in only one section,  it disrupts the whole picture, good use of sub- headings.&lt;br /&gt;
&lt;br /&gt;
*Clinical manifestations: good summary of the symptoms in the drawing, the classes and the five specific features would look better in a table, otherwise good section&lt;br /&gt;
&lt;br /&gt;
*Diagnostic tests: the video subheading needs to be fixed, really irritating. Very detailed, I would put all images to the same side &lt;br /&gt;
&lt;br /&gt;
*Treadment: mechanism of tetrabenazine inhibition image could have been done with more effort&lt;br /&gt;
&lt;br /&gt;
*Research: very nice clear section&lt;br /&gt;
--[[User:Z3387190|Z3387190]] 21:27, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''group peer assessment'''&lt;br /&gt;
*Introduction is well structured though image of the Huntington gene protein would be more beneficial to where I’m looking relating to genetics&lt;br /&gt;
*Genetics could expand more on the inheritance and the Huntington gene&lt;br /&gt;
*Role in transcription  sub heading image removed&lt;br /&gt;
*Diagnostic test image needs to placed in correct section and the video should be placed at the end of the section, placement of the video cause confusion of the other diagnosis tests&lt;br /&gt;
*Treatment should have an introduction which introduces the drug used to manage diseases and therapies, better layout where most commonly used drug form management and therapies following the table to show alternative treatment.&lt;br /&gt;
*Current/future research should have some future research and images placed have no description which research project image belongs to&lt;br /&gt;
*References contain mistakes with repetitions and blanks also some done incorrectly such as reference “3” where not properly inputted on the wiki page&lt;br /&gt;
*Glossary was not linked to the web page as well while reading was lost without referring to a dictionary due to no indications definition is in the glossary&lt;br /&gt;
z3332250 23:46, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4 Peer Review&lt;br /&gt;
&lt;br /&gt;
*Punchy introduction-well done&lt;br /&gt;
*Timeline under history was excellent&lt;br /&gt;
*Seemed very scientific and wordy at times-a lot of detail is unnecessary; “less is more”&lt;br /&gt;
*Great balance of text and images-very readable&lt;br /&gt;
*Page flowed well in a logical manner&lt;br /&gt;
*Diagnosis section is very well done however there seems to be too much content/focus relative to the rest of the page. Perhaps add some more to other sections or make this section more concise?&lt;br /&gt;
*An extensive glossary and reference list-thorough research&lt;br /&gt;
*I learnt a lot from this page so well done!&lt;br /&gt;
*Overall, an impressive page. A few more things to tweak to make it excellent. &lt;br /&gt;
--[[User:Z3308965|Fleur McGregor]] 19:13, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Critique'''&lt;br /&gt;
&lt;br /&gt;
#•	Introduction was quite good&lt;br /&gt;
#•	History was good. I liked the timeline&lt;br /&gt;
#•	Tables in the epidemiology were good&lt;br /&gt;
#•	The genetics was clearly explained&lt;br /&gt;
#•	Pathogenesis was really good. I quite liked it&lt;br /&gt;
#•	Clinical manifestations is good&lt;br /&gt;
#•	Diagnostic tests could be more detailed&lt;br /&gt;
#•	Overall, quite a well written project. Well done. Maybe add a little more about the medications. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289991|Robert Klein]] 18:47, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Huntington's Disease'''&lt;br /&gt;
&lt;br /&gt;
*The intro and history look really good, I like the timeline and the quote box&lt;br /&gt;
*What year was the information in the table in 'Epidemiology' sourced? Because from looking at the references, it seems to be within a 20yr period.  Is this enitrely accurate to compare these?&lt;br /&gt;
*What are HTT and HD halotypes (in 'Epidemiology')? You've only put 'halotypes' in the glossary, you also need to a give a brief definition within the text, not just glossary&lt;br /&gt;
*Nice image in 'Genetics', lots of good easy to understand information there as well&lt;br /&gt;
*You need to fix the file under 'Role in Transcription Inhibition'&lt;br /&gt;
*The diagnosis section looks really good, make sure you get rid of that subheading for the video though&lt;br /&gt;
*Interesting table in 'Treatment', however the section on 'Tetrabenazine' does not has complete sentences and seems a bit unnecessary.  Honestly I don't really care how the drug works (ie receptors) I'm more interesting in it's implications regarding HD&lt;br /&gt;
*The 'Therapies' section was good and succinct&lt;br /&gt;
*Current/Future Research looks really good&lt;br /&gt;
*Overall the page isn't bad, just need to confirm some details to improve it ie dates and definitions&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
* On first looking at the project it looks like there is a good text/image ratio. However an image in the introduction would work well&lt;br /&gt;
* The content of the introduction is very clear and introduces the reader to the topic well&lt;br /&gt;
* I really like the history section. The story makes me a little excited about the condition in a way. I am left feeling keen to know more and there is an extensive list of discoveries. There needs to be more after 2002 though. I find it difficult to believe that nothing has been found in the last 9 years.&lt;br /&gt;
* The epidemiology table is a nice way of showing the data. But maybe you should put the Australian states in bold and at the top- also maybe include all of the states or Australia as a whole, not just NSW and TAS&lt;br /&gt;
* There is a file in the pathogenesis that is not accessible- either get the file up or remove the link&lt;br /&gt;
* The image in the pathogenesis has no copyright information&lt;br /&gt;
* A couple of grammar problems in the pathogenesis that could be fixed up- full stops mid sentence for example&lt;br /&gt;
* The clinical manifestations sections outlines the types of classes of manifestations but it is difficult to actually access the information on what the manifestations are. It would work well in a table with a little more detail on what the patient experiences&lt;br /&gt;
* The video is put as a new subheading within diagnosis. It needs to be made into the smaller subheading because I thought diagnosis section was over but it continues underneath&lt;br /&gt;
* The diagnosis section is in great detail, somewhat more detail than other sections. This is very interesting and shows that this team member worked hard on their section.&lt;br /&gt;
* Good work on the project, just a little editing and formatting to make it a finished product!&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
* Nice structure of headings and subheadings, it breaks up the text and makes it a readable page. Extremely interesting topic! &lt;br /&gt;
* I found the history very interesting and enjoyed the quote from Huntington.&lt;br /&gt;
* maybe bold the dates in the timeline, just to make the page easy to follow. Or maybe a table could be appropriate. &lt;br /&gt;
* I liked the structure of the epidemiology section and the tabulated prevalences! good work! &lt;br /&gt;
* Molecular Mechanisms &amp;amp; Pathogenesis: unsure as to why some sentences were bolded. &lt;br /&gt;
* Differential Diagnosis: very interesting I liked that you added this in. &lt;br /&gt;
* Treatments table very succinct  easy to understand and follow! Great! &lt;br /&gt;
* Good to see that most of your references were grouped. only a few that were doubled. &lt;br /&gt;
* Maybe have a continuos colour scheme for the page and type of table used. &lt;br /&gt;
* Good use of tables and I like that you explained what they were about. &lt;br /&gt;
* Make sure all acronyms and scientific language is in the glossary&lt;br /&gt;
* good student illustrations &lt;br /&gt;
* overall great ratio of text and pictures!&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Assessment'''&lt;br /&gt;
*This might be a bit nit-picky, but for the references given throughout the wiki, there isn’t any consistency.  The [#] is sometimes right after the sentence, sometimes a space is given between the sentence and citation number, and the end of the sentence (period or comma) is sometimes before or after the reference #...&lt;br /&gt;
*The information within the introduction seems to be substantial.  Only suggestion would be to add a picture to add to the overall look. &lt;br /&gt;
*In the history section, it was a good idea to have the single quote stand out in a colored box to itself.  First time I’ve seen this.  Looks professional.  I question though, if all the events within the timeline are absolutely necessary… &lt;br /&gt;
*Epidemiology- Both tables are well organized and look extremely professional.   Good information within this section, although it might be a good idea to reference a few more not-so-common terms in the glossary, such as SNP’s and others which may not be common knowledge for all. &lt;br /&gt;
*The Genetics section is well formatted with what I believe is the vital information needed in this section.  Only complaint is the first picture (Inheritance Pattern…) doesn’t have the copyright information claiming that it is okay to use this image.  &lt;br /&gt;
*The “Key cellular pathogenic mechanisms in HD” image likewise does not have the copyright information to verify its legal usage.  &lt;br /&gt;
*Molecular Mechanisms and Pathogenesis section-  Very well formatted and aesthetically appeasing.  Why are some of the words in purple though?  Are they meant to be defined the glossary, or just key points?   “The Mutant Huntington gene…” file is also not on the page… Where is it? &lt;br /&gt;
*Diagnostic Tests  Research – I have no complaints.  These sections look immaculate.  &lt;br /&gt;
*In the glossary, try having a bullet list and also having the words within the wiki page to link to its definition in the glossary.&lt;br /&gt;
*Some of the references are repetitive.  Make sure to fix this so they all link to a single reference instead of numerous ones of the same resource.  &lt;br /&gt;
*Overall, good content within the page and very appealing visually.  Just minor editing needs to be done I think.  Good job!&lt;br /&gt;
--[[User:Z3391078|Z3391078]] 14:31, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Peer Assessment: Group Project 4'''&lt;br /&gt;
*The introduction and history sections are concise and well formatted.&lt;br /&gt;
*A few of the points in the timeline would be improved by containing a bit more information such as 'Mendel's work' and 'The Venezuala project'&lt;br /&gt;
*The tables used in the epidemiology section are clear and highly informative.&lt;br /&gt;
*The abbreviation HTT is used throughout the epidemiology section before it is stated what it means in the genetics section. This should be changed.&lt;br /&gt;
*The picture related to transcription factors needs to be fixed so that it can be displayed.&lt;br /&gt;
*The section entitled 'Video of Huntington's disease patient' should have a more appropriate heading to encompass the rest of the written information in that section.&lt;br /&gt;
*Under the information in some of the images you have uploaded, you still need to add &amp;lt;nowiki&amp;gt;{{Template:2011 Student Image}}&amp;lt;/nowiki&amp;gt;.&lt;br /&gt;
*Some of the references are duplicated. They can instead be linked together using the 'multiple instances on a page' editing guidelines: http://embryology.med.unsw.edu.au/embryology/index.php?title=References#Multiple_Instances_on_Page.&lt;br /&gt;
*Overall the project is highly informative, well written and formatted.&lt;br /&gt;
--[[User:Z3217345|z3217345]] 21:34, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 3:&lt;br /&gt;
* The introduction is very lengthy, some parts feel as though they would be more appropriate in other sections. The image here fits nicely with the text but it could benefit from a more descriptive legend and needs to include “{{Template:2011 Student Image}}”.&lt;br /&gt;
* In the history, you begin to use the short hand “KS” without an initially stating that this is the abbreviation for “Klinefelters syndrome (KS)”. The dates that are mentioned are very detailed although it ends in 1970, were there any other breakthroughs since then? A picture of Klinefelter would be a nice touch here.&lt;br /&gt;
* Epidemiology requires some proof reading as there are a couple of little mistakes and the images would have more of an impact if they were slightly larger.&lt;br /&gt;
* I like how you have linked figure 1 to the non-disjunction sub-heading under aetiology. The image in this section could benefit from a coloured legend, ie. Instead of saying “Blue circles are male cells”, in a box include an actual blue circle = male cells along with the other descriptions. It also needs to be properly cited. &lt;br /&gt;
* There is too much repetition between pathogenesis and aetiology, maybe discussion between these two students is needed to minimise repetition. Good hand drawn images but you need to include the student template as mentioned previously.&lt;br /&gt;
* Signs and symptoms would look better in a coloured table and with more images. I don’t think it is necessary to repeat the image comparing age and intellect here.&lt;br /&gt;
* Diagnosis; nice use of another form of media – a video. The abbreviation of KS in this section needs to be established first by placing KS after the first time you mention Klinefelters syndrome.   &lt;br /&gt;
* Management is very concise and thorough &lt;br /&gt;
* Other similar defects; nice touch, it could look more appealing with the use of colour and larger images though.&lt;br /&gt;
* Current research is formatted nicely and flows well&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4: '''&lt;br /&gt;
* The introduction provides a great overview but remember it needs to be easy to read, even for those who have never heard of Huntington’s disease. If you explain scientific and medical terms (such as neurodegenerative and CAG trinucleotide tract) more generally/broadly, it will solve this problem. &lt;br /&gt;
* History: great use of a quote and image. The timeline would look better and make it easier to read if the dates were bolded or if it were in a table. The explanations could be elaborated more such as “1900: Mendel’s work was rediscovered”. Image needs to include &amp;lt;nowiki&amp;gt;“{{Template:2011 Student Image}}”&amp;lt;/nowiki&amp;gt;. &lt;br /&gt;
* Epidemiology: Although you’ve stated that Venezuela and North Ireland have notably high prevalence of this disease, you haven’t stated the actual prevalence of Venezuela. You also need to re-read this section as there are a couple of mistakes eg “There &amp;lt;font color=red&amp;gt;seem&amp;lt;/font&amp;gt; to be an increased prevalence of Huntington's disease...” and this sentence doesn’t make sense “Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela and Northern Ireland”. What are HTTP haplotypes?, overall I found the explanation of the paper by Warby et al hard to understand, maybe another attempt of explaining this paper is needed by spelling out the haplotypes even more so.  In saying this, the tables are formatted very nicely. &lt;br /&gt;
* Genetics: Nice student drawn images but just make sure you include the student template as mentioned above. The “Huntingtin Gene” section would benefit from an image of the specific regions on the chromosome as it is hard to follow with just text.&lt;br /&gt;
* Molecular mechanisms and pathogenesis: a lot to take on but is made easier to read through the use of good sub-headings and highlighted words and large image. Make sure you include the student template here as well and there is an image missing in this section though.  &lt;br /&gt;
* Clinical manifestations: You have mentioned 3 classes of symptoms but have only gone into detail about one of them; motor movement impairment. What happened to cognitive and behavioural explanations?  Nice student drawn image, I like how it is oriented to the left to change it up a bit.&lt;br /&gt;
* Diagnostic test: The table could be formatted with more colour to make it more aesthetically pleasing. I personally don’t understand including an image of another disease, i would stick to images specifically relating to HD.&lt;br /&gt;
* Under neuropathogy there is a little typo “The neuropathological hallmark of Huntington’s disease is now &amp;lt;font color=red&amp;gt;know&amp;lt;/font&amp;gt; to be the gradual loss of spiny GABAergic...”, there could be more so i would advise to check this section again. &lt;br /&gt;
*Under genetic testing there is also another little typo “However it wasn’t &amp;lt;font colour=red&amp;gt;until the 1993&amp;lt;/font&amp;gt; when...”&lt;br /&gt;
*Treatment and future research: very well researched and I really liked the use of the table and images here, it provides great balance and flow. &lt;br /&gt;
&lt;br /&gt;
--z3290815 19:05, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4: '''&lt;br /&gt;
&lt;br /&gt;
*The page had a nice format that was appealing to read. &lt;br /&gt;
*The structuring of the images between and beside the text was perfect because it was not too big and not too small. It was easy to view and nice to see.&lt;br /&gt;
*The table for the treatment heading was nice but the last column is hard to read because the information was listed in a horizontal fashion maybe changing it and putting it into dot point form would be good.&lt;br /&gt;
*The student drawn image was clear!&lt;br /&gt;
*Fixing the formatting/structure of the glossary heading is needed&lt;br /&gt;
*Double referencing can be seen&lt;br /&gt;
*Sub heading for the video would be nice to see. The idea of including a video is quite nice.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3330313|z3330313]] 19:57, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Peer Review'''&lt;br /&gt;
&lt;br /&gt;
* Organised well&lt;br /&gt;
* Subheadings in the epidemiology section not in the centre of table&lt;br /&gt;
* images in the current/future research section is disorganised&lt;br /&gt;
* a lot of referencing was done and maybe not necessary&lt;br /&gt;
* choice of pictures were good examples&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3060621|z3060621]] 21:14, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
'''*The key points relating to the topic that your group allocated are clearly described.'''&lt;br /&gt;
Main sections are there, Not sure if 'video of huntington's patient' should be a big heading - maybe put it in an 'external links' section?&lt;br /&gt;
&lt;br /&gt;
'''*The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area.'''&lt;br /&gt;
Content is well done and headings/sub-headings are organised well.&lt;br /&gt;
&lt;br /&gt;
'''*Content is correctly cited and referenced.'''&lt;br /&gt;
Fix up doubling of references. File:Mutant Huntingtin gene and its effects on transcription.jpg is missing. No references in therapies?&lt;br /&gt;
&lt;br /&gt;
'''*The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.'''&lt;br /&gt;
Student image well done and explanation works well.&lt;br /&gt;
&lt;br /&gt;
'''*Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities.'''&lt;br /&gt;
Comprehensive research, but maybe more information in glossary as the wiki uses quite a lot of technical language.&lt;br /&gt;
&lt;br /&gt;
'''*Relates the topic and content of the Wiki entry to learning aims of embryology.'''&lt;br /&gt;
Any thing else on diagnosis? As mentioned by Mark, since this is a disease that presents complications after birth, more information should be added. Perhaps include some information on diagnostic tests? The imaging section in neuropathy could be added to diagnostic tests if diagnosis is possible by examining neurological changes?&lt;br /&gt;
&lt;br /&gt;
'''*Develops and edits the wiki entries in accordance with the above guidelines.'''&lt;br /&gt;
Development of wiki page has followed above guidelines, but some minor adjustments can be made.&lt;br /&gt;
&lt;br /&gt;
--z3329495 21:15, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*'''Intro''': Content is fine, but revise some of your sentences - they are a bit long winded and hard to follow.&lt;br /&gt;
*'''History''': Looks good.&lt;br /&gt;
*'''Epidemiology''': Nice detail.&lt;br /&gt;
*'''Genetics''': Your first sentence doesn't quite make sense. That is not an adequate explanation of autosomal-dominant. Also, in case both parents have the disease, the likelihood of the offspring having the disease is still not 100% - it's 75%.&lt;br /&gt;
Also, are you sure there is a mutation that causes the repeat to expand? Repeats in general are susceptible to mutations, especially expansions - that is different from there being another mutation elsewhere in the genome causing the repeat to expand. More terms need to be explained in the glossary. Nice hand-drawn figure though.&lt;br /&gt;
There's a reasonable amount of information why the disease tends to be inherited in an anticipating pattern, so you could possibly add that information.&lt;br /&gt;
*'''Molecular Mechanisms &amp;amp; Pathogenesis''': Nice detail. Why are some terms in bold and coloured? More terms need to be explained in the glossary.&lt;br /&gt;
*'''Clinical Manifestations''': Good.&lt;br /&gt;
*'''Diagnostic Tests''': Otherwise fine, but you could briefly mention which genetic tests can be used to diagnose the test genetically.&lt;br /&gt;
*'''Video of Huntington's disease patient''': Why is this the main heading for this section? Doesn't quite make sense. Otherwise, the section is good, I like the use of figures to break up the text.&lt;br /&gt;
*'''Treatment''': Nicely comprehensive. Rather few explanations in text form though, maybe expand on this a little bit more?&lt;br /&gt;
*'''Current/Future Research''': Your &amp;quot;Culling out complex traits&amp;quot; figure doesn't have any explanation on the project page. Also, what exactly does it contribute, but a picture? It seems a bit redundant. Otherwise, nice detail.&lt;br /&gt;
*'''Glossary''': Looks good, but some more terms still need explaining.&lt;br /&gt;
*'''References''': Needs fixing, some papers appear multiple times, and some references lead to emptiness.&lt;br /&gt;
&lt;br /&gt;
==Discussion==&lt;br /&gt;
&lt;br /&gt;
Hey girls, Found a photo for the introduction. Let me know what you think/feel free to change it if you wish :)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 17:10, 1 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Liz, I posted on the fb page regarding the genetics and pathogenesis part. The student drawn image I'm okay with doing yes. So far I was thinking about doing a picture showing the autosomal dominant nature of the gene. Basically a &amp;quot;tree diagram&amp;quot; of what happens when one parent is affected and the offspring has a 50% chance of inheriting HD. &lt;br /&gt;
But I'm okay at drawing so if someone else has something better they'd like me to draw I'm okay with it. :)&lt;br /&gt;
Girls please check fb, bit of a crisis. &lt;br /&gt;
:)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 06:00, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
hey girls, i think we really need to start hurrying things along with our project. Maedeh, i know you said that peer reviews arnt getting marked, but we need to have our project FINISHED by then because after that we are only making finishing touches based on teh peer reviews. Also, are you still doing the student drawn image? Ta&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:41, 13 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Genetics + Pathogenesis &lt;br /&gt;
&lt;br /&gt;
Yea I think so, it would make it more relative. If anyone comes across any studies just post the link here or on fb. :) &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|z3290270]] 23:36, 24 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hmm, are epidemiological studies on HD? If there is, we should add. It will make our webpage more comprehensive.&lt;br /&gt;
And I don't mind doing that section.&lt;br /&gt;
&lt;br /&gt;
--Nur Sharalyn Abdullah 20:24, 23 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Girls, do you think we need an 'Epidemiology' heading?? &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 17:25, 23 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Introduction + Clinical Manifestations.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290558|Lisa Lee]] 14:42, 23 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Current + Future Research &amp;amp; Diagnostic Tests. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 09:30, 22 August 2011 (EST)&lt;br /&gt;
 &lt;br /&gt;
Sharalyn: History &amp;amp; treatment&lt;br /&gt;
&lt;br /&gt;
--Nur Sharalyn Abdullah 20:15, 20 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''White blood cell populations from Huntington's Disease patients'''&lt;br /&gt;
&lt;br /&gt;
[[File:White_blood_HD.gif]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290558|z3290558]] 23:46, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
===Establishment of HD hybrid cell line===&lt;br /&gt;
&lt;br /&gt;
[[File:Establishment of HD hybrid cell line.jpg]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
(A) First polar body of mature rhesus macaque oocyte was removed by gentle squeezing through a slit of zona pellucida (A-a). Staining of 1st polar body DNA (arrowhead) and oocyte DNA (arrow) (A-b). HD monkey skin cell was placed under the zona pellucida (black arrow) (A-c). Reconstructed oocyte with HD monkey skin cell (A-d; yellow arrow) was placed between two electrodes for electrofusion (A-d). (B) Day 12 hatching blastocyst derived from HD monkey hybrid embryo (B-a; arrow indicated ICM). HD monkey hybrid blastocyst outgrowth at six days after attached onto feeder cells (B-b). High magnification of selected region (inset) of the ICM outgrowth (arrowhead). HD monkey hybrid cell line (TrES1) at passage 10 (B-c). (C) G-banding analysis of TrES1. Cytogenetic analysis of TrES1 demonstrated tetraploid chromosome (84; XXXY). (D) Expression of ES-cell specific markers: Alkaline phosphatase, Oct4, SSEA4 and TRA-1-60.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833146/?tool=pmcentrez&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 21:30, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Large stem cell-derived neurospheres were generated from 33-week old HD hippocampus, but not WT hippocampus.'''&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 15:06, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Melatonin levels in Huntington's disease patients and controls'''&lt;br /&gt;
&lt;br /&gt;
[[File:Melatonin levels in HD patients and controls.jpg]]&lt;br /&gt;
&lt;br /&gt;
The diurnal melatonin rise was significantly delayed in HD patients by about 01:30 h (p = 0.048). The black bar on the abscissa indicates the dark period (23:00–7:30 h).&lt;br /&gt;
&lt;br /&gt;
--Nur Sharalyn Abdullah 12:21, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
We decided on Huntington's Disease, I believe Nur spoke to you at the end of the class. :) &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 16:44, 13 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 18:28, 11 August 2011 (EST) Your group left the lab today without notifying me of your selected group topic.&lt;br /&gt;
&lt;br /&gt;
Group 4 Topic: Neural Tube Defect&lt;br /&gt;
&lt;br /&gt;
Research Article:&lt;br /&gt;
&lt;br /&gt;
Conway S.J., Gosnell M., Rogers R., Simmons O., Snider P., Young R. (2011), Notochordal and foregut abnormalities correlate with elevated neural crest apoptosis in Patch embryos. Birth Defects Research Part A: Clinical and Molecular Teratology. doi: 10.1002/bdra.20802. Epub 2011 May 6.&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/21557455&lt;br /&gt;
 &lt;br /&gt;
Review Article:&lt;br /&gt;
&lt;br /&gt;
Abdel-Hamed Z., Johnson C.A., Logan C.V. (2011), Molecular genetics and pathogenic mechanisms for the severe ciliopathies: insights into neurodevelopment and pathogenesis of neural tube defects. Molecular Neurobiology&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/21110233&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290558|z3290558]] 02:07, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Neural Tube Defects'''&lt;br /&gt;
&lt;br /&gt;
[[Review:]] Padmanabhan, R. (2006). Etiology, pathogenesis and prevention of neural tube defects. ''Congenital Anomalies'', 46(2), 55-67.&lt;br /&gt;
&lt;br /&gt;
[[Research:]] Joó, J. G., Beke, A., Papp, C., Tóth-Pál, E., Csaba, A., Szigeti, Z., Papp, Z. (2007). Neural tube defects in the sample of genetic counselling. ''Prenatal Diagnosis'', 27(10), 912-21.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|z3290270]] 02:34, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''Review'': Bassuk AG, Kibar Z. '''Genetic basis of neural tube defects.''' Semin Pediatr Neurol. 2009 Sep;16(3):101-10 [http://www.ncbi.nlm.nih.gov/pubmed/19778707]&lt;br /&gt;
&lt;br /&gt;
''Research'': De Marco P, Merello E, Cama A, Kibar Z, Capra V.''' Human neural tube defects: Genetic causes and prevention.''' Biofactors. 2011 Jun 14.[http://www.ncbi.nlm.nih.gov/pubmed/21674647]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 14:24, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
We are doing on neural tube defects! &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 13:47, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Neural Tube Defects&lt;br /&gt;
&lt;br /&gt;
Article: &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19120526&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Review: &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18182339&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===References===&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 22:25, 9 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi girls (: I actually managed to find some genetics-related articles on neural tube defects. It has something to do with folate and folate-related genes from what I have read so far. So how about it? Shall our website be based on neural tube defects? (:&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 08:12, 9 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey girls,&lt;br /&gt;
&lt;br /&gt;
So I've done a bit of research on a few of them. &lt;br /&gt;
One of the things we need to keep in mind is that it has to relate to the '''learning outcomes''', which I think is the embryological process, and how the genetic disorder relates to it or how its affected by it? (I tried looking it up but couldnt find it).&lt;br /&gt;
&lt;br /&gt;
Here's a list of the topics I've been looking into:&lt;br /&gt;
&lt;br /&gt;
[[Turner Syndrome:]] commonly known to have one missing sex chromosome, (or both) - LOTS of info on this. (only thing is, because its such a broad topic, we might have articles that contradict each other, or might not have that many embryology related new articles...?)&lt;br /&gt;
&lt;br /&gt;
[[Klinefelter's Syndrome:]] the gigantic disease with the extra chromosome (XXY). there's a decent amount of info on this, but not as much as Turner.&lt;br /&gt;
&lt;br /&gt;
[[Neural Tube defects:]] problems happening in the first month of baby formation because of the folate deficiency in the mother. But i'm not too sure where the genetics come into this..&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Which topics have you guys been looking at? Let us know! cos we need to have some articles in '''[[2-3days time!]]''' :)&lt;br /&gt;
&lt;br /&gt;
Ye it's better to research an area instead of just one disease then, because that will give us more to talk about... especially the genetic components which Mark commented on. So I was thinking Neural Tube Defects instead. That will give us Anencephaly, Encephaloceles, Hydranencephaly, Iniencephaly and Spina bifida.  ?--[[User:Z3290270|Maeda Sadeghpour]] 01:09, 8 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
You need to think about what the genetic component will be for the disease you select. --[[User:S8600021|Mark Hill]] 23:51, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
I don't think that having 4 categories will be a problem. I actually think that it will be good to have extra stuff to talk about. Have a look at the other pages from previous years, they are very elaborated so I think it's actually a good thing to have alot of things to talk about. But anyway lets decide on something so that we can post up our articles&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 22:00, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey! I get what you mean, Maeda. Doing 4 categories can be quite heavy. Hmm, but I was thinking, since this is going to be a wikipage and the elaboration for the 'original' wikipage for spina bifida is not very deep for the 4 categories, maybe we could leverage on this weakness and make ours more detailed? :) But if you guys think it is too much, I don't mind doing the other suggestions too! Anyway, this is just a preliminary decision. It depends on the topics that other groups have chosen too. Would it be possible for us to finalise the topic by tomorrow?&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 17:18, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hello people. I was basically trying to see which diseases had the most current information available online, and cystic fibrosis seems to be very well known. Spina Bifida is very interesting as well, my only concern with it is the 4 categories it's divided into, which I thought might make it a bit more work. What do you guys think? :) &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 00:25, 6 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey, girls! I'm thinking of spina bifida and hydrocephalus. Cheers!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 20:26, 5 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
hey guys, had a quick look and Spina bifida and Turner's Syndrome both seem to have a decent amount of information on them &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 14:26, 5 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Peer Assessments==&lt;br /&gt;
* Interesting but good use of a quote&lt;br /&gt;
* The introductory paragraph for the “history” section could probably be cut down or eliminated altogether &lt;br /&gt;
* Great inclusion of statistics in regards to epidemiology &lt;br /&gt;
* Student images were excellent, well drawn and were engaging&lt;br /&gt;
* Pathogenesis section could have been placed in a table just to change up the formatting &lt;br /&gt;
* The video inclusion was good and relevant &lt;br /&gt;
* You’re referencing needs to be tidied up; there are multiple entries from the same source that tends to clutter your reference section.  &lt;br /&gt;
--[[User:Z3332629|z3332629]] 15:24, 22 September 2011 (EST)&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75578</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75578"/>
		<updated>2011-10-06T00:51:02Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
[[Image:George Huntington.jpg|thumb|right|George Huntington]]. &lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1983'''&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1:''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2:''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|left|300px|Inheritance pattern in Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Huntington's disease is an autosomal-dominant disorder caused by a faulty gene on the 4th autosomal chromosome (meaning it’s found on one of the first 22 pairs of chromosomes).  Since it is not expressed on the last two sex chromosomes, it can equally affect both males and females. &lt;br /&gt;
&lt;br /&gt;
An affected parent is capable of passing either the HD gene or the healthy gene to their offspring. Due to its autosomal dominant nature, if the individual has a HD gene it will ‘overpower’ the healthy gene and the offspring will become affected by HD.  Hence, with each pregnancy, the child is at 50% chance of inheriting HD if one parent is affected.&lt;br /&gt;
In rare cases where both parents are affected, the child will have a 75% chance of inheriting HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
[[File:Huntingtin gene.jpeg|thumb|400px|Huntingtin gene]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times. This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Destruction of Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN) are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output from the afferant neurons pf thalamus and the cortex, making striatal cells highly sensitive to glutamate. Even though striatal cells depend on glutamate for function and survival, glutamate in excessive amounts found in autoptic human brain tissues of HD patients is shown to an an excitotoxin. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interaction===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Additionally, mutant HTT protein is also able to bind to the inositol 1,4,5- triphosphate receptor 1 (InsP3R1) on the endoplasmic reticulum and stimulate the inositol triphosphate (IP3) signalling pathway. The activation of the IP3 pathway leads to elevated calcium release from InsP3R1 of cells containing mutant HTT.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15336977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Over time, this increase in cystolic calcium levels causes the mitochondrial calciumm intake to also increase, which eventually leads to mitochondrial swelling and the subsequent release of proapoptotic factors such as cytochrome ''c'' and apoptosis-inducing factor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18193642&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region of the DNA strand. Several of the transcription factors such as CBP contain glutamine as part of their integral structure, which is able to interact with the polyglutamine chain on the mutant HTT protein and aggregate; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|150px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|250px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|150px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|150px|Current is needed to help symptoms due to the atrophy|thumb]] [[File:Huntington disease atrophy 3.jpg|left|150px|Future research is needed in hope to one day find a cure for this fatal disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75576</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75576"/>
		<updated>2011-10-06T00:48:37Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Genetic testing and prenatal diagnosis */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
[[Image:George Huntington.jpg|thumb|right|George Huntington]]. &lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1983'''&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1:''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2:''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|left|300px|Inheritance pattern in Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Huntington's disease is an autosomal-dominant disorder caused by a faulty gene on the 4th autosomal chromosome (meaning it’s found on one of the first 22 pairs of chromosomes).  Since it is not expressed on the last two sex chromosomes, it can equally affect both males and females. &lt;br /&gt;
&lt;br /&gt;
An affected parent is capable of passing either the HD gene or the healthy gene to their offspring. Due to its autosomal dominant nature, if the individual has a HD gene it will ‘overpower’ the healthy gene and the offspring will become affected by HD.  Hence, with each pregnancy, the child is at 50% chance of inheriting HD if one parent is affected.&lt;br /&gt;
In rare cases where both parents are affected, the child will have a 75% chance of inheriting HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
[[File:Huntingtin gene.jpeg|thumb|400px|Huntingtin gene]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times. This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Destruction of Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN) are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output from the afferant neurons pf thalamus and the cortex, making striatal cells highly sensitive to glutamate. Even though striatal cells depend on glutamate for function and survival, glutamate in excessive amounts found in autoptic human brain tissues of HD patients is shown to an an excitotoxin. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interaction===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Additionally, mutant HTT protein is also able to bind to the inositol 1,4,5- triphosphate receptor 1 (InsP3R1) on the endoplasmic reticulum and stimulate the inositol triphosphate (IP3) signalling pathway. The activation of the IP3 pathway leads to elevated calcium release from InsP3R1 of cells containing mutant HTT.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15336977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Over time, this increase in cystolic calcium levels causes the mitochondrial calciumm intake to also increase, which eventually leads to mitochondrial swelling and the subsequent release of proapoptotic factors such as cytochrome ''c'' and apoptosis-inducing factor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18193642&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region of the DNA strand. Several of the transcription factors such as CBP contain glutamine as part of their integral structure, which is able to interact with the polyglutamine chain on the mutant HTT protein and aggregate; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|150px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|250px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|150px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|150px|Current is needed to help symptoms due to the atrophy|thumb]] [[File:Huntington disease atrophy 3.jpg|left|150px|Future research is needed in hope to one day find a cure for this fatal disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75573</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75573"/>
		<updated>2011-10-06T00:46:16Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
[[Image:George Huntington.jpg|thumb|right|George Huntington]]. &lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1983'''&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1:''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2:''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|left|300px|Inheritance pattern in Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Huntington's disease is an autosomal-dominant disorder caused by a faulty gene on the 4th autosomal chromosome (meaning it’s found on one of the first 22 pairs of chromosomes).  Since it is not expressed on the last two sex chromosomes, it can equally affect both males and females. &lt;br /&gt;
&lt;br /&gt;
An affected parent is capable of passing either the HD gene or the healthy gene to their offspring. Due to its autosomal dominant nature, if the individual has a HD gene it will ‘overpower’ the healthy gene and the offspring will become affected by HD.  Hence, with each pregnancy, the child is at 50% chance of inheriting HD if one parent is affected.&lt;br /&gt;
In rare cases where both parents are affected, the child will have a 75% chance of inheriting HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
[[File:Huntingtin gene.jpeg|thumb|400px|Huntingtin gene]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times. This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Destruction of Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN) are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output from the afferant neurons pf thalamus and the cortex, making striatal cells highly sensitive to glutamate. Even though striatal cells depend on glutamate for function and survival, glutamate in excessive amounts found in autoptic human brain tissues of HD patients is shown to an an excitotoxin. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interaction===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Additionally, mutant HTT protein is also able to bind to the inositol 1,4,5- triphosphate receptor 1 (InsP3R1) on the endoplasmic reticulum and stimulate the inositol triphosphate (IP3) signalling pathway. The activation of the IP3 pathway leads to elevated calcium release from InsP3R1 of cells containing mutant HTT.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15336977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Over time, this increase in cystolic calcium levels causes the mitochondrial calciumm intake to also increase, which eventually leads to mitochondrial swelling and the subsequent release of proapoptotic factors such as cytochrome ''c'' and apoptosis-inducing factor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18193642&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region of the DNA strand. Several of the transcription factors such as CBP contain glutamine as part of their integral structure, which is able to interact with the polyglutamine chain on the mutant HTT protein and aggregate; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|150px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|150px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|150px|Current is needed to help symptoms due to the atrophy|thumb]] [[File:Huntington disease atrophy 3.jpg|left|150px|Future research is needed in hope to one day find a cure for this fatal disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75571</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75571"/>
		<updated>2011-10-06T00:44:30Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
[[Image:George Huntington.jpg|thumb|right|George Huntington]]. &lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1983'''&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1:''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2:''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|left|300px|Inheritance pattern in Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Huntington's disease is an autosomal-dominant disorder caused by a faulty gene on the 4th autosomal chromosome (meaning it’s found on one of the first 22 pairs of chromosomes).  Since it is not expressed on the last two sex chromosomes, it can equally affect both males and females. &lt;br /&gt;
&lt;br /&gt;
An affected parent is capable of passing either the HD gene or the healthy gene to their offspring. Due to its autosomal dominant nature, if the individual has a HD gene it will ‘overpower’ the healthy gene and the offspring will become affected by HD.  Hence, with each pregnancy, the child is at 50% chance of inheriting HD if one parent is affected.&lt;br /&gt;
In rare cases where both parents are affected, the child will have a 75% chance of inheriting HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
[[File:Huntingtin gene.jpeg|thumb|400px|Huntingtin gene]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times. This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Destruction of Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN) are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output from the afferant neurons pf thalamus and the cortex, making striatal cells highly sensitive to glutamate. Even though striatal cells depend on glutamate for function and survival, glutamate in excessive amounts found in autoptic human brain tissues of HD patients is shown to an an excitotoxin. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interaction===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Additionally, mutant HTT protein is also able to bind to the inositol 1,4,5- triphosphate receptor 1 (InsP3R1) on the endoplasmic reticulum and stimulate the inositol triphosphate (IP3) signalling pathway. The activation of the IP3 pathway leads to elevated calcium release from InsP3R1 of cells containing mutant HTT.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15336977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Over time, this increase in cystolic calcium levels causes the mitochondrial calciumm intake to also increase, which eventually leads to mitochondrial swelling and the subsequent release of proapoptotic factors such as cytochrome ''c'' and apoptosis-inducing factor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18193642&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region of the DNA strand. Several of the transcription factors such as CBP contain glutamine as part of their integral structure, which is able to interact with the polyglutamine chain on the mutant HTT protein and aggregate; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|150px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|150px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|150px|Current is needed to help symptoms due to the atrophy|thumb]] [[File:Huntington disease atrophy 3.jpg|left|150px|Future research is needed in hope to one day find a cure for this fatal disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75563</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75563"/>
		<updated>2011-10-06T00:40:51Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
[[Image:George Huntington.jpg|thumb|right|George Huntington]]. &lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1983'''&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1:''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2:''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|left|300px|Inheritance pattern in Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Huntington's disease is an autosomal-dominant disorder caused by a faulty gene on the 4th autosomal chromosome (meaning it’s found on one of the first 22 pairs of chromosomes).  Since it is not expressed on the last two sex chromosomes, it can equally affect both males and females. &lt;br /&gt;
&lt;br /&gt;
An affected parent is capable of passing either the HD gene or the healthy gene to their offspring. Due to its autosomal dominant nature, if the individual has a HD gene it will ‘overpower’ the healthy gene and the offspring will become affected by HD.  Hence, with each pregnancy, the child is at 50% chance of inheriting HD if one parent is affected.&lt;br /&gt;
In rare cases where both parents are affected, the child will have a 75% chance of inheriting HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
[[File:Huntingtin gene.jpeg|thumb|400px|Huntingtin gene]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times. This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Destruction of Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN) are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output from the afferant neurons pf thalamus and the cortex, making striatal cells highly sensitive to glutamate. Even though striatal cells depend on glutamate for function and survival, glutamate in excessive amounts found in autoptic human brain tissues of HD patients is shown to an an excitotoxin. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interaction===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Additionally, mutant HTT protein is also able to bind to the inositol 1,4,5- triphosphate receptor 1 (InsP3R1) on the endoplasmic reticulum and stimulate the inositol triphosphate (IP3) signalling pathway. The activation of the IP3 pathway leads to elevated calcium release from InsP3R1 of cells containing mutant HTT.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15336977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Over time, this increase in cystolic calcium levels causes the mitochondrial calciumm intake to also increase, which eventually leads to mitochondrial swelling and the subsequent release of proapoptotic factors such as cytochrome ''c'' and apoptosis-inducing factor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18193642&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region of the DNA strand. Several of the transcription factors such as CBP contain glutamine as part of their integral structure, which is able to interact with the polyglutamine chain on the mutant HTT protein and aggregate; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|150px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|150px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|150px|Current is needed to help symptoms due to the atrophy|thumb]] [[File:Huntington disease atrophy 3.jpg|left|150px|Future research is needed in hope to one day find a cure for this fatal disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75553</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75553"/>
		<updated>2011-10-06T00:36:31Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Current/Future Research */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
[[Image:George Huntington.jpg|thumb|right|George Huntington]]. &lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1983'''&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1:''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2:''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|left|300px|Inheritance pattern in Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Huntington's disease is an autosomal-dominant disorder caused by a faulty gene on the 4th autosomal chromosome (meaning it’s found on one of the first 22 pairs of chromosomes).  Since it is not expressed on the last two sex chromosomes, it can equally affect both males and females. &lt;br /&gt;
&lt;br /&gt;
An affected parent is capable of passing either the HD gene or the healthy gene to their offspring. Due to its autosomal dominant nature, if the individual has a HD gene it will ‘overpower’ the healthy gene and the offspring will become affected by HD.  Hence, with each pregnancy, the child is at 50% chance of inheriting HD if one parent is affected.&lt;br /&gt;
In rare cases where both parents are affected, the child will have a 75% chance of inheriting HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
[[File:Huntingtin gene.jpeg|thumb|400px|Huntingtin gene]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times. This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Destruction of Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN) are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output from the afferant neurons pf thalamus and the cortex, making striatal cells highly sensitive to glutamate. Even though striatal cells depend on glutamate for function and survival, glutamate in excessive amounts found in autoptic human brain tissues of HD patients is shown to an an excitotoxin. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interaction===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Additionally, mutant HTT protein is also able to bind to the inositol 1,4,5- triphosphate receptor 1 (InsP3R1) on the endoplasmic reticulum and stimulate the inositol triphosphate (IP3) signalling pathway. The activation of the IP3 pathway leads to elevated calcium release from InsP3R1 of cells containing mutant HTT.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15336977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Over time, this increase in cystolic calcium levels causes the mitochondrial calciumm intake to also increase, which eventually leads to mitochondrial swelling and the subsequent release of proapoptotic factors such as cytochrome ''c'' and apoptosis-inducing factor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18193642&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region of the DNA strand. Several of the transcription factors such as CBP contain glutamine as part of their integral structure, which is able to interact with the polyglutamine chain on the mutant HTT protein and aggregate; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|150px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|150px|Current is needed to help symptoms due to the atrophy|thumb]] [[File:Huntington disease atrophy 3.jpg|left|150px|Future research is needed in hope to one day find a cure for this fatal disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75547</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75547"/>
		<updated>2011-10-06T00:34:18Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Current/Future Research */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
[[Image:George Huntington.jpg|thumb|right|George Huntington]]. &lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1983'''&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1:''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2:''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|left|300px|Inheritance pattern in Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Huntington's disease is an autosomal-dominant disorder caused by a faulty gene on the 4th autosomal chromosome (meaning it’s found on one of the first 22 pairs of chromosomes).  Since it is not expressed on the last two sex chromosomes, it can equally affect both males and females. &lt;br /&gt;
&lt;br /&gt;
An affected parent is capable of passing either the HD gene or the healthy gene to their offspring. Due to its autosomal dominant nature, if the individual has a HD gene it will ‘overpower’ the healthy gene and the offspring will become affected by HD.  Hence, with each pregnancy, the child is at 50% chance of inheriting HD if one parent is affected.&lt;br /&gt;
In rare cases where both parents are affected, the child will have a 75% chance of inheriting HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
[[File:Huntingtin gene.jpeg|thumb|400px|Huntingtin gene]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times. This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Destruction of Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN) are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output from the afferant neurons pf thalamus and the cortex, making striatal cells highly sensitive to glutamate. Even though striatal cells depend on glutamate for function and survival, glutamate in excessive amounts found in autoptic human brain tissues of HD patients is shown to an an excitotoxin. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interaction===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Additionally, mutant HTT protein is also able to bind to the inositol 1,4,5- triphosphate receptor 1 (InsP3R1) on the endoplasmic reticulum and stimulate the inositol triphosphate (IP3) signalling pathway. The activation of the IP3 pathway leads to elevated calcium release from InsP3R1 of cells containing mutant HTT.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15336977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Over time, this increase in cystolic calcium levels causes the mitochondrial calciumm intake to also increase, which eventually leads to mitochondrial swelling and the subsequent release of proapoptotic factors such as cytochrome ''c'' and apoptosis-inducing factor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18193642&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region of the DNA strand. Several of the transcription factors such as CBP contain glutamine as part of their integral structure, which is able to interact with the polyglutamine chain on the mutant HTT protein and aggregate; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Current is needed to help symptoms due to the atrophy|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Future research is needed in hope to one day find a cure for this fatal disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75543</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75543"/>
		<updated>2011-10-06T00:31:25Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Current/Future Research */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
[[Image:George Huntington.jpg|thumb|right|George Huntington]]. &lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1983'''&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1:''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2:''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|left|300px|Inheritance pattern in Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Huntington's disease is an autosomal-dominant disorder caused by a faulty gene on the 4th autosomal chromosome (meaning it’s found on one of the first 22 pairs of chromosomes).  Since it is not expressed on the last two sex chromosomes, it can equally affect both males and females. &lt;br /&gt;
&lt;br /&gt;
An affected parent is capable of passing either the HD gene or the healthy gene to their offspring. Due to its autosomal dominant nature, if the individual has a HD gene it will ‘overpower’ the healthy gene and the offspring will become affected by HD.  Hence, with each pregnancy, the child is at 50% chance of inheriting HD if one parent is affected.&lt;br /&gt;
In rare cases where both parents are affected, the child will have a 75% chance of inheriting HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
[[File:Huntingtin gene.jpeg|thumb|400px|Huntingtin gene]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times. This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Destruction of Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN) are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output from the afferant neurons pf thalamus and the cortex, making striatal cells highly sensitive to glutamate. Even though striatal cells depend on glutamate for function and survival, glutamate in excessive amounts found in autoptic human brain tissues of HD patients is shown to an an excitotoxin. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interaction===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Additionally, mutant HTT protein is also able to bind to the inositol 1,4,5- triphosphate receptor 1 (InsP3R1) on the endoplasmic reticulum and stimulate the inositol triphosphate (IP3) signalling pathway. The activation of the IP3 pathway leads to elevated calcium release from InsP3R1 of cells containing mutant HTT.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15336977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Over time, this increase in cystolic calcium levels causes the mitochondrial calciumm intake to also increase, which eventually leads to mitochondrial swelling and the subsequent release of proapoptotic factors such as cytochrome ''c'' and apoptosis-inducing factor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18193642&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region of the DNA strand. Several of the transcription factors such as CBP contain glutamine as part of their integral structure, which is able to interact with the polyglutamine chain on the mutant HTT protein and aggregate; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Current is needed to help symptoms due to the atrophy|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Future research is needed in hope to one day find a cure for this fatal disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75499</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=75499"/>
		<updated>2011-10-06T00:16:18Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Current/Future Research */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
[[Image:George Huntington.jpg|thumb|right|George Huntington]]. &lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1983'''&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1:''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2:''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|left|300px|Inheritance pattern in Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Huntington's disease is an autosomal-dominant disorder caused by a faulty gene on the 4th autosomal chromosome (meaning it’s found on one of the first 22 pairs of chromosomes).  Since it is not expressed on the last two sex chromosomes, it can equally affect both males and females. &lt;br /&gt;
&lt;br /&gt;
An affected parent is capable of passing either the HD gene or the healthy gene to their offspring. Due to its autosomal dominant nature, if the individual has a HD gene it will ‘overpower’ the healthy gene and the offspring will become affected by HD.  Hence, with each pregnancy, the child is at 50% chance of inheriting HD if one parent is affected.&lt;br /&gt;
In rare cases where both parents are affected, the child will have a 75% chance of inheriting HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
[[File:Huntingtin gene.jpeg|thumb|400px|Huntingtin gene]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times. This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Destruction of Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN) are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output from the afferant neurons pf thalamus and the cortex, making striatal cells highly sensitive to glutamate. Even though striatal cells depend on glutamate for function and survival, glutamate in excessive amounts found in autoptic human brain tissues of HD patients is shown to an an excitotoxin. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interaction===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Additionally, mutant HTT protein is also able to bind to the inositol 1,4,5- triphosphate receptor 1 (InsP3R1) on the endoplasmic reticulum and stimulate the inositol triphosphate (IP3) signalling pathway. The activation of the IP3 pathway leads to elevated calcium release from InsP3R1 of cells containing mutant HTT.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15336977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Over time, this increase in cystolic calcium levels causes the mitochondrial calciumm intake to also increase, which eventually leads to mitochondrial swelling and the subsequent release of proapoptotic factors such as cytochrome ''c'' and apoptosis-inducing factor.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18193642&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region of the DNA strand. Several of the transcription factors such as CBP contain glutamine as part of their integral structure, which is able to interact with the polyglutamine chain on the mutant HTT protein and aggregate; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=75481</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=75481"/>
		<updated>2011-10-06T00:11:33Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Lab Attendance */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:11, 6 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74443</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74443"/>
		<updated>2011-10-03T05:08:15Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|1983&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN)are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum.Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic , therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74442</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74442"/>
		<updated>2011-10-03T05:02:50Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|1983&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN)are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum.Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic , therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74440</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74440"/>
		<updated>2011-10-03T05:01:00Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|1983&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN)are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum.Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic , therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74439</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74439"/>
		<updated>2011-10-03T04:57:05Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|1983&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN)are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum.Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic , therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74437</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=74437"/>
		<updated>2011-10-03T04:55:02Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level.&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; HD was originally known as chorea before great detail of the disease was found, and in 1872, physician George Huntington first documented the clinical profile of the disease and HD was named after him.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;&amp;gt;H L Paulson, R L Albin '''Huntington’s Disease: Clinical Features and Routes to Therapy.''' In: D C Lo, R E Hughes (editors). Neurobiology of Huntington's Disease: Applications to Drug Discovery (2nd ed.), Boca Raton (FL): CRC Press; 2011. Chapter 1. Frontiers in Neuroscience. PMID:21882418[http://www.ncbi.nlm.nih.gov/pubmed/21882418]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:50px&amp;quot;|'''Year''' &lt;br /&gt;
|'''Milestones'''&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1842'''&lt;br /&gt;
| Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1846''' &lt;br /&gt;
| Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1860''' &lt;br /&gt;
| Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5.&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1872''' &lt;br /&gt;
| George Huntington’s paper was published.&amp;lt;ref name=&amp;quot;PMID11232352&amp;quot;/&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1888''' &lt;br /&gt;
| Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1900'''&lt;br /&gt;
| Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1908''' &lt;br /&gt;
| Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1978''' &lt;br /&gt;
| Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1981''' &lt;br /&gt;
| The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|1983&lt;br /&gt;
| The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1989''' &lt;br /&gt;
| Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1993'''&lt;br /&gt;
| The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1994''' &lt;br /&gt;
| The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1996'''&lt;br /&gt;
| The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''1997''' &lt;br /&gt;
| Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2000'''&lt;br /&gt;
| An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- &lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2001''' &lt;br /&gt;
| The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|'''2002'''&lt;br /&gt;
| The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania (Australia) &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
{| align=&amp;quot;center&amp;quot;&lt;br /&gt;
|'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref name=&amp;quot;PMID19249009&amp;quot;/&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref name=&amp;quot;PMID20881427&amp;quot;/&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref name=&amp;quot;PMID7562964&amp;quot;/&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15100720&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref name=&amp;quot;MM&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;20664076&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21601164&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers.&amp;lt;ref name=&amp;quot;Patho&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17999380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10665265&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as medium-sized spiny neurons (MSN)are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells.&amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum.Hence the accumulation of long polyglutamine chains in the striatum of a patient affected with HD, is strongly linked to the degeneration of MSN which will disturb it’s key functions. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). '''Molecular Pathogenesis of Huntington's Disease'''. ''Advances in Clinical Neuroscience and Rehabilitation,'' 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, interactions between these tissues are altered. &lt;br /&gt;
HTT is known to react with HTT-associated protein1 (HAP1) and HTT-interacting protein 1 (HIP1).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18466116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
In HD, the polyglutamine chain on the mutant HTT increases the binding capacity for HAP1 and therefore reduces its availability in neural tissue. HAP1 is involved in regulating the stabilisation of membrane receptors on the cell surface that are involved in neural response to neurotransmitters and neutrophic factors.  &amp;lt;ref&amp;gt;&amp;lt;Pubmed&amp;gt;19262167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
HTT protein interaction with HIP1 is however decreased with lengthening polyglutamine chains. An over-expression of HIP1 is known to be neurotoxic , therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18637945&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref name=&amp;quot;HD Modelling&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation.&amp;lt;ref name=&amp;quot;MM&amp;quot;/&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However proteosome efficiency is highly reduced in HD patients, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10770929&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11331615&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription.&amp;lt;ref name=&amp;quot;Patho&amp;quot;/&amp;gt; &lt;br /&gt;
Transcription factors such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12087131&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11408619&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;PMID15459747&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea.&amp;lt;ref name=&amp;quot;Clinical&amp;quot;/&amp;gt; The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42.&amp;lt;ref name=&amp;quot;PMID6451036&amp;quot;/&amp;gt; The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:150px&amp;quot;|'''Disease''' ||'''Characteristics'''&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; &lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496582&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|align=&amp;quot;center&amp;quot;| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus.&amp;lt;ref name=&amp;quot;PMID21496571&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss.&amp;lt;ref name=&amp;quot;PMID2932539&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)'''.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref name=&amp;quot;PMID17240289&amp;quot;/&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt; The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills.&amp;lt;ref name=&amp;quot;PMID8929153&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task.&amp;lt;ref name=&amp;quot;PMID16496032&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref name=&amp;quot;PMID6316146&amp;quot;/&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref name=&amp;quot;PMID19588393&amp;quot;/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  &lt;br /&gt;
&lt;br /&gt;
There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===='''Other drugs'''====&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|'''Types of symptoms''' &lt;br /&gt;
|'''Types of medications'''&lt;br /&gt;
|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref name=&amp;quot;PMID19832967&amp;quot;/&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' One part of a pair of genes.&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease.&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' A disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' A disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' Of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images.&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:''' A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter.&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' Diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' This type of disorders are characterised by excessive abnormal involuntary movements. Movements may be irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes.&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' A medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' Inability to sustain simple voluntary muscular actions such as keeping the eyes closed.&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' A nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' A nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' Pertains to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:HD_patients.jpg&amp;diff=74072</id>
		<title>File:HD patients.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:HD_patients.jpg&amp;diff=74072"/>
		<updated>2011-10-01T13:57:03Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Reference */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Fig 1. Phenotypically identical twins (A) and skull computed tomography showing head of caudate nucleus atrophy (B and C)&lt;br /&gt;
&lt;br /&gt;
Patients were female, 24 years-old when first examined, and phenotypically identical (Fig 1A). The onset of their disease, as reported by relatives, was at 17 and 20 years of age, the initial manifestations being balance and gait impairment with a progressive course. Neurologic examination showed bradykinesia, rigidity with cogwheel phenomenon, choreic movements of trunk and limbs (mild degree), dysarthria, hyperactive tendon reflexes and flexor plantar responses. The patient with earlier onset of the disease was more severely affected. Neurologic examination was repeated approximately six months and one year after the initial examination, and both patients worsened on each successive examination. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10751926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Reference==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License &lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_4&amp;diff=73989</id>
		<title>Talk:2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_4&amp;diff=73989"/>
		<updated>2011-10-01T07:10:45Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Discussion */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[2011_Group_Project_4|'''Group 4''']]: [[User:z3389806]] | [[User:z3290270]] | [[User:z3290379]] | [[User:z3290558]]&lt;br /&gt;
&lt;br /&gt;
{{2011GroupDiscussionMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Page Edits 30 Sep'''&lt;br /&gt;
&amp;lt;gallery&amp;gt;&lt;br /&gt;
File:2011_Project_Group_4_edits.jpg|Project Page&lt;br /&gt;
File:2011_Project_Group_1-11_edits.jpg|All Groups (1-11) Project&lt;br /&gt;
File:2011_Talk_Group_4_edits.jpg|Discussion Page&lt;br /&gt;
File:2011 Talk Group 1-11 edits.jpg|All Groups (1-11) Discussion&lt;br /&gt;
&amp;lt;/gallery&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Peer Review==&lt;br /&gt;
&lt;br /&gt;
Group 4: &lt;br /&gt;
Truly amazing work on this page. The balance between the images and text is phenomenal. It seems quite simple but easy to read well referenced. &lt;br /&gt;
I like how you used tables to illustrate the epidemiology &lt;br /&gt;
Nicely drawn images in Genetics Section. &lt;br /&gt;
I really don’t see many things wrong with the page… It is well done.. the tables and images all speak up for the quality of the page. However, pay closer attention to the references because some of them are repeated or empty when you look at the list. &lt;br /&gt;
Great work. &lt;br /&gt;
--[[User:Z3284061|z3284061]] 11:55, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
* Overall the project is good&lt;br /&gt;
* An image could be good in the introduction&lt;br /&gt;
* History and Timeline are good&lt;br /&gt;
* In the History section it might be useful to have the years in bold&lt;br /&gt;
* Well researched&lt;br /&gt;
* Image for &amp;quot;Role in Transciption inhibition&amp;quot; needs to be fixed&lt;br /&gt;
* Good table in treatment&lt;br /&gt;
* Image in Pathogenesis needs copyright info&lt;br /&gt;
* Good use of text/tables/images&lt;br /&gt;
--[[User:Z3292953|z3292953]] 11:10, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''''Huntington’s Disease (Group 4) Peer Review:'''''&lt;br /&gt;
&lt;br /&gt;
Introduction: Good content. Possibly include a picture to get the reader interested from the beginning. &lt;br /&gt;
&lt;br /&gt;
History: Great section! Many references which shows you have done your research. Possibly make the dates bold so that they stand out more. Good use of quote. Image needs to be referenced properly and lacks a student template. &lt;br /&gt;
&lt;br /&gt;
Epidemiology: Extensive! Great use of tables and explanation of the tables! Well done. &lt;br /&gt;
&lt;br /&gt;
Genetics: Great detail in this section. Images are well drawn and relevant to the information. Remember to include a student template in these images. &lt;br /&gt;
&lt;br /&gt;
Molecular Mechanisms and Pathogenesis: Great use of subheadings to organize the text. Image is good, just try to format the reference better and once again, include the student template. &lt;br /&gt;
&lt;br /&gt;
Clinical Manifestations: Image is slightly too small as a thumbnail. Good information, however, I think this section would benefit with a table to help better organize the information.&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests: Very extensive section. Good use of images, however maybe their placement needs to be more thought out. Also, delete the subheading for the video as this is irrelevant. Great use of video- stimulates the viewer! &lt;br /&gt;
&lt;br /&gt;
Treatment: Table is very extensive and well done. This section is impressive! Images need to have a student template and correct referencing. &lt;br /&gt;
&lt;br /&gt;
Current/ Future Research: Good information in this section. Image on right needs a label at the bottom. &lt;br /&gt;
&lt;br /&gt;
Glossary: Heading needs to be to the left – it is slightly distorted by the image above it. &lt;br /&gt;
Extensive glossary. &lt;br /&gt;
&lt;br /&gt;
References: Well done, a lot of research has been done. &lt;br /&gt;
&lt;br /&gt;
Overall, impressive page! --[[User:Z3290808|z3290808]] 10:43, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Huntingtons – Group 4&lt;br /&gt;
&lt;br /&gt;
*	This page looks very good and highly detailed. Some of the images do not have correct referencing information and could also contain a little more of a description. &lt;br /&gt;
*	Excellent use of referencing. This seems highly detailed and looks like a lot of work has been done to get the page to this standard. &lt;br /&gt;
*	Some formatting issues such as the image in future research and in diagnostic tests headings. &lt;br /&gt;
*	Video of Huntington’s patient doesn’t need such a big heading, ruins the flow of the page in my opinion. &lt;br /&gt;
*	Timeline could give a bit more information, and the importance of these events explained better. &lt;br /&gt;
*	Overall was very good work of a high standard&lt;br /&gt;
--[[User:Z3288196|Z3288196]] 10:41, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 4:&lt;br /&gt;
&lt;br /&gt;
Glossary and reference take up half the page because the glossary has terms which should probably be explained in the text instead of being an item in the glossary. The references section should also be checked, for example 56, 57,60, 69 all reference Zuccato, C, 2009. There is an excessive amount of references. Not every sentence needs to be referenced. &lt;br /&gt;
&lt;br /&gt;
Title “video of Huntington’s disease patient” should probably go as a subheading not a heading coz then all of the information that should be refering to diagnostic test becomes a subheading of the video. But its a good idea to have the links to videos for extra information.&lt;br /&gt;
&lt;br /&gt;
Apart from that, good assignment. Good use of pictures and written text. And tables.&lt;br /&gt;
&lt;br /&gt;
z3332178 =]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Peer review:&lt;br /&gt;
&lt;br /&gt;
*intro is a bit wordy e.g polyglutamate&lt;br /&gt;
*history: indent the quotes, maybe italcis too. timeline can be bolded to make it more readable.&lt;br /&gt;
*epidemiology: could have verbose words simplified and explained (the ones that are not in the glossary)&lt;br /&gt;
*genetics could have a picture about where the gene is located abnd also be simplified into tables. &lt;br /&gt;
*the picture in pathogenesis could have alot less writing or have it simplified, spaced and bolded.&lt;br /&gt;
*clinical manifestations is well written and succinct&lt;br /&gt;
*picture in diagnosis could be explained better so we can see the link to HD&lt;br /&gt;
*expand glossary and recheck the references&lt;br /&gt;
--[[User:Z3291423|Jasjit Walia]] 10:14, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4 peer review'''&lt;br /&gt;
&lt;br /&gt;
History: I love the idea of the quote. Is 'On Chorea' a book, article or report? Clarifying this would be nice.&lt;br /&gt;
&lt;br /&gt;
Epidemiology: I like how you have elaborate on table one. I found the paragraph on Warby et al paper hard to understand. I think it may become easier to understand if you linked terminologies (like HTT and Halotypes) to the glossary, even if a particular terminology has been linked before in other sections because some readers might be just reading your section.&lt;br /&gt;
&lt;br /&gt;
Clinical manifestations: It was an interesting read. :) But one suggestion ( this is what I got suggested for my section and I thought it was a good idea) is to enlarge the image so that the writing can be seen clearly. I understand that you may think that readers can click on it and see the enlarged picture but some readers may not be bothered and would prefer being able to read it on the main page. Plus, you have unlimited space and with a large image the webpage may look more interesting.&lt;br /&gt;
&lt;br /&gt;
Treatment: In the clinical manifestation, the symptoms are divided into three classes: motor, cognitive and behaviour. It may be more consistant if you reorganise the classes of medication so that it falls into the three classes described in clinical manifestation. I know, this may sound like a huge task, if so, why don't you just ask the clinical manifestation person to change their classes to two, motor and psychiatric.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289301|z3289301]] 09:44, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Peer Assessment'''&lt;br /&gt;
*Good introduction: concise and easy to understand. It might be a good idea to hyperlink some words in this section with the glossary. &lt;br /&gt;
*History and time line; well written and researched. I really like how you inserted one the original quotes in the text. I suggest you putting the timeline into a table so it looks better. &lt;br /&gt;
*Epidemiology; Good use of tables to summarize the figures/numbers. The placement of the tables between paragraphs also break up the text nicely. &lt;br /&gt;
*I strongly suggest hyperlinking words to the glossary. Makes the page more user friendly.&lt;br /&gt;
*Small typo in &amp;quot;Hungtingtin&amp;quot; title in the genetics section, but that's just a minor fix up. The section was well written. Good us of student drawn images to explain the concepts. I like how the genetics was sub-sectioned into the normal and diseased parts, makes it easier to understand.  &lt;br /&gt;
*Other sections were also well done. Maybe include a table in the 'clinical manifestations' section. Also I'm not sure if this is beyond the scope of the course but have they been able to link the five specific features of this disease to specific genetic abnormalities or pathways that happens due to this disease? What causes these features? (This is just out of my curiosity). &lt;br /&gt;
*Maybe it would look neater if the &amp;quot;imaging&amp;quot; heading was also placed on the most left hand side of the page so it aligns with other headings such as 'neuropathy'. It seems a bit messy atm. Same goes for genetic testing and prenatal diagnosis. &lt;br /&gt;
*Excellent table in the treatment section. Is there a specific reason only the actions of 'Tetrabenazine' was explained below the table? if so, what are the reasons?&lt;br /&gt;
*Overall, good job :)&lt;br /&gt;
--[[User:Z3291622|z3291622]] 09:19, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Peer evaluation'''&lt;br /&gt;
&lt;br /&gt;
*The introduction is very informative and actually introduced most of the subheadings that will be discussed in the page. The downfall of this introduction is the failure to introduce all of the sections of and proof-reading this section it is fine. &lt;br /&gt;
*The history of the disease is very well-done. The quick description or beginning of the history combined with the timeline is utilised well. Only improvement that would make it better is making the dates stand out by putting it I bold or something. &lt;br /&gt;
*I can find no fault in the epidemiology. It is the best one I have seen so far. You have described the demography of the disease and the statistics of other mutations. The tables were used appropriately as well, and the fact that it was described straight after the table is perfect. &lt;br /&gt;
*I like the genetics section of the page. It made sense and easy to understand. The diagrams are all relevant to the page section. Only criticism I can say is the description of the gene could probably be organised in a much simpler or better fashion, like a table, rather than just one whole sentence. Also I don’t know if it is typo or if that’s how you actually spell it, but I would just like to mention “Huntingtin gene”. &lt;br /&gt;
*The pathogenesis section is very informative of the disease. Unfortunately it is very disjointed. One idea was introduced after the other and they did not really connect properly. I think as the reader I am looking for some sort of direction that leads Huntington’s, like a step by step thing. &lt;br /&gt;
*I am assuming that the clinical manifestation is not yet finished, so I won’t say anything else other than change the positioning of the image to the other side because it breaks the page and it does not aid in getting the information across to your readers. &lt;br /&gt;
*The diagnostic test is a bit of a disappointment. I’m pretty sure that since it is a genetic disease there is some form of genetic testing that doctors can use to diagnose the onset of the disease, unless the etiology is still under debate and not sure of, and from what I have read from your page so far it is pretty definite that mutation in a particular gene is already implicated in the disease. So I think this section could probably do a lot more research and work. &lt;br /&gt;
*The video… section of your page is pointless, why isn’t this in the diagnostic section?? I think synthesizing both section is needed, as this section alone is pointless.   &lt;br /&gt;
*The really like the table in the treatment section it is a a very good summary. If you could add the actual effect of each drugs to the patient, it would make this table better than what it actually is. The tetrabenzaine part is a bit out of place. If you are elaborating on the entire active chemical ingredients, I believe this is a good idea. &lt;br /&gt;
*I like the current and future research section of the page, as it informs the reader that the page is current and well informed about the recent endeavors on the disease. The only let down is that there is not a single research on finding a cure for the disease or looking for other treatments, which I think is one of the most popular topic on this disease. If you could add this in this section it would make this area much better. You could even add it in the treatment section. &lt;br /&gt;
*Not really a big fan of the glossary, but it is good idea anyway.&lt;br /&gt;
--[[User:Z3290841|z3290841]] 10:23, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
*Very clear introduction, seems well researched and easy to understand&lt;br /&gt;
*History – good structure, my only suggestion is to put the timeline into a table and to highlight or bold the years mentioned, it’d look sweet as then.&lt;br /&gt;
*I like the tables in epidemiology, same colour structure could be used for the timeline under history maybe?&lt;br /&gt;
*Genetics – quite possibly the best heading on this page, I’m sure other people have mentioned this but ‘Huntington Gene’ the sub-heading is spelt wrong. Great incorporation of the student drawn image, this heading is very clear and easy to follow.&lt;br /&gt;
*Image under ‘Molecular Mechanisms &amp;amp; Pathogenesis’ is a bit big in my opinion, maybe consider reformatting it so the text is not broken up so suddenly.&lt;br /&gt;
*Image under ‘Clinical Manifestations’ could be better placed on the right hand side of the page so that there is continuity on the page, same with the other images under ‘Video of Huntington's disease patient’ and ‘Treatment’ and ‘Current/Future Research’&lt;br /&gt;
*Overall a well detailed page that is easy to understand and clear in its aims.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 06:59, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Peer Review'''&lt;br /&gt;
&lt;br /&gt;
•	Great sub-heading structure, and the overall flow of the page is neat.  Although, it would appear more orderly if all images were on &lt;br /&gt;
the right hand side of the page, in alignment with the text (it looks messy otherwise).&lt;br /&gt;
&lt;br /&gt;
•	The introduction is very clear and to the point, I think a picture which portrays the abnormality would  look good here.&lt;br /&gt;
&lt;br /&gt;
•	History is done really well, I loved the quote and the picture of George Huntington. The only thing in this section would be to make &lt;br /&gt;
the dates bold or possibly even use a table.&lt;br /&gt;
&lt;br /&gt;
•	Nice use of tables in epidemiology, they make the information easy to read and easily accessible. &lt;br /&gt;
&lt;br /&gt;
•	Well described genetics component and nice incorporation of the student drawn image. I’m not sure if there’s a need to break down &lt;br /&gt;
Huntington (misspelt as ‘Huntingtin’ in the heading) gene into more headings. &lt;br /&gt;
&lt;br /&gt;
•	Molecular mechanisms and pathogenesis is done well. I actually think the image is a good size, as its side-by-side to the text and clearly explains what most of the text is about.&lt;br /&gt;
&lt;br /&gt;
•	I think a table would be helpful in clinical manifestations. Also, the image would look better larger and on the right hand side of the page. &lt;br /&gt;
&lt;br /&gt;
•	Treatment section was a little overwhelming. Too much detail in the table, possibly?&lt;br /&gt;
	&lt;br /&gt;
•	Good glossary and a vast range of references, good work thus far!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289829|z3289829]] 02:42, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Peer Review'''&lt;br /&gt;
* Introduction does well in that it briefly addresses each of the facets of the topic that follow.&lt;br /&gt;
* Relevance of each historical point in the timeline is not adequately explained.&lt;br /&gt;
* Use of the table to show epidemiology is very nicely set up. &lt;br /&gt;
* Epidemiology is very much at the level required, delving into specific research details.&lt;br /&gt;
* You misspelled &amp;quot;Huntington&amp;quot; in &amp;quot;Huntingtin Gene&amp;quot;. Really?&lt;br /&gt;
* Image error in the Molecular Mechanisms section. Remaining picture is very comprehensive though.&lt;br /&gt;
* Could potentially use more references in the Molecular Mechanisms section; otherwise decently referenced.&lt;br /&gt;
* The Diagnostic tests aren't actually mentioned, only their significance is outlined.&lt;br /&gt;
* &amp;quot;Neuropathology&amp;quot; section is not properly titled - it seems to be a subset of the Video section (which, incidentally, can probably be moved within Clinical Manifestations)&lt;br /&gt;
* Medication table is very nicely set out.&lt;br /&gt;
* Picture in Current/Future research (mouse/person/etc) seems irrelevant, and is not actually explained.&lt;br /&gt;
* Glossary is thorough&lt;br /&gt;
--[[User:Z3290689|z3290689]] 00:46, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Peer Review for Group 4'''&lt;br /&gt;
&lt;br /&gt;
*Introduction is informative but not catchy. You need the reader to feel eager to read on the rest of the page.&lt;br /&gt;
*I like the way the history has a portrait and how there is a blue box around the quote. Maybe In the timeline you should bold the dates so it looks better on the page.&lt;br /&gt;
*Information found in the epidemiology is great, and the use of tables is very good. Just wanted to let yous know that whenever I read HD I always remember High Definition, a little distraction to my reading. Just wanted to make that point.&lt;br /&gt;
*Information in the HTT &amp;amp; normal functions section seems a bit disjointed and doesn’t seem to flow well.&lt;br /&gt;
*The HTT and Huntington’s disease section showed be reformatted so it is one nice flowing informative paragraph.&lt;br /&gt;
*Image found in the molecular mechanisms and pathogenesis section doesn’t show. Please fix it or remove the thumb altogether. However included information in this section is informative&lt;br /&gt;
*In clinical manifestations, it would be really good if you could describe how the clinical manifestations are brought about at a neurological level.&lt;br /&gt;
*It’s not necessary to have a large subheading for’ Video of Huntington's disease patient’&lt;br /&gt;
*Diagnostics has lots of info so formatting it so it’s spread out will be good.&lt;br /&gt;
*The image of Amniocentesis seems not to have the copyright clearance for it to be modified. Please fix it.&lt;br /&gt;
*Table in the treatments section is cool and massive, try to make it a bit smaller?&lt;br /&gt;
*I believe if the tetrabenzine information should come first then the massive medications table it would make the treatments part look and flow better.&lt;br /&gt;
*Current and future research section has information that very informative and portrays a good view on the current research arena for HD. However I don’t understand the relevance of having the brain scans in this section. Maybe have another section as a glossary which you could use for all other miscellaneous pictures.&lt;br /&gt;
*Some parts of the referencing include multiple referencing, just fix that up it will make it much better&lt;br /&gt;
*Overall, page is really well constructed, put a lot of work in and I’m impressed. Good word to picture ratio thus makes the page to be wanted to be read. Good work people of group 4.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291317|Z3291317]] 23:50, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
Introduction: Introduction is alright but could be more detailed.&lt;br /&gt;
&lt;br /&gt;
History: This section is good but the timeline would be better with more information/ more detailed explanation of the points already there.&lt;br /&gt;
&lt;br /&gt;
Epidemiology: This section seems too concerned with the occurrence of the HD. I think this section could use some more general &lt;br /&gt;
epidemiological information as well.&lt;br /&gt;
&lt;br /&gt;
Genetics: This section is explained clearly and done quite well. The pictures need to be bigger though.&lt;br /&gt;
&lt;br /&gt;
Pathogenesis: This section is good. The image could be a tiny bit bigger and would be better if it had a caption explaining the different parts of the diagram.&lt;br /&gt;
&lt;br /&gt;
Clinical manifestations: This section could be longer/more detailed. You could explain some of the symptoms. Eg.what is chorea? Also, the picture is good but needs to be much bigger.&lt;br /&gt;
&lt;br /&gt;
Diagnosis: This section doesn’t seem to actually explain how HD is diagnosed. Where is the diagnosis? Also, the picture is good but needs a more detailed caption.&lt;br /&gt;
&lt;br /&gt;
Treatment: This table is not very nice to read and seems a bit complicated. I think it would work better simplified and put into paragraphs.&lt;br /&gt;
&lt;br /&gt;
Future research: Good pictures and text. I think the images need more explaining. Eg. where is the caudate located in the brain. Maybe arrows could show this.&lt;br /&gt;
--[[User:Z3291324|z3291324]] 23:21, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
&lt;br /&gt;
Hey, this is a nicely structured page with interesting content that is presented well. There is a nice balance of text and image&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
#The key points relating to the topic that your group allocated are clearly described. &lt;br /&gt;
#* Introduction: good, to the point&lt;br /&gt;
#* History: Nice section, perhaps bold the years?&lt;br /&gt;
#* Epidemiology: I really liked this section, both visually and content wise. The table is easy to read and I liked your explanations for the HD prevalence, well done&lt;br /&gt;
#* Genetics: Perhaps you could have the 'CAG (cytosine-adenine-glutamine)' in the introduction when you first refer to it? Referencing is required in i'HTT and normal functions'. I really liked your subheadings, made it very easy to understand and follow &lt;br /&gt;
#* Pathogenesis: Image is too big, good subheadings, I suggest that if you write in purple to highlight some words, maybe you could do that for the whole page?&lt;br /&gt;
#* Clinical: liked the motor impairment explanations, how about explaining the cognitive and behaviour impairments as well? (it'll be worth it!)&lt;br /&gt;
#* Diagnosis: Nice content, but it just feels a bit too crowded, maybe rearrange the images and decrease image size&lt;br /&gt;
#* Treatment: Very nice section with nice images and good format!&lt;br /&gt;
#The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area. &lt;br /&gt;
#* Good balance of images and text, though some rearrangement of images would make this page look better. Very good use of subheadings to make the content more easy to digest&lt;br /&gt;
#Content is correctly cited and referenced.&lt;br /&gt;
#* overall referencing was well done&lt;br /&gt;
#The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.&lt;br /&gt;
* good range of tables, images and self drawn images&lt;br /&gt;
#Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities. &lt;br /&gt;
#* Nice range of references used&lt;br /&gt;
#Relates the topic and content of the Wiki entry to learning aims of embryology. &lt;br /&gt;
#Clearly reflects on editing/feedback from group peers and articulates how the Wiki could be improved (or not) based on peer comments/feedback. Demonstrates an ability to review own work when criticised in an open edited wiki format. Reflects on what was learned from the process of editing a peer's wiki. &lt;br /&gt;
#Evaluates own performance and that of group peers to give a rounded summary of this wiki process in terms of group effort and achievement. &lt;br /&gt;
#The content of the wiki should demonstrate to the reader that your group has researched adequately on this topic and covered the key areas necessary to inform your peers in their learning. &lt;br /&gt;
#Develops and edits the wiki entries in accordance with the above guidelines&lt;br /&gt;
&lt;br /&gt;
&amp;quot;What would improve this project....&amp;quot; &lt;br /&gt;
&lt;br /&gt;
* just minor changes such as resizing some of the images, making the sections consistent in format&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291643|z3291643]] 22:32, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4:'''&lt;br /&gt;
&lt;br /&gt;
•Formatting of the page seems well done, I like the inclusion of the quote in the history section, maybe put the timeline into a table as this would make it more visually appealing&lt;br /&gt;
&lt;br /&gt;
•The file Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg, does not have the correct copyright information for the student drawn images&lt;br /&gt;
&lt;br /&gt;
•I like the inclusion of the video, but am not sure about the subheading choice for this section. Does the video need its own separate heading?&lt;br /&gt;
&lt;br /&gt;
•Good balance of text and images&lt;br /&gt;
&lt;br /&gt;
•A couple of the references seem to be missing some of the information, but you have a large number of references so it looks like a lot of research has gone into this, good work so far.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332183|z3332183]] 21:26, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4: Peer Assessment'''&lt;br /&gt;
* Your page has a good balance of text, images and tables&lt;br /&gt;
* I like that your introduction is brief and to the point&lt;br /&gt;
* You history section is the best one have seen so far, it looks good and it easy to read&lt;br /&gt;
* The image in the pathogenesis has no copyright information&lt;br /&gt;
* In clinical manifestations are quite important I think and your section seems a little weak in comparison to the rest&lt;br /&gt;
* Treatment: I'm sure the table was a lot of work but it is quite complex ad all the drug names make me a bid dizzy. May be you can shorten it to the most relevant?&lt;br /&gt;
*Overall the page has a good content and it's fun to read. The diagrams and drawings are great --z3279511 17:09, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''GROUP 4: Huntington's Disease'''&lt;br /&gt;
*Intro has good summary of the disease, however the first paragraph is a little too technical, could you maybe simplify it a little so you don't lose the reader right at the start (reference 5 is missing though)&lt;br /&gt;
*History is succinct and summarised well, i like the quote included, could you have gone a little further with the timeline? (maybe include some of the more recent developments), maybe the timeline could be better formatted in a table&lt;br /&gt;
*Good info from a variety of sources in epidemiology, good use of tables, I like how prevalence has been compared and how the table is explained (one little thing: could you maybe find more statistics for Australia?)&lt;br /&gt;
*Inheritance image needs student template added and maybe made a little bigger so detail can be seen&lt;br /&gt;
*Genetics section is informative but could use an image of the gene maybe&lt;br /&gt;
*Molecular Mechanisms &amp;amp; Pathogenesis section is well researched and good summary is provided. I like how key words have been highlighted. images need fixing (more descriptive legend is needed for the first image and what happened to the second image?&lt;br /&gt;
*I don't think you need to explain what the disease is again in the clinical manifestation segment (don't want to sound repetitive), image in this section isn't very clear, I feel that this section is a tad incomplete-maybe some expansion is needed e.g. classes 2 and 3 could be expanded on more &lt;br /&gt;
*I feel that diagnosis section could go further up? This section is very informative, but could be summarised a little more Some of the images in this section need better explaining, good balance of text and images in this section&lt;br /&gt;
*good use of table in treatment section, however more info could be provided as to how these drugs help the disorder &lt;br /&gt;
*Current/Future Research is very up to date, images here again need more description&lt;br /&gt;
&lt;br /&gt;
Overall:&lt;br /&gt;
*it is evident that this project has been extensively researched&lt;br /&gt;
*good use of subheadings and headings&lt;br /&gt;
*maybe include the acronyms in the glossary and it would be good if glossary words were linked to text&lt;br /&gt;
*make sure all images include the student template required and legends of some images need to be expanded (more info on what the image is about)&lt;br /&gt;
*fix repetitive sentences&lt;br /&gt;
*good balance of images and text, good use of tables&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 15:27, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Peer Assessment Group 4'''&lt;br /&gt;
&lt;br /&gt;
*Second sentence of intro is WAY too detailed for the intro, it means very little as the disease has not yet been explained to us and is too technical – OR, keep it but explain it in a more general way. &lt;br /&gt;
*What do you mean by familially or sporadical development? Define what you mean by this (intro)&lt;br /&gt;
*Timeline – events need to be explained. E.g. Venezuela Project – what is this? Why is it significant? (this is needed for most of the history entries)&lt;br /&gt;
*HTT and normal functions – can you explain what some of the processes are? E.g. dynactin complex, clathrin-mediated endocytosis are?&lt;br /&gt;
*Calcium signalling in pathogenesis – maybe explain why the calcium signalling pathway is important?&lt;br /&gt;
*The video file – make sure you write a little para about it. It has a new headings – shouldn’t it be a subheading?&lt;br /&gt;
*The paragraph of ‘Imaging’ in diagnostic tests needs to be pushed so its under the pics from neuropathology&lt;br /&gt;
*Tetrabenazine – I think have an intro sentence about it to highlight that this is the most commonly used one, as you only discuss it in depth (as a drug treatment) – unless you are going to add in explanations of other drugs?&lt;br /&gt;
*In Current/future research, refer to the pics on the RHS if they are relevant, otherwise I think they need to go somewhere else&lt;br /&gt;
*Overall comment: its good, lots of research, but even as someone who has a background in bio, we still don’t know everything about everything, so I think as you go, explain some of the more complicated processes so you can really understand what is going on. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332824|z3332824]] 11:48, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 4: Huntington’s Disease&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Peer Review'''&lt;br /&gt;
* Good introduction, history seems adequate - although the timeline stops at 2002? Is there anything after this?&lt;br /&gt;
* Nice table for epidemiology; although some terms require explaining&lt;br /&gt;
* Excellent student-drawn diagrams and genetics section with a good balance between the text, bullet points and images. One image has been removed so be sure that that is re-uploaded!&lt;br /&gt;
* Video section: Formatting is a bit of a pain to read when the left hand margin keeps shifting with the images being placed here. Fix this please so that it is easier to track the page with our eyes.&lt;br /&gt;
* Treatment section is overwhelming, whilst some might have said that it looks great (and it really does), to suddenly be hit with such a huge table is exhausting. Perhaps shorten this section by mentioning that there is only treatment available for the symptoms, list them, and then link to an image containing the table in its entirety.&lt;br /&gt;
* Current/Future research section seems a bit short. &lt;br /&gt;
* Overall, it looks like an excellent project that has had a lot of thought put into it. Well done guys :)&lt;br /&gt;
--[[User:Z3288827|Leonard Tiong]] 10:25, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Initial thoughts, was wow! Clearly immense time and effort was put into this! Loved the structure of the headings and sub-headings. &lt;br /&gt;
*Introduction: Top notch, just needs an image to complete it.&lt;br /&gt;
*History: Nice use of the quote box, this section was done very well, except BOLD the years. Personally, I would have liked it more if the timeline itself was in a coloured table, no biggie. &lt;br /&gt;
*Epidemiology: Add “(Australia)” After Tasmania? Or just listing countries would be better? Overall, nicely done.&lt;br /&gt;
*Genetics: “Inheritance” part feels a little too short. Preferred if the image had black text over a white background. Everything else was great!&lt;br /&gt;
*Molecular Mechanisms &amp;amp; Pathogenesis: The space between the purple words and commas could be removed. The purple colour, made me think they were hyperlinks, maybe chose either to bold or colour the words, as having both is a bit much.&lt;br /&gt;
*Clinical Manifestations: The features would look better in a table, in my opinion. I like the image, very nice indeed! Good summary.&lt;br /&gt;
*Diagnostic Tests: Done well, though compared to the rest of the webpage, it looks very insignificant. I suggest adding more information!&lt;br /&gt;
*Video: Fix the formatting please!&lt;br /&gt;
*Treatment: Nice table, informative. The “Tetrabenzine” section, the text needs some formatting, sentences are cut off to the next line for some reason, to be honest Medications and Therapies seem to be most important part, so they should maybe be expanded on? &lt;br /&gt;
*Glossary: Looks good, just a few full stops missing!&lt;br /&gt;
--[[User:Z3332327|Lisa Xiao]] 01:24, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
*Very good introduction&lt;br /&gt;
&lt;br /&gt;
*History: looks very nice, but the layout of the quote disrupts the page. I think it would be better to use bold letters, good idea though. &lt;br /&gt;
&lt;br /&gt;
*Epidemiology: nice section, useful tables&lt;br /&gt;
&lt;br /&gt;
*Genetics: good detailed content and drawings&lt;br /&gt;
&lt;br /&gt;
*Pathogenesis: do not bold words in only one section,  it disrupts the whole picture, good use of sub- headings.&lt;br /&gt;
&lt;br /&gt;
*Clinical manifestations: good summary of the symptoms in the drawing, the classes and the five specific features would look better in a table, otherwise good section&lt;br /&gt;
&lt;br /&gt;
*Diagnostic tests: the video subheading needs to be fixed, really irritating. Very detailed, I would put all images to the same side &lt;br /&gt;
&lt;br /&gt;
*Treadment: mechanism of tetrabenazine inhibition image could have been done with more effort&lt;br /&gt;
&lt;br /&gt;
*Research: very nice clear section&lt;br /&gt;
--[[User:Z3387190|Z3387190]] 21:27, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''group peer assessment'''&lt;br /&gt;
*Introduction is well structured though image of the Huntington gene protein would be more beneficial to where I’m looking relating to genetics&lt;br /&gt;
*Genetics could expand more on the inheritance and the Huntington gene&lt;br /&gt;
*Role in transcription  sub heading image removed&lt;br /&gt;
*Diagnostic test image needs to placed in correct section and the video should be placed at the end of the section, placement of the video cause confusion of the other diagnosis tests&lt;br /&gt;
*Treatment should have an introduction which introduces the drug used to manage diseases and therapies, better layout where most commonly used drug form management and therapies following the table to show alternative treatment.&lt;br /&gt;
*Current/future research should have some future research and images placed have no description which research project image belongs to&lt;br /&gt;
*References contain mistakes with repetitions and blanks also some done incorrectly such as reference “3” where not properly inputted on the wiki page&lt;br /&gt;
*Glossary was not linked to the web page as well while reading was lost without referring to a dictionary due to no indications definition is in the glossary&lt;br /&gt;
z3332250 23:46, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4 Peer Review&lt;br /&gt;
&lt;br /&gt;
*Punchy introduction-well done&lt;br /&gt;
*Timeline under history was excellent&lt;br /&gt;
*Seemed very scientific and wordy at times-a lot of detail is unnecessary; “less is more”&lt;br /&gt;
*Great balance of text and images-very readable&lt;br /&gt;
*Page flowed well in a logical manner&lt;br /&gt;
*Diagnosis section is very well done however there seems to be too much content/focus relative to the rest of the page. Perhaps add some more to other sections or make this section more concise?&lt;br /&gt;
*An extensive glossary and reference list-thorough research&lt;br /&gt;
*I learnt a lot from this page so well done!&lt;br /&gt;
*Overall, an impressive page. A few more things to tweak to make it excellent. &lt;br /&gt;
--[[User:Z3308965|Fleur McGregor]] 19:13, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Critique'''&lt;br /&gt;
&lt;br /&gt;
#•	Introduction was quite good&lt;br /&gt;
#•	History was good. I liked the timeline&lt;br /&gt;
#•	Tables in the epidemiology were good&lt;br /&gt;
#•	The genetics was clearly explained&lt;br /&gt;
#•	Pathogenesis was really good. I quite liked it&lt;br /&gt;
#•	Clinical manifestations is good&lt;br /&gt;
#•	Diagnostic tests could be more detailed&lt;br /&gt;
#•	Overall, quite a well written project. Well done. Maybe add a little more about the medications. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289991|Robert Klein]] 18:47, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Huntington's Disease'''&lt;br /&gt;
&lt;br /&gt;
*The intro and history look really good, I like the timeline and the quote box&lt;br /&gt;
*What year was the information in the table in 'Epidemiology' sourced? Because from looking at the references, it seems to be within a 20yr period.  Is this enitrely accurate to compare these?&lt;br /&gt;
*What are HTT and HD halotypes (in 'Epidemiology')? You've only put 'halotypes' in the glossary, you also need to a give a brief definition within the text, not just glossary&lt;br /&gt;
*Nice image in 'Genetics', lots of good easy to understand information there as well&lt;br /&gt;
*You need to fix the file under 'Role in Transcription Inhibition'&lt;br /&gt;
*The diagnosis section looks really good, make sure you get rid of that subheading for the video though&lt;br /&gt;
*Interesting table in 'Treatment', however the section on 'Tetrabenazine' does not has complete sentences and seems a bit unnecessary.  Honestly I don't really care how the drug works (ie receptors) I'm more interesting in it's implications regarding HD&lt;br /&gt;
*The 'Therapies' section was good and succinct&lt;br /&gt;
*Current/Future Research looks really good&lt;br /&gt;
*Overall the page isn't bad, just need to confirm some details to improve it ie dates and definitions&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 4&lt;br /&gt;
* On first looking at the project it looks like there is a good text/image ratio. However an image in the introduction would work well&lt;br /&gt;
* The content of the introduction is very clear and introduces the reader to the topic well&lt;br /&gt;
* I really like the history section. The story makes me a little excited about the condition in a way. I am left feeling keen to know more and there is an extensive list of discoveries. There needs to be more after 2002 though. I find it difficult to believe that nothing has been found in the last 9 years.&lt;br /&gt;
* The epidemiology table is a nice way of showing the data. But maybe you should put the Australian states in bold and at the top- also maybe include all of the states or Australia as a whole, not just NSW and TAS&lt;br /&gt;
* There is a file in the pathogenesis that is not accessible- either get the file up or remove the link&lt;br /&gt;
* The image in the pathogenesis has no copyright information&lt;br /&gt;
* A couple of grammar problems in the pathogenesis that could be fixed up- full stops mid sentence for example&lt;br /&gt;
* The clinical manifestations sections outlines the types of classes of manifestations but it is difficult to actually access the information on what the manifestations are. It would work well in a table with a little more detail on what the patient experiences&lt;br /&gt;
* The video is put as a new subheading within diagnosis. It needs to be made into the smaller subheading because I thought diagnosis section was over but it continues underneath&lt;br /&gt;
* The diagnosis section is in great detail, somewhat more detail than other sections. This is very interesting and shows that this team member worked hard on their section.&lt;br /&gt;
* Good work on the project, just a little editing and formatting to make it a finished product!&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
* Nice structure of headings and subheadings, it breaks up the text and makes it a readable page. Extremely interesting topic! &lt;br /&gt;
* I found the history very interesting and enjoyed the quote from Huntington.&lt;br /&gt;
* maybe bold the dates in the timeline, just to make the page easy to follow. Or maybe a table could be appropriate. &lt;br /&gt;
* I liked the structure of the epidemiology section and the tabulated prevalences! good work! &lt;br /&gt;
* Molecular Mechanisms &amp;amp; Pathogenesis: unsure as to why some sentences were bolded. &lt;br /&gt;
* Differential Diagnosis: very interesting I liked that you added this in. &lt;br /&gt;
* Treatments table very succinct  easy to understand and follow! Great! &lt;br /&gt;
* Good to see that most of your references were grouped. only a few that were doubled. &lt;br /&gt;
* Maybe have a continuos colour scheme for the page and type of table used. &lt;br /&gt;
* Good use of tables and I like that you explained what they were about. &lt;br /&gt;
* Make sure all acronyms and scientific language is in the glossary&lt;br /&gt;
* good student illustrations &lt;br /&gt;
* overall great ratio of text and pictures!&lt;br /&gt;
&lt;br /&gt;
'''Group 4 Assessment'''&lt;br /&gt;
*This might be a bit nit-picky, but for the references given throughout the wiki, there isn’t any consistency.  The [#] is sometimes right after the sentence, sometimes a space is given between the sentence and citation number, and the end of the sentence (period or comma) is sometimes before or after the reference #...&lt;br /&gt;
*The information within the introduction seems to be substantial.  Only suggestion would be to add a picture to add to the overall look. &lt;br /&gt;
*In the history section, it was a good idea to have the single quote stand out in a colored box to itself.  First time I’ve seen this.  Looks professional.  I question though, if all the events within the timeline are absolutely necessary… &lt;br /&gt;
*Epidemiology- Both tables are well organized and look extremely professional.   Good information within this section, although it might be a good idea to reference a few more not-so-common terms in the glossary, such as SNP’s and others which may not be common knowledge for all. &lt;br /&gt;
*The Genetics section is well formatted with what I believe is the vital information needed in this section.  Only complaint is the first picture (Inheritance Pattern…) doesn’t have the copyright information claiming that it is okay to use this image.  &lt;br /&gt;
*The “Key cellular pathogenic mechanisms in HD” image likewise does not have the copyright information to verify its legal usage.  &lt;br /&gt;
*Molecular Mechanisms and Pathogenesis section-  Very well formatted and aesthetically appeasing.  Why are some of the words in purple though?  Are they meant to be defined the glossary, or just key points?   “The Mutant Huntington gene…” file is also not on the page… Where is it? &lt;br /&gt;
*Diagnostic Tests  Research – I have no complaints.  These sections look immaculate.  &lt;br /&gt;
*In the glossary, try having a bullet list and also having the words within the wiki page to link to its definition in the glossary.&lt;br /&gt;
*Some of the references are repetitive.  Make sure to fix this so they all link to a single reference instead of numerous ones of the same resource.  &lt;br /&gt;
*Overall, good content within the page and very appealing visually.  Just minor editing needs to be done I think.  Good job!&lt;br /&gt;
--[[User:Z3391078|Z3391078]] 14:31, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Peer Assessment: Group Project 4'''&lt;br /&gt;
*The introduction and history sections are concise and well formatted.&lt;br /&gt;
*A few of the points in the timeline would be improved by containing a bit more information such as 'Mendel's work' and 'The Venezuala project'&lt;br /&gt;
*The tables used in the epidemiology section are clear and highly informative.&lt;br /&gt;
*The abbreviation HTT is used throughout the epidemiology section before it is stated what it means in the genetics section. This should be changed.&lt;br /&gt;
*The picture related to transcription factors needs to be fixed so that it can be displayed.&lt;br /&gt;
*The section entitled 'Video of Huntington's disease patient' should have a more appropriate heading to encompass the rest of the written information in that section.&lt;br /&gt;
*Under the information in some of the images you have uploaded, you still need to add &amp;lt;nowiki&amp;gt;{{Template:2011 Student Image}}&amp;lt;/nowiki&amp;gt;.&lt;br /&gt;
*Some of the references are duplicated. They can instead be linked together using the 'multiple instances on a page' editing guidelines: http://embryology.med.unsw.edu.au/embryology/index.php?title=References#Multiple_Instances_on_Page.&lt;br /&gt;
*Overall the project is highly informative, well written and formatted.&lt;br /&gt;
--[[User:Z3217345|z3217345]] 21:34, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 3:&lt;br /&gt;
* The introduction is very lengthy, some parts feel as though they would be more appropriate in other sections. The image here fits nicely with the text but it could benefit from a more descriptive legend and needs to include “{{Template:2011 Student Image}}”.&lt;br /&gt;
* In the history, you begin to use the short hand “KS” without an initially stating that this is the abbreviation for “Klinefelters syndrome (KS)”. The dates that are mentioned are very detailed although it ends in 1970, were there any other breakthroughs since then? A picture of Klinefelter would be a nice touch here.&lt;br /&gt;
* Epidemiology requires some proof reading as there are a couple of little mistakes and the images would have more of an impact if they were slightly larger.&lt;br /&gt;
* I like how you have linked figure 1 to the non-disjunction sub-heading under aetiology. The image in this section could benefit from a coloured legend, ie. Instead of saying “Blue circles are male cells”, in a box include an actual blue circle = male cells along with the other descriptions. It also needs to be properly cited. &lt;br /&gt;
* There is too much repetition between pathogenesis and aetiology, maybe discussion between these two students is needed to minimise repetition. Good hand drawn images but you need to include the student template as mentioned previously.&lt;br /&gt;
* Signs and symptoms would look better in a coloured table and with more images. I don’t think it is necessary to repeat the image comparing age and intellect here.&lt;br /&gt;
* Diagnosis; nice use of another form of media – a video. The abbreviation of KS in this section needs to be established first by placing KS after the first time you mention Klinefelters syndrome.   &lt;br /&gt;
* Management is very concise and thorough &lt;br /&gt;
* Other similar defects; nice touch, it could look more appealing with the use of colour and larger images though.&lt;br /&gt;
* Current research is formatted nicely and flows well&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4: '''&lt;br /&gt;
* The introduction provides a great overview but remember it needs to be easy to read, even for those who have never heard of Huntington’s disease. If you explain scientific and medical terms (such as neurodegenerative and CAG trinucleotide tract) more generally/broadly, it will solve this problem. &lt;br /&gt;
* History: great use of a quote and image. The timeline would look better and make it easier to read if the dates were bolded or if it were in a table. The explanations could be elaborated more such as “1900: Mendel’s work was rediscovered”. Image needs to include &amp;lt;nowiki&amp;gt;“{{Template:2011 Student Image}}”&amp;lt;/nowiki&amp;gt;. &lt;br /&gt;
* Epidemiology: Although you’ve stated that Venezuela and North Ireland have notably high prevalence of this disease, you haven’t stated the actual prevalence of Venezuela. You also need to re-read this section as there are a couple of mistakes eg “There &amp;lt;font color=red&amp;gt;seem&amp;lt;/font&amp;gt; to be an increased prevalence of Huntington's disease...” and this sentence doesn’t make sense “Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela and Northern Ireland”. What are HTTP haplotypes?, overall I found the explanation of the paper by Warby et al hard to understand, maybe another attempt of explaining this paper is needed by spelling out the haplotypes even more so.  In saying this, the tables are formatted very nicely. &lt;br /&gt;
* Genetics: Nice student drawn images but just make sure you include the student template as mentioned above. The “Huntingtin Gene” section would benefit from an image of the specific regions on the chromosome as it is hard to follow with just text.&lt;br /&gt;
* Molecular mechanisms and pathogenesis: a lot to take on but is made easier to read through the use of good sub-headings and highlighted words and large image. Make sure you include the student template here as well and there is an image missing in this section though.  &lt;br /&gt;
* Clinical manifestations: You have mentioned 3 classes of symptoms but have only gone into detail about one of them; motor movement impairment. What happened to cognitive and behavioural explanations?  Nice student drawn image, I like how it is oriented to the left to change it up a bit.&lt;br /&gt;
* Diagnostic test: The table could be formatted with more colour to make it more aesthetically pleasing. I personally don’t understand including an image of another disease, i would stick to images specifically relating to HD.&lt;br /&gt;
* Under neuropathogy there is a little typo “The neuropathological hallmark of Huntington’s disease is now &amp;lt;font color=red&amp;gt;know&amp;lt;/font&amp;gt; to be the gradual loss of spiny GABAergic...”, there could be more so i would advise to check this section again. &lt;br /&gt;
*Under genetic testing there is also another little typo “However it wasn’t &amp;lt;font colour=red&amp;gt;until the 1993&amp;lt;/font&amp;gt; when...”&lt;br /&gt;
*Treatment and future research: very well researched and I really liked the use of the table and images here, it provides great balance and flow. &lt;br /&gt;
&lt;br /&gt;
--z3290815 19:05, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 4: '''&lt;br /&gt;
&lt;br /&gt;
*The page had a nice format that was appealing to read. &lt;br /&gt;
*The structuring of the images between and beside the text was perfect because it was not too big and not too small. It was easy to view and nice to see.&lt;br /&gt;
*The table for the treatment heading was nice but the last column is hard to read because the information was listed in a horizontal fashion maybe changing it and putting it into dot point form would be good.&lt;br /&gt;
*The student drawn image was clear!&lt;br /&gt;
*Fixing the formatting/structure of the glossary heading is needed&lt;br /&gt;
*Double referencing can be seen&lt;br /&gt;
*Sub heading for the video would be nice to see. The idea of including a video is quite nice.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3330313|z3330313]] 19:57, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Peer Review'''&lt;br /&gt;
&lt;br /&gt;
* Organised well&lt;br /&gt;
* Subheadings in the epidemiology section not in the centre of table&lt;br /&gt;
* images in the current/future research section is disorganised&lt;br /&gt;
* a lot of referencing was done and maybe not necessary&lt;br /&gt;
* choice of pictures were good examples&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3060621|z3060621]] 21:14, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 4'''&lt;br /&gt;
&lt;br /&gt;
'''*The key points relating to the topic that your group allocated are clearly described.'''&lt;br /&gt;
Main sections are there, Not sure if 'video of huntington's patient' should be a big heading - maybe put it in an 'external links' section?&lt;br /&gt;
&lt;br /&gt;
'''*The choice of content, headings and sub-headings, diagrams, tables, graphs show a good understanding of the topic area.'''&lt;br /&gt;
Content is well done and headings/sub-headings are organised well.&lt;br /&gt;
&lt;br /&gt;
'''*Content is correctly cited and referenced.'''&lt;br /&gt;
Fix up doubling of references. File:Mutant Huntingtin gene and its effects on transcription.jpg is missing. No references in therapies?&lt;br /&gt;
&lt;br /&gt;
'''*The wiki has an element of teaching at a peer level using the student's own innovative diagrams, tables or figures and/or using interesting examples or explanations.'''&lt;br /&gt;
Student image well done and explanation works well.&lt;br /&gt;
&lt;br /&gt;
'''*Evidence of significant research relating to basic and applied sciences that goes beyond the formal teaching activities.'''&lt;br /&gt;
Comprehensive research, but maybe more information in glossary as the wiki uses quite a lot of technical language.&lt;br /&gt;
&lt;br /&gt;
'''*Relates the topic and content of the Wiki entry to learning aims of embryology.'''&lt;br /&gt;
Any thing else on diagnosis? As mentioned by Mark, since this is a disease that presents complications after birth, more information should be added. Perhaps include some information on diagnostic tests? The imaging section in neuropathy could be added to diagnostic tests if diagnosis is possible by examining neurological changes?&lt;br /&gt;
&lt;br /&gt;
'''*Develops and edits the wiki entries in accordance with the above guidelines.'''&lt;br /&gt;
Development of wiki page has followed above guidelines, but some minor adjustments can be made.&lt;br /&gt;
&lt;br /&gt;
--z3329495 21:15, 28 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*'''Intro''': Content is fine, but revise some of your sentences - they are a bit long winded and hard to follow.&lt;br /&gt;
*'''History''': Looks good.&lt;br /&gt;
*'''Epidemiology''': Nice detail.&lt;br /&gt;
*'''Genetics''': Your first sentence doesn't quite make sense. That is not an adequate explanation of autosomal-dominant. Also, in case both parents have the disease, the likelihood of the offspring having the disease is still not 100% - it's 75%.&lt;br /&gt;
Also, are you sure there is a mutation that causes the repeat to expand? Repeats in general are susceptible to mutations, especially expansions - that is different from there being another mutation elsewhere in the genome causing the repeat to expand. More terms need to be explained in the glossary. Nice hand-drawn figure though.&lt;br /&gt;
There's a reasonable amount of information why the disease tends to be inherited in an anticipating pattern, so you could possibly add that information.&lt;br /&gt;
*'''Molecular Mechanisms &amp;amp; Pathogenesis''': Nice detail. Why are some terms in bold and coloured? More terms need to be explained in the glossary.&lt;br /&gt;
*'''Clinical Manifestations''': Good.&lt;br /&gt;
*'''Diagnostic Tests''': Otherwise fine, but you could briefly mention which genetic tests can be used to diagnose the test genetically.&lt;br /&gt;
*'''Video of Huntington's disease patient''': Why is this the main heading for this section? Doesn't quite make sense. Otherwise, the section is good, I like the use of figures to break up the text.&lt;br /&gt;
*'''Treatment''': Nicely comprehensive. Rather few explanations in text form though, maybe expand on this a little bit more?&lt;br /&gt;
*'''Current/Future Research''': Your &amp;quot;Culling out complex traits&amp;quot; figure doesn't have any explanation on the project page. Also, what exactly does it contribute, but a picture? It seems a bit redundant. Otherwise, nice detail.&lt;br /&gt;
*'''Glossary''': Looks good, but some more terms still need explaining.&lt;br /&gt;
*'''References''': Needs fixing, some papers appear multiple times, and some references lead to emptiness.&lt;br /&gt;
&lt;br /&gt;
==Discussion==&lt;br /&gt;
&lt;br /&gt;
Hey girls, Found a photo for the introduction. Let me know what you think/feel free to change it if you wish :)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 17:10, 1 October 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Liz, I posted on the fb page regarding the genetics and pathogenesis part. The student drawn image I'm okay with doing yes. So far I was thinking about doing a picture showing the autosomal dominant nature of the gene. Basically a &amp;quot;tree diagram&amp;quot; of what happens when one parent is affected and the offspring has a 50% chance of inheriting HD. &lt;br /&gt;
But I'm okay at drawing so if someone else has something better they'd like me to draw I'm okay with it. :)&lt;br /&gt;
Girls please check fb, bit of a crisis. &lt;br /&gt;
:)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 06:00, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
hey girls, i think we really need to start hurrying things along with our project. Maedeh, i know you said that peer reviews arnt getting marked, but we need to have our project FINISHED by then because after that we are only making finishing touches based on teh peer reviews. Also, are you still doing the student drawn image? Ta&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:41, 13 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Genetics + Pathogenesis &lt;br /&gt;
&lt;br /&gt;
Yea I think so, it would make it more relative. If anyone comes across any studies just post the link here or on fb. :) &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|z3290270]] 23:36, 24 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hmm, are epidemiological studies on HD? If there is, we should add. It will make our webpage more comprehensive.&lt;br /&gt;
And I don't mind doing that section.&lt;br /&gt;
&lt;br /&gt;
--Nur Sharalyn Abdullah 20:24, 23 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Girls, do you think we need an 'Epidemiology' heading?? &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 17:25, 23 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Introduction + Clinical Manifestations.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290558|Lisa Lee]] 14:42, 23 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Current + Future Research &amp;amp; Diagnostic Tests. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 09:30, 22 August 2011 (EST)&lt;br /&gt;
 &lt;br /&gt;
Sharalyn: History &amp;amp; treatment&lt;br /&gt;
&lt;br /&gt;
--Nur Sharalyn Abdullah 20:15, 20 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''White blood cell populations from Huntington's Disease patients'''&lt;br /&gt;
&lt;br /&gt;
[[File:White_blood_HD.gif]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290558|z3290558]] 23:46, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
===Establishment of HD hybrid cell line===&lt;br /&gt;
&lt;br /&gt;
[[File:Establishment of HD hybrid cell line.jpg]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
(A) First polar body of mature rhesus macaque oocyte was removed by gentle squeezing through a slit of zona pellucida (A-a). Staining of 1st polar body DNA (arrowhead) and oocyte DNA (arrow) (A-b). HD monkey skin cell was placed under the zona pellucida (black arrow) (A-c). Reconstructed oocyte with HD monkey skin cell (A-d; yellow arrow) was placed between two electrodes for electrofusion (A-d). (B) Day 12 hatching blastocyst derived from HD monkey hybrid embryo (B-a; arrow indicated ICM). HD monkey hybrid blastocyst outgrowth at six days after attached onto feeder cells (B-b). High magnification of selected region (inset) of the ICM outgrowth (arrowhead). HD monkey hybrid cell line (TrES1) at passage 10 (B-c). (C) G-banding analysis of TrES1. Cytogenetic analysis of TrES1 demonstrated tetraploid chromosome (84; XXXY). (D) Expression of ES-cell specific markers: Alkaline phosphatase, Oct4, SSEA4 and TRA-1-60.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833146/?tool=pmcentrez&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 21:30, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Large stem cell-derived neurospheres were generated from 33-week old HD hippocampus, but not WT hippocampus.'''&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 15:06, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Melatonin levels in Huntington's disease patients and controls'''&lt;br /&gt;
&lt;br /&gt;
[[File:Melatonin levels in HD patients and controls.jpg]]&lt;br /&gt;
&lt;br /&gt;
The diurnal melatonin rise was significantly delayed in HD patients by about 01:30 h (p = 0.048). The black bar on the abscissa indicates the dark period (23:00–7:30 h).&lt;br /&gt;
&lt;br /&gt;
--Nur Sharalyn Abdullah 12:21, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
We decided on Huntington's Disease, I believe Nur spoke to you at the end of the class. :) &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 16:44, 13 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 18:28, 11 August 2011 (EST) Your group left the lab today without notifying me of your selected group topic.&lt;br /&gt;
&lt;br /&gt;
Group 4 Topic: Neural Tube Defect&lt;br /&gt;
&lt;br /&gt;
Research Article:&lt;br /&gt;
&lt;br /&gt;
Conway S.J., Gosnell M., Rogers R., Simmons O., Snider P., Young R. (2011), Notochordal and foregut abnormalities correlate with elevated neural crest apoptosis in Patch embryos. Birth Defects Research Part A: Clinical and Molecular Teratology. doi: 10.1002/bdra.20802. Epub 2011 May 6.&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/21557455&lt;br /&gt;
 &lt;br /&gt;
Review Article:&lt;br /&gt;
&lt;br /&gt;
Abdel-Hamed Z., Johnson C.A., Logan C.V. (2011), Molecular genetics and pathogenic mechanisms for the severe ciliopathies: insights into neurodevelopment and pathogenesis of neural tube defects. Molecular Neurobiology&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/21110233&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290558|z3290558]] 02:07, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Neural Tube Defects'''&lt;br /&gt;
&lt;br /&gt;
[[Review:]] Padmanabhan, R. (2006). Etiology, pathogenesis and prevention of neural tube defects. ''Congenital Anomalies'', 46(2), 55-67.&lt;br /&gt;
&lt;br /&gt;
[[Research:]] Joó, J. G., Beke, A., Papp, C., Tóth-Pál, E., Csaba, A., Szigeti, Z., Papp, Z. (2007). Neural tube defects in the sample of genetic counselling. ''Prenatal Diagnosis'', 27(10), 912-21.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|z3290270]] 02:34, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''Review'': Bassuk AG, Kibar Z. '''Genetic basis of neural tube defects.''' Semin Pediatr Neurol. 2009 Sep;16(3):101-10 [http://www.ncbi.nlm.nih.gov/pubmed/19778707]&lt;br /&gt;
&lt;br /&gt;
''Research'': De Marco P, Merello E, Cama A, Kibar Z, Capra V.''' Human neural tube defects: Genetic causes and prevention.''' Biofactors. 2011 Jun 14.[http://www.ncbi.nlm.nih.gov/pubmed/21674647]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 14:24, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
We are doing on neural tube defects! &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 13:47, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Neural Tube Defects&lt;br /&gt;
&lt;br /&gt;
Article: &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19120526&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
Review: &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18182339&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===References===&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 22:25, 9 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi girls (: I actually managed to find some genetics-related articles on neural tube defects. It has something to do with folate and folate-related genes from what I have read so far. So how about it? Shall our website be based on neural tube defects? (:&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 08:12, 9 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey girls,&lt;br /&gt;
&lt;br /&gt;
So I've done a bit of research on a few of them. &lt;br /&gt;
One of the things we need to keep in mind is that it has to relate to the '''learning outcomes''', which I think is the embryological process, and how the genetic disorder relates to it or how its affected by it? (I tried looking it up but couldnt find it).&lt;br /&gt;
&lt;br /&gt;
Here's a list of the topics I've been looking into:&lt;br /&gt;
&lt;br /&gt;
[[Turner Syndrome:]] commonly known to have one missing sex chromosome, (or both) - LOTS of info on this. (only thing is, because its such a broad topic, we might have articles that contradict each other, or might not have that many embryology related new articles...?)&lt;br /&gt;
&lt;br /&gt;
[[Klinefelter's Syndrome:]] the gigantic disease with the extra chromosome (XXY). there's a decent amount of info on this, but not as much as Turner.&lt;br /&gt;
&lt;br /&gt;
[[Neural Tube defects:]] problems happening in the first month of baby formation because of the folate deficiency in the mother. But i'm not too sure where the genetics come into this..&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Which topics have you guys been looking at? Let us know! cos we need to have some articles in '''[[2-3days time!]]''' :)&lt;br /&gt;
&lt;br /&gt;
Ye it's better to research an area instead of just one disease then, because that will give us more to talk about... especially the genetic components which Mark commented on. So I was thinking Neural Tube Defects instead. That will give us Anencephaly, Encephaloceles, Hydranencephaly, Iniencephaly and Spina bifida.  ?--[[User:Z3290270|Maeda Sadeghpour]] 01:09, 8 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
You need to think about what the genetic component will be for the disease you select. --[[User:S8600021|Mark Hill]] 23:51, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
I don't think that having 4 categories will be a problem. I actually think that it will be good to have extra stuff to talk about. Have a look at the other pages from previous years, they are very elaborated so I think it's actually a good thing to have alot of things to talk about. But anyway lets decide on something so that we can post up our articles&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 22:00, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey! I get what you mean, Maeda. Doing 4 categories can be quite heavy. Hmm, but I was thinking, since this is going to be a wikipage and the elaboration for the 'original' wikipage for spina bifida is not very deep for the 4 categories, maybe we could leverage on this weakness and make ours more detailed? :) But if you guys think it is too much, I don't mind doing the other suggestions too! Anyway, this is just a preliminary decision. It depends on the topics that other groups have chosen too. Would it be possible for us to finalise the topic by tomorrow?&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 17:18, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hello people. I was basically trying to see which diseases had the most current information available online, and cystic fibrosis seems to be very well known. Spina Bifida is very interesting as well, my only concern with it is the 4 categories it's divided into, which I thought might make it a bit more work. What do you guys think? :) &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290270|Maeda Sadeghpour]] 00:25, 6 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey, girls! I'm thinking of spina bifida and hydrocephalus. Cheers!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389806|Nur Sharalyn Abdullah]] 20:26, 5 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
hey guys, had a quick look and Spina bifida and Turner's Syndrome both seem to have a decent amount of information on them &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 14:26, 5 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Peer Assessments==&lt;br /&gt;
* Interesting but good use of a quote&lt;br /&gt;
* The introductory paragraph for the “history” section could probably be cut down or eliminated altogether &lt;br /&gt;
* Great inclusion of statistics in regards to epidemiology &lt;br /&gt;
* Student images were excellent, well drawn and were engaging&lt;br /&gt;
* Pathogenesis section could have been placed in a table just to change up the formatting &lt;br /&gt;
* The video inclusion was good and relevant &lt;br /&gt;
* You’re referencing needs to be tidied up; there are multiple entries from the same source that tends to clutter your reference section.  &lt;br /&gt;
--[[User:Z3332629|z3332629]] 15:24, 22 September 2011 (EST)&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73987</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73987"/>
		<updated>2011-10-01T07:05:34Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Introduction */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|350px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73986</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73986"/>
		<updated>2011-10-01T07:03:29Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Introduction */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|right|300px]]&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73985</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73985"/>
		<updated>2011-10-01T07:00:29Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Introduction */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
[[File:HD patients.jpg|left|300px]]&lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=File:HD_patients.jpg&amp;diff=73984</id>
		<title>File:HD patients.jpg</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=File:HD_patients.jpg&amp;diff=73984"/>
		<updated>2011-10-01T06:54:03Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: Fig 1. Phenotypically identical twins (A) and skull computed tomography showing head of caudate nucleus atrophy (B and C)

Patients were female, 24 years-old when first examined, and phenotypically identical (Fig 1A). The onset of their disease, as report&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Fig 1. Phenotypically identical twins (A) and skull computed tomography showing head of caudate nucleus atrophy (B and C)&lt;br /&gt;
&lt;br /&gt;
Patients were female, 24 years-old when first examined, and phenotypically identical (Fig 1A). The onset of their disease, as reported by relatives, was at 17 and 20 years of age, the initial manifestations being balance and gait impairment with a progressive course. Neurologic examination showed bradykinesia, rigidity with cogwheel phenomenon, choreic movements of trunk and limbs (mild degree), dysarthria, hyperactive tendon reflexes and flexor plantar responses. The patient with earlier onset of the disease was more severely affected. Neurologic examination was repeated approximately six months and one year after the initial examination, and both patients worsened on each successive examination. &lt;br /&gt;
&lt;br /&gt;
==Reference==&lt;br /&gt;
&lt;br /&gt;
LEVY, GILBERTO et al. Juvenile Huntington's disease confirmed by genetic examination in twins. Arq. Neuro-Psiquiatr. [online]. 1999, vol.57, n.3B [cited  2011-10-01], pp. 867-869 . Available from: &amp;lt;http://www.scielo.br/scielo.php?script=sci_arttext&amp;amp;pid=S0004-282X1999000500022&amp;amp;lng=en&amp;amp;nrm=iso&amp;gt;. ISSN 0004-282X.  http://dx.doi.org/10.1590/S0004-282X1999000500022.&lt;br /&gt;
&lt;br /&gt;
Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License &lt;br /&gt;
&lt;br /&gt;
{{Template:2011 Student Image}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73395</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73395"/>
		<updated>2011-09-29T04:12:53Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|200px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73394</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73394"/>
		<updated>2011-09-29T04:10:30Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|250px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73393</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73393"/>
		<updated>2011-09-29T04:08:13Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|250px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73392</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73392"/>
		<updated>2011-09-29T04:05:57Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Imaging */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|250px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73390</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73390"/>
		<updated>2011-09-29T04:02:22Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|300px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73389</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73389"/>
		<updated>2011-09-29T03:59:46Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|300px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb|300px]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73388</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73388"/>
		<updated>2011-09-29T03:54:35Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Clinical Manifestations */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|300px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73385</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73385"/>
		<updated>2011-09-29T03:52:33Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|300px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73376</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73376"/>
		<updated>2011-09-29T03:28:29Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* History */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1842''': Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1846''': Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''1860''': Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1872''': George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1888''': Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1900''': Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1908''': Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1978''': Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1981''': The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1983''': The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1989''': Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1993''': The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1994''': The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
'''1996''': The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''1997''': Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2000''': An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2001''': The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''2002''': The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|300px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|300px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73311</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73311"/>
		<updated>2011-09-29T02:09:27Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1842: Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1846: Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
1860: Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1872: George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1888: Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1900: Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1908: Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1978: Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1981: The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1983: The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1989: Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
1993: The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1994: The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
1996: The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1997: Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2000: An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2001: The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2002: The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|150px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|300px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73259</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73259"/>
		<updated>2011-09-29T01:39:58Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Diagnostic Tests */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1842: Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1846: Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
1860: Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1872: George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1888: Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1900: Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1908: Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1978: Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1981: The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1983: The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1989: Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
1993: The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1994: The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
1996: The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1997: Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2000: An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2001: The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2002: The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|150px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|300px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73256</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73256"/>
		<updated>2011-09-29T01:37:09Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Video of Huntington's disease patient */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1842: Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1846: Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
1860: Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1872: George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1888: Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1900: Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1908: Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1978: Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1981: The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1983: The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1989: Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
1993: The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1994: The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
1996: The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1997: Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2000: An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2001: The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2002: The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|150px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
'''Video of Huntington's disease patient'''&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|300px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73252</id>
		<title>2011 Group Project 4</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=2011_Group_Project_4&amp;diff=73252"/>
		<updated>2011-09-29T01:34:51Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Video of Huntington's disease patient */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011ProjectsMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
=Huntington's Disease=&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 14:58, 8 September 2011 (EST) Good sub-heading structure, as I have discussed this will be postnatal rather than prenatal effects, so diagnosis should be covered in some depth. Content in some sections is still very light and not researched. Currently there is not a single figure on the project page.&lt;br /&gt;
* Introduction - brief and to the point. There are some terms that may require clarification (cerebral cortex, striatum, chorea). There is no mention of it belonging to a group of known disease types.&lt;br /&gt;
* History - This is a genetic disease, it probably had &amp;quot;existed&amp;quot; before the seventeenth century, this was when it was described. It appears that there is only a single time point (the discovery) in the history of this disease, fix this please.&lt;br /&gt;
* Epidemiology - &amp;quot;white people as compared to Africans and Asians&amp;quot; is this the correct terminology? The country by country information would look better in the form of a table. &amp;quot;HTT haplotypes&amp;quot; without any explanation. Sub-headings would fix some of the disjointed feel to this section.&lt;br /&gt;
* Pathogenesis and Genetics - same content, with typos. Typos suggest that you (or your group) have not reviewed the work. This is a very poor sub-section.&lt;br /&gt;
* Diagnostic Tests - &amp;quot;the middle ages&amp;quot; as opposed to the medieval period? These &amp;quot;similar diseases, which mimic similar characteristics&amp;quot; need to be better organised to show how they are similar. Neuropathology, is this not a postmortem diagnosis?&lt;br /&gt;
* Clinical Manifestations - no text here.&lt;br /&gt;
* Treatment -  a list of bullet points with no accurate descriptions of these treatments. Breakthroughs, is this not Current/Future Research?&lt;br /&gt;
* Current/Future Research - Nothing here of interest nor referenced.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
&lt;br /&gt;
Huntington’s disease (HD) is an autosomal dominant disease caused by the mutated huntingtin protein gene. HD is under the family of neurodegenerative diseases which only becomes identified by an expanded, repeated CAG trinucleotide tract, resulting in the formation of abnormal long proteins called polyglutamine seen at the molecular level &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
HD is characterised by degeneration and dysfunction of the cerebral cortex and striatum causing deterioration in neurons which may be the reason for its clinical manifestations in jerky, involuntary movements such as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21841917&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt; pubmed&amp;gt;21847326&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. HD was originally known as chorea before great detail of the disease was found, and in 1872 physician George Huntington first documented the clinical profile of the disease and HD was named after him &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
The disease is developed familially or sporadically. The majority of cases of development of HD is familial, caused by the inherited defective gene from the parent to the child. However in some rare cases, it is sporadically developed from new genetic mutation in alleles with no relation to inheritance &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
HD has a late onset of symptoms thus it is possible for someone to be the carrier of the mutated huntingtin gene without showing any symptoms of HD until in their later years. Diagnosis of the disease is made by the onset of symptoms and may vary between different people but is commonly revealed between the ages of 35-42. The tendency for symptoms to arise earlier is the result of further expansion of the CAG tract. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
While there is no current cure for HD, there are treatments and medications available to help ease the symptoms of HD. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==History==&lt;br /&gt;
&lt;br /&gt;
[[Image:George_Huntington.jpg|thumb|right|George Huntington|150px]] Huntington's disease has existed since at least the seventeenth century and several physicians provided earlier descriptions of hereditary chorea but without much detail. In 1872, Huntington’s disease was first documented with great details by George Huntington in “On Chorea” &amp;lt;ref&amp;gt;Huntington G (1872). &amp;quot;On Chorea&amp;quot;. Medical and Surgical Reporter of Philadelphia (The Hague: Nijhoff) 26 (15): 317–321. ISBN 9061860113. [http://en.wikisource.org/wiki/On_Chorea] &amp;lt;/ref&amp;gt;. Huntington’s disease was initially known as chorea, derived from the Greek word ''khoreia'' which means dancing in unison. George Huntington described the disease as “an heirloom from generations away back in the dim past” as he realized that HD was hereditary. This conclusion was reached when he observed that if one of the parents had the disease, the offspring will inevitably have the disease too. In his paper, “On Chorea”, he described:&lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|&amp;quot;Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.&amp;quot;.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Huntington thus was able to explain the precise pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''TIMELINE OF HUNTINGTON'S DISEASE RESEARCH''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16136077&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1842: Huntington's disease was first described by Charles Oscar Waters in a letter in Robley Dunglinson's &amp;quot;Practice of Medicine.&amp;quot; &amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;&amp;gt;Harper P (2002). &amp;quot;Huntington's disease: a historical background&amp;quot;. In Bates G, Harper P, and Jones L. Huntington's Disease – Third Edition. Oxford: Oxford University Press. pp. 3–24. ISBN 0-19-851060-8.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1846: Charles Gorman noticed that the symptoms associated with the disease seemed to affect many people in particular regions. HD is observed as being localised.&amp;lt;ref name=&amp;quot;OxfordMonographHistory&amp;quot;/&amp;gt; &lt;br /&gt;
&lt;br /&gt;
1860: Johan Christian Lund produced the first description of the illness while working at Jefferson Medical College.&amp;lt;ref&amp;gt;Wexler A, Wexler N (2008). [http://yalepress.yale.edu/yupbooks/book.asp?isbn=9780300105025 The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease.] Yale University Press. p. 288. ISBN 978-0-300-10502-5. .  &lt;br /&gt;
&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1872: George Huntington’s paper was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11232352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1888: Hoffman describes juvenile HD.&amp;lt;ref&amp;gt;Hoffmann, J. Über Chorea chronica progressiva (Huntingtonsche Chorea, Chorea hereditaria). Virchows Arch. A 111, 513–548 (1888) (in German)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1900: Mendel’s work was rediscovered.&amp;lt;ref&amp;gt;On the Origin of Mendelian Genetics  Amer. Zool. (1986) 26 (3): 753-768. [http://icb.oxfordjournals.org/content/26/3/753.abstract#fn-1]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1908: Punnett cites HD as autosomal dominant.&amp;lt;ref&amp;gt;Punnett, R. C. Mendelian inheritance in man. Proc. R. Soc. Med. 1, 135–168 (1908)&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1978: Restriction fragment-length polymorphisms (RFLPs) were first described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;281713&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1981: The Venezeula Project was initiated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2881213&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1983: The HD gene was mapped to the short arm of chromosome 4.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1989: Linkage disequilibrium indicated a 2 Mb candidate region.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531223&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2531224&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1680285&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
1993: The HD gene was isolated and a CAG repeat mutation was identified.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8504314&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1994: The Working Group on HD of the WFN/IHA published guidelines on counseling for predictive testing.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7966192&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;   &lt;br /&gt;
&lt;br /&gt;
1996: The first mouse model for HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9267033&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
1997: Aggregates were described in mouse &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8898202&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and patient brains.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9302293&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2000: An inducible mouse model of HD was described.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10778856&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2001: The first phase-III clinical trials for HD were published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11502903&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2002: The first high-throughput screen was published.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12200548&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Epidemiology==&lt;br /&gt;
&lt;br /&gt;
There seem to be an increased prevalence of Huntington's disease among Europeans as compared to Africans and Asians. European populations exhibit a comparatively high prevalence with 4-8 per 100,000 individuals suffering from HD.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1535611&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Two of the most well-known populations in which high prevalence of HD was notably in the state of Zulia, Venezuela&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2139171&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and Northern Ireland.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; The overall prevalence of HD in Mexico was also expected to be comparable or even higher to that of European populations.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19672992&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|style=&amp;quot;width:220px&amp;quot;|'''Country/Region''' &lt;br /&gt;
|style=&amp;quot;width:300px&amp;quot;|'''Prevalence of HD (individuals per 100,000)'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|Tasmania &lt;br /&gt;
| 12.1 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2142982&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Northern Ireland &lt;br /&gt;
| 6.4 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| South East Wales (UK) &lt;br /&gt;
| 6.2 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9231935&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Olmsted County, Minnesota (US) &lt;br /&gt;
| 6 - 6.6 (1960) &amp;amp; 1.8 - 2 (1990) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8018043&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Valencia Region (Spain) &lt;br /&gt;
| 5.38 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9528016&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Slovenia &lt;br /&gt;
| 5.16 &amp;lt;ref&amp;gt;Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L.'''Epidemiology of Huntington’s disease in Slovenia.''' Acta Neurol Scand.: 2009 PMID:18976322 [http://www.ncbi.nlm.nih.gov/pubmed/18976322]&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Oxford Region (UK) &lt;br /&gt;
| 4.0 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21088431&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108531&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| New South Wales (Australia) &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11008591&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Japan &lt;br /&gt;
| 0.65 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8752454&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Finland &lt;br /&gt;
| 0.5 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889026&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Taiwan &lt;br /&gt;
| 0.42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
| Hong Kong &lt;br /&gt;
| 0.37 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7586664&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
:::::::::::::'''Table 1''' ''Prevalence of Huntington's Disease in various parts of the world''&lt;br /&gt;
&lt;br /&gt;
Table 1 shows the prevalence of HD in different parts of the world, with regions ranked according to how prevalent HD is.&lt;br /&gt;
Countries with the highest prevalence are from Europe with most appearing at the top of the table whereas Asian countries are found at the bottom half of this table. This indicates the lower prevalence of HD in Asia as compared to that in European populations. This observation is further supported by a study done by Shiwach and Lindenbaum (1990), it was found that the minimum prevalence of HD among immigrants from the Indian subcontinent was found to be almost half that found in the indigenous UK population.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2151860&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; For those areas where there are intermarriages with Europeans, there is a higher occurrence of the disease. This is related to the higher frequency of huntingtin alleles with 28–35 CAG repeats in Europeans and the fact that the disease is autosomal dominant. &amp;lt;ref&amp;gt;DC Rubinsztein, Molecular biology of Huntington's disease (HD) and HD-like disorders. In: S Pulst, Editor, Genetics of movement disorders, Academic Press, California (2003), pp. 365–377.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In a paper by Warby et al. (2011), it was reported that HTT haplotypes contribute to the difference in prevalence of HD between European and East Asian populations. Haplotypes are sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated. Different HD haplotypes have different mutation rates, resulting in expansion of CAG tract (marker for HD).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Hence, for HTT haplotypes with higher mutation risk such as A1 and A2 halotypes, individuals are more susceptible to HD due to CAG expansion and this corresponds to higher prevalence. This is supported by the findings that higher risk A1 and A2 HD halotypes composed the majority of HD chromosomes in Europe whereas it is absent in China and Japan.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21248742&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 1px #a0a0ff&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
|rowspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Halotypes''' &lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''General Population'''&lt;br /&gt;
|colspan=&amp;quot;2&amp;quot; style=&amp;quot;width:150px&amp;quot;|'''HD Chromosomes'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#9ea1ff&amp;quot;&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|East Asia&lt;br /&gt;
|Europe&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|A1 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.07&lt;br /&gt;
|0.00&lt;br /&gt;
|0.50&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|A2 &lt;br /&gt;
|0.00&lt;br /&gt;
|0.13&lt;br /&gt;
|0.00&lt;br /&gt;
|0.29&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|B&lt;br /&gt;
|0.16&lt;br /&gt;
|0.04&lt;br /&gt;
|0.10&lt;br /&gt;
|0.00&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;&lt;br /&gt;
|C &lt;br /&gt;
|0.40&lt;br /&gt;
|0.47&lt;br /&gt;
|0.77&lt;br /&gt;
|0.02&lt;br /&gt;
|}&lt;br /&gt;
::::::::::::::'''Table 2''' ''HTT haplotype frequency in East Asia and Europe'' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19249009&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The incidence rate of HD increases with age. It was reported in Taiwan that the range of age at which most onset of HD occurs is between 40-49 years in males and between 50-59 years in females.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20881427&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; This trend is similar to that reflected in a Northern Ireland study, whereby the age group in which the highest number of HD onset occurs is 40-44 years.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7562964&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Both of the above-mentioned studies concluded that there is no significant difference for the age of onset between males and females, indicating no sexual predominance for HD.&lt;br /&gt;
&lt;br /&gt;
==Genetics==&lt;br /&gt;
&lt;br /&gt;
===Inheritance===&lt;br /&gt;
[[File:Inheritance pattern in Huntington's Disease.jpeg|thumb|250px|Inheritance pattern in Huntington's Disease.jpeg]]&lt;br /&gt;
Huntington's Disease is an autosomal-dominant disorder, meaning that it is not inherited according to sex of the parent, rather the severity of the CAG repeat.&lt;br /&gt;
&lt;br /&gt;
The offspring of one affected and one unaffected parent will have a 50% chance of inheriting HD. In rare cases where both parents are affected the child will have a 100% chance of inheriting the disease. &amp;lt;ref&amp;gt; Beal, M.F., &amp;amp; Ferrante, R.J. (2004). '''Experimental therapeutics in transgenic mouse models of Huntington's disease.''' Nature Reviews Neuroscience,  5, 373-384. doi:10.1038/nrn1386 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Huntingtin Gene===&lt;br /&gt;
Huntington’s Disease is due to a mutation causing an expanded CAG (cytosine-adenine-glutamine) trinucleotide repeat tract in the Huntingtin (HTT) gene. &lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; normal functions:'''&lt;br /&gt;
&lt;br /&gt;
The HTT gene is comprised of 67 exons and is located between the markers D45127 and D45180 on the short arm 4th chromosome (4p) at position 16.3, spanning over a genomic region of over 200kb.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The huntingtin protein is found in the nucleus, cell body, dendrites and nerve terminals and is also associated with cellular organelles such as golgi apparatus, endoplasmic retiniculum and mitochondria. It is found in many body tissues but is predominantly active in the brain, specifically in the striatum (integral part of basal ganglia). &lt;br /&gt;
&lt;br /&gt;
The precise function of HTT remains unknown. Many studies have tried to determine the pathological effects of HTT, with conclusion that it has a complex role at several cellular levels. &lt;br /&gt;
&lt;br /&gt;
*	HTT is a primary constituent of the dynactin complex which networks with microtubules in dendrites, signifying a role in vesicle transport and cytoskeleton anchoring. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
*	It has been shown to have a significant role in clathrin-mediated endocytosis, neuronal transport and postsynaptic signalling. &lt;br /&gt;
&lt;br /&gt;
*	Additionally, HTT is capable of protecting neuronal cells from apoptotic stress, hence having pro-survival role in neural tissue. &lt;br /&gt;
&lt;br /&gt;
*	A study by Bates &amp;amp; Murphy, 2001 showed that knocking out the HTT gene in mice will result in death of the embryo by day 7.5 due to atypical brain development. It was therefore concluded that HTT is necessary for cell survival and its loss is most likely to cause neurodegeneration. &amp;lt;ref&amp;gt; Bates GP, Murphy KP (2002) '''in Huntington's Disease''' (eds Bates GP, Harper PS, Jones AL) 387–426. Oxford, UK: Oxford University Press. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
HTT contains a polymorphic region containing the CAG repeat, normally 10-35 times (i.e. CAGCAGCAG...). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''HTT &amp;amp; Huntington’s Disease:'''&lt;br /&gt;
[[File:Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease.jpg|thumb|400px|Healthy Huntingtin protein and Huntingtin gene mutated by Huntington's Disease]]&lt;br /&gt;
&lt;br /&gt;
Huntington Disease - caused by a mutation on the 1st exon of the HTT gene.&lt;br /&gt;
&lt;br /&gt;
As previously discussed the huntingtin protein is found in unaffected individuals, It is however associated with HD when the CAG trinucleotide is repeated more than 36 times (i.e. CAGCAGCAG...). This abnormal repeat of CAG leads to formation of long proteins known as polyglutamine. &amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''.  &amp;lt;/ref&amp;gt; In unaffected individuals the polyglutamine chains are formed by maximum 36 repetitions of CAG. Conversely, in HD patients the repeats vary from 36-121 times with increasing number of repeats being inversely correlated with the age of HD onset and severity of the loss cognitive abilities.&amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease.''' Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Patients with repeats of 36-40 times may or may not develop the clinical manifestations of HD, whilst those with CAG repeats of more than 40 almost always develop the disorder.&lt;br /&gt;
&lt;br /&gt;
With each altered pass of the HTT gene to the next generation, the CAG repeat length elongates leading to more severe and earlier onset of symptoms.&lt;br /&gt;
&lt;br /&gt;
Individuals with CAG repeats of 27-35 in HTT gene do not develop HD; however their offspring is at high risk of developing the disease with CAG repeats of more than 35 in the HTT gene. &amp;lt;ref&amp;gt; Weir, d.W., Sturrock, A., &amp;amp; Leavitt, B.R. (2011). '''Development of biomarkers for Huntington’s disease.''' Lancet Neurol, 10,573–90. &amp;lt;/ref&amp;gt;&lt;br /&gt;
CAG expansions are therefore the biomarkers used for genetic tests to identify mutant HTT carriers. &lt;br /&gt;
.&amp;lt;ref&amp;gt; C, Landles., &amp;amp; G, P. Bates. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO reports, 5, 958-963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Molecular Mechanisms &amp;amp; Pathogenesis ==&lt;br /&gt;
&lt;br /&gt;
Although HD is a broad area of current research, the exact pathogenesis by which HTT mutation leads to the neurodegeneration and serious loss of cognitive abilities has not yet been fully understood.&lt;br /&gt;
There are key unproven pathological mechanisms that seem to be used to explain the pathways by which a mutation in the HTT gene can cause cellular and clinical complications. &lt;br /&gt;
&lt;br /&gt;
The neurodegenerative changes that occur in HD patients are most commonly localised to the putamen and caudate nuclei which are substructures of the basal ganglia forming the striatum region of the brain.&amp;lt;ref&amp;gt; Martin, B,. Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M., &amp;amp; Maudsley, S. (2008). Therapeutic perspectives for the treatment of Huntington’s disease: Treating the whole body. Histol Histopathol, 23(2), 237–250. &amp;lt;/ref&amp;gt; The function of the basal ganglia has major consequences on the organisation of motor behaviour. Destruction of neural tissue is also located within the temporal and frontal lobes of the cerebral cortex which are significant in mental functioning, movement and sensation. &amp;lt;ref&amp;gt;Rosenblatt, A., &amp;amp; Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics. 41, 24–30.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Striatal cells===&lt;br /&gt;
The nerve cells of the striatum known as &amp;lt;font color=indigo&amp;gt;'''medium-sized spiny neurons (MSN)''' &amp;lt;/font&amp;gt;are the predominant nerve cells affected by mutant HTT. These specific neurons are responsible for the release of gamma-aminobutyric acid (GABA), which is capable of inhibiting neurotransmitter release by other nerve cells. &amp;lt;ref&amp;gt; Zala, D. (2004). HUNTINGTON'S DISEASE MODELING AND TREATMENT:&lt;br /&gt;
FROM PRIMARY NEURONAL CULTURES TO RODENTS.&amp;lt;/ref&amp;gt;&lt;br /&gt;
The striatum is the main target for glutamatergic output neurons from the thalamus and the cortex, making striatal cells highly sensitive to glutamate. Neurodegenration and excitotoxicity is therefore inducible by directly injecting glutamate into the striatum. &lt;br /&gt;
&amp;lt;ref&amp;gt; Morton, J. (2004). Molecular Pathogenesis of Huntington's Disease. Advances in Clinical Neuroscience and Rehabilitation, 1(4),617-628.&amp;lt;/ref&amp;gt;It has been suggested that MSN destruction leads to decreased inhibition of the thalamus, hence increasing thalamus activity and the release of its contents to certain regions of the brain. It is speculated that this inhibition results in disorganised and hyperkinetic movements known as chorea. &lt;br /&gt;
&lt;br /&gt;
[[File:Key cellular pathogenic mechanisms in HD.jpg|Left |thumb|500px|Key cellular pathogenic mechanisms in HD]]&lt;br /&gt;
&lt;br /&gt;
===Abnormal protein-protein interactions===&lt;br /&gt;
HTT protein is widespread through many neural tissues, hence when the mutated protein carries an expanded polyglutamine tract, these interactions are altered.  &lt;br /&gt;
HTT is known to react with HTT-associated protein I (HAPI) and HTT-interacting protein (HIPI).&amp;lt;ref&amp;gt; Imarisio, S, Carmichael, J,. Korolchuk, V,. Chen, C,. Saiki, S,. Rose, c,. Krishna, g,. Davies, J.E., Ttofi, E,. Underwood, B.R., &amp;amp; Rubinsztein, D.C. (2008). '''Huntington’s disease: from pathology and genetics to potential therapies'''. Biochemistry Journal, 412, 191–209. doi:10.1042/BJ20071619 &amp;lt;/ref&amp;gt; In HD, the HTT protein’s interaction with HAPI is increased, and interaction with HIPI is decreased with lengthening polyglutamine chains. An &amp;lt;font color=indigo&amp;gt;'''over-expression of HIPI is known to be neurotoxic''' &amp;lt;/font&amp;gt;, therefore if mutated HTT has a reduced binding capacity for HIPI, it can easily accumulate in cells and become pathological.&amp;lt;ref&amp;gt; Zala, D. (2004). '''Huntington’s Disease modelling and treatment: from primary neuronal cultures to rodents'''. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Aggregate formation===&lt;br /&gt;
The mutated HTT protein causes unfolding or abnormal folding of this protein. This toxic protein is recognised by molecular chaperones which are involved with assembly of proteins. Once unsuccessful the misshapen proteins are tagged and targeted by proteosomes in the cytoplasm for degradation. &amp;lt;ref&amp;gt; Zuccato, C, Valenza, M., &amp;amp; Cattaneo, E. (2009). '''Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease'''. Physiol Rev, 90( 3),  905-981. doi: 10.1152 &amp;lt;/ref&amp;gt; HTT is cleaved by a different number of proteases such as ''caspases'' and calcium-dependent proteases such as ''calpain''. However &amp;lt;font color=indigo&amp;gt; '''proteosome efficiency is highly reduced in HD patients''' &amp;lt;/font&amp;gt;, which not only leads to aggregating toxic material in striatal cells but it also means that the proteases become incapable of breaking down other toxic products in the cell.&amp;lt;ref&amp;gt; Wellington, C.L.,  Singaraja, R.,  Ellerby, L., Savill, J.,  Roy, S.,  Leavitt,  B., Cattaneo, E., Hackam,  M., Sharp, A., Thornberry, N., Nicholson,  D.W., Bredesen, D.E., &amp;amp; Hayden, M.R. (2000).  '''Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells'''. J Biol Chem, 275,19831–19838. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Calcium Signalling===&lt;br /&gt;
The accumulation of toxic HTT proteins with elongated polyglutamine chains impairs the calcium signalling pathway and disrupts cellular homeostasis and mitochondrial function. In transgenic mice with mutated HD, the mutated HTT has shown to trigger mitochondrial membrane permeabilization and apoptotic cell death by impairing proteosome activity and interfering with Ca2+ signaling. &amp;lt;ref&amp;gt; Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049–1059, 2001. &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==='''Role in transcription inhibition'''===&lt;br /&gt;
&lt;br /&gt;
[[File:Mutant Huntingtin gene and its effects on transcription.jpg|thumb|left|File:Mutant Huntingtin gene and its effects on transcription.jpg||300px]]&lt;br /&gt;
&lt;br /&gt;
The mutant HTT fragments are able to translocate into the nucleus where they most commonly interrupt DNA transcription or form intracellular inclusions. &lt;br /&gt;
Studies have shown that unusually long polyglutamine tracts such as those in HD are able to disrupt normal function of transcription factors and inhibit or alter DNA transcription. &amp;lt;ref&amp;gt; Landles, C., &amp;amp; Bates, G.B. (2004). Huntingtin and the molecular pathogenesis of Huntington's disease. Embo reports, 5, 958 – 963. doi:10.1038/sj.embor.7400250 &amp;lt;/ref&amp;gt; &lt;br /&gt;
&amp;lt;font color=indigo&amp;gt;'''Transcription factors''' &amp;lt;/font&amp;gt; such as p53, CREB-binding protein (CBP), specifity protein 1 (S1) and TATA-binding protein. can bind to the polyglutamine chain of mutated HTT and inhibit RNA polymerase binding to the promoter region; hence repressing DNA transcription of specific proteins such as brain-derived neutrophic factor (BDNF).&amp;lt;ref&amp;gt; Mattson, M.P., Chan, S.L., &amp;amp; Duan, Wenzhen. (2002). Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior. Physio Rev, 82(3),  637-672. &amp;lt;/ref&amp;gt; BDNF belongs to the neutrophin family of growth factors found specifically in the hippocampus, cortex and basal ganglia. It functions to assist in neuron cell survival and also to support growth and differentiation of new neurons.&amp;lt;ref&amp;gt;1.	Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L.,  MacDonald, M.E.,  Friedlander, R.M.,  Silani, V., Hayden,  M.R., Timmusk, T.,  Sipione, S., &amp;amp; Cattaneo, E. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493–498.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Clinical Manifestations==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is a hyperkinetic disorder which is caused by the degeneration of neurons in the cerebral cortex and striatum. Clinical manifestations that occur from a hyperkinetic disorder, in particular reference to HD is marked by five specific features:&lt;br /&gt;
[[Image:Peripheral and Central Nervous System impairment in Huntington's Disease..JPG|thumb|left|Symptoms and impairment of the human body that manifests in patients diagnosed of Huntington's Disease regardless of gender|150px]]&lt;br /&gt;
&lt;br /&gt;
* Chorea movements&lt;br /&gt;
* Heritability; HD is autosomally dominant&lt;br /&gt;
* Physical and behavioural disturbances; unbalanced stance and personality changes&lt;br /&gt;
* Cognitive impairment; causes depression, dementia&lt;br /&gt;
* Death common in 15-20 years after intial onset &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15036808&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21209352&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
A diverse range of signs and symptoms can develop in those who are affected thus making symptoms clinically unique for different individuals. However, the typical symptoms that manifest in the majority of HD carriers are chorea and behavioural changes which occur at adult-onset between the ages 35-42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11442329&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progression of the disease continues to develop from the first signs of onset over 10-30 years, eventually leading to death.&lt;br /&gt;
&lt;br /&gt;
In the case of HD, symptoms are manifested in three classes – &lt;br /&gt;
&lt;br /&gt;
1) motor, it affects the body by progressively developing a disorder in movements which is most commonly seen as chorea; &lt;br /&gt;
&lt;br /&gt;
2) cognitive, a progressive impairment in the brain that leads commonly to dementia; &lt;br /&gt;
&lt;br /&gt;
3) behaviour/psychiatric, also caused by a progressive impairment in the cortex, however leading to behavioural disturbances and can vary depending on the severity and the degree of the state of disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;15459747&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
'''Motor movement Impairment'''&lt;br /&gt;
&lt;br /&gt;
As HD is a neurodegenerative disorder, the cortex of the brain is affected thus naturally giving rise to the impairment in motor functions. Although there are a range of defective motor movements which may occur, chorea remains to be the one typically known to characterise HD. Derived from the Greek work khoreia which means dance, this involuntary movement typically involves an involuntary jerky dance like movement. Motor impersistence is also very common in HD patients and is often classified under the same branch as chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21882418&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The juvenile cases, younger onset of HD individuals may show symptoms of involuntary muscle twitching, abnormal eye movements, dystonia and parkinsonism which may be manifested rather than chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10987900&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Further down the track however, these involuntary movements will increase and become prevalent and spread to the arms, legs, trunk, and head of the patient and may develop into chorea. The individuals with an adult-onset of HD who start off with the symptoms of chorea, may develop an evolved complicated series of movements as the disease progresses which may include dystonia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;7753064&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Diagnostic Tests==&lt;br /&gt;
&lt;br /&gt;
Huntington’s Disease is most commonly diagnosed at the onset on symptoms, typically between the ages of 35 and 42 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6451036&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The diagnosis is relatively simple in patients with typical symptoms. Diagnosis is important to ensure that this disease is not confused with similar diseases, which mimic similar characteristics &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These include tardive dyskinesia, chorea gravidarum, hyperthyroid chorea and Neuroacanthocytosis (refer to table below) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16003113&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. In children, subacute sclerosing panencephalitis can easily be mistaken for Huntington’s disease as they both present with very similar clinical presentations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11807185&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Huntington’s disease can also be diagnosed when a patient is asymptomatic, by genetic testing. This also enables detection of the disease in embryos.&lt;br /&gt;
&lt;br /&gt;
===Differential Diagnosis===&lt;br /&gt;
&lt;br /&gt;
[[File:Neuroacanthocytosis.jpg|right|200px|Neuroacanthocytosis|thumb]]&lt;br /&gt;
&lt;br /&gt;
{| border=&amp;quot;1&amp;quot; &lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
|&amp;lt;font color=crimson&amp;gt;Disease&amp;lt;/font&amp;gt; ||&amp;lt;font color=crimson&amp;gt;Characteristics&amp;lt;/font&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
|Huntington’s Disease || Random involuntary jerky movements, lack of coordination, uncompleted motions as well as saccadic eye movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;  &lt;br /&gt;
|-&lt;br /&gt;
| Tardive Dyskinesia || Involuntary movements occurring particularly in older patients. These consist of chewing movements, tongue protrusions, licking and rotating tongue movements, as well as choreoathetoid limb movements &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2898870&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Chorea Gravidarum || A complication of pregnancy which consists of involuntary, brief and nonrhtymic movements. These are non repetitive and can be associated with any limbs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;25742087&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Hyperthyroid Chorea || Abnormal, involuntary movements due to an increased response of striatal dopamine receptors to dopamine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;474817&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| Neuroacanthocytosis || Spicualted erythrocytes with symptoms including involuntary or slow movements, muscle weakness and abnormal body postures &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1998879&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
=Video of Huntington's disease patient=&lt;br /&gt;
&lt;br /&gt;
[[File:HD patient with no treatment.mov]]&lt;br /&gt;
&lt;br /&gt;
===Neuropathology===&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington Disease patient and control MRI.gif|400px|thumb|left|Caudate,putamen, cerebral and cerebellar volumes. Huntington's disease (top) control (bottom)]]&lt;br /&gt;
&lt;br /&gt;
Anton (1896) and Lannois (1897) were the first to observe neuropathological changes associated with Huntington’s disease. They independently noted the degeneration of the striatum in patients with Huntington’s disease &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2147116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Numerous other neuropathological abnormalities have now been identified in different parts of the brain including the subtalamic regions, pons and medulla oblongata, the spinal cord, cerebellum, superior olive, claustrum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; as well as the amygdala, dorsal striatum and globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; . &lt;br /&gt;
&lt;br /&gt;
Other brain areas greatly affected include the substantia nigra &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8505640&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and the centromedial-parafascicular complex of the thalamus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10378380&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The neuropathological hallmark of Huntington’s disease is now know to be the gradual loss of spiny GABAergic projection neurons of the neostriatum. This is accompanied with the atrophy of the caudate of nucleus, putamen and external segment of the globus pallidus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21496571&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
In 1895, Vonsattel et al. developed a five-tiered pathological grading system based on this hallmark, based on gross and pathological observations. A grading from 0 to 4 is given to patients based upon the amount of neuronal loss and atrophy in the striatum. Grade 0 presents with no evident  cell loss and progresses to grade 4, in which a patient has approximately 95% neural loss &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2932539&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
===Imaging===&lt;br /&gt;
&lt;br /&gt;
During the course of Huntington’s disease, morphological changes that occur in the brain can be observed using brain imaging techniques. These techniques include volumetric analysis of '''computed tomography (CT) scans''', '''magnetic resonance images (MRIs)''', '''single-photon emission computed tomography (SPECT)''' as well as '''positron emission tomography (PET)''' &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
[[File:SPECT scanner.jpg|right|300px|SPECT scanner|thumb]]&lt;br /&gt;
&lt;br /&gt;
Routine MRI and CT scan have proven to be extremely helpful in the detection of moderate-severe progression of Huntington's disease, however they are usually unhelpful in the detection and diagnosis of early disorder.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17240289&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Studies using scans have suggested that the earliest change in Huntington’s disease occurs in the caudate nucleus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. The progressive bilateral atrophy of the striatum throughout a patient’s life can be detected using CT scans as well as MRIs &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2524678&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. During the advancement of the disease, other regions of the striatum such as the putamen and globus palidus can also be noted as being affected &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9040728&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. These changes in the striatum have been related with specific cognitive defects such as problems with attention and memory function. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1531910&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Harries et al found, using MRI and single-photon emission computed tomography, that the putamen was the area that showed the greatest amount of atrophy while the caudate was the area that presented with the greatest reduction in cerebral blood flow in patients with Huntington’s disease compared with controls. This correlates with some of the symptoms presented in patients with Huntington’s disease such as difficulty with motor skills. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8929153&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington's disease MRI.jpg|left|300px|MRI of patient with Huntington's disease|thumb]]&lt;br /&gt;
&lt;br /&gt;
PET scans as well as functional MRI studies allow the detection of changes in affected brain areas even before the onset of symptoms. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10805336&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Functional brain imaging is based on the fact that neural activity is related to either regional cerebral blood blow, the local degree of glucose metabolism or regional changes in receptor binding. This can be measured by a resting-state study, where the patterns of activity are measured in a resting state or by a neurocognitive-activation study where patterns of activity are measured during the performance of a given task. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16496032&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Studies using SPECT have shown metabolic abnormalities in the striatal and extra-striatal regions of patients with Huntington’s disease. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9313639&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; They have also demonstrated that there is a reduction in the regional cerebral blood flow in the striatum and prefrontal cortex of these patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2933014&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
PET scans have also been used to identify that patients with Huntington’s disease show a marked reduction in dopamine binding in the striatum &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9126061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; which shows a strong correlation with verbal fluency, visuospatial skills and perceptual speed and reasoning &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9448576&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Genetic testing and prenatal diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
After the ''Huntingtin'' gene’s discovery in 1983 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6316146&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, genetic testing first became available using '''linkage analysis'''. However it wasn’t until the 1993 when the CAG repeat on the affected chromosome was identified that accurate diagnosis could be made. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21171977&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Although genetic testing is widely available to diagnose Huntington’s disease, less than 5% of at risk individuals actually chose to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10489044&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;. Those that choose to get tested generally do so in order to make career and family choices whereas those that choose not to get genetically tested commonly make this decision due to the lack of effective treatment. It is also important to note that suicide is very common following positive results. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10205260&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Amniocentesis.jpg|right|Amniocentesis|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Current protocols are designed to exclude certain people from getting genetically tested as well as ensure proper genetic counseling before an individual can be tested.  &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1968570&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Those excluded from the procedure include minors under the age of 18, persons with severe psychiatric illnesses and those who have external pressure to get tested. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8058167&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Antenatal testing is available due to the fact that genetic testing can be performed on any cell containing DNA. '''Chorionic villus sampling''' can be carried out between the 10th and 12th week of pregnancy whereas '''amniocentesis''' is performed between the 15th and 17th weeks and subsequent DNA-testing can be carried out. Parents who know their genetic status who choose not to get tested prenatally often do so in the hope that treatment will eventually become available for affected offspring.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11973620&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Preimplantation diagnoses have now recently been available in several countries. This in vitro procedure begins when the embryo is in its eight-cell stage where a single cell is screened. The embryo without the elongated CAG repeat is placed in the mother’s womb in hope for a normal pregnancy. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17245406&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Treatment==&lt;br /&gt;
&lt;br /&gt;
There is no cure for Huntington's disease. Similar to AIDS, only the symptoms of HD can be treated.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19588393&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Medications===&lt;br /&gt;
&lt;br /&gt;
{| align=&amp;quot;center&amp;quot; style=&amp;quot;border: solid 2px #a0a0ff&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; style=&amp;quot;background:#8eb2ec&amp;quot;&lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of symptoms''' &lt;br /&gt;
| style=&amp;quot;width:150px&amp;quot;|'''Types of medications'''&lt;br /&gt;
| style=&amp;quot;width:160px&amp;quot;|'''Active chemical ingredient'''&lt;br /&gt;
| style=&amp;quot;width:1%&amp;quot;|'''Drugs'''&lt;br /&gt;
| style=&amp;quot;width:300px&amp;quot;|'''Possible negative side-effects'''&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;7&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Movement disorders &lt;br /&gt;
| rowspan=&amp;quot;6&amp;quot;|Antiseizure drugs&lt;br /&gt;
(anticonvulsants)&lt;br /&gt;
| Valproic acid &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16507108&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|Depakene Depakote&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal toxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8108303&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21868496&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatoxicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21492891&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hemorrhagic pancreatitis, coagulopathies, bone marrow suppression and encephalopathy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18201150&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot; &lt;br /&gt;
| Lorazepam &lt;br /&gt;
| Ativan&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|sleepiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;4341107&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, withdrawal symptoms &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6131080&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, memory impairment and  confusion &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3960963&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Lamotrigine &lt;br /&gt;
| Lamictal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|chorea &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16900938&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, toxic epidermal necrolysis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;9061826&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12892003&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; and multiorgan failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19380079&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Levetiracetam &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16340384&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Keppra&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|somnolence, lethargy &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18728811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, rhinitis, asthenia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10908898&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, headache and dizziness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;10999557&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Tetrabenazine &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16476934&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
| Xenazine&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness,  depression, nausea, worsening of parkinsonism, xerostomia, hypotension &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19050408&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clonazepam &lt;br /&gt;
|Klonopin Rivotril&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|drowsiness &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12390050&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;,	depression, disinhibition and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2889724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Antianxiety drugs &lt;br /&gt;
| Diazepam&lt;br /&gt;
|Valium Antenex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|rebound anxiety after withdrawal &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;6145363&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;9&amp;quot; style=&amp;quot;background:#eeeeff&amp;quot;|Psychiatric disorders&lt;br /&gt;
| rowspan=&amp;quot;5&amp;quot;|Antidepressants&lt;br /&gt;
| Escitalopram&lt;br /&gt;
|Lexapro Lexamil Lexam&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|insomnia, somnolence, dizziness, sweating, constipation, fatigue &amp;lt;ref&amp;gt;US Food and Drug Administration ''' [http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Medr_P1.pdf Review and Evaluation of Clinical Data: Escitalopram Oxalate]&amp;lt;/ref&amp;gt;, sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16430968&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Fluoxetine&lt;br /&gt;
|Prozac Sarafem Fontex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|mania &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;3485926&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, akathisia &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2549018&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, asthenia, tremor, nausea &amp;lt;ref&amp;gt;Eli Lilly and Company [http://pi.lilly.com/us/prozac.pdf '''Prescribing Information of Prozac'''](June 15, 2011) &amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Sertraline &lt;br /&gt;
|Zoloft Lustral&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|similar effects to flouxetine and escitalopram: movement disorders and sexual dysfunction &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8909330&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11229450&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Nortriptyline&lt;br /&gt;
|Aventyl Noritren Sensoval Pamelor&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|suicidal ideation &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19832967&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, hepatic failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8848811&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, dry mouth, sedation, constipation and increased appetite&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Mirtazapine &lt;br /&gt;
| Remeron Avanza Zispin&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|dry mouth, sedation, and increases in appetite and body weight &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11607047&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, restless legs syndrome (RLS) &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18756499&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Antipsychotic drugs&lt;br /&gt;
| Haloperidol&lt;br /&gt;
|Haldol Serenase Linton&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|acute dystonia, akathisia, parkinsonism &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17054159&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, cognitive decline &amp;amp; brain damage &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18228005&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Clozapine&lt;br /&gt;
|Clozaril Clopine Zaponex&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|agranulocytosis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8515788&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, myocarditis &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;17194170&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, gastrointestinal hypomotility &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;18452342&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| rowspan=&amp;quot;2&amp;quot;|Mood-stabilizing drugs&lt;br /&gt;
| Lithium&lt;br /&gt;
| Lithobid&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|renal failure &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19940841&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, nystagmus &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12552061&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, teratogenicity &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11948561&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|- align=&amp;quot;center&amp;quot;&lt;br /&gt;
| Carbamazepine&lt;br /&gt;
|Tegretol Carbatol Sirtal&lt;br /&gt;
| align=&amp;quot;center&amp;quot;|congenital malformations &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21127116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;, pitch perception deficit &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;12581810&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
|}&lt;br /&gt;
'''Table 3''' ''Symptomatic medications for Huntington's disease''&lt;br /&gt;
&lt;br /&gt;
''Note: Some drugs have overlapping effects eg. valproic acid and lamotrigine can also used as mood-stabilising drugs.''&lt;br /&gt;
&lt;br /&gt;
'''Disclaimer:''' The table above is not a comprehensive reference. Please consult your doctor for further information.&lt;br /&gt;
&lt;br /&gt;
===='''Tetrabenazine'''====&lt;br /&gt;
[[Image:Tetrabenazine structure.JPG|thumb|right|Chemical structure of Tetrabenazine]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine is a dopamine-depleting agent which helps to suppress chorea in HD and other hyperkinetic movement disorders such as Tourette's syndrome and tardive dyskinesia.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16466307&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
 &lt;br /&gt;
Its role as a dopamine-depleting agent is achieved by inhibiting the vesicular monoamine transporters (VMAT).  There are two types of VMAT: VMAT1 (located in pheripheral endocrine and paracrine cells) and VMAT2 (located predominantly in the brain and in sympathetic neurons).&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8643547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; Tetrabenazine binds selectively with a &lt;br /&gt;
&lt;br /&gt;
high affinity to VMAT2 and low affinity for VMAT1.  VMAT2 is the only transporter that transports dopamine from the cytoplasm into synaptic vesicles for storage and eventual release.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2751365&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; By inhibiting VMAT2, dopamine will not be packaged into vesicles and hence, unable to travel across the synaptic cleft. Tetrabenazine also &lt;br /&gt;
&lt;br /&gt;
binds and inhibit to dopamine receptors. This suppresses the amount of dopamine binding to the dopamine receptor located at the post synaptic nerve terminal. &lt;br /&gt;
&lt;br /&gt;
Thus, the neurones will not be stimulated and no cascade for the inducement of kinetic movements will be triggered.  &lt;br /&gt;
&lt;br /&gt;
[[Image:Mechanism of tetrabenazine.jpg|thumb|center|Mechanism of tetrabenazine inhibition|500px]]&lt;br /&gt;
&lt;br /&gt;
Tetrabenazine was approved by the U.S. Food and Drug Administration in August 2008 to treat HD, making it the first drug approved for use in the United States to treat the disease.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20957126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===Therapies===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Psychotherapy:''' Aims to help a person manage behavioural problems, develop coping strategies, manage expectations during progression of the disease and facilitate effective communication among family members.&lt;br /&gt;
&lt;br /&gt;
'''Speech therapy:''' HD significantly impairs control of muscles of the mouth and throat that are essential for speech, eating and swallowing&lt;br /&gt;
Hence, this therapy addresses difficulties with muscles used in eating and swallowing.  &lt;br /&gt;
&lt;br /&gt;
'''Physical Therapy:''' It helps to enhance strength, flexibility, balance and coordination. These exercises can help maintain mobility as long as possible and may reduce the risk of falls. Patients may need to use a walker or wheelchair to assist them.&lt;br /&gt;
&lt;br /&gt;
'''Occupational Therapy:''' This therapy requires the use of assistive devices that improve functional abilities.&lt;br /&gt;
::::::*Handrails at home &lt;br /&gt;
::::::*Assistive devices for activities such as bathing and dressing &lt;br /&gt;
::::::*Eating and drinking utensils adapted for people with limited capabilities&lt;br /&gt;
&lt;br /&gt;
==Current/Future Research==&lt;br /&gt;
&lt;br /&gt;
[[File:HD future research.jpg|right|300px]]&lt;br /&gt;
The main area for future research into Huntington’s disease is aimed at finding therapeutic ways to treat the disease in the asymptomatic phase. Research is also being done into finding treatment options to cure symptoms at different stages of the disease. Animal models (mouse) have been used since the 1970s &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;8731&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; to demonstrate the degenerative progression of the disease.  Success in these model as well as the advancement of effective treatments for the symptomatic phases of the disease have provided much hope for the Huntington’s disease community &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;16569382&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Huntington disease atrophy 1.jpg|left|200px|Atrophy of the Caudate Heads|thumb]] [[File:Huntington disease atrophy 2.jpg|left|200px|Atrophy in Huntington's disease|thumb]] [[File:Huntington disease atrophy 3.jpg|left|200px|Seen in a 50yr old man with movement disorder|thumb]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Cholesterol metabolism in Huntington disease. (2011)'''&lt;br /&gt;
&lt;br /&gt;
Cholesterol plays an important role in neuronal development and optimal activity. Huntington’s disease has been linked to changes in cellular cholesterol metabolism. Karasinska and Hayden (2011) investigate how the changes in the synthesis and accumulation of cholesterol in neurones influence the survival of neurons and the pathogenesis of Huntington’s disease. With better understanding of this, it is hoped that effective therapies based on cholesterol regulation can eventually be found. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21894212&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Assessing Behavioural Manifestations Prior to Clinical Diagnosis of Huntington Disease: &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; (2011)'''&lt;br /&gt;
&lt;br /&gt;
A comprehensive rating system called the Functional Rating Scale Taskforce for pre-Huntington’s Disease (FuRST-pHD) was developed to assess symptoms and functional ability in patients who express the mutated Huntingtin gene but have not yet fully developed the symptoms. This complex system involves data from various sources including information from the patients themselves, carers and experts. Vaccarino et al. (2011) aim to assess and improve the interview questions designed to analyse &amp;quot;Anger and Irritability&amp;quot; and &amp;quot;Obsessions and Compulsions&amp;quot; using FuRST-pHD in early Huntington’s disease patients. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21826116&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.(2011)'''&lt;br /&gt;
&lt;br /&gt;
Animal models of Huntington’s disease have been extremely helpful in illustrating the progress of behavioural and physiological changes in Huntington’s disease. Raymond et al (2011) have developed trangenic Huntington’s disease mice in hope to provide insights regarding the striatal neuronal dysfucntion and degernation as well as changes in the excitation and inhibiton of the straitum and cerebral cortex. The focus was on synaptic and receptor modifications of striatal medium-sized spiny and cortical pyramidal neurons in these mouse models. The changes were compared between the early stages of the disease vs changes in the late stages. The findings prove that treatments need to be varied according to which stage the disease is in as well as considering which regions of the brain are affected. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21907762&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective (2011)'''&lt;br /&gt;
&lt;br /&gt;
Ho et al (2011) aimed to gather information regarding what Huntington’s disease suffers are most concerned about during the different stages of the disease progression. Very little is known about this and it therefore needed to be addressed. Interviews were conducted with 31 patients currently living with different stages of Huntington’s disease ranging from pre-clinical gene carriers to advanced stage. Different issues arose depending on which stage of the disease the individuals were in, such as physical, functional, social and emotional issues. These discoveries are then able to provide insight into possible management and interventions across different Huntington’s disease stages. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21736564&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Neuronal degeneration in striatal transplants and Huntington’s disease: potential mechanisms and clinical implications (2011)'''&lt;br /&gt;
&lt;br /&gt;
The symptoms associated with Huntington’s disease (and other neurodegenerative disorders) have thought to be improved using cell therapy to replace degenerated neuronal cells.  However, Cicchetti et al. (2011) have found that the clinical benefits of cell therapy in patients with Huntington’s disease have been very short-lived. If such therapies are to be used in the future enabling significant clinical benefits, it is essential to explain and overcome the problem of the degeneration of the grafts. This study aims to discuss problems relating to long-term graft survival including the cellular responses.&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21278084&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Glossary==&lt;br /&gt;
&lt;br /&gt;
'''Agranulocytosis:''' Failure of the bone marrow to make enough white blood cells (neutrophils).&lt;br /&gt;
&lt;br /&gt;
'''Akathisia:''' Also known as the restless legs syndrome (RLS), it is a disorder in which there is an urge or need to move the legs to stop unpleasant sensations.&lt;br /&gt;
&lt;br /&gt;
'''Allele:''' one part of a pair of genes&lt;br /&gt;
&lt;br /&gt;
'''Asthenia:''' The lack of strength or energy.&lt;br /&gt;
&lt;br /&gt;
'''Asymptomatic:''' Showing no evidence of disease&lt;br /&gt;
&lt;br /&gt;
'''Atrophy:''' A wasting away of the body or of an organ or part, as from defective nutrition or nerve damage. &lt;br /&gt;
&lt;br /&gt;
'''Autosomal dominant:''' An inheritance pattern in which a gene on one of the non-sex chromosomes that is always expressed, even if only one copy is present.&lt;br /&gt;
&lt;br /&gt;
'''Cerebral Cortex:''' Grey, neural tissue (1.5mm to 5mm) that covers the outermost layer of the brain. It is involved in important functions of the brain such as language, motor function, planning and organisation, attention, personality, memory, touch and consciousness.&lt;br /&gt;
&lt;br /&gt;
'''Chorea:''' a disorder characterised by an abnormal involuntary jerky dance-like movement. Chorea is derived from the Greek word ''khoreia'' which means dance. &lt;br /&gt;
&lt;br /&gt;
'''Coagulopathies:''' a disease or condition affecting the blood's ability to coagulate.&lt;br /&gt;
&lt;br /&gt;
'''Cognitive:''' of or pertaining to the mental processes of perception, memory, judgment, and reasoning, as contrasted with emotional and volitional processes. &lt;br /&gt;
&lt;br /&gt;
'''Computed tomography (CT):''' A technique for producing 2-D and 3-D cross-sectional images of an object from flat X-ray images&lt;br /&gt;
&lt;br /&gt;
'''Degeneration:'''A process by which a tissue deteriorates, loses functional activity, and may become converted into or replaced by other kinds of tissue. &lt;br /&gt;
&lt;br /&gt;
'''Dopamine:''' A catecholamine neurotransmitter&lt;br /&gt;
&lt;br /&gt;
'''Dystonia:''' A movement disorder which causes involuntary repetitive contractions of muscles.&lt;br /&gt;
&lt;br /&gt;
'''Encephalopathy:''' diseases of the brain.&lt;br /&gt;
&lt;br /&gt;
'''Gastrointestinal hypomotility:''' A condition resulted from the lack of gastrointestinal movement, giving rise to severe constipation, fecal impaction, paralytic ileus, bowel obstruction, acute megacolon, ischemia or necrosis.&lt;br /&gt;
&lt;br /&gt;
'''Haplotypes:''' Sets of single-nucleotide polymorphisms (SNPs) on a single chromosome of a chromosome pair that are statistically associated.&lt;br /&gt;
&lt;br /&gt;
'''Hemorrhagic pancreatitis:''' Inflammation of the pancreas accompanied by the formation of necrotic areas on the surface of the pancreas and in the omentum and, frequently, also accompanied by hemorrhages into the substance of the gland.&lt;br /&gt;
&lt;br /&gt;
'''Hepatoxicity:''' Poisoning of the liver.&lt;br /&gt;
&lt;br /&gt;
'''Hypotension:''' Low blood pressure.&lt;br /&gt;
&lt;br /&gt;
'''Hyperkinetic disorder:''' characterised by excessive abnormal involuntary movements. Movements may be regular, irregular, rhythmic, random, sustained or temporary and are commonly in the form of jerky movements or a tremor.&lt;br /&gt;
&lt;br /&gt;
'''Linkage Analysis:''' Study aimed at establishing linkage between genes&lt;br /&gt;
&lt;br /&gt;
'''Magnetic Resonance Images (MRI):''' a medical imaging technique used in radiology to visualize detailed internal structures. MRI makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of atoms inside the body.&lt;br /&gt;
&lt;br /&gt;
'''Mania:''' A state of abnormally elevated or irritable mood, arousal or energy levels.&lt;br /&gt;
&lt;br /&gt;
'''Motor impersistence:''' inability to sustain simple voluntary muscular actions such as keeping the eyes closed&lt;br /&gt;
&lt;br /&gt;
'''Myocarditis:''' Inflammation of the heart muscle.&lt;br /&gt;
&lt;br /&gt;
'''Neuronal:''' A specialized, impulse-conducting cell that is the functional unit of the nervous system, consisting of the cell body and its processes, the axon and dendrites. &lt;br /&gt;
&lt;br /&gt;
'''Neuropathological:''' The pathology  of the nervous system.&lt;br /&gt;
&lt;br /&gt;
'''Nystagmus:''' Involuntary eye movements.&lt;br /&gt;
&lt;br /&gt;
'''Parkinsonism:''' A neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.&lt;br /&gt;
 &lt;br /&gt;
'''Polymorphisms:''' The existence of two or more clearly different phenotypes in the same population of a species.&lt;br /&gt;
&lt;br /&gt;
'''Positron Emission Tomography (PET):''' a nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body.&lt;br /&gt;
&lt;br /&gt;
'''Renal toxicity:''' Poisoning of the kidney.&lt;br /&gt;
&lt;br /&gt;
'''Rhinitis:''' Irritation and inflammation of some internal areas of the nose, resulting in ‘stuffy nose’.&lt;br /&gt;
&lt;br /&gt;
'''Single-photon emission computed tomography (SPECT):''' a nuclear medicine tomographic[1] imaging technique using gamma rays.&lt;br /&gt;
&lt;br /&gt;
'''Somnolence:''' Better known as drowsiness, it is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods.&lt;br /&gt;
&lt;br /&gt;
'''Striatum:''' A subcortical part that is situated in the centre of the brain and is part of a larger system called the basal ganglia. It receives input from the cerebral cortex.&lt;br /&gt;
&lt;br /&gt;
'''Teratogenicity:''' The capability of inducing fetal malformations.&lt;br /&gt;
&lt;br /&gt;
'''Toxic epidermal necrolysis:''' A life-threatening dermatological condition in which the epidermis is deattached from the dermis all over the body.&lt;br /&gt;
&lt;br /&gt;
''' Transcription factor:''' A protein that interacts with the promoter region on DNA and regulates a gene by initiating transcription (RNA to DNA) and hence the synthesis of the specific protein.&lt;br /&gt;
&lt;br /&gt;
'''Visuospatial:''' pertaining to perception of the spatial relationships among objects within the field of vision.&lt;br /&gt;
&lt;br /&gt;
'''Xerostomia:''' Dry mouth resulting from reduced or absent saliva flow.&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
{{2011Projects}}&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=73244</id>
		<title>User:Z3290379</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=User:Z3290379&amp;diff=73244"/>
		<updated>2011-09-29T01:30:11Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Lab Attendance */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{2011Student}}&lt;br /&gt;
&lt;br /&gt;
==Lab Attendance==&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Z3290379]] 12:55, 28 July 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 12:53, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:15, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:58, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:05, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|z3290379]] 11:59, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 12:05, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:54, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290379|Elizabeth Blanchard]] 11:30, 29 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Individual Assessments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 1===&lt;br /&gt;
&lt;br /&gt;
'''Identify the origin of In Vitro Fertilization and the 2010 nobel prize winner associated with this technique.'''&lt;br /&gt;
&lt;br /&gt;
In Vitro Fertilization began in the UK in 1978, with Edwards RG succeeding with this process. He was awarded the Nobel Prize in Medicine in 2010 for his work. &lt;br /&gt;
&lt;br /&gt;
'''Identify a recent paper on fertilization and describe its key findings.''' &lt;br /&gt;
&lt;br /&gt;
''Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells'' &lt;br /&gt;
&lt;br /&gt;
Co-Culture of sperm and Sertoli cell feeder (CCSCF) were able to maintain normal sperm motility, viability and mitochondrial function for 7 days. This is of great importance to ART technologies for long-term culture and enabling sperm to be transferred between 2 distant centers while maintaining their potential. &lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21771775 Improvements in human sperm quality by long-term in vitro co-culture with isolated porcine Sertoli cells]&lt;br /&gt;
&lt;br /&gt;
'''Identify 2 congenital anomalies.'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Atrial Septal Defect- lacking of the interatrial septum, enabling blood flow between the left and right atria. &lt;br /&gt;
&lt;br /&gt;
Arnold-Chiari Malformation- downward displacement of the cerebellar tonsils through foramen magnum.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 09:52, 3 August 2011 (EST) These answers are fine for Lab 1 assessment.&lt;br /&gt;
&lt;br /&gt;
===Lab 2===&lt;br /&gt;
&lt;br /&gt;
'''Identify the ZP protein that spermatozoa binds and how is this changed (altered) after fertilization'''&lt;br /&gt;
&lt;br /&gt;
In humans, zona pellucida sperm-binding protein 3 (ZP3), is the receptor in which sperm binds to. Modifications by enzymes occur after fertilization, inactivating ZP3 thus preventing sperm to bind.&lt;br /&gt;
&lt;br /&gt;
===Lab 3===&lt;br /&gt;
&lt;br /&gt;
'''What is the maternal dietary requirement for late neural development?'''&lt;br /&gt;
&lt;br /&gt;
To prevent birth defects associated with neural development (such as spina bifida), the Australian government recommends a daily intake of folate of 600µg for pregnant women. [http://www.health.gov.au/internet/healthyactive/publishing.nsf/content/pregnant-women Pregnancy Requirements]&lt;br /&gt;
&lt;br /&gt;
[[File:Stem cells neurospheres drived from Huntingtons Disease hippocampus.png]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 4===&lt;br /&gt;
&lt;br /&gt;
'''The allantois, identified in the placental cord, is continuous with what anatomical structure?'''&lt;br /&gt;
&lt;br /&gt;
The allantois functions to exchange materials (e.g. gases and nutrients). This invagination of the endoderm forms part of the hindgut. &lt;br /&gt;
&lt;br /&gt;
'''Identify the 3 vascular shunts, and their location, in the embryonic circulation.'''&lt;br /&gt;
&lt;br /&gt;
- Ductus Arteriosus: between pulmonary artery and aortic arch&lt;br /&gt;
&lt;br /&gt;
- Ductus Venosus: between umbilical vein to inferior vena cava&lt;br /&gt;
&lt;br /&gt;
- Foramen Ovale: between left and right atrium &lt;br /&gt;
&lt;br /&gt;
'''Group Project'''&lt;br /&gt;
&lt;br /&gt;
Current and Future Research&lt;br /&gt;
&lt;br /&gt;
Diagnostic Tests&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 5===&lt;br /&gt;
&lt;br /&gt;
'''Which side (L/R) is most common for diaphragmatic hernia and why?''' &lt;br /&gt;
&lt;br /&gt;
The left side is the most common for a diaphragmatic hernia. These occur if the pleuroperitoneal folds (which separate lungs from the gut) fail to close properly. The right side fuses first, and therefore leaves more chance for the left side to fuse abnormally.&lt;br /&gt;
&lt;br /&gt;
===Lab 6===&lt;br /&gt;
&lt;br /&gt;
'''What week of development do the palatal shelves fuse?'''&lt;br /&gt;
&lt;br /&gt;
These shelves fuse in week nine&lt;br /&gt;
&lt;br /&gt;
'''What early animal model helped elucidate the neural crest origin and migration of neural crest cells?''' &lt;br /&gt;
&lt;br /&gt;
The quail-chick chimera model helped to elucidate these. &lt;br /&gt;
&lt;br /&gt;
'''What abnormality results from neural crest not migrating into the cardiac outflow tract'''&lt;br /&gt;
&lt;br /&gt;
Tetralogy of Fallot is the congenital heart defect which results from neural crest not migrating into the cardiac outflow tract&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Lab 7===&lt;br /&gt;
&lt;br /&gt;
'''Are satellite cells (a) necessary for muscle hypertrophy '''&lt;br /&gt;
&lt;br /&gt;
No- muscle lacking satellite cells can still undergo hypertrophy&lt;br /&gt;
&lt;br /&gt;
''' (b) generally involved in hypertrophy? '''&lt;br /&gt;
&lt;br /&gt;
Yes- they definitely contribute, however they are not essential. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''' Why does chronic low frequency stimulation cause a fast to slow fibre type shift?'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Chronic low frequency stimulation increases the aerobic capacity of some muscle cells. A decrease in relaxation time is noticed and this enables the muscle cells to resist fatigue.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Trisomy 21 Peer Assessment'''&lt;br /&gt;
&lt;br /&gt;
*To begin with, the way you have arranged the order of the headings doesn’t flow very nicely&lt;br /&gt;
*Although the intro is concise, it doesn’t introduce the topic as much as it could- a little more detail could help. The historical reference would also be better suited elsewhere.&lt;br /&gt;
*Recent findings would be better suited towards the end of the page, and a short summary of the actual paper would be better than a direct quote.&lt;br /&gt;
*Where are your historical references? (besides the one point in the introduction)&lt;br /&gt;
*How does karyotyping work? This is not explained very well- expand on this.&lt;br /&gt;
*Associated Congenital abnormalities would be better under one heading rather than having a separate one for each defect (i.e. heart defect, limb defect)&lt;br /&gt;
*Heart defects should be explained in more detail and an image would help back this up&lt;br /&gt;
*A list of signs and symptoms would fit nicely with congenital abnormalities.&lt;br /&gt;
*Copyright info is missing for the John Langdon Down image- and what is its purpose here?&lt;br /&gt;
*Prevalence: only Ireland and the USA are listed- this shows that not much research has been done. You need a more worldwide distribution. &lt;br /&gt;
*The meiosis section is a little confusing, and does not exaplin how meiosis actually occurs- this section would also be better under ‘recent findings’&lt;br /&gt;
*Growth charts are interesting&lt;br /&gt;
*Your ‘terms’ list should not be placed under your references- they would be better suited above the references to make them easier to find.&lt;br /&gt;
*No student drawn image here?&lt;br /&gt;
*Overall, interesting information that has potential for a good project&lt;br /&gt;
&lt;br /&gt;
===Peer Assessments===&lt;br /&gt;
&lt;br /&gt;
Group 1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*An image would nicely complement your introduction. &lt;br /&gt;
*A history timeline would be nice to include&lt;br /&gt;
*A few sentences should be restructured in epidemiology &lt;br /&gt;
*Clinical manifestations should be explained a little or include an image to break up the text&lt;br /&gt;
*Nice tables in diagnosis- although some pictures should be made a little smaller&lt;br /&gt;
*The student drawn maternal serum sampling image is really good&lt;br /&gt;
*Treatment would benefit a picture&lt;br /&gt;
*Good research section&lt;br /&gt;
*Overall, good project you just need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 2&lt;br /&gt;
&lt;br /&gt;
*The whole page is very nicely formatted&lt;br /&gt;
*Introduction is clear and concise although would it be more efficient to start talking about DiGeorge straight away rather then define congenital abnormalities?&lt;br /&gt;
*Historical background is obviously well researched&lt;br /&gt;
*There needs to be an image in epidemiology and/or etiology to break up the text or present some of the information in a table&lt;br /&gt;
*The pathogenesis section flows nicely although a few words need to be added to the glossary&lt;br /&gt;
*Great table for diagnostic tests- this makes it easy to follow&lt;br /&gt;
*A few more pictures would be great for clinical manifestation and maybe this would be better in dot points?&lt;br /&gt;
*Student drawn images of tetralogy of fallot were excellent &lt;br /&gt;
*Subheadings are needed for Current/future research&lt;br /&gt;
*Good project overall, obviously a lot of effort has been put into this.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 3&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*I think the introduction should be a little more concise&lt;br /&gt;
*History could work better if all the information was summarised in a table/timeline rather than having paragraphs then a timeline. *Also, I find it a little hard to believe that no findings have been made since the 1970s.&lt;br /&gt;
*Epidemiology would probably benefit with subheadings&lt;br /&gt;
*Signs and symptoms are nicely set out&lt;br /&gt;
*I like that you have added a comparison of other diseases&lt;br /&gt;
*Maybe add a few more researches from 2011 rather than 2010 (if possible)&lt;br /&gt;
*Overall, quite a good project with some minor adjustments needed&lt;br /&gt;
&lt;br /&gt;
Group 5&lt;br /&gt;
&lt;br /&gt;
*Introduction should be explained a little better and also referenced&lt;br /&gt;
*Hand drawn image needs the correct referencing/copyright info&lt;br /&gt;
*Good use of subheadings in epidemiology &lt;br /&gt;
*Etiology is a little hard to follow&lt;br /&gt;
*Development of disease needs an image to break up the text&lt;br /&gt;
*Signs and symptoms is very text heavy- try to change it up a bit i.e. use of dot points&lt;br /&gt;
*Good use of table in treatment&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall, this has potential to be a good project with a few adjustments &lt;br /&gt;
&lt;br /&gt;
Group 6&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
Group 7&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
Group 9&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
Group 10&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_11&amp;diff=72537</id>
		<title>Talk:2011 Group Project 11</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_11&amp;diff=72537"/>
		<updated>2011-09-27T13:26:00Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Peer review of Group Project 11 */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;'''Group 11:''' [[User:z3308965]] | [[User:z3292953]] | [[User:z3308968]] | [[User:z3272325]] | [[User:z3284061]]&lt;br /&gt;
&lt;br /&gt;
{{2011GroupDiscussionMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== Peer review of Group Project 11 ==&lt;br /&gt;
Please include your reviews below this section, and nowhere else in this discussion. This is to facilitate easy reference later. Thank you.  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 11'''&lt;br /&gt;
&lt;br /&gt;
*Introduction is way too short and should include an image&lt;br /&gt;
*History would work better just in a timeline&lt;br /&gt;
*I think you should rearrange your headings from here on to make your project flow in a logical way&lt;br /&gt;
*Current/future research should be extended and explained&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*I also can’t seem to find your student drawing&lt;br /&gt;
*Some sections repeat some information- go through this&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Comments on Group Project 11===&lt;br /&gt;
'''Strengths:'''&lt;br /&gt;
*Good use of tables especially under Diagnosis.&lt;br /&gt;
*Some of the images are quite good especially on the correcting process (surgery) for cleft palate. &lt;br /&gt;
'''Weaknesses:'''&lt;br /&gt;
*Placement of headings is not quite appropriate. It gives the page a disjointed feel to it.&lt;br /&gt;
*There is a lack of use of subheadings. &lt;br /&gt;
*The introduction did not give an overview of the condition. &lt;br /&gt;
'''Specific corrections:'''&lt;br /&gt;
*Timeline should be a subheading under History section&lt;br /&gt;
*Introduction should answer these questions: What is it characterised by? How does it appear on individuals with this condition? What causes it? etc. It will be good to include a picture/ cartoon of an individual with cleft palate and lip.&lt;br /&gt;
*Duplication of references should be avoided.&lt;br /&gt;
*Some of the references are not formatted correctly.&lt;br /&gt;
*For current and future research, it will be good to give a brief synopsis (2-3 sentences) of each point so that readers can get the gist of the direction of cleft palate and lip research that it is heading towards.&lt;br /&gt;
*For genetic configuration, it might be better to use subheadings to point out the 4 different types of environmental factors. &lt;br /&gt;
*Do include a student-drawn image.&lt;br /&gt;
*Some words that should be included in the glossary are Malocclusion, nodules etc.&lt;br /&gt;
*It would be better to make use of tables under treatment.&lt;br /&gt;
&lt;br /&gt;
--Z3389806 11:50, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 11 Peer Assessment'''&lt;br /&gt;
*Introduction needs to be expanded a bit seems like the description of the incidence&lt;br /&gt;
*History needs together with the timeline which would benefit the section, where the timeline is done properly with the image of the founder though time line better together then separated&lt;br /&gt;
*Diagnosis is well done though images would benefit this section &lt;br /&gt;
*Syndromes and anomalies should be expanded a bit though good linkage of the images to the rare cases  *Development should be changed to aetiology instead&lt;br /&gt;
*Pathophysiology needs more images though nice use of tables&lt;br /&gt;
*Genetic configuration needs references to back up the evidence otherwise is just statements&lt;br /&gt;
*Neurology greatly structured and well presented and has image to liven the section&lt;br /&gt;
*Treatment generally well structured though ex[and more on the surgical aspect as well problems associated with cleft palate &lt;br /&gt;
*Current and future research needs more information as well separation between the current and the future research.&lt;br /&gt;
*Glossary needs to be expanded further and linked either to section or bolded throughout the web page.&lt;br /&gt;
*References need a little tweaking with the removal of the repeats, also no other information in the sub heading textbooks&lt;br /&gt;
z3332250 00:01, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 11 Critique'''&lt;br /&gt;
&lt;br /&gt;
#•	Introduction is far too short and more work needs to be done&lt;br /&gt;
#•	History is also very short and more information needs to be added&lt;br /&gt;
#•	The timeline is quite good&lt;br /&gt;
#•	Diagnosis is alright&lt;br /&gt;
#•	Syndromes and anomalies associated with cleft is detailed. Good job!&lt;br /&gt;
#•	Development is good. Maybe use more images&lt;br /&gt;
#•	The other sections are good, up until current research. More work needs to be done here as there is not enough information&lt;br /&gt;
#•	Glossary is too short&lt;br /&gt;
#•	Is the gallery really needed if you have images illustrating your text?&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289991|Robert Klein]] 16:38, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
''Cleft Palate and Lip''&lt;br /&gt;
&lt;br /&gt;
*Your introduction needs to be ''seriously'' expanded. What exactly is it? Defining features? Anything?&lt;br /&gt;
*'History' could be expanded on a bit, but the timeline looks good.  Try to take the spaces out between each date of the timeline, at the moment it's a bit unneccesarily long&lt;br /&gt;
*'Diagnosis' would fit better towards the end of the page closer to treatment.  It is a bit hard to understand before we've even had a proper description of the disorder and clinical symptoms&lt;br /&gt;
*Though the information in 'Diagnosis' is quite good, the table is also quite interesting&lt;br /&gt;
*'Syndromes and Anomalies Associated with Cleft', title should fixed up 'Associated Syndromes and Anomalies' sound better.  It also needs to be finised!&lt;br /&gt;
*There's not even a single reference in 'Atiology'&lt;br /&gt;
*'Developmental Staging' are you refering to Carnegie stages? If so, say so.&lt;br /&gt;
*Reference!! And finish 'Pathophysiology'.  You won't get the marks for just saying 'it will be done soon', think of the rest of your group&lt;br /&gt;
*There is not a ''single'' reference in 'Genetic Configuruation', so where then did you get your information?  This section also needs images, and a bit of formating.  There isn't much consistency in the use of captial letters for 'Cleft Lip'. Either use it or don't, &amp;quot;seems to be related to the cause of Cleft palate and cleft lip incidence&amp;quot; and throughout the page aswell&lt;br /&gt;
*For 'Treatment' and 'Complications' a table would be good.  It is not very visually appealing as a long list.  That way you can incorporate some more information as well.&lt;br /&gt;
*'Problems Associated with Cleft Palate' would be better positioned higher up in the page.  How do you know what your treating if you don't even know the associated problems. Reference!&lt;br /&gt;
*'Current and Future Research' really needs to be expanded.  There is no where near enough information here&lt;br /&gt;
*The page is coming along, but it really needs to be finished, there are far too many gaps, and no where near enough references.  Try reading multiple papers before adding information.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 11'''&lt;br /&gt;
* Interesting topic with good use of pictures, you guys have a great topic with a lot of interesting areas to discuss. &lt;br /&gt;
* The headings could be reorganised  for example diagnosis could come after explaining in detail what cleft lips are and how they are formed embryonically. &lt;br /&gt;
* The introduction should introduce the main topics that you will be discussing but only briefly like what cleft palate is.. the information in the intro would fit nicely in epidemiology. (maybe you could add this section in).&lt;br /&gt;
* History section is very interesting I liked the extra research.&lt;br /&gt;
* The time line takes up a lot of room maybe condense it into a table format. &lt;br /&gt;
* Development?? is this a section?? &lt;br /&gt;
* maybe put the type of cleft lip/palate into a table with a pictures corresponding to the specific type. &lt;br /&gt;
* Make sure all acronyms are in the glossary.&lt;br /&gt;
* It would be nice if the colours of the tables were continuous throughout the page. &lt;br /&gt;
* Neuroembryology and functional anatomy of craniofacial clefts section is very well written and enjoyable to read. &lt;br /&gt;
* Treatment &amp;amp; Problems associated with Cleft Palate sections have no referencing. It would strengthen and give your page some authority if you cited where your information was from. &lt;br /&gt;
* A little summary for your future and current research would make this section a bit more interesting rather then just using dot points.  &lt;br /&gt;
* Make sure your references aren't doubled. &lt;br /&gt;
* Ensure your pictures are referenced correctly.&lt;br /&gt;
* Furlow Z-plasty technique picture is positioned so that it interrupts the flow of reading maybe rethink the position of this picture. &lt;br /&gt;
* Variations of Cleft Lip or Palate picture is great and I think it could be more of a &amp;quot;key &amp;quot; picture on your page maybe centralise it?.&lt;br /&gt;
* No student drawing.&lt;br /&gt;
* Gallery seems a little irrelevant.&lt;br /&gt;
* More needs to be added into glossary eg. Otitis media&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 11&lt;br /&gt;
* The introduction is no where near long enough and needs an image&lt;br /&gt;
* History needs to be expanded and dates made more obvious to the reader&lt;br /&gt;
* Timeline- should be combined with history. So that my previous point is not needed&lt;br /&gt;
* The order of your subheadings is a little confusing&lt;br /&gt;
* Some sections double up the information&lt;br /&gt;
* Current research needs to be completed, as do other sections&lt;br /&gt;
* The glossary needs to be expanded&lt;br /&gt;
* The project has started to take form but there is work to go to complete the information and format it into a more easily accessible piece of work.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*'''Introduction''': Too short. Also, how come there are no references? How about starting with a brief anatomical description?&lt;br /&gt;
*'''History''': No reference for the first paragraph? I like the idea of mentioning Plato, but could you then also expand a little bit more on his thoughts? Also, what was the explanation offered by Philippe Frederick Blandin?&lt;br /&gt;
*'''Timeline''': Looks good to me, though some terms should be explained in the glossary.&lt;br /&gt;
*'''Diagnosis''': I'm not sure I'd make this follow on immediately from the Timeline. I would put this section between Types of Cleft Palate/Lip &amp;amp; Pathophysiology, maybe? While you do talk about the technical difficulties just before the Cleft Soft Palate Detection part, but considering you start a new subsection, it's confusing to keep talking as if it was the same paragraph. Maybe say &amp;quot;the technical difficulties mentionned above&amp;quot; instead? An explanation in the glossary of what a cleft soft palate actually is, is definately needed! The Cleft Hard Palate section is very well done.&lt;br /&gt;
*'''Syndromes and Anomalies associated with cleft''': Looks fine.&lt;br /&gt;
*'''Development''': Under construction? or is there meant to be no text, and you're simply splitting this section into the two subsections? If yes, you might want to make that clearer.&lt;br /&gt;
*'''Aetiology''': This part is slightly technical and could do with some more detailed explanations. It doesn't feel like a coherent section.&lt;br /&gt;
*'''Developmental Staging''': Well explained.&lt;br /&gt;
*'''Types of Cleft Palate/Lip''': Looks fine. Though the &amp;quot;algorhythm for repair...&amp;quot; figure seems to be in a slightly random place..? How does it relate to this section (or the next)?&lt;br /&gt;
*'''Pathophysiology''': The cranio-facial development pathway is a very complex process. Since the several points of development at which “Clefting” might occur is based on the condition and the wide range of its phonotypical expression. Make this one sentence? You start talking about neural crest cells quite out of the blue. Has there been any mention of them before? It's quite confusing to have them added into the story without having previously told why. The first two paragraphs under the table lack references? This part repeats what has been partly said before, but adds more physiological detail to it. I'd find it more logical to combine the different aspects to give one, more complete picture.&lt;br /&gt;
*'''Genetic configuration''': Very poor language/sentence structure. Where are the references? Putting womb and external environment together does make sense, but you might want to explain in a sentence why.&lt;br /&gt;
*'''Neuroembryology and functional anatomy of craniofacial clefts''': Excellent explanation, though some terms should be explained in the glossary. Why are some words in bold? Again, this sort of repeats previous information, again with more detail from a different point of view, apparently unrelated to what's been told before, as this section doesn't follow the previous sections?&lt;br /&gt;
*'''Treatment''': Can you explain the different techniques a little bit more, instead of just having bullet points? The figures are really nice, but don't illustrate all of the techniques mentioned.&lt;br /&gt;
*'''Problems associated with Cleft Palate''': Mere list with bullet points isn't enough, more explanations needed.&lt;br /&gt;
*'''Current and Future Research''': Very poor. There must be more than 3 articles?&lt;br /&gt;
*'''Glossary''': Poor. Many more terms need explanations.&lt;br /&gt;
*'''References''': Need fixing. The same article appears lots of times in the list. Watch out with your german references... the fact that you misspell the german makes me wonder whether you could have actually read the papers? In case you're citing a reference cited within the reference you've read, there usually is a special way of doing it.&lt;br /&gt;
*General: Your sections are really random and don't follow logically from one another. There is a lot of repetition of similar content in multiple different places, which is confusing. It is hard to keep an overview. Nevertheless, some of the sections are well done.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 11 Assessment'''&lt;br /&gt;
*The introduction and history sections are not very long… Maybe try adding more information and some pictures.  &lt;br /&gt;
*The timeline should be a subheading under the history portion.  Also, rather than doing a bulleted list, how about trying to format the information into a chart?  This would be more aesthetically appealing.  &lt;br /&gt;
*For the diagnosis section, the charts look great.  Referencing is completed well also.  Only thing I’d suggest is to possibly add a picture. &lt;br /&gt;
*For the references given throughout the wiki, there isn’t any consistency in how the [#] is given.  The [#] is sometimes right after the sentence, sometimes a space is given between the sentence and citation number, and the end of the sentence (period or comma) is sometimes before or after the reference #...&lt;br /&gt;
*There are several sentences throughout the wiki page which are missing punctuation at the ends of the sentences.  &lt;br /&gt;
*The first portion of Aetiology doesn’t have any referencing…&lt;br /&gt;
*“Normal Palate Shelf…” jpg needs a sentence below it briefly describing it still. &lt;br /&gt;
*The Genetic Configuration section has absolutely no referencing.  Neither does the Treatment section or Problems section.  Where did all this information come from? &lt;br /&gt;
*Treatment and Problems would also flow better if they were placed into a chart format.  Pictures could also be added.  &lt;br /&gt;
*The Glossary seems a bit short.  Are you sure there are no other words that would be helpful if they were defined?  It would also flow better if it were bullet listed.&lt;br /&gt;
*Some of the references are repetitive.  Make sure to fix this so they all link to a single reference instead of numerous ones of the same resource.  &lt;br /&gt;
*A lot of the information is repetitive as well, and things should be formatted to flow better.  Also work on the referencing issues and making the overall page more aesthetically appealing.  &lt;br /&gt;
--[[User:Z3391078|Z3391078]] 17:26, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Discussion==&lt;br /&gt;
&lt;br /&gt;
hey guys- keep abreast of the reviews coming in. some of them have valid points. it would be prudent to keep working on our relevant sections (without uploading it and altering the content of the wiki of course). hope you're all having a good weekend. i should be uploading the timeline later today. --[[User:Z3272325|Rahul Mohan]] 17:55, 25 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
uploaded another heading 'associated anomalies' --[[User:Z3308968|Tahmina Lata]] 10:58, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
{|border=&amp;quot;1px&amp;quot; cellspacing=&amp;quot;1&amp;quot; align=&amp;quot;center&amp;quot; cellpadding=&amp;quot;3&amp;quot; &lt;br /&gt;
&lt;br /&gt;
! Type !! Comment !! Picture!&lt;br /&gt;
|-&lt;br /&gt;
|'''Unilateral Cleft Lip'''&lt;br /&gt;
|This type of cleft refers to cleft of the lip that have only occurred on one side of the lip.&lt;br /&gt;
|[[File:.jpg|centre]]&lt;br /&gt;
|-&lt;br /&gt;
|'''Unilateral Cleft Palate'''&lt;br /&gt;
|This type of cleft refers to a cleft of the soft palate that occurs on one side of the palate. The cleft starts medially and extends laterally.&lt;br /&gt;
|[[File:.jpg|centre]]&lt;br /&gt;
|-&lt;br /&gt;
|'''Unilateral cleft lip with a cleft hard palate ''' &lt;br /&gt;
|This refers to a cleft that has extended through the lip and into the hard palate. This cleft is on only one side of the lip and palate.&lt;br /&gt;
|[[File:.jpg|200px|centre]]&lt;br /&gt;
|-&lt;br /&gt;
|'''Unilateral cleft lip with cleft hard and soft palate'''&lt;br /&gt;
|This type of cleft refers to a cleft that extends through the lip, hard palate and into the soft palate. It also occurs on only one side.&lt;br /&gt;
|[[File:.jpg|centre]]&lt;br /&gt;
|-&lt;br /&gt;
|'''Bilateral cleft palate '''&lt;br /&gt;
|This refers to a cleft of the soft palate which occurs on both sides of the palate and appears as a opening medially.&lt;br /&gt;
|[[File:.jpg|300px|centre]]&lt;br /&gt;
|-&lt;br /&gt;
|'''Bilateral cleft lip'''&lt;br /&gt;
|This refers to a cleft of the lip that has occurred on both sides of the lip. There are many variations of this.&lt;br /&gt;
|[[File:.jpg|300px|centre]]&lt;br /&gt;
|-&lt;br /&gt;
|'''Bilateral cleft lip with cleft hard palate'''&lt;br /&gt;
|This refers to a cleft of the lip and hard palate that occurs on both sides.&lt;br /&gt;
|[[File:.jpg|300px|centre]]&lt;br /&gt;
|-&lt;br /&gt;
|'''Bilateral cleft lip with cleft hard and soft palate'''&lt;br /&gt;
|This refers to a cleft that has occurred on both sides of the lip and extended into both the hard and soft palates resulting in an medial opening of the soft palate.&lt;br /&gt;
|[[File:.jpg|300px|centre]]&lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
hey guys heres the table so far. I'm having a bit of trouble uploading the photos and finding sources for the info in the middle but I'm working on it&lt;br /&gt;
--[[User:Z3292953|Elizabeth Wren]] 10:36, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys, just letting you know whats on the page under aetiology and treatment has not been finalised. I will need to upload images and tables. --[[User:Z3308965|Fleur McGregor]] 09:55, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Team, Found some amazing radiology images but they are under copyright. Would like to brainstorm with you all to se how we can request access. http://radiology.rsna.org/content/217/1/236.long&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 00:15, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Rahul, I am still working on the resolution of the image, I am considering rediesigining the orginial design and increasing the font size. Will update on it soon.&lt;br /&gt;
I also have uploaded another brief subsection 'Problems associated with Cleft Palate'-hope it is useful.&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 23:56, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Guys, &lt;br /&gt;
&lt;br /&gt;
I have just uploaded the Draft section Genetic Configuration... It is under review since I'm doing this with Rahul. the final version will  be integrated later on. --[[User:Z3284061|z3284061]] 21:37, 21 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey Rahul, &lt;br /&gt;
&lt;br /&gt;
I think we should go with the Articles we have, because this is our project, yes we can have a look at the other textbooks. But in the end, remember, this is designed by us as a group! &lt;br /&gt;
and the mdconsult website does not work! --[[User:Z3284061|z3284061]] 20:53, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Meedo, pursuant to our conversation- here are the 2 links that seem to conflict. &amp;lt;br&amp;gt;&lt;br /&gt;
http://embryology.med.unsw.edu.au/Notes/face2.htm&amp;lt;br&amp;gt;&lt;br /&gt;
http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4160-3706-4..50012-8&amp;amp;isbn=978-1-4160-3706-4&amp;amp;uniqId=282776049-2#4-u1.0-B978-1-4160-3706-4..50012-8&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
and I've spotted an error in reference 40 and 41. The chapter referred to is chapter 9, not 10. The necessary changes have been made. Timeline should be up soon.  &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3272325|Rahul Mohan]] 17:53, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey Rahul, I got that info from the text book but I'd probably go by what Dr Hill has.&lt;br /&gt;
Beth --[[User:Z3292953|z3292953]] 12:20, 21 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
guys- i have a problem. in development so far- i'm trying to work on the time line for cleft lip/palate development. it so turns out that there's conflicting information everywhere. on one hand- we have (google turned this up for me) &amp;lt;http://embryology.med.unsw.edu.au/Notes/face2.htm&amp;gt; which is by Dr Hill- in which its stated that &amp;quot;Cleft lip and palate develop between the 4th and 8th week of gestation&amp;quot;. On the other hand- we have what's already written up for the section under dev- which has it stated that cleft lip happens from/between carnegie stage 16 and 18- and cleft palate erin week 6 to 10 (which equates roughly to carnegie stage 15 onwards. if we follow what Dr HIll's said- that would amount to stages 10-around 21. so which do we follow?&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3272325|Rahul Mohan]] 23:45, 20 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Tahmina- the resolution could be slightly better. have you tried saving the document as a pdf file? with maximum resolution or something? I'm not entirely certain- but i'm fairly sure it can be done. mm. on another note, guys- here're a few resources that you could check out for your relevant sections if you haven't already:&lt;br /&gt;
&lt;br /&gt;
http://www.organizedwisdom.com/Cleft_Palate (scroll down to the journals section)&lt;br /&gt;
http://www.jci.org/articles/view/22154/version/1 (particularly helpful for genetic---Meedo)&lt;br /&gt;
http://dev.biologists.org/content/103/Supplement/41.full.pdf (helpful for development- what i'm working on right now. the last bit on genes might be useful to meedo as well.)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3272325|Rahul Mohan]] 23:00, 20 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
[[File:Figure Shows How the CNS is divided to supply different structures.jpg|800px|right|thumb|Figure Shows How the CNS is divided to supply different structures]]&lt;br /&gt;
Guys I am parking this image here for the time being as the resolution has not come out that well and I would like some feedback from you to see if we should add this to the page.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 20:33, 20 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Ravichandra KS, Vijayaprasad KE, Vasa AA, Suzan S.&lt;br /&gt;
&lt;br /&gt;
J Indian Soc Pedod Prev Dent. 2010 Oct-Dec;28(4):311-4.&lt;br /&gt;
&lt;br /&gt;
PMID: 21273723 [PubMed - indexed for MEDLINE]&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/15479962&lt;br /&gt;
--[[User:Z3308965|Fleur McGregor]] 12:15, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Permission to post figure:&lt;br /&gt;
https://s100.copyright.com/CustomerAdmin/PLF.jsp?lID=2011090_1316046741757&lt;br /&gt;
picture: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086810/bin/nihms284150f2.jpg&lt;br /&gt;
&lt;br /&gt;
I have also included a hand drawn hierarchical table as I could not format such table in wiki. hope it is not looking too poorly done. --[[User:Z3308968|Tahmina Lata]] 23:30, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi Everyone,&lt;br /&gt;
&lt;br /&gt;
I have tried to stretch as much as possible and uploaded my final versions of my headings. --[[User:Z3308968|Tahmina Lata]] 23:28, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hello People, &lt;br /&gt;
&lt;br /&gt;
I have uploaded my section which is just a DRAFT. References are not all completed, and my photos are to be uploaded soon with drawings. &lt;br /&gt;
--[[User:Z3284061|Maqdad Al Saif]] 20:35, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Guys, &lt;br /&gt;
&lt;br /&gt;
As we have 5 people in our group we must have more content than other groups so I am adding a third heading 'Neuroembryology and functional anatomy of craniofacial cleft.' We really need to work hard on this as the page so far is not looking the best. I hope that someone will come up with an impressive table.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 23:03, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi Guys,&lt;br /&gt;
&lt;br /&gt;
I will be writing about 'Diagnosis of prenatal cleft lip and palate' for my second heading. --[[User:Z3308968|Tahmina Lata]] 22:44, 6 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Here are some more useful links with photos in them.&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2562450/?tool=pubmed&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC420504/&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825074/?tool=pubmed&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/19884685&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/20694165&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 22:46, 6 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hello Everyone,&lt;br /&gt;
&lt;br /&gt;
I have uploaded the timeline here and under the heading- 'History' I am just going to include some interesting historical facts but after researching the other heading- 'Developmental Process' it seems to coincide with developmental staging and so it might not be a good idea to have that as a broad heading. Please let me know if you have any ideas on another heading or I will come up with a different heading and research that. Let me know what you think--[[User:Z3308968|Tahmina Lata]] 22:55, 5 September 2011 EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey Guys, &lt;br /&gt;
&lt;br /&gt;
Great Work finding the articles :)  I noticed in the second article of Tahmina, you can use the pictures to make the content more interesting. The same goes for Fleur, the last 2 articles have great information and pictures. &lt;br /&gt;
&lt;br /&gt;
let's try updating the page before the end of the weekend &lt;br /&gt;
&lt;br /&gt;
Cheers Guys... --[[User:Z3284061|Maqdad Al Saif]] 16:57, 5 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Here are the articles I am studying at this stage:&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825059/&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825068/?tool=pubmed&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 21:18, 4 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
hey guys, &lt;br /&gt;
&lt;br /&gt;
I've found some pictures which we can either use in the gallery or on the front page. &lt;br /&gt;
&lt;br /&gt;
about my work, it will be all updated during the break but I will share with you what I'm doing. Meedo&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3284061|z3284061]] 11:29, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
I also found these useful&lt;br /&gt;
&lt;br /&gt;
http://www.cincinnatichildrens.org/assets/0/78/1067/1395/1883/1a654a12-a1b6-42cb-8a6b-9b270e322f4c.pdf&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2312243/pdf/annrcse00255-0003.pdf&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825076/&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308965|Fleur McGregor]] 10:41, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys here some references I found that were kinda useful&lt;br /&gt;
&lt;br /&gt;
Plast Reconstr Surg. 2011 Feb;127(2):812-21.The spectrum of median craniofacial dysplasia.Allam KA, Wan DC, Kawamoto HK, Bradley JP, Sedano HO, Saied S. PMID: 21285785 &lt;br /&gt;
&lt;br /&gt;
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Aug;112(2):249-57. Epub 2011 Jun 12.Comparison between multislice and cone-beam computerized tomography in the volumetric assessment of cleft palate.Albuquerque MA, Gaia BF, Cavalcanti MG. PMID: 21664153&lt;br /&gt;
&lt;br /&gt;
Nat Rev Genet. 2011 Mar;12(3):167-78.Cleft lip and palate: understanding genetic and environmental influences.Dixon MJ, Marazita ML, Beaty TH, Murray JC. PMID:21331089&lt;br /&gt;
&lt;br /&gt;
I also found the Larsons textbook had some stuff on cleft palate and lip.&lt;br /&gt;
&lt;br /&gt;
Beth --[[User:Z3292953|z3292953]] 10:20, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey fellas, I reckon we could have inserted a brief discussion of the etymology of the word in the introduction. I don't reckon its big enough to warrant a heading of its own. Thus, I've gone ahead and taken the liberty to remove that heading from the page. Also included an &amp;quot;aetiology&amp;quot; section under development of disease- since its looking at causation of disease. Changed current research into Current and Future Research- to increase the scope of that heading. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3272325|Rahul Mohan]] 12:48, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
I am doing history and developmental process.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 10:06, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Guys, &lt;br /&gt;
&lt;br /&gt;
There has been some changes in our page in terms of Subheading order. &lt;br /&gt;
&lt;br /&gt;
Hey Rahul, I'd be happy to share the Genetic Configuration with you... and your comments have been taken into consideration. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3284061|z3284061]] 11:43, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Thankyou z3284061 for the heads up on what to do.&lt;br /&gt;
&lt;br /&gt;
I've put myself down as finding current research and associated figures. However- pertaining to the latter- this would involve finding figures and diagrams relevant to our research I suppose? I'm definitely not good at art- and as for the diagrams and pics- that would be dependent more on the content we come up with. Also, as a sub-section- isn't it weird to lump all animations and figures under one subsection- isolating it away from the rest of the topic? Thus being the case, I propose that we individually keep a look out for relevant animations under our own sub-heading and I would help out anyone doing a large topic. z3284061 has indicated that that genetic configuration is a large sub heading- so I'll be happy to help with that. &lt;br /&gt;
&lt;br /&gt;
See you in a couple of hours, fellas. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3272325|z3272325]] 04:18, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Guys, &lt;br /&gt;
&lt;br /&gt;
I think after we discussed last time, I'll be doing Pathophysiology and Genetic Configuration.Hmm, I just think it will be kinda big especially for Genetic Configuration :) if you guys find anything related to it, pleaase don't hesitate to post it in the discussion. &lt;br /&gt;
&lt;br /&gt;
The only one who might not have been allocated to do something specific is  z3272325- I think you are meant to do The Animations and figures + Current Associated research :) &lt;br /&gt;
&lt;br /&gt;
Let's Start updating the page whenever we have information :) &lt;br /&gt;
&lt;br /&gt;
Cheers --[[User:Z3284061|z3284061]] 23:11, 24 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For the groupo project I will be researching Developmental Staging and Abnormaility Classification.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3292953|z3292953]] 11:21, 24 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
I am researching the following sub headings: surgical timeline and etimiology. If you all post what you are researching we can forward any information we find regarding your sub heading. --[[User:Z3308965|Fleur McGregor]] 12:16, 23 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Here's the image I've found. --[[User:Z3284061|Maqdad Al Saif]] 13:10, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
[[File:Cleft lip.jpg]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
completely forgot I was meant to add a picture here as well. My apologies. And the group discussion's picking up- shall be more productive henceforth. here's a pic for cleft palate. &lt;br /&gt;
&lt;br /&gt;
[[Image:In vitro fetal palate explant culture.jpg|frame|alt=Alt|In vitro fetal palate explant culture&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;PMC2841638&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;|center]]&lt;br /&gt;
&lt;br /&gt;
'''References'''&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
Wow!! That is sad Meedo! I didnt know you were in hospital!&lt;br /&gt;
Yes I think the condition is cleft lip and palate however I am working on the classifications of cleft lip as they can be disjoint at many different sites of the lip.&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 10:11, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Fantasitc Work Tahmina!!!! I can See a flow coming up!!! &lt;br /&gt;
and z3292953 - Great Photos!!!! Please save the references somewhere Safe :D &lt;br /&gt;
&lt;br /&gt;
As for me, I haven't been able to attend classes since Thursday. I was at the hospital, extremely dysfunctional.&lt;br /&gt;
&lt;br /&gt;
Anyways, I can say that we should finilize the topic to This one... I prefer not to change because it's week 5 now. It will be wise if we dig deeper in the topic and we shall get better information. I will start my search from tomorrow and sorry for the delay. I HAVE ONLY ONE QUESTION IS  CLEFT PALATE and LIP KNOWN as the WHOLE condition???&lt;br /&gt;
--[[User:Z3284061|z3284061]] 23:46, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
History&lt;br /&gt;
&lt;br /&gt;
The earliest known history of cleft lip is based on a combination of religion, superstition, invention and charlatanism. While Greeks were indifferent of their existence, Spartans and Romans would kill the children with this condition as they were considered to harbour evil spirits.&lt;br /&gt;
&lt;br /&gt;
Between (1295- 1351) the first to note the congenital origin of the cleft was made by Jean Yperman. He also classified the various forms of the condition and laid down the principles for their treatment.&lt;br /&gt;
&lt;br /&gt;
Between (1537-1619) Fabricius ab Aquapendente first suggested the embryological basis of cleft lip.&lt;br /&gt;
&lt;br /&gt;
This is how I started the history, please comment if you think anything needs changing. I will continue the list on and the references at the end.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 20:00, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:File-Cleft palate in newborn mice.jpg]] &lt;br /&gt;
&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;2924885&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3292953|z3292953]] 12:08, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi Guys, I have started working on pathophysiology &amp;amp; history and modified some of the headings to include ones that were more relevant for Cleft palate and Lip.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 21:51, 15 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
[[File:Mice mutants exhibit cleft palate and umbilical hernia.jpg|frame|alt=Alt|Mice mutants exhibit cleft palate and umbilical hernia&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;PMC2841638&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;|center]]&lt;br /&gt;
&lt;br /&gt;
Mice mutants exhibit cleft palate and umbilical hernia&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 19:16, 15 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
So after careful consideration we have come to realise that Cleft Palate/Lip will be a more relevant topic to create a page about.&lt;br /&gt;
Some of you guys left last week when we registered this topic with Dr Hill. Please post here if you are still unsure of the topic. At this stage we are all reseraching different things on the topic so we can discuss about it this week.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 16:44, 15 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
There appears to be no group discussion here on possible project topics?? --[[User:S8600021|Mark Hill]] 23:55, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
We have decided to research each subheading listed on the Group Project page and then share all the information found next week. We will then be able to determine a clearer structure to the page based on what literature is available.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 12:34, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Review Article'''&lt;br /&gt;
&amp;quot;Cystic fibrosis: pathogenesis and future treatment strategies&amp;quot;-This review summarizes our current understanding of the pathophysiology and treatment of cystic fibrosis lung disease&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19393104&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
'''Research Article'''&lt;br /&gt;
&amp;quot;Nasal endoscopic evaluation of children and adolescents with cystic fibrosis&amp;quot;-The questionnaire, clinical examination and especially nasal endoscopy performed as part of this research lead to a detailed assessment of the nasal characteristics of children and adolescents with cystic fibrosis. &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;20209279&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3308968|Tahmina Lata]] 23:13, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi Guys, &lt;br /&gt;
&lt;br /&gt;
I've modified the page with the required subheadings, we can change them later but it's important to get our heads around the foundations. &lt;br /&gt;
&lt;br /&gt;
If have have anything to add, please do so. if you have any questions, post it here and we will try and help. --[[User:Z3284061|z3284061]] 22:52, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis.Rogers GB, Hoffman LR, Döring G. J Cyst Fibros.2011 Jul 18. [Epub ahead of print]&lt;br /&gt;
&lt;br /&gt;
Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis.McNally P, Coughlan C, Bergsson G, Doyle M, Taggart C, Adorini L, Uskokovic MR, El-Nazir B, Murphy P, Greally P, Greene CM, McElvaney NG.J Cyst Fibros. 2011 Jul 22. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3292953|z3292953]] 15:59, 9 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey Guys: &lt;br /&gt;
&lt;br /&gt;
How are we going in the research process? Well, In case anyone wants to change the topic Tomorrow will be the last day we get to change! That’s if everyone agrees to do so. &lt;br /&gt;
&lt;br /&gt;
For the time being, we are working on Cystic Fibrosis. I’ve found some interesting articles regarding the treatment. &lt;br /&gt;
The first one is a research while the other 2 are both Reviews. &lt;br /&gt;
&lt;br /&gt;
I’ve Moved the articles of z3292953 to the discussion Page :) &lt;br /&gt;
&lt;br /&gt;
Looking forward to create a great wiki page. --[[User:Z3284061|z3284061]] 22:34, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
1. ''Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation ''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909825  Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
2. ''Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis'' &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Abstract'''&lt;br /&gt;
&lt;br /&gt;
Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients is caused by biofilm-growing mucoid strains. Biofilms can be prevented by early aggressive antibiotic prophylaxis or therapy, and they can be treated by chronic suppressive therapy. New results from one small trial suggest that addition of oral ciprofloxacin to inhaled tobramycin may reduce lung inflammation. Clinical trials with new formulations of old antibiotics for inhalation therapy (aztreonam lysine) against chronic P. aeruginosa infection improved patient-reported outcome, lung function, time to acute exacerbations and sputum density of P. aeruginosa. Other drugs such as quinolones are currently under investigation for inhalation therapy. A trial of the use of anti-Pseudomonas antibiotics for long-term prophylaxis showed no effect in patients who were not already infected. Use of azithromycin to treat CF patients without P. aeruginosa infection did not improve lung function. Here I review the recent advances in the treatment of P. aeruginosa lung infections with a focus on inhalation treatments targeted at prophylaxis and chronic suppressive therapy.&lt;br /&gt;
&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21463524&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
3. ''Changes in strategies for optimal antibacterial therapy in cystic fibrosis.''&lt;br /&gt;
&lt;br /&gt;
'''Abstract''' &lt;br /&gt;
&lt;br /&gt;
Aggressive antibiotic therapy of bacterial airway infection is one of the main reasons for the dramatic increase in life expectancy over the last few decades. Staphylococcus aureus and Haemophilus influenzae are the predominant pathogens in younger patients, but the choice of antibiotic therapy against these pathogens remains highly controversial. There is general agreement that patients with pulmonary exacerbations should be treated and many cystic fibrosis (CF) centres will also try to eradicate bacteria in the absence of symptoms. Prophylactic antibiotic therapy, with anti-staphylococcal medications started at the time of diagnosis, is advocated by some groups but its positive effect remains unproven. In fact, recent studies have suggested that continuous prophylactic treatment with anti-staphylococcal antibiotics may increase the risk of early colonisation with Pseudomonas aeruginosa. P. aeruginosa is the main pathogen in older children with CF. While chronic airway infection with mucoid P. aeruginosa is considered irreversible, both the combination of oral ciprofloxacin with inhaled colistin and inhaled tobramycin alone has been used successfully in the early phase of colonisation. In patients chronically infected with P. aeruginosa, standard treatment of pulmonary exacerbations consists of intravenous combination therapy for 2-3 weeks. Controversy exists whether this treatment should be performed routinely every 3 months or only in the presence of a pulmonary exacerbation. Inhaled antibiotics such as tobramycin have been shown to improve lung function and reduce sputum density of P. aeruginosa, but both the optimal dose and the duration of therapy are unclear at the present time&lt;br /&gt;
&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11165111&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt; &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Review: &lt;br /&gt;
Inhaled bronchodilators for cystic fibrosis. Halfhide C, Evans HJ, Couriel J. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD003428. DOI: 10.1002/14651858.CD003428.pub2 from http://www2.cochrane.org/reviews/en/ab003428.html&lt;br /&gt;
&lt;br /&gt;
Research Article:&lt;br /&gt;
Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Jones AM, Govan JR, Doherty CJ, Dodd ME. Isalska BJ, Stanbridge TN, Webb AK. Thorax 58(6), 525-527. &lt;br /&gt;
from http://www.ncbi.nlm.nih.gov/pubmed/12775867&lt;br /&gt;
--[[User:Z3272325|Rahul Mohan]] 10:58, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Peer Assessments==&lt;br /&gt;
* I would suggest expanding on the current and future research section, maybe add in links to current research institutes or research papers.&lt;br /&gt;
* Perhaps add an image in for problems associated with cleft palate, just to add some dynamics and colour to the page. &lt;br /&gt;
* Perhaps tabulate the treatment section just so that the information is clearer &lt;br /&gt;
* Placing words in bold, although it was just a little touch, helped to highlight the main points you were trying to get across which was good.&lt;br /&gt;
* Good incorporation of tables and different formatting styles&lt;br /&gt;
* Your introduction was clear, simple and straight to the point. &lt;br /&gt;
* You’re referencing needs to be tidied up; there are multiple entries from the same source that tends to clutter your reference section.&lt;br /&gt;
* Your timeline was extremely spaced out, I would suggest deleting the space between your dot points just so that it reads easier.&lt;br /&gt;
--[[User:Z3332629|z3332629]] 15:31, 22 September 2011 (EST)&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_10&amp;diff=72536</id>
		<title>Talk:2011 Group Project 10</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_10&amp;diff=72536"/>
		<updated>2011-09-27T13:25:19Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Peer Review */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[2011_Group_Project_10|'''Group 10''']]: [[User:z3332327]] | [[User:z3332629]] | [[User:z3332824]] | [[User:z3330313]]&lt;br /&gt;
&lt;br /&gt;
{{2011GroupDiscussionMH}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Peer Review==&lt;br /&gt;
&lt;br /&gt;
'''Group 10'''&lt;br /&gt;
&lt;br /&gt;
*Very poor image/text ratio – you need more images to break up the text&lt;br /&gt;
*Good intro&lt;br /&gt;
*History would work better in a timeline- you also mention nothing after the 1800s, more recent findings need to be included&lt;br /&gt;
*An image would be nice for pathogenesis to help the reader follow&lt;br /&gt;
*Not sure why you have made signs and symptoms a different heading to clinical manifestation- these could be combined&lt;br /&gt;
*Diagnosis is very brief and needs to be extended&lt;br /&gt;
*Glossary needs to be added to&lt;br /&gt;
*Maybe add a current research heading&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Comments on Group Project 10===&lt;br /&gt;
'''Strengths:'''&lt;br /&gt;
*The flow of the page is smooth with appropriate placement of the various headings.&lt;br /&gt;
*Clinical manifestation section looks really decent without appearing too verbose but yet sufficient information is given.&lt;br /&gt;
*The last image has correct referencing and the copyright statement is also included. &lt;br /&gt;
'''Weaknesses:'''&lt;br /&gt;
*Some of the references are not formatted properly. There are also a couple of duplications under References.&lt;br /&gt;
*Glossary is not complete.&lt;br /&gt;
*The formatting for the overall page is not as consistent as it can be.&lt;br /&gt;
'''Specific corrections:'''&lt;br /&gt;
*Maybe it would be better to have a heading for the genetic condition just on its own and not put it with the introduction heading.&lt;br /&gt;
* Maybe future treatments can come under a new heading “future research”?&lt;br /&gt;
*It will be good to elaborate more on current treatments.&lt;br /&gt;
*Diagnosis can be more detailed.&lt;br /&gt;
*Include a timeline under history to summarise that section.&lt;br /&gt;
*The copyright statement that allows wikiusers to use the student image after 6 months is not included.&lt;br /&gt;
&lt;br /&gt;
--Z3389806 07:04, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 10 Peer assessment'''&lt;br /&gt;
*Heading order needs to re-arranged and done properly with diagnosis above before signs and symptoms.&lt;br /&gt;
*Introduction done sort of well needs to integrate image as an example of the myofibres.&lt;br /&gt;
*History rather bulky with too much text and no image, image of the founder would be fine. Also no time line present of DM needs to be added&lt;br /&gt;
*Epidemiology seems rather empty, images would benefit this section also more stats, further expansion of sub headings would also do well for this section&lt;br /&gt;
*Genetics aetiology needs to be expanded where seems to be cramped, though usage of image needs to be noted&lt;br /&gt;
*Pathogenesis needs images and further information&lt;br /&gt;
*Signs and symptoms needs to be expanded and image of some signs or tables&lt;br /&gt;
*Clinical manifestation done well with image and further sub-headings &lt;br /&gt;
*Diagnosis requires more attention with further methods of detection of DM&lt;br /&gt;
*Treatment is well done with the usage of the table&lt;br /&gt;
*Glossary needs to further expanded also linked to the pages so easy to follow the page&lt;br /&gt;
*References are not complete with links and repeats of the references&lt;br /&gt;
z3332250 23:59, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 10  Critique'''&lt;br /&gt;
&lt;br /&gt;
#•	The introduction was very good. Good use of images to give it a little decoration!&lt;br /&gt;
#•	History is good&lt;br /&gt;
#•	Epidemiology is good, however if possible try and make it longer/ include more information&lt;br /&gt;
#•	The Genetics section is a bit too short. Add more information. Good hand drawn image!&lt;br /&gt;
#•	Pathogenesis is a little short. Needs more information&lt;br /&gt;
#•	Signs and Symptoms is good&lt;br /&gt;
#•	Clinical manifestations is ok&lt;br /&gt;
#•	Diagnosis, treatment and glossary are all well written. These sections should not require any change&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289991|Robert Klein]] 16:27, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Group 10 ''Duchenne Muscular Dystrophy''&lt;br /&gt;
*The first paragraph of the introduction has no reference.&lt;br /&gt;
*The paragraphs in history are quite long, often with grammar mistakes, incorrect punctuations and many of the ideas within a  sentence separated by a ''-''. For example the second last paragraph within history.&lt;br /&gt;
*The history is too verbose, a timeline with bullet points will look better&lt;br /&gt;
*Aetiology is quite concise and informative however gramatical errors are a distraction. For example ''There a multiple forms of dystrophin''. It might be a good idea to proofread the page.&lt;br /&gt;
*Well done with the student drawn image&lt;br /&gt;
*'Pathogenesis' is again well written however an image might have given it a balance between the text in the section and the pictures or tables&lt;br /&gt;
*The future therapies table is a little confusing, you might want to add more columns and define the therapy, and then discuss what the challenges and findings are and at the end column finish off with what the implication might be if the research is to be completed successfully. At the moment you have discussed all that in one big paragraph and the way the descriptions start, it sounds like there is no background to the description, just a little abrupt. &lt;br /&gt;
*The glossary is very short and you should include terms like de novo mutation.&lt;br /&gt;
*The existing definitions are unclear and incomplete&lt;br /&gt;
&lt;br /&gt;
''Duchenne Muscular Dystrophy''&lt;br /&gt;
&lt;br /&gt;
*Make sure you add a proper heading for the page, so it doesn't just start with 'Introduction'&lt;br /&gt;
*The 'Introduction' is a good start to the page, very easy to read and understand&lt;br /&gt;
*'History' is a bit difficult to read, try to make is sequential order, or at least '''bold''' the dates&lt;br /&gt;
*In 'History' we don't really want a story, but key dates in the history of the discovery of the disorder.  Surely something has happened in the past 150 years?&lt;br /&gt;
*Good work with 'Pathogenesis', it is a good description of the development of the disorder&lt;br /&gt;
*Can we see an image relating to the signs and symptoms?&lt;br /&gt;
*'Clinical Manifestations' is a good thorough description, though I don't understand what going on with the last section 'Smooth Muscle' with the random '''&amp;amp;&amp;amp;&amp;amp;'''.  It is also a whole lot more general than the preceeding sections.  Is it finished?&lt;br /&gt;
*Could you give a bit more detail in 'Diagnosis'.  It would be good to explain each method a bit more and explain why they are relevant.&lt;br /&gt;
*Can you expand on the table a bit? ie P188, what exactly is it used for? How does it treat it? How effective is it? When is it administered etc&lt;br /&gt;
*No current research section? This could be a good conclusion to the page - the 'Stem Cell Transplant' section from 'Treatments' would fit better here&lt;br /&gt;
*The glossary needs to be finished and expanded on&lt;br /&gt;
*Overall the page is not bad, but more images are needed and some clarification on topics&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 10-&lt;br /&gt;
* Need more images to break up the text&lt;br /&gt;
* The introduction was really easy to read and had relevant information in it&lt;br /&gt;
* History should be in bullet point form to make it easier to access or at least have the dates in BOLD&lt;br /&gt;
* Does the history include dates after the 1800s? or did all research stop then?&lt;br /&gt;
* Epidemiology was good. Had all the relevant info&lt;br /&gt;
* Pathogenesis would benefit an image or a diagram&lt;br /&gt;
* Signs and symptoms could be put with clinical manifestations. &lt;br /&gt;
* What is the point of the ‘&amp;amp;&amp;amp;&amp;amp;’? in clinical manifestations and complications?&lt;br /&gt;
* Diagnosis could be expanded upon to explain how and why these methods work&lt;br /&gt;
* Treatment could also be expanded on. A list of drugs doesn’t explain much&lt;br /&gt;
* There is not current/future research section&lt;br /&gt;
* This is a good start to the project but more research needs to be done&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 10'''&lt;br /&gt;
* The structure and use of headings and subheadings is good, make sure you title your page. &lt;br /&gt;
* Good info very informative and it gives a good overview to DMD.&lt;br /&gt;
* HIstory has a lot of text could you use a timeline here? &lt;br /&gt;
* i think a picture of the pathogenesis would improve this section. &lt;br /&gt;
* Has your group look at the CNS and cognitive function of DMD boys its a controversial area as many people have different attitudes towards this but Dr Stewart Head a UNSW lecture actually studies DMD and is very informative in the area and recently published a article in the journal Brain.  &lt;br /&gt;
* The CNS is highly affected by the lack of dystrophin as well as GABA receptors. I think this area is very import to consider as it highly affects the boys at school. &lt;br /&gt;
* Could you add some pictures to your page or break it up with the use of more tables as it a lot of text in comparison to pictures and tables. &lt;br /&gt;
* Make sure your reference list is not doubled.&lt;br /&gt;
* Ensure all your pictures are referenced properly.&lt;br /&gt;
* Student image is present. &lt;br /&gt;
* This is a good start.&lt;br /&gt;
&lt;br /&gt;
'''Group 10 Assessment'''&lt;br /&gt;
*The history is a bit wordy…  Maybe consider consolidating the information into a table format for ease of reading.  Could also use a picture to add to it. &lt;br /&gt;
*The Epidemiology section could also use a picture and maybe some more information, if possible.  &lt;br /&gt;
*Point vs Frameshift mutation jpg:  Good drawing, but in the last portion of the picture the product is labeled as a ‘tunicated protein product.’  Isn’t it supposed to be a ‘truncated’ product? &lt;br /&gt;
*The Signs and Symptoms section could use some formatting; it just looks rather dull currently.  Maybe a chart or add in a picture? &lt;br /&gt;
*Smooth muscle section:  Why are there random &amp;amp;&amp;amp;&amp;amp;’s? &lt;br /&gt;
*The top portion of the Treatment section could use some more referencing… Good chart though! Only thing I’d suggest for it is to add some pictures if possible? &lt;br /&gt;
*Glossary term list is rather short… Are you sure there’s nothing else that needs defining for clarification for the reader? &lt;br /&gt;
*It would be a good idea also to have the glossary terms linked with the words in the wiki page, so that the reader can easily get access to the word in the glossary.  &lt;br /&gt;
*Some of the references are repetitive.  Make sure to fix this so they all link to a single reference instead of numerous ones of the same resource.  &lt;br /&gt;
*For the references given throughout the wiki, there isn’t any consistency in how the [#] is given.  The [#] is sometimes right after the sentence, sometimes a space is given between the sentence and citation number, and the end of the sentence (period or comma) is sometimes before or after the reference #...&lt;br /&gt;
*Overall, good information is included, just work on referencing things and the overall structure and you should be good! &lt;br /&gt;
--[[User:Z3391078|Z3391078]] 17:00, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Discussion==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''GROUP 10!''' &lt;br /&gt;
&lt;br /&gt;
'''To make everything easier to follow, we have agreed to write any updates, info, discussion etc at the BOTTOM of this page, it will just stop us having to keep going up and down and wasting time trying to find the information we want.''' &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey Everyone,&lt;br /&gt;
&lt;br /&gt;
So Mark went through each group today during the lab and the webpages and discussed where we should be up to. By next week, he expects the subheadings &amp;amp; some content to be up and running. He also recommended that we should have some more research going on in our discussion page. E.g. Research articles links, interesting sites etc.&lt;br /&gt;
&lt;br /&gt;
Topics have been allocated so please begin your research and typing up some content. We can further divide our headings if necessary, take a look at some other groups, they have some pretty good ideas. Mark will be checking this next week during our lab. He'll be coming around to each of us. &lt;br /&gt;
&lt;br /&gt;
So hopefully see you all next week !&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332327|z3332327]] 12:53, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Subheadings for assignment== &lt;br /&gt;
&lt;br /&gt;
Intro what is DMD&lt;br /&gt;
&lt;br /&gt;
History/timeline&lt;br /&gt;
&lt;br /&gt;
Genetic component&lt;br /&gt;
&lt;br /&gt;
Why is it an abnormality - Symptoms effect &lt;br /&gt;
&lt;br /&gt;
Diagnosis, future/current prospect (treatments?)&lt;br /&gt;
&lt;br /&gt;
2 case studies &lt;br /&gt;
&lt;br /&gt;
Glossary of terms &lt;br /&gt;
&lt;br /&gt;
====Post online any preferences you may have in terms of the topics you wish to research and by Sunday we will allocate sub topics====&lt;br /&gt;
--[[User:Z3332629|z3332629]] 13:09, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Okay hey guys just to get the discussion going, umm I don't mind doing the first 2 on the list. And the &amp;quot;Why is it an abnormality - Symptoms effect&amp;quot; sounds pretty interesting as well. &lt;br /&gt;
What are your preferences?? :)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3330313|z3330313]] 14:55, 23 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Everyone, Im happy to do the diagnosis/current/future prospects point and a case study.&lt;br /&gt;
&lt;br /&gt;
--z3332327 15:36, 23 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hello,&lt;br /&gt;
I would like to do the 'why is it an abnormality - symptoms effect' and then it will be easy to incorporate that with a case study. So I guess that leaves Ashleigh to do the genetic component mostly, but we will ALL help out with that :D&lt;br /&gt;
How does this sound?&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332824]] 10:22, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Duchenne Muscular Dystrophy - recessive X-linked form of muscular dystrophy, which results in muscle degeneration, difficulty walking, breathing, and death. It  is caused by a mutation of the dystrophin gene at locus Xp21.&lt;br /&gt;
&lt;br /&gt;
Osteogenesis Imperfecta - caused by defect in the gene that produces type 1 collagen, an important building block of bone. Most cases of OI are inherited from a parent, although some cases are the result of new genetic mutations. A person with OI has a 50% chance of passing on the gene and the disease to their children.&lt;br /&gt;
&lt;br /&gt;
Congenital Adrenal Hyperplasia - refers to any of several autosomal recessive diseases resulting from mutations of genes for enzymes mediating the biochemical steps of production of cortisol from cholesterol by the adrenal glands (steroidogenesis).&lt;br /&gt;
&lt;br /&gt;
DiGeorge Syndrome - congenital immunodeficiency. Di George syndrome is an inherited condition that lies at the more severe end of a spectrum of syndromes (also known as CATCH22 or 22q11.2 deletion syndrome) that occur when a part of the DNA on chromosome 22 is missing. Several different genes are lost, resulting in a collection of different features, including problems with the immune system, congenital heart defects and abnormalities of the parathyroid glands.&lt;br /&gt;
[[User:Z3332327|z3332327]] 22:28, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Review Article: Targeting RNA to treat neuromuscular disease. Muntoni, F &amp;amp; Wood, M.J.A. (2011) Nature Reviews Drug Discovery 10, 621-637.&lt;br /&gt;
http://www.nature.com.wwwproxy0.library.unsw.edu.au/nrd/journal/v10/n8/full/nrd3459.html &lt;br /&gt;
&lt;br /&gt;
Research Article: Ahmad N, Welch I, Grange R, Hadway J, Dhanvantari S, Hill D, Lee TY, Hoffman LM. Use of imaging biomarkers to assess perfusion and glucose metabolism in the skeletal muscle of dystrophic mice. BMC Musculoskelet Disord.&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141608/pdf/1471-2474-12-127.pdf&lt;br /&gt;
&lt;br /&gt;
z3332327 23:11, 10 August 2011 (EST)&lt;br /&gt;
______________________________________________________________________________________________________________________________________________&lt;br /&gt;
&lt;br /&gt;
'''Friedreich Ataxia –''' Is caused by defect/mutation of the gene FXN, the disorder is recessive. It is an inherited disease that causes nervous system damage and impaired muscle coordination (ataxia) through spinal cord, peripheral nerve and cerebellum degeneration.&lt;br /&gt;
&lt;br /&gt;
'''Lesch-Nyhan Syndrome –''' Rare inherited disorder where there is a deficiency of the enzyme: hypoxanthine-guanine phosphoribosyl transferase (HPRT). This is caused by mutations of the HPRT gene located on the x-chromosome. This disorder is an x-linked recession disease, it causes kidney probems (building up of uric acid in all body fluids) and moderate mental retardation. &lt;br /&gt;
&lt;br /&gt;
'''Farber's Disease –''' Is an inherited autosomal recessive lysosomal storage disease. The gene responsible making the enzyme ceramidase is mutated. This enzyme breaks down fatty material in the body’s cell.  [not recommended to do, limited disease]&lt;br /&gt;
&lt;br /&gt;
'''Mucopolysaccharidoses –''' Inherited metabolic disease where a defective or missing enzyme cause large amounts of complex sugar molecules to accumulate in harmful amounts in the bodies cells and tissues. They can’t break down these glycosaminoglycans into smaller chains. It ends up causing progressive cellular damage which affects appearance, physical abilities, organ and system functioning, and, in most cases, mental development.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3330313|z3330313]] 23:43, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
{{2011ProjectsMH}}&lt;br /&gt;
Hey group 10 members!&lt;br /&gt;
I've quickly done some research on the top 4 listed disorders.&lt;br /&gt;
All of them had loads of info!!&lt;br /&gt;
Let me know what you think and lets say by monday we should pick a topic?&lt;br /&gt;
&lt;br /&gt;
Angelman syndrome &lt;br /&gt;
-	rare neuro-genetic disorder&lt;br /&gt;
-	characterised by severe intellectual disability, speech impediment, sleep disturbance, unstable jerky gait, seizures and usually a happy demeanour&lt;br /&gt;
-	occurs about one in 20,000 births&lt;br /&gt;
-	Severe intellectual disability and developmental delay&lt;br /&gt;
-	Profound speech impairment&lt;br /&gt;
-	Movement for balance disorder&lt;br /&gt;
&lt;br /&gt;
Turner’s syndrome&lt;br /&gt;
-	affects about 1 in every 2,500 girls&lt;br /&gt;
-	usually short in height&lt;br /&gt;
-	born with only one X chromosome or they are missing part of one X chromosome&lt;br /&gt;
-	prevents the ovaries from developing properly&lt;br /&gt;
-	kidney problems, high blood pressure, heart problems, overweight, hearing difficulties, diabetes, and thyroid problems&lt;br /&gt;
&lt;br /&gt;
Williams Syndrome&lt;br /&gt;
-	rare genetic disorder characterized by mild to moderate mental retardation or learning difficulties, a distinctive facial appearance, and a unique personality that combines over-friendliness and high levels of empathy with anxiety.&lt;br /&gt;
-	Common problem: cardiovascular disease caused by narrowed arteries&lt;br /&gt;
-	A random genetic mutation (deletion of a small piece of chromosome 7), rather than inheritance, most often causes the disorder&lt;br /&gt;
-	50 percent chance of passing it on if they decide to have children&lt;br /&gt;
&lt;br /&gt;
Cystic Fibrosis&lt;br /&gt;
-	Cystic fibrosis (CF) is a recessive genetic disease of the mucus and sweat glands, which affects the entire body.&lt;br /&gt;
-	affects mostly your lungs, pancreas, liver, intestines, sinuses and sex organs&lt;br /&gt;
-	makes it easy for bacteria to grow  &lt;br /&gt;
-	Difficulty breathing&lt;br /&gt;
-	multitude of other symptoms, including sinus infections, poor growth, diarrhea, and infertility result from the effects of CF on other parts of the body&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332629|z3332629]] 14:10, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Sorry i accidently posted it on the actual project page lol&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332629|Ashleigh Pontifex]] 13:31, 10 August 2011 (EST)&lt;br /&gt;
Review article: Functional characteristics of dystrophic skeletal muscle: insights from animal models.&lt;br /&gt;
Jon F. Watchko1, Terrence L. O'Day1, and Eric P. Hoffman2 &lt;br /&gt;
http://jap.physiology.org/content/93/2/407.long&lt;br /&gt;
&lt;br /&gt;
Research article: The common missense mutation D489N in TRIM32 causing limb girdle muscular dystrophy 2H leads to loss of the mutated protein in knock-in mice resulting in a Trim32-null phenotype &lt;br /&gt;
Elena Kudryashova1, Arie Struyk2,†, Ekaterina Mokhonova1, Stephen C. Cannon2 and Melissa J. Spencer1,* &lt;br /&gt;
http://hmg.oxfordjournals.org/content/early/2011/07/28/hmg.ddr311.long&lt;br /&gt;
--[[User:Z3332629|Ashleigh Pontifex]] 13:31, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
Hello!&lt;br /&gt;
So my four diseases:&lt;br /&gt;
&lt;br /&gt;
'''1. Fragile X Retardation:''' males mostly, the code CGG is repeated on a fragile area of the X chromosome. The more repeats, the more problems. See http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002633/ for more details on symptoms etc.&lt;br /&gt;
&lt;br /&gt;
'''2. Klinefelter Syndrome:''' extra X chromosome in males - XXY. Abnormal body proportions, infertility, less hair, big boobs, problems with their genitals (poor things). http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001420/&lt;br /&gt;
&lt;br /&gt;
'''3. Triple X:''' I think this is a trisomy and should be avoided? It is having XXX in females. &lt;br /&gt;
&lt;br /&gt;
'''4. Thalassemia:''' blood disorder in which you have abnormal haemoglobin. Results lead to excessive destruction of RBC which leads to anaemia. Inherited from BOTH parents. Bone deformities in face, fatigue, growth failure, jaundice. See http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001613/&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Personally, out of my four I think either Fragile X or Thalassemia will be the most interesting. Angelman Syndrome and Duchenne Muscular Dystrophy also sound cool. I think we should avoid all ones that are really specific biochem disorders (or to that effect)- something like Mucopolysaccharidoses - because we might get bogged down in the details and have to spend ages figuring out what its actually doing. &lt;br /&gt;
&lt;br /&gt;
What is everyone else's thoughts?&lt;br /&gt;
See you tomorrow, &lt;br /&gt;
Rhiannon.&lt;br /&gt;
&lt;br /&gt;
I think we should do Duchenne Muscular Dystrophy. &lt;br /&gt;
--[[User:Z3332629|Ashleigh Pontifex]] 11:03, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
I agree !&lt;br /&gt;
Lisa Xiao 11:04, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Yes that sounds good, lets do it :) &lt;br /&gt;
--[[User:Z3330313|Joanna Pak]] 11:38, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Yep, I'm all for it. I'm glad we can bags it before everyone else :D&lt;br /&gt;
Rhiannon &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332824|Rhiannon Bice]] 11:40, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== Useful Links ==&lt;br /&gt;
&lt;br /&gt;
[http://www.genome.gov/19518854]National Human Genome Research Institute: Fact Sheet on Duchennes&lt;br /&gt;
&lt;br /&gt;
'''Treatment'''&lt;br /&gt;
&lt;br /&gt;
No known cure. However treatment aims to manage symptoms to maximize the quality of life. &lt;br /&gt;
Treatments includes:&lt;br /&gt;
- Physical Therapy: in order to maintain muscle strength and function. (Inactivity leads to weakened muscles and can worsen the condition)&lt;br /&gt;
- Orthopedic appliances such as braces and wheelchairs are available to improve mobility&lt;br /&gt;
- Aggressive management of dilated cardiomyopathy with anti-congestive medications&lt;br /&gt;
- The medication prednisone — a steroid — is given to improve the strength and function of individuals with DMD (However there are side affects associated with this medication)&lt;br /&gt;
&lt;br /&gt;
'''Future Prospects'''&lt;br /&gt;
- Gene Therapy&lt;br /&gt;
&lt;br /&gt;
[http://www.nlm.nih.gov/medlineplus/ency/article/000705.htm]Medline Plus: Encyclopedia&lt;br /&gt;
&lt;br /&gt;
--z3332327 15:48, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey guys, I couldn't copy a picture relating to Duchenne, so i just got a random one :)&lt;br /&gt;
Rhiannon. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Patterns of zona pellucida deposition and ZPC-ubiquitin colocalization in porcine ocyte-cumulus complexes isolated from small antral follicles.JPG]]&lt;br /&gt;
&lt;br /&gt;
Patterns of zona pellucida deposition and ZPC-ubiquitin colocalization in porcine ocyte-cumulus complexes isolated from small antral follicles. &lt;br /&gt;
&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21383844&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Flow of participants.JPG]]&lt;br /&gt;
&lt;br /&gt;
File: Flow of Participants&lt;br /&gt;
--Lisa Xiao 12:43, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
[[File:1532-429X-13-20-1.jpg]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3330313|z3330313]] 12:51, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey girls its Ashleigh, sorry I've been quite sick over the last week. &lt;br /&gt;
How about me copy and paste the headings again and write our names next to our bit and we can leave suggests as to what can fit into that heading etc? Ps did I miss anything from last weeks lab??&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332629|Ashleigh Pontifex]] 19:38, 30 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== Official discussion ==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''Subheadings for assignment'' &lt;br /&gt;
&lt;br /&gt;
Intro what is DMD&lt;br /&gt;
&lt;br /&gt;
History/timeline&lt;br /&gt;
&lt;br /&gt;
Genetic component&lt;br /&gt;
&lt;br /&gt;
Why is it an abnormality - Symptoms effect &lt;br /&gt;
&lt;br /&gt;
Diagnosis, future/current prospect (treatments?)&lt;br /&gt;
&lt;br /&gt;
2 case studies &lt;br /&gt;
&lt;br /&gt;
Glossary of terms &lt;br /&gt;
&lt;br /&gt;
====Post online any preferences you may have in terms of the topics you wish to research and by Sunday we will allocate sub topics====&lt;br /&gt;
--[[User:Z3332629|z3332629]] 13:09, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Just found an awesome website!&lt;br /&gt;
&lt;br /&gt;
http://emedicine.medscape.com/article/1173204-overview&lt;br /&gt;
&lt;br /&gt;
Check it out when you can, it has info on history &amp;amp; treatment as well as some really good images.&lt;br /&gt;
&lt;br /&gt;
[[File:Point vs frameshift mutations.jpg|500px|]]&lt;br /&gt;
&lt;br /&gt;
Whoever is doing future direction of treatment etc., check out this article on PubMed&lt;br /&gt;
&lt;br /&gt;
Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions.&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/21674516?tool=MedlinePlus&lt;br /&gt;
&lt;br /&gt;
Abstract&lt;br /&gt;
&lt;br /&gt;
Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy and occurs in 1 in 3500 male births. Improved survival due to improvements in clinical care of the musculoskeletal and respiratory systems has led to an increased incidence of cardiomyopathy. Cardiac-related deaths are now seen in approximately 20% of DMD patients. Our current understanding of DMD cardiomyopathy has increased significantly over the past 10 years, but further research is required to improve cardiac treatment and outcomes in DMD. This review provides a summary of the current literature and discussion of potential new therapies for DMD cardiomyopathy.&lt;br /&gt;
&lt;br /&gt;
Copyright © 2011 Wiley Periodicals, Inc.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332629|Ashleigh Pontifex]] 20:00, 30 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Some quick points from:&lt;br /&gt;
http://ghr.nlm.nih.gov/condition/duchenne-and-becker-muscular-dystrophy&lt;br /&gt;
&lt;br /&gt;
-	Mutations in the DMD gene causes DMD&lt;br /&gt;
&lt;br /&gt;
-	The DMD gene provides instructions for making a protein called dystrophin that helps stabilize and protect muscle fibers and may play a role in chemical signaling within cells.&lt;br /&gt;
 &lt;br /&gt;
-	Mutations alter the structure or function of dystrophin, or prevent any functional dystrophin from being produced.&lt;br /&gt;
 &lt;br /&gt;
-	Muscle cells without this protein become damaged as muscles repeatedly contract and relax with use. The damaged fibers weaken and die over time, leading to the muscle weakness and heart problems characteristic of Duchenne and Becker muscular dystrophies.&lt;br /&gt;
&lt;br /&gt;
-	This condition is inherited in an X-linked recessive pattern.&lt;br /&gt;
 &lt;br /&gt;
-	Males are affected by X-linked recessive disorders much more frequently than females. &lt;br /&gt;
&lt;br /&gt;
-	Fathers cannot pass X-linked traits to their sons.&lt;br /&gt;
&lt;br /&gt;
-	Females who carry a DMD gene mutation also have an increased risk of developing heart abnormalities including dilated cardiomyopathy.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey guys &lt;br /&gt;
I found this slide show on DMD, quite easy to understand because all u have to do is listen!&lt;br /&gt;
So its http://hstalks.com.wwwproxy0.library.unsw.edu.au/main/citation_info.php?c=252&lt;br /&gt;
Oh and I'm not 100% sure on how to reference properly so bear with me if I make a mistake on the group page. And I'm going to try and borrow some books DMD to see if there's more of an indepth history of the disorder. &lt;br /&gt;
If u guys feel your part is too big, let me know because I'm willing to help out!!&lt;br /&gt;
&lt;br /&gt;
(http://www.whonamedit.com/doctor.cfm/950.html)&lt;br /&gt;
--[[User:Z3330313|Joanna Pak]] 02:10, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
I've been doing a bit of research and found some good papers.&lt;br /&gt;
&lt;br /&gt;
Rodino-Klapac LR, Chicoine LG, Kaspar BK, Mendell JR. Gene therapy for duchenne muscular dystrophy: expectations and challenges. Arch Neurol. Sep 2007;64(9):1236-41&lt;br /&gt;
&lt;br /&gt;
Bogdanovich S, Perkins KJ, Krag TO. Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. J Mol Med. Feb 2004;82(2):102-15&lt;br /&gt;
&lt;br /&gt;
Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends Mol Med. Dec 2007;13(12):520-6&lt;br /&gt;
&lt;br /&gt;
AND the a copy of original book by Gower (one of the first to describe the disease etc) is at the library! Its called ' A manual of Diseases of the Nervous System'. Pages 378-393. I will be checking that out tonight or tomorrow.&lt;br /&gt;
-Rhi. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Treatment:&lt;br /&gt;
http://emedicine.medscape.com/article/1173204-overview -- Useful link&lt;br /&gt;
&lt;br /&gt;
Inflammation is implicated in the pathogenesis of the dystrophinopathies despite the fact that most biopsies in patients with Duchenne muscular dystrophy do not show inflammatory cells. Corticosteroids have been used for more than 40 years with some success to treat patients with Duchenne muscular dystrophy. The central role of inflammation in the pathogenesis of the dystrophinopathies is suggested by the fact that use of corticosteroids, such as prednisone, results in prolongation of ambulation, maintenance of strength and function, and delay in the development of scoliosis. The side effects are well-known and do temper many clinicians enthusiasm to recommend its use in small children, patients with behavior or learning issues, or any patient for chronic use. A detailed understanding of the mechanism of action for corticosteroids on the body is still a large mystery.&lt;br /&gt;
&lt;br /&gt;
To date, corticosteroids are the only medication that has demonstrated a modest benefit in modifying the course of the disease.[5] Clinical improvement is seen as early as 1 month after starting treatment and lasts as long as 3 years. Children who discontinue corticosteroids for various reasons soon revert to natural downward progression of the disease. It is hypothesized that prednisone reduces tissue inflammation, suppresses cytotoxic cells, improves calcium homeostasis, and stimulates myoblasts.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332327|Lisa Xiao]] 16:45, 31 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== '''Clarification on components of the assignment''' ==&lt;br /&gt;
&lt;br /&gt;
*If we find papers/books/info relating to another section that isn't ours, clearly write the name of the person it goes to and link/mention it e.g. Lisa: xyz&lt;br /&gt;
(this will just make it really easy to find)&lt;br /&gt;
&lt;br /&gt;
*When we have the majority of the info up, we can meet and format the page, as well as edit it to make it flow. &lt;br /&gt;
&lt;br /&gt;
*Keep checking this page for updates! Make this the main communication method between us, so keep an eye on it :D&lt;br /&gt;
&lt;br /&gt;
*We also agreed that any updates will be here at the bottom of the page, just makes the flow easier. So keep updates down here!!&lt;br /&gt;
&lt;br /&gt;
Sections:&lt;br /&gt;
&lt;br /&gt;
Jo: intro/history/epidemiology&lt;br /&gt;
&lt;br /&gt;
Ashleigh: genetic component/aetiology/pathogenesis (close work with Rhiannon)&lt;br /&gt;
 &lt;br /&gt;
Rhiannon: signs and symptoms/clinical manifestations/pathogenesis/CASE STUDY 1 (close work with Ashleigh)&lt;br /&gt;
&lt;br /&gt;
Lisa: Diagnosis/treatment/futher research and directions/CASE STUDY 2&lt;br /&gt;
&lt;br /&gt;
*Also, do we want to write anything about Becker's syndrome (the milder version of DMD?) Maybe we could do a comparison table if we can be bothered?&lt;br /&gt;
--[[User:Z3332824|Rhiannon Bice]] 13:02, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey guys, during my own research I've come across a lot of resources that each of you could use. They are only suggestions, but a few look really good!! I just thought I'd put them here to help us all along instead of you starting from scratch. I've spent most of today researching so its a bit of a waste if I don't pass it on :)&lt;br /&gt;
&lt;br /&gt;
*'''Ashleigh'''- you may find details these sites helpful: http://www.nature.com/nature/journal/v333/n6172/abs/333466a0.html;  http://www.unsworks.unsw.edu.au/primo_library/libweb/action/dlDisplay.do?vid=UNSWORKS&amp;amp;docId=unsworks_8295;  http://docentes.cs.urjc.es/~odeluis/Docencia/ABP/Articulos/davies.pdf&lt;br /&gt;
&lt;br /&gt;
*'''Lisa:''' http://www.sciencedirect.com/science/article/pii/0959437X9180033I. There is also a book at the library called &amp;quot;''Myoblast Transfer Therapy&amp;quot;'' written by the Muscular Dystrophy Association that you may find useful. It can be found at the library at Level 8, Main Library (MB 617.4730592/1). Also, I used a lot information found in the paper at {http://onlinelibrary.wiley.com/doi/10.1002/mus.22097/full}, so this may be a good starting point for treatment, especially about problems relating to the cardiac/respiratory systems. They also give some good info on the treatments available. Basically, you will get a lot out of that paper! If you can't download it properly, buzz me your email and I'll send it to you. &lt;br /&gt;
&lt;br /&gt;
*'''Jo:''' Book called ''The history of a genetic disease : Duchenne muscular dystrophy or Meryon's disease''  Level 8, Main Library (MB 616.748/6). I think also when we all have our info about the actual disease written it will be heaps easier to write the introduction. &lt;br /&gt;
&lt;br /&gt;
*YO! '''Found a LECTURE''' from a guy in America about it: http://hstalks.com/main/browse_talk_view.php?t=72&amp;amp;s=72&amp;amp;s_id=33&amp;amp;c=252. You can download the lecture slides too and use them (of course, we have to reference it properly as well). I think you found this before Jo? Anyway, check it out!!!&lt;br /&gt;
&lt;br /&gt;
*I have found a tonne of papers as well, so if everyone puts up their emails I can send it to you all. Even if you get one good sentence to use out of the whole paper then thats great!&lt;br /&gt;
&lt;br /&gt;
-Chamberlain, J. (2007), &amp;quot;Duchenne Muscular Dystrophy&amp;quot;, in Dunn, B. (ed.), Protein Epidemiology: Diseases at the Level of Protein Structure and Function, The Biomedical &amp;amp; Life Sciences Collection, London (online at http://hstalks.com/bio)&lt;br /&gt;
&lt;br /&gt;
Ashleigh's writing - maybe use?: Normal functioning of Dystrophin verses impaired functioning&lt;br /&gt;
&lt;br /&gt;
Dystrophin is part of a group of proteins found in skeletal and cardiac muscle that work to protect and strengthen muscles fibers as they contract and relax upon movement. Dystrophin also functions in connecting muscle cell’s with other proteins and molecules in order to send and receive chemical signals amongst cells and to anchor muscle fibers. &amp;lt;ref&amp;gt;U.S. National Library of Medicine (2011). “Duchenne and Becker muscular dystrophy”. Author unknown, Genetics Home Reference. Accessed via http://ghr.nlm.nih.gov/condition/duchenne-and-becker-muscular-dystrophy &amp;lt;/ref&amp;gt;	&lt;br /&gt;
&lt;br /&gt;
Skeletal and cardiac muscle cells of Duchennes patients have no functional dystrophin present and therefore the muscle fibers become extensively damaged as they contract and relax with use. Overtime, these damaged cells weaken and eventually die resulting in multiple health implications. &amp;lt;ref&amp;gt;U.S. National Library of Medicine (2011). “Duchenne and Becker muscular dystrophy”. Author unknown, Genetics Home Reference. Accessed via http://ghr.nlm.nih.gov/condition/duchenne-and-becker-muscular-dystrophy &amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
---Rhiannon.&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_9&amp;diff=72535</id>
		<title>Talk:2011 Group Project 9</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_9&amp;diff=72535"/>
		<updated>2011-09-27T13:24:46Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Peer Review */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[2011_Group_Project_9|'''Group 9''']]: [[User:z3331469]] | [[User:z3331556]] | [[User:z3332178]] | [[User:z3332183]]&lt;br /&gt;
&lt;br /&gt;
{{2011GroupDiscussionMH}}&lt;br /&gt;
&lt;br /&gt;
==Peer Review==&lt;br /&gt;
&lt;br /&gt;
'''Group 9'''&lt;br /&gt;
&lt;br /&gt;
*You don’t have a very good image/text ratio. More images are needed to break up the text.&lt;br /&gt;
*Good information in your introduction although you need an image&lt;br /&gt;
*Maybe try and condense your history just into a timeline?&lt;br /&gt;
*Genetic factors and etiology and diagnosis are good and have a nice flow&lt;br /&gt;
*I think the section epidemiology should closer to the beginning of your project- also not sure why management and treatment are mentioned here.&lt;br /&gt;
*Phenotypes should be organised better&lt;br /&gt;
*Good table for associated medical conditions&lt;br /&gt;
*A few of your headings should be reformatted&lt;br /&gt;
*Specialised facilities and supportive associations seems a little unnecessary&lt;br /&gt;
*Glossary is incomplete&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 9'''&lt;br /&gt;
&lt;br /&gt;
*Introduction: contend is fine&lt;br /&gt;
&lt;br /&gt;
*History: could be a bit shortened, otherwise good&lt;br /&gt;
&lt;br /&gt;
*Genetic and Etiology: well done&lt;br /&gt;
&lt;br /&gt;
*Diagnosis: looks good&lt;br /&gt;
&lt;br /&gt;
*Epidemiology: treatment doesn’t belong there (own section?), the contend is good&lt;br /&gt;
&lt;br /&gt;
*Phenotype: references missing&lt;br /&gt;
&lt;br /&gt;
*Cardiac conditions: well done, but what’s with other conditions?&lt;br /&gt;
&lt;br /&gt;
*Genitourinary Conditions: the contend is good, but the structure could be clearer, a table for the grading system would be nice&lt;br /&gt;
&lt;br /&gt;
*Endocrine: missing references, otherwise good section&lt;br /&gt;
&lt;br /&gt;
*Other associated conditions: looks fine&lt;br /&gt;
&lt;br /&gt;
*Cognitive, behavioural Phenotype: references missing?&lt;br /&gt;
&lt;br /&gt;
*Structural diff. in the brain: is there really only one resource? Lack of structure and subheadings&lt;br /&gt;
&lt;br /&gt;
*Special Facilities: I don’t think it is necessary to list the addresses of the foundations, and write down all their aims. The online link is enough.&lt;br /&gt;
&lt;br /&gt;
*Research: could have more detailed information&lt;br /&gt;
&lt;br /&gt;
*Glossary: incomplete&lt;br /&gt;
&lt;br /&gt;
*The phenotype sections should be put together&lt;br /&gt;
--[[User:Z3387190|Z3387190]] 23:20, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Comments on Group Project 9===&lt;br /&gt;
'''Strengths:'''&lt;br /&gt;
*Good use of subheadings. It gives the page a structured feel to it.&lt;br /&gt;
*For most part of the references, it is good with the initiative to prevent duplication of references.&lt;br /&gt;
* I really like the “Specialised Facilities and Supportive Associations” section. Parents who just found out about their child’s condition would probably want to know more and seek help and this would be good for them.&lt;br /&gt;
'''Weaknesses:'''&lt;br /&gt;
*The history section looks really overwhelming. &lt;br /&gt;
*The glossary section is poorly done, with missing definitions for some words. There are other words that should be included in the glossary but was not.&lt;br /&gt;
*The image of the typical facial feature of an individual with WS looks similar to the one shown during lecture by Dr Palmer. It would be good to acknowledge what the image drawn was based on.&lt;br /&gt;
'''Specific corrections:'''&lt;br /&gt;
*It will be good to include an image in either the introduction or history section. At least it will be able to grab some attention.&lt;br /&gt;
*Reference 23 is missing its source.&lt;br /&gt;
*It will be good to elaborate more on some of the research studies being done to give the readers a feel of the direction in which the research for Williams Syn is gearing towards.&lt;br /&gt;
&lt;br /&gt;
--Z3389806 06:45, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 9 Peer Assessment'''&lt;br /&gt;
*Introduction has clear explanation of the topic though image would liven the section up&lt;br /&gt;
*History is very informative though have no images, image of the founder would suit this area. While the time line done properly and looks good but bullet points would make look better&lt;br /&gt;
*Genetic factors should incorporate the image used “fig 2”, although the use of the table is well made explaining the cases of genetic transmission.&lt;br /&gt;
*Diagnosis introduction done well though image “fig 3” not mentioned in the text which should also be integrated into the text.&lt;br /&gt;
*Epidemiology should be first before the diagnosis and treatment would be better as its own heading and below near the end.&lt;br /&gt;
*Headings needs to be more organised and some more images which are linked to the text otherwise very bulky with text&lt;br /&gt;
*Current research/ future research done well and separated with sub headings&lt;br /&gt;
*Glossary need to be expanded as most terms not understood without a dictionary&lt;br /&gt;
*Reference 23 and 2 needs to be fixed otherwise all done well&lt;br /&gt;
z3332250 23:57, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 9 Critique'''&lt;br /&gt;
&lt;br /&gt;
#•	Introduction is ok. Maybe add a picture or two to make the introduction look a little bit more interesting&lt;br /&gt;
#•	History is pretty good. Nice work on the timeline!&lt;br /&gt;
#•	The table in the section on genetic factors is appropriate. Good job!&lt;br /&gt;
#•	Diagnosis is good&lt;br /&gt;
#•	Epidemiology should be after introduction, not diagnosis, but otherwise ok&lt;br /&gt;
#•	The overall project is quite good, however diagnosis should be at the end and not one of the first sections&lt;br /&gt;
#•	Also, is it necessary to put in information about support groups? Something to think about&lt;br /&gt;
#•	Glossary is unfinished&lt;br /&gt;
#•	The current research and developments section should have more information in it. Two lines of information is not enough detail&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289991|Robert Klein]] 16:16, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Peer Assessment Group 9 '''Williams-Beuren Syndrome'''&lt;br /&gt;
&lt;br /&gt;
*The introduction could use a simple image of the chromosome 7q11.23 just to make the introduction look a bit more interesting&lt;br /&gt;
*History is too detailed and in a few instances a repetition of the timeline&lt;br /&gt;
*An image in the timeline section will make it a bit more interesting&lt;br /&gt;
*The section 'Genetic factors and Etiology' is a great balance of image, table and text. Interesting information presented simply and clearly&lt;br /&gt;
*Interesting image of the deleted gene location&lt;br /&gt;
*Under Epidemiology you could also talk about prevalence of the condition in certain regions of the world etc. It looks like a one sentence section. &lt;br /&gt;
*The management section looks like it is part of epidemiology. You might want to reformat this to make it look like it is a topic by itself.&lt;br /&gt;
* Too many one sentence paragraphs under 'Treatment'. It might be a good idea to organise the thoughts and bunch them into small paragraphs. Half a line in a paragraph doesn't look great, surely these single lines can relate to another paragraph. &lt;br /&gt;
*The heading 'other problems' don't sound descriptive enough, you might want to call it, 'Associated Abnormalities'.&lt;br /&gt;
*Please add 'Genitourinary Conditions' in addition to a heap of other unexplained terms in the glossary&lt;br /&gt;
*I like the addition of Figure 6. It is an interesting observation.&lt;br /&gt;
*The addition of support groups in Australia and other places is a useful section.&lt;br /&gt;
*Overall the page has been well researched, just find a balance between texts, images and tables and it will be an informative page to refer back to.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Williams-Beuren Syndrome'''&lt;br /&gt;
&lt;br /&gt;
*'Introduction' is good, but need an image to open up the page&lt;br /&gt;
*Can you try to compile all that text in 'History' into the timeline?  Otherwise it's a bit much and a bit repetitive; an image couldn't hurt either&lt;br /&gt;
*Good work with 'Genetics', easy to read and interesting&lt;br /&gt;
*Diagnosis might fit better below the signs and symptoms, ie after we know enough about the syndrome to fully appreciate the diagnosis&lt;br /&gt;
*'Treatment' doesn't really fit in 'Epidemiology', again this would be better towards the end of the page&lt;br /&gt;
*Nice table for 'Phenotype of Williams Syndrome', very clear and informative&lt;br /&gt;
*Your subtitles are a little confusing, you might want to try incorporating all the condions ie cardiac and genitinary into one section&lt;br /&gt;
*Though the information within these sections is very good&lt;br /&gt;
*You seem to be missing a ''lot'' of images, it's difficult to read when it's just blocks of text&lt;br /&gt;
*For 'Cognitive, Behavioural and Neurological Phenotype' you need more references.  You should back up what your saying with at least 2 references; though there seems to be a lot of interesting information here&lt;br /&gt;
*'Structural Differences in Brain' - only 1 reference for all that information? That doesn't seem very reliable&lt;br /&gt;
*I like the topic 'Specialised Facilities and Supportive Associations', really interesting choice. Very good&lt;br /&gt;
*For 'Current Research', instead of just an article reference, make a brief summary of the paper and describe why it is significant?  Otherwise this section is a bit pointless.&lt;br /&gt;
*The glossary can't hurt to be expanded..... and finished.&lt;br /&gt;
*Overall, the page looks good, clearly a lot of research has gone into it.  Just focus on making it more visually appealing, and work on those references&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 9- &lt;br /&gt;
* Glossary is incomplete&lt;br /&gt;
* There are very few images on the page to break up the text&lt;br /&gt;
* Introduction needs an image. Other than that the information is good&lt;br /&gt;
* History- not sure if you need the text AND the list of dates. Maybe you could combine it all into one&lt;br /&gt;
* Genetic factors and etiology- really good. Easy to understand and visually appealing&lt;br /&gt;
* Diagnosis is also easy to take in&lt;br /&gt;
* Epidemiology should be up the top before diagnosis&lt;br /&gt;
* Also you need to sort out your subheadings. Management and treatment are not part of epidemiology&lt;br /&gt;
* More information is needed on the actually epidemiology&lt;br /&gt;
* Phenotype should come before treatment so we know why the treatments are necessary &lt;br /&gt;
* Also- cardiac, endocrine and genitourinary conditions are part of the phenotype. Maybe consider including these in the table&lt;br /&gt;
* The whole phenotype section is confusing sorry. It is ALL phenotype but you have put it in different sections. Not really sure why you have done this. It needs to be formatted better.&lt;br /&gt;
* The information is all there it just isn’t organised properly&lt;br /&gt;
* Do you need this? ‘Specialised Facilities and Supportive Associations&lt;br /&gt;
* You have done a great job of researching and the information is all there its just really confusing sorry. You need to find a way of organizing it so that it is more accessible to the reader.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 9'''&lt;br /&gt;
* The structure and use of headings and subheadings is good but i think you need to rethink the order of your headings eg epidemiology should be closer to the beginning. &lt;br /&gt;
* Intro informative. maybe you could bullet point the phenotypic characteristics, just make it easier to read. could you add a picture in this section?&lt;br /&gt;
* Nice history, could you maybe put your timeline into a table.&lt;br /&gt;
* good use of the table in genetics and aetiology and nice to see the accompanying picture referenced. &lt;br /&gt;
* I feel treatment should be its own heading and not a subheading.&lt;br /&gt;
* Phenotype of Williams Syndrome- a nice easy to read section breaking up the text. Could you add anymore pictures here?&lt;br /&gt;
* Genitourinary Conditions is very text heavy could you add in some pictures here or tabulate some of the information, just to keep the page flowing nicely. &lt;br /&gt;
* The endocrine section should be renamed, as it does not really explain to the reader what your going to talk about. &lt;br /&gt;
* Other Associated Medical Conditions- is a nice section good use of the table. &lt;br /&gt;
* Cognitive, Behavioural and Neurological Phenotype section is very text heavy it needs to be broken up either by pictures or a table. but it seems like a lot of effort has been put into the research in this section.&lt;br /&gt;
* Im not sure whether this section is necessary for our assessment Specialised Facilities and Supportive Associations??&lt;br /&gt;
* Current research and developments should be above the preceding section and a summary of the information would be nice instead of dot points.&lt;br /&gt;
&lt;br /&gt;
'''Group 9 Assessment'''&lt;br /&gt;
*Great job of linking the same resource to the same reference number in the reference section!&lt;br /&gt;
*The introduction and history are very thorough, but what’s missing are pictures to help it look more appealing.  &lt;br /&gt;
*The timeline- the information it good, but it might look better in a table format.  &lt;br /&gt;
*The genetic factors chart is good, but the last row doesn’t have any referencing… &lt;br /&gt;
*The diagnosis section definitely needs more referencing for all of the information. &lt;br /&gt;
*Epidemiology- This section could also really use some pictures to add to the section. &lt;br /&gt;
*The phenotype chart also needs all of the information referenced…  It might also be helpful to have more pictures, at least one for each subgroup within the chart. &lt;br /&gt;
*The Genitourinary Conditions section is rather wordy… Pictures could definitely be helpful here as well as more bullet lists or possibly another chart to simplify the info.&lt;br /&gt;
*The complete list of problems and associated medical conditions is rather lengthy… It might be a good idea to simplify all of this information as much as possible and simply compile it ALL together into one chart….&lt;br /&gt;
 *The whole “Cognitive, Behavioral and Neurological Phenotype” as well as the “Structural Differences in the Brain” sections definitely need more referencing.  &lt;br /&gt;
*Are support groups really necessary to be included for this project?  &lt;br /&gt;
*Current research could also a picture or two.  &lt;br /&gt;
*Not all the words are defined in the glossary, and it might look better if a bullet list were used here.  Also, it would be nice to have the glossary words linked to the actual words in the wiki page for easy reference.&lt;br /&gt;
*Overall, not bad.  Just work on fixing the overall flow and referencing and you will be fine! &lt;br /&gt;
--[[User:Z3391078|Z3391078]] 16:35, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Discussion==&lt;br /&gt;
&lt;br /&gt;
hahaha everyone is commenting on the lack of images. yes guys, we know but there are little to no copyright free images out there.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 14:36, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey, i've got no problem with that, i think it's a fair idea&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 19:06, 18 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys ive been thinking that epidemiology isn't really in the right spot.... management and treatment should really go after all the descriptions of the abnormalities and incidence shoukd go at the beginning... so what i'm thinking is that we should split up the subheading and add incidence to the intro and have management and treatment as one heading towards the end...??? what do u guys suggest?&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 23:20, 17 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys i found this really good article that deals with embryology in WS!! but i don't know where the info fits in...can u please have a quick glance over it and see where you think some of the info can go??? i just don't wanna mess up your parts by adding random info...&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629217/?tool=pubmed&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 17:36, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Yay!!! Yeah thats fine...were just gonna fix our ones up...coz we have another assignment to do tonight...so you n nobby can edit all u want tonight! Ohh and yeah sure...just post up the info you have for the timeline n then ill put it into a table!!&lt;br /&gt;
&lt;br /&gt;
Hey, yeh no worries, im going to be working on it for the rest of the day now that my exams are over....i ll try get as much of it done ASAP. Oh and after i finish typing up the timeline, would one of u guys format it in a table for me??? i seriously tried to do it but I got a bit confused lol&lt;br /&gt;
Oh btw great job on the drawings!!! :)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 13:54, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey sister 1 can you work on cardiac? I'll do other associated instead of sister 3.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332178|Z3332178]] 10:42, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
and also, i just came across this page which is on the unsw embryo page....&lt;br /&gt;
http://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:Williams_Syndrome#Australia_-_Support_Groups&lt;br /&gt;
&lt;br /&gt;
it lists some recent papers and current research, including one of steve palmer's papers.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 08:31, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
hey guys, yes moving epidemiology up is a great idea!!!!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 07:25, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288273/ '''article for the visuospatial construction i.e. not able to draw house, bicycle etc, think this can be for our case studies...'''&lt;br /&gt;
&lt;br /&gt;
yes i think that's a good idea, i was just about to mention that, shall i move it?? I fixed up a bit of the intro, is it ok? Btw I sware i thought i was on another page when i hit save cause all these tables and images came up, then i realised it was laticia and felicia's AWSOME WORK :), it looks really good!!! just thought i should mention that... I've spent hours trying to find images and most of the articles i've found have really good ones but we cant use them!! ahhh it's soo frustrating&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 23:58, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Also, in Marks feedback he said that epidemology should be linked earlier to diagnosis, so shall we just move it up and have it straight after diagnosis before the physical characteristics?&lt;br /&gt;
--[[User:Z3332183|z3332183]] 23:14, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129970/?tool=pubmed Hey guys...heres another open access article that we can use pics from!!!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332183|z3332183]] 22:48, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
i think we can all use this article http://www.ncbi.nlm.nih.gov/books/NBK1249/ --[[User:Z3331556|z3331556]] 22:06, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
http://www.nejm.org.wwwproxy0.library.unsw.edu.au/doi/full/10.1056/NEJMra0903074#t=article '''pretty good recent article :) but i don't know if we can use the pics, can someone double check...'''&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 21:46, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1511580/?tool=pubmed] Clinical and molecular cytogenetic (FISH) diagnosis of Williams syndrome.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332183|z3332183]] 13:34, 7 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys found this AWESOME article we can get pics off =D Leftward Lateralization of Auditory Cortex Underlies Holistic Sound Perception in Williams Syndrome PMID: 20808792 (forgot how to ref so this'll do for now)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332178|z3332178]] 22:51, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey! Yeah it think its better if they just go under the same heading because they go together and its impossible to separate them anyway...so yeah 'Genetic Factors and Etiology' should be fine...and we can add in any subheadings if we need em later... :D&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332183|z3332183]] 19:54, 3 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys i just changed the etiology, genetic factors/ cause headings, before we had genetic factors and etiology as separate headings with cause as a subheading below genetic factors and it didn't really make sense... so is it ok if we just have the heading 'Genetic Factors and Etiology'???&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 15:44, 3 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
Hey guys i just emailed Dr. Steve Palmer, will hope for a quick reply. Apparently he's taking the next lecture or something when we get back, but by then it will be too late, so it's best if we can arrange a meeting. Who wants to come with me to see him..........................................................................................=/&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 17:16, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Here's an article for diagnosis and management of the disease&lt;br /&gt;
&lt;br /&gt;
[http://onlinelibrary.wiley.com/doi/10.1002/ajmg.c.30139/abstract;jsessionid=E69D4793044A7511E77F50CA141F0825.d02t04?systemMessage=Wiley+Online+Library+will+be+disrupted+3+Sep+from+10-12+BST+for+monthly+maintenance]&lt;br /&gt;
&lt;br /&gt;
Hey that's heaps good, we'll compare timetables tomorrow during the lab or something, this page is coming alongggggggggggg!&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 16:00, 31 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Happy sister 1, you are awesome! I'll do Coronary artery stenosis, Pulmonary valve stenosis, Atrial septal defect, Ventricular septal defect if you didnt already start on any... I'm doin my williams research now so hopefully, i'll have my bit up tonight! *crosses fingers* I'm so sick of readin articles... =P Is there a time we can all go meet up with the WS proff?&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332178|Z3332178]] 20:37, 30 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey i found out who the researcher of WS at uni is, it's Dr Steve Palmer, here's his email s.palmer@unsw.edu.au, on the course outline it says that we have to make an appointment if we want to see him. We should try get together sometime this week or next week so we can go see him and ask about his current research???&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 18:51, 27 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
So i finally figured out how to reference on this thing, thought you guys might need help.... if you look on the main project page I've started to put some info up, so if you click on the edit button (on the side of each heading) the info and references come up, just copy and paste the ref name....blah blah part after your info BUT REPLACE THE PMID NUMBER WITH THE ONE YOU NEED FOR YOUR ARTICLE. When u save, the reference is automatically made in the reference heading at the bottom of the pages&lt;br /&gt;
&lt;br /&gt;
Hope this makes sense lol&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 17:17, 27 August 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
Hey guys i've posted up some links to articles that may help in your research, they're on the reference list below. Oh and Felicia i think we should further split up the cardiovascular heading so we can research specific types and make them subheadings??? The OMIM clinical synopsis web page [http://omim.org/clinicalSynopsis/194050] has these as abnormalities associated with the heart:&lt;br /&gt;
&lt;br /&gt;
Supravalvular aortic stenosis&lt;br /&gt;
&lt;br /&gt;
Valvular aortic stenosis&lt;br /&gt;
&lt;br /&gt;
Bicuspid aortic valve&lt;br /&gt;
&lt;br /&gt;
Mitral valve prolapse&lt;br /&gt;
&lt;br /&gt;
Mitral regurgitation&lt;br /&gt;
&lt;br /&gt;
Coronary artery stenosis&lt;br /&gt;
&lt;br /&gt;
Pulmonary valve stenosis&lt;br /&gt;
&lt;br /&gt;
Atrial septal defect&lt;br /&gt;
&lt;br /&gt;
Ventricular septal defect&lt;br /&gt;
&lt;br /&gt;
which ones do you want to search???&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 15:22, 27 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
“The behavioral phenotype of Williams syndrome: A recognizable pattern of neurodevelopment” by Colleen A. Morris&lt;br /&gt;
The review article concludes that a person with William syndrome share distinct cognitive and behavioural features. The phenotype of a typical patient will be due to the deleted genes of chromosome 7 q11.23.[http://onlinelibrary.wiley.com.wwwproxy0.library.unsw.edu.au/doi/10.1002/ajmg.c.30286/full]&lt;br /&gt;
&lt;br /&gt;
“Impaired geometric reorientation caused by genetic defect” by Laura Lakusta, Banchiamlack Dessalegn, and Barbara Landau&lt;br /&gt;
By testing participants in a plain or single blue walled chamber, the study was able to show that William syndrome patients show a failure to reconstruct and use geometric representations of the chamber o find hidden objecs.[http://www.ncbi.nlm.nih.gov.wwwproxy0.library.unsw.edu.au/pmc/articles/PMC2840366/?tool=pmcentrez]&lt;br /&gt;
--z3332178 22:42, 9 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
http://omim.org/entry/194050&lt;br /&gt;
&lt;br /&gt;
Review Article: Research Review: Williams syndrome: a critical review of the cognitive, behavioral, and neuroanatomical phenotype. [http://www.ncbi.nlm.nih.gov/pubmed/18489677]&lt;br /&gt;
&lt;br /&gt;
Research Article: Elevated Ambulatory Blood Pressure in 20 Subjects With Williams Syndrome[http://userwww.service.emory.edu/~erein/research/broder-et-al.pdf]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 21:35, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 13:19, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
The genomic basis of the Williams - Beuren syndrome&lt;br /&gt;
C Schubert. Cellular and Molecular Life Sciences. Basel: Apr 2009. Vol. 66, Iss. 7; p. 1178&lt;br /&gt;
[http://proquest.umi.com/pqdweb?index=0&amp;amp;did=1892633801&amp;amp;SrchMode=1&amp;amp;sid=2&amp;amp;Fmt=6&amp;amp;VInst=PROD&amp;amp;VType=PQD&amp;amp;RQT=309&amp;amp;VName=PQD&amp;amp;TS=1312428336&amp;amp;clientId=25620]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332183|Z3332183]] 13:28, 4 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
J Hum Genet. 2009 Apr;54(4):193-8. Epub 2009 Mar 13.&lt;br /&gt;
William's syndrome: gene expression is related to parental origin and regional coordinate control.&lt;br /&gt;
Collette JC, Chen XN, Mills DL, Galaburda AM, Reiss AL, Bellugi U, Korenberg JR.&lt;br /&gt;
Source&lt;br /&gt;
&lt;br /&gt;
Division of Neurogenetics, Cedars-Sinai Medical Center and Departments of Human Genetics and Pediatrics, UCLA, Los Angeles, CA, USA.&lt;br /&gt;
&lt;br /&gt;
'''Abstract'''&lt;br /&gt;
&lt;br /&gt;
William's syndrome (WS) features a spectrum of neurocognitive and behavioral abnormalities due to a rare 1.5 MB deletion that includes about 24-28 genes on chromosome band 7q11.23. Study of the expression of these genes from the single normal copy provides an opportunity to elucidate the genetic and epigenetic controls on these genes as well as their roles in both WS and normal brain development and function. We used quantitative RT-PCR to determine the transcriptional level of 14 WS gene markers in a cohort of 77 persons with WS and 48 normal controls. Results reported here: (1) show that the expression of the genes deleted in WS is decreased in some but not all cases, (2) demonstrate that the parental origin of the deletion contributes to the level of expression of GTF2I independently of age and gender and (3) indicate that the correlation of expression between GTF2I and some other genes in the WS region differs in WS subjects and normal controls, which in turn points toward a regulatory role for this gene. Interspecies comparisons suggest GTF2I may play a key role in normal brain development.&lt;br /&gt;
&lt;br /&gt;
PMID:19282872[http://www.ncbi.nlm.nih.gov/pubmed/19282872]  '''hey guys this is one of the articles i found but i've tried getting the whole article to read but sirius doesn't seem to have this particular volume '''&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 18:09, 6 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''Review Article:The genomic basis of the Williams – Beuren syndrome''&lt;br /&gt;
•Williams syndrome is a genomic disorder with symptoms including mental retardation, visuospatial impairment &amp;amp; overfriendliness.&lt;br /&gt;
&lt;br /&gt;
•It is caused due to a hemizygous contiguous gene deletion with regards to chromosome  7q11.23. &lt;br /&gt;
&lt;br /&gt;
•This review article deals with the genomic assembly of the region involved in Williams syndrome as well as the chromosomal mechanisms such as deletions and duplications and the consequences of these.&lt;br /&gt;
&lt;br /&gt;
Reference:&lt;br /&gt;
Schubert, C. The genomic basis of the Williams – Beuren syndrome. Cell, Mol. Life Sci. 66:1178-1197, 2009 [http://www.springerlink.com.wwwproxy0.library.unsw.edu.au/content/r41l072283g5222u/fulltext.pdf]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
''Research Article: Functional, structural and metabolic abnormalities of the hippocampl formation in Williams syndrome''&lt;br /&gt;
•In this study, neuroimaging (PET and fMRI) was used to investigate the hippocampal structure, function and metabolic integrity of 12 people with Williams syndrome compared to 12 healthy controls.&lt;br /&gt;
&lt;br /&gt;
•N-acetul aspartate can be seen as a marker for synaptic activity and measures of this were reduced in those with Williams syndrome&lt;br /&gt;
&lt;br /&gt;
•Although regular hippocampal size was maintained in both groups, slight changes in the shape were present.&lt;br /&gt;
&lt;br /&gt;
•Through the results of the investigation, it was suggested that the neurocognitive abnormalities seen in Williams syndrome may be partly due to hippocampal dysfunction.&lt;br /&gt;
&lt;br /&gt;
Reference: &lt;br /&gt;
Meyer-Lindenberg A., et al. Functional, structural and metabolic abnormalities of the hippocampal formation in Williams syndrome. J Clin Invest. 115(7):1888-95, 2005 [http://www.ncbi.nlm.nih.gov.wwwproxy0.library.unsw.edu.au/pubmed/15951840/]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332183|z3332183]] 23:02, 9 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''ARTICLE'''&lt;br /&gt;
&lt;br /&gt;
PLoS One. 2010 Apr 21;5(4):e10292.&lt;br /&gt;
Intelligence in Williams Syndrome is related to STX1A, which encodes a component of the presynaptic SNARE complex.&lt;br /&gt;
Gao MC, Bellugi U, Dai L, Mills DL, Sobel EM, Lange K, Korenberg JR.&lt;br /&gt;
Source&lt;br /&gt;
&lt;br /&gt;
Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.&lt;br /&gt;
&lt;br /&gt;
'''Abstract'''&lt;br /&gt;
Although genetics is the most significant known determinant of human intelligence, specific gene contributions remain largely unknown. To accelerate understanding in this area, we have taken a new approach by studying the relationship between quantitative gene expression and intelligence in a cohort of 65 patients with Williams Syndrome (WS), a neurodevelopmental disorder caused by a 1.5 Mb deletion on chromosome 7q11.23. We find that variation in the transcript levels of the brain gene STX1A correlates significantly with intelligence in WS patients measured by principal component analysis (PCA) of standardized WAIS-R subtests, r = 0.40 (Pearson correlation, Bonferroni corrected p-value = 0.007), accounting for 15.6% of the cognitive variation. These results suggest that syntaxin 1A, a neuronal regulator of presynaptic vesicle release, may play a role in WS and be a component of the cellular pathway determining human intelligence.&lt;br /&gt;
&lt;br /&gt;
PMID:20422020 [http://www.ncbi.nlm.nih.gov/pubmed/20422020]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* Williams Syndrome presents with a distinct pattern of intellectual disabilities that differ from normal on subtests of the WAIS-R (Wechsler Adult Intelligence Scale-Revised). Found that relative to their overall performance, WS subjects tended to do well in tests of vocabulary (Vocabulary) and abstract reasoning (Similarities, Picture Arrangement), and poorly in tests of numeracy (Arithmetic), visual-spatial (Digit Symbol, Block Design, Object Assembly), and memory (Digit Span)&lt;br /&gt;
&lt;br /&gt;
* Gene expression in the tissue of interest (brain) is not possible so quantitated gene expression in lymphoblastoid (LB) cell lines&lt;br /&gt;
&lt;br /&gt;
* STX1A is best known as an important component of the presynaptic SNARE complex involved in priming of synaptic vesicles for release.&lt;br /&gt;
&lt;br /&gt;
* Data indicate that peripheral STX1A expression levels measured in lymphoblastoid cell lines strictly grown, is related to an emergent property of the CNS, intelligence.&lt;br /&gt;
&lt;br /&gt;
'''here's the actual article''' [http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0010292]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''REVIEW ARTICLE'''&lt;br /&gt;
&lt;br /&gt;
Arch Pediatr. 2009 Mar;16(3):273-82. Epub 2008 Dec 18.&lt;br /&gt;
[Williams-Beuren syndrome: a multidisciplinary approach].&lt;br /&gt;
[Article in French]&lt;br /&gt;
Lacroix A, Pezet M, Capel A, Bonnet D, Hennequin M, Jacob MP, Bricca G, Couet D, Faury G, Bernicot J, Gilbert-Dussardier B.&lt;br /&gt;
Source&lt;br /&gt;
&lt;br /&gt;
Laboratoire langage, mémoire et développement cognitif, CNRS, UMR 6215, 99, avenue du Recteur-Pineau, 86000 Poitiers, France. agnes.lacroix@uhb.fr&lt;br /&gt;
&lt;br /&gt;
'''Abstract'''&lt;br /&gt;
Williams-Beuren syndrome (WBS) (OMIM# 194050) is a rare, most often sporadic, genetic disease caused by a chromosomal microdeletion at locus 7q11.23 involving 28 genes. Among these, the elastin gene codes for the essential component of the arterial extracellular matrix. Developmental disorders usually associate an atypical face, cardiovascular malformations (most often supravalvular aortic stenosis and/or pulmonary artery stenosis) and a unique neuropsychological profile. This profile is defined by moderate mental retardation, relatively well-preserved language skills, visuospatial deficits and hypersociability. Other less known or rarer features, such as neonatal hypercalcemia, nutrition problems in infancy, ophthalmological anomalies, hypothyroidism, growth retardation, joint disturbances, dental anomalies and hypertension arising in adolescence or adulthood, should be treated. The aim of this paper is to summarize the major points of WBS regarding: (i) the different genes involved in the deletion and their function, especially the elastin gene and recent reports of rare forms of partial WBS or of an opposite syndrome stemming from a microduplication of the 7q11.23 locus, (ii) the clinical features in children and adults with a focus on cardiovascular injury, and (iii) the specific neuropsychological profile of people with WBS through its characteristics, the brain structures involved, and learning.&lt;br /&gt;
&lt;br /&gt;
PMID:19097873 [http://www.ncbi.nlm.nih.gov/pubmed/19097873]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 19:40, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Here's  the image i showed you guys'''&lt;br /&gt;
&lt;br /&gt;
[[File:Distribution of quantitative transcription of genes deleted in WS.png|Distribution of quantitative transcription of genes deleted in WS]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 12:23, 12 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Auditory Cortex Location - Comparison Between Control Subject and WS Subject.jpg|300px]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 17:33, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The frequency of SD cells for RB1 and SNRPN in WS and control individuals.&lt;br /&gt;
&lt;br /&gt;
[[File:The frequency of SD cells for RB1 and SNRPN in WS and control individuals.jpg|The frequency of SD cells for RB1 and SNRPN in WS and control individuals|400px]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3332178|z3332178]] 23:22, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
I've found a good case study for WS, maybe we could have a case study sub-heading?? [http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1754.1993.tb03023.x/abstract]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 13:38, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Suggestions for areas of research==&lt;br /&gt;
I thought I could get the ball rolling, let me know if you want to add or remove anything.&lt;br /&gt;
&lt;br /&gt;
===INTRODUCTION=== &lt;br /&gt;
(z3331556)&lt;br /&gt;
-What is William’s Syndrome? &lt;br /&gt;
&lt;br /&gt;
===History of the disease=== &lt;br /&gt;
(z3331556)&lt;br /&gt;
-How it was discovered &lt;br /&gt;
-Who discovered it? &lt;br /&gt;
-Timeline of how knowledge developed &lt;br /&gt;
&lt;br /&gt;
===Etiology===&lt;br /&gt;
(z3332183)&lt;br /&gt;
- Cause &lt;br /&gt;
- Susceptibility of the patient&lt;br /&gt;
&lt;br /&gt;
===Diagnosis===&lt;br /&gt;
(z3332183)&lt;br /&gt;
-How it’s detected (tests/examinations)&lt;br /&gt;
-How soon it can be detected?&lt;br /&gt;
&lt;br /&gt;
===Genetic Factors===&lt;br /&gt;
-deletions&lt;br /&gt;
(all)&lt;br /&gt;
&lt;br /&gt;
===Physical Characteristics===&lt;br /&gt;
-Facial characteristics etc.&lt;br /&gt;
(z3332178)&lt;br /&gt;
&lt;br /&gt;
===Associated medical conditions===&lt;br /&gt;
-Cardiac abnormalities (z3331556),(z3332178)&lt;br /&gt;
&lt;br /&gt;
-Renal abnormalities (z3331469) &lt;br /&gt;
&lt;br /&gt;
-other (hoarse voice, inguinal hernia, orthopaedic problems, hypercalcaemia etc.)&lt;br /&gt;
(z3332183)&lt;br /&gt;
&lt;br /&gt;
===Cognitive, Behavioural and Neurological Problems===&lt;br /&gt;
(z3332178)&lt;br /&gt;
&lt;br /&gt;
===Epidemiology===&lt;br /&gt;
-Incidence, distribution, and control of disease&lt;br /&gt;
(z3331469)&lt;br /&gt;
&lt;br /&gt;
===Management/treatment===&lt;br /&gt;
-Treatment of individual symptoms, avoid taking increased levels of calcium and Vitamin D&lt;br /&gt;
(z3331469)&lt;br /&gt;
&lt;br /&gt;
===Specialized Facilities/ supportive associations===&lt;br /&gt;
-Williams Syndrome Foundation (UK), Williams Syndrome Association&lt;br /&gt;
(all)&lt;br /&gt;
&lt;br /&gt;
===Case studies===&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288273/&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862007/&lt;br /&gt;
&lt;br /&gt;
===Interesting facts===&lt;br /&gt;
(all)&lt;br /&gt;
&lt;br /&gt;
===Current research and developments===&lt;br /&gt;
(all)&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
http://www.cddh.monash.org/assets/williams-synd.pdf&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 18:09, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
http://books.google.com.au/books?id=qvKaSNg0pUcC&amp;amp;pg=PA158&amp;amp;lpg=PA158&amp;amp;dq=Williams+and+Barrett-Boyes&amp;amp;source=bl&amp;amp;ots=0SIpaamHuh&amp;amp;sig=4ouDsgFvt8XBbuwKPThFGWX9b4Y&amp;amp;hl=en&amp;amp;ei=8F5MTurlGuuNmQWA6eCyAg&amp;amp;sa=X&amp;amp;oi=book_result&amp;amp;ct=result&amp;amp;resnum=7&amp;amp;ved=0CEMQ6AEwBg#v=onepage&amp;amp;q=Williams%20and%20Barrett-Boyes&amp;amp;f=false  &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 13:09, 18 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Williams Syndrome Foundation, accessed 22 August 2011, http://www.williams-syndrome.org.uk/&lt;br /&gt;
&lt;br /&gt;
Williams Syndrome Association, accessed 22 August 2011,  http://williams-syndrome.org/&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331469|z3331469]] 13:12, 22 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
http://omim.org/clinicalSynopsis/194050 '''this is a clinical synopsis that is a good starting point for medical and physical abnormalities, it basically lists all complications associated with WS. I think we can use these as subheadings???'''&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728781/pdf/v080p00205.pdf '''This is a source for cardiac abnormalities'''&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946897/?tool=pmcentrez&lt;br /&gt;
&lt;br /&gt;
http://www.nature.com/ejhg/journal/v18/n1/full/ejhg2009108a.html&lt;br /&gt;
&lt;br /&gt;
'''These last two are basically introductory info on WS and they have info for the Genetics heading'''&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 15:44, 27 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
http://books.google.com.au/books?id=9E9q5112WBgC&amp;amp;pg=PA151&amp;amp;lpg=PA151&amp;amp;dq=hallux+valgus+in+williams+syndrome&amp;amp;source=bl&amp;amp;ots=LdaFmjSds_&amp;amp;sig=QW_9bjbIgo44rXQrwKTh2TF5hSo&amp;amp;hl=en&amp;amp;ei=__teTu2oNMjEmAXCx80B&amp;amp;sa=X&amp;amp;oi=book_result&amp;amp;ct=result&amp;amp;resnum=4&amp;amp;sqi=2&amp;amp;ved=0CCwQ6AEwAw#v=onepage&amp;amp;q&amp;amp;f=false&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 13:38, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/books/NBK1249/ '''another good source'''&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3331556|z3331556]] 14:39, 3 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Peer Assessments==&lt;br /&gt;
* Intro was good, it was brief and straight to the point&lt;br /&gt;
* The beginning paragraphs of the history could be more summarised especially considering that you have a timeline beneath&lt;br /&gt;
* Your use of a table for the genetics’ component was great. It was easy to read and concise. It was a different approach but it worked well. &lt;br /&gt;
* More information could have been added to the treatment section such as comparisons between key methods/strategies, the pros and cons&lt;br /&gt;
* The phenotype section was well set out although I believe it should have been placed up after the genetics section so that the information flows more consistently&lt;br /&gt;
* The layout of the implications section was slightly unclear. Maybe here you could have large heading for implications, followed by a list (dot point) of the implications occurred then have in paragraph form a description of each. Having headings such as: Other problems and other associated medical conditions tended to drag on this segment.&lt;br /&gt;
* The inclusion of the supportive associations was a nice little touch!&lt;br /&gt;
* Great use of referencing&lt;br /&gt;
--[[User:Z3332629|z3332629]] 15:30, 22 September 2011 (EST)&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_8&amp;diff=72534</id>
		<title>Talk:2011 Group Project 8</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_8&amp;diff=72534"/>
		<updated>2011-09-27T13:24:04Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Peer Review */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[2011_Group_Project_8|'''Group 8''']]: [[User:z3294943]] | [[User:z3389343]] | [[User:z3329495]] | [[User:z3332250]]&lt;br /&gt;
&lt;br /&gt;
{{2011GroupDiscussionMH}}&lt;br /&gt;
&lt;br /&gt;
==Peer Review==&lt;br /&gt;
&lt;br /&gt;
'''Group 8'''&lt;br /&gt;
&lt;br /&gt;
*Good introduction&lt;br /&gt;
*I find it hard to believe that you have only found 5 significant findings to put in your timeline, it should also more recent findings &lt;br /&gt;
*Good epidemiology&lt;br /&gt;
*There is a lot of information in etiology- although the subheadings are good try and think of a way to break up the text&lt;br /&gt;
(For further detail on the mechanisms of replication slippage, see Viguera et al (2001) is unnecessary&lt;br /&gt;
*Postnatal diagnosis table also seems a little unnecessary &lt;br /&gt;
*Treatment needs an image&lt;br /&gt;
*Current research should be explained &lt;br /&gt;
*Not sure why you put your glossary under your references but this should be the other way around so the reader can easily access the glossary&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 8'''&lt;br /&gt;
&lt;br /&gt;
*The index should be on the left side&lt;br /&gt;
&lt;br /&gt;
*Introduction: contend is fine, but could be a little more general&lt;br /&gt;
&lt;br /&gt;
*History: is there mo important milestone after 1996?&lt;br /&gt;
&lt;br /&gt;
*Epidemiology: the first two subheadings could have more contend, the others are well done &lt;br /&gt;
&lt;br /&gt;
*Aetiology: well done, good structure and contend, but the chromosome image could have been done with more effort&lt;br /&gt;
&lt;br /&gt;
*Pathogenesis: looks good&lt;br /&gt;
&lt;br /&gt;
*Neuropathology: well done, very nice drawings&lt;br /&gt;
&lt;br /&gt;
*Clinical Presentation: good contend, but more subheadings to break up the text would look better&lt;br /&gt;
&lt;br /&gt;
*Diagnosis: very well done&lt;br /&gt;
&lt;br /&gt;
*Treatment: well done&lt;br /&gt;
&lt;br /&gt;
*Research: should be more detailed contend&lt;br /&gt;
&lt;br /&gt;
*The Glossary should be placed before the references&lt;br /&gt;
--[[User:Z3387190|Z3387190]] 22:37, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
===Comments on Group Project===&lt;br /&gt;
'''Strengths:'''&lt;br /&gt;
*Smooth flow to the page due to good placements of headings, subheadings and subsubheadings.&lt;br /&gt;
*The referencing is well-done with correct formatting and there seemed to be no duplication.&lt;br /&gt;
*The external links section is good.&lt;br /&gt;
'''Weaknesses:'''&lt;br /&gt;
*There are some inconsistencies in formatting. &lt;br /&gt;
*Some of the images do not come with descriptions and copyright statements allowing wikiusers to use images, especially for student drawn ones.&lt;br /&gt;
'''Specific corrections:'''&lt;br /&gt;
*Maybe include “frataxin” in the glossary?&lt;br /&gt;
*Reference 38 is missing.&lt;br /&gt;
*The image on the frataxin gene is a bit faint, maybe it would be better to make the outline darker?&lt;br /&gt;
&lt;br /&gt;
--Z3389806 06:25, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 8 Critique'''&lt;br /&gt;
&lt;br /&gt;
#•	Epidemiologic figures should not be included in the introduction. Also, neither should pathogenesis. Maybe just explain very simply what the condition is and explain the genes in the pathogenesis. The introduction should be organised a little better.&lt;br /&gt;
#•	The history is rather short. You need to explain in a little more detail how the disease was discovered, and don’t mention pathogenesis or gene function.&lt;br /&gt;
#•	The epidemiology is ok&lt;br /&gt;
#•	Aetiology is fine. Good use of images to support your points&lt;br /&gt;
#•	Pathogenesis should include the sentences on genes found in the introduction&lt;br /&gt;
#•	Neuropathology is good, but you need to explain the image of the cross section of the spinal cord&lt;br /&gt;
#•	Clinical presentation is quite good&lt;br /&gt;
#•	Diagnosis is very good. Your tables in this section are excellent. Good use of images&lt;br /&gt;
#•	Treatment and Current Research is very good.&lt;br /&gt;
#•	Glossary is fine&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289991|Robert Klein]] 16:05, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Peer Assessment Group 8-Friedreich's Ataxia'''&lt;br /&gt;
&lt;br /&gt;
*I am sure you will fix the big gap at the beginning of the page where the contents are supposed to be&lt;br /&gt;
*While the introducton is good with relevant information, the paragraph is too long.Maybe consider breaking it into two paragraphs.&lt;br /&gt;
*The history section is repititive of the actual timeline. All the information under history could be summarized to incorporate in the timeline. &lt;br /&gt;
*The timeline needs further information of what has happened since 1996&lt;br /&gt;
*I like how you have the different sections within 'Epidemiology' highlighted. Only improvement you could make is maybe expand on 'Distribution,' 'Populations,' and 'Gender'.&lt;br /&gt;
*'Aetiology' has a good balance of interesting information, referencing and pictures. &lt;br /&gt;
* The image 'The frataxin gene on chromosome 9' has very poor resolution and missing the copyright information. The description could be a bit more detailed too&lt;br /&gt;
*The image 'Cross Section of the Spinal Cord' is missing a description.&lt;br /&gt;
*There are a number of student drawn images which is relevant to the section and makes the page look quite original&lt;br /&gt;
*The table under 'Diagnosis' is well done and informative&lt;br /&gt;
*The 'Current Research Section' will look better as paragraphs rather than bullet points.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Friedreich's Ataxia'''&lt;br /&gt;
&lt;br /&gt;
*Where did the contents go?&lt;br /&gt;
*Try splitting the introduction up into a few paragraphs as opposed to just the one&lt;br /&gt;
*Is there ''nothing'' else to put in history? What you've got is good, but i'm interested in seeing a bit more&lt;br /&gt;
*'Atiology' looks good, there seems to be quite a bit of work gone into it.  But how are there no references for 'Inheritance'&lt;br /&gt;
*Split your paragraphs up a bit more in 'Neuropathy', at the moment it is quite difficult to read&lt;br /&gt;
*Can you try to include all of the signs and symptoms into a table? It's a bit difficult to read when you list the in text; though the table already present looks really good&lt;br /&gt;
*Diagnosis looks fantastic, very nicely set out and lots of interesting information&lt;br /&gt;
*Try to get a picture for either 'Diagnosis' or 'Treatment'.  The bottom half of the page looks a bit bare&lt;br /&gt;
*Can you expand 'Current Research' a bit, explain what and how they do the research etc&lt;br /&gt;
*No glossary?&lt;br /&gt;
*The page looks quite good, you've clearly got a lot of information there, just need to make it a bit easier to read&lt;br /&gt;
*'Glossary' will fit better before the references&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 8&lt;br /&gt;
* Glossary under the references? This needs to be moved up so people can actually find it&lt;br /&gt;
* Good introduction. Gives the background and information that is needed&lt;br /&gt;
* History is very short. I believe there is more research after 1996 and what you have supplied is very limited&lt;br /&gt;
* Epidemiology is great. I like how you divided it up in sections! Easy to read and gauge the spectrum of the condition&lt;br /&gt;
* ‘(For further detail on the mechanisms of replication slippage, see Viguera et al (2001)’ This is not necessary&lt;br /&gt;
* etiology is very detailed! Maybe think of ways to break up the text for the reader. The subheadings are great but there is just A LOT to get through&lt;br /&gt;
* the diagnosis is great&lt;br /&gt;
* postnatal diagnosis- I don’t really understand why you need the table here&lt;br /&gt;
* treatment could do with an image. Other than that its really good information&lt;br /&gt;
* current research should not be a list. It should shed light on what is to come and the significance of current research- not just a list of papers published recently&lt;br /&gt;
&lt;br /&gt;
'''Group 8 Assessment'''&lt;br /&gt;
*Kind of random, but I noticed all the pictures are formatted the same exact way and on the right hand side.  It might be good to switch some of them around just so it looks more appealing and not cluttered.  &lt;br /&gt;
*Great job of linking the same resource to the same reference number in the reference section.  &lt;br /&gt;
*Good job of condensing down the timeline into a few major incidents.  Maybe consider compiling them into a chart? &lt;br /&gt;
*The diagnostic tests chart was impeccable!  Superb job on it.  My only concern are the videos and whether or not they need better referencing.  &lt;br /&gt;
*Only parts I saw that needed more referencing were: the Cerebellum and the symptoms chart. &lt;br /&gt;
*This is the best referencing job I have noticed thus far.  Great job!!! &lt;br /&gt;
Only real negative comment is that it looks kind of jumbled and very wordy.  Maybe separating things out into charts and bullet points would help to fix this problem… &lt;br /&gt;
*Glossary would also probably look a bit more organized if it were a bullet list.  Also, do the definitions need to have references also? &lt;br /&gt;
*Might be a good idea to also have the glossary terms linked with the words in the wiki page, so that the reader can easily get access to the word in the glossary.  Good job at least bolding them though! &lt;br /&gt;
*Great job guys!  Just a few formatting things and some referencing and you should be good to go.&lt;br /&gt;
--[[User:Z3391078|Z3391078]] 16:14, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==Discussion==&lt;br /&gt;
&lt;br /&gt;
--[[User:S8600021|Mark Hill]] 18:28, 11 August 2011 (EST) Your group left the lab today without notifying me of your selected group topic.&lt;br /&gt;
&lt;br /&gt;
Sorry, we were the group that hadn't quite made up their mind yet, as you said we should have a think but decide within the next few days, we thought we didn't have to make a decision on the spot. Sorry, we will make our choice soon.&lt;br /&gt;
--[[User:Z3389343|z3389343]] 18:40, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hi guys!&lt;br /&gt;
I agree with Elina we should just contact each other via this discussion page.&lt;br /&gt;
I have checked out some topics and I think Duchenne Muscular Dystrophy and Angelman's syndrome look very interesting.&lt;br /&gt;
They have many components associated like cognitive and skeletal disabilities.. &lt;br /&gt;
Anyway let me know what you think or if you guys have looked into any topics yourselves.&lt;br /&gt;
I also think we should meet next week if we all have a break in between the lecture and lab would you guys like to meet then?&lt;br /&gt;
--z3294943 11:47, 6 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Sorry I couldn't write at the bottom of page I'm on my iPhone. I think we need to choose some with both anatomical changes as well as neurological and I think duchenne MD and angelman's fit those categories. They are also both genetic so let's look into both as another group maybe interested in either topic. So let's come to the lab with the two journal article required and have our first choice ready and decide during the break. How does that sound? &lt;br /&gt;
&lt;br /&gt;
--Karmen Magi 07:32, 8 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
(Shifted Elina's contribution to discussion page. --[[User:Z3329495|Z3329495]] 22:45, 7 August 2011 (EST))&lt;br /&gt;
Hey all,&lt;br /&gt;
&lt;br /&gt;
I had a look at the list and thought I'd start making some suggestions. I am a neuroscience student, so my interest lies in anomalies that are related to the nervous system, but I won't insist on doing something about that if noone else wants to!&lt;br /&gt;
&lt;br /&gt;
Here are the ones that so far seem most appealing to me:&lt;br /&gt;
* Holoprosencephaly: the forebrain of the developing embryo fails to fold into two hemispheres. Caused by Hox genes failing to activate along the midline of the developing brain. (I've done uni stuff on Hox genes before, so I know where to start looking for material.)&lt;br /&gt;
* Angelman's Syndrome: neurogenetic disorder with a variety of clinical features. characterised by a loss of a region of chromosome 15. this loss can be the result of varying genetic problems, including gender-related epigenetic imprinting, which makes me think that the genetics behind this Syndrome are very interesting (but I totally understand if that's just me).&lt;br /&gt;
* Fragile X syndrome: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002633/ again, I find the genetics behind this very interesting.&lt;br /&gt;
&lt;br /&gt;
Then here's a list of the ones I [[wouldn't]] recommend doing:&lt;br /&gt;
* DiGeorge's Syndrome, Farber's Disease, Anencephaly, as there seems to be very little known about that (correct me if I'm wrong!)&lt;br /&gt;
* Turner's &amp;amp; Klinefelter Syndromes, Cystic Fibrosis - I'm just not particularly interested in them/sick of them (sorry)&lt;br /&gt;
&lt;br /&gt;
And here are some I had a look at and feel neutral about:&lt;br /&gt;
* Williams Syndrome, Duchenne Muscular Dystrophy, Osteogenesis Imperfecta, Friedreich's Ataxia, Lesch-Nyhan Syndrome.&lt;br /&gt;
&lt;br /&gt;
As you see, I didn't go through the whole list.&lt;br /&gt;
&lt;br /&gt;
Let me know what you think :)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389343|Elina Jacobs]] 18:43, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi guys,&lt;br /&gt;
&lt;br /&gt;
Duchenne Muscular Dystrophy sounds quite interesting to me - the anatomical changes (musculoskeletal) would be something i'm more comfortable in as i haven't done any physl, neuro or genetics course. as i'm an anatomy major i think i can contribute more with physical changes - as for molecular problems i'm not very strong with that.&lt;br /&gt;
Meeting up before the practical on Thursday sounds like a good time to meet up.&lt;br /&gt;
--[[User:Z3329495|Z3329495]] 22:45, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey All&lt;br /&gt;
&lt;br /&gt;
looks like I'm last to contribute though, even so i did some searching for journals and reasearch papers and there is a fair bit on Duchenne Muscular Dystrophy though i am sorry i wasn't able to find a abnormality myself as it was my Mums birthday on the weekend so was busy planning that so i will find one by the next lab. Also im free the gap before the lab so if we are meeting after the lecture then I'm available.&lt;br /&gt;
&lt;br /&gt;
--z3332250 22:29, 8 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
Articles&lt;br /&gt;
*Review article [http://www.ncbi.nlm.nih.gov.wwwproxy0.library.unsw.edu.au/pubmed/11834588 PMID:11834588]&lt;br /&gt;
*Research article[http://www.ncbi.nlm.nih.gov.wwwproxy0.library.unsw.edu.au/pubmed/20139167 PMID:20139167]&lt;br /&gt;
--z3294943 19:28, 8 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
There are at least two other groups that are looking at Duchenne Muscular Dystrophy, so I think it's good if we keep Angelman's Syndrome as our consideration as well. I think that still has enough anatomical features to it, and as I've done some molecular biology &amp;amp; genetics, I'd be happy to be the one focusing on that aspect. I'll try and find research and review articles on that today, so we can compare on thursday!&lt;br /&gt;
--[[User:Z3389343|z3389343]] 11:15, 9 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Sure thing, so we're looking up articles on angelman's syndrome then?&lt;br /&gt;
&lt;br /&gt;
Review article: http://jmg.bmj.com/content/40/2/87.short&lt;br /&gt;
Research article: http://jmg.bmj.com/content/38/12/834.abstract&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3329495|Z3329495]] 11:45, 9 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Hi,&lt;br /&gt;
&lt;br /&gt;
I choose to do a congenial abnormality more related to anatomy abnormality of the cleft and cleft pallets.&lt;br /&gt;
&lt;br /&gt;
Articles:&lt;br /&gt;
* Review Article [http://www.ncbi.nlm.nih.gov/pubmed/21358192 PMID: 21358192]&lt;br /&gt;
*Research Article [http://http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124302/?tool=pubmed PMCID: PMC3124302]&lt;br /&gt;
&lt;br /&gt;
--Ryan Tran 12:39, 9 August 2011 (EST)&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Here are two more about Angelman Syndrome:&lt;br /&gt;
&lt;br /&gt;
* Review: http://www.ncbi.nlm.nih.gov/pubmed/15668046&lt;br /&gt;
* Research: http://www.ncbi.nlm.nih.gov/pubmed/8958335&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389343|z3389343]] 21:09, 9 August 2011 (EST)&lt;br /&gt;
----&lt;br /&gt;
hey, the second link seems to be broken?&lt;br /&gt;
--Z3329495 22:25, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
Hi everyone,&lt;br /&gt;
I think we need to choose exactly what we are doing for the assessment before the week end.&lt;br /&gt;
I checked out holoprosenchephaly i think it is really neuro based and from what i have read ryan and i would like to do something more anatomical..&lt;br /&gt;
maybe we could try and decide on something that has all the components we are interested in and by the end of the weekend have made a decision.&lt;br /&gt;
&lt;br /&gt;
I thought maybe Friedreich Ataxia kind of embodies all aspects we are interested in..&lt;br /&gt;
It is a defect of the nervous system which lead to muscular problems, special sensory organ problems, diabetes, heart problems and the genetics are well understood..&lt;br /&gt;
from what i see there is quite a lot of info on it..&lt;br /&gt;
so can we please come to a decision soon.. I think it will be easy to section think disease up eg history, embryonic development, the abnormality and when/where.how it occurs, the genetic component, neurological problems, skeletal muscle degeneration, structural/anatomical problems in the heart optic and auditory, diagnosis, treatment and what may happen in the future.&lt;br /&gt;
let me know what you think or if you have any other disease with similar categories so everyone in the group is happy with our choice.&lt;br /&gt;
--z3294943 17:37, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Jup I'm happy with that, as I've kinda mentioned already above, it's one of the topics that I'm not fuzzed about either way. If the others agree, I'm happy to go ahead. And thinking about it, it will probably be easier than deciding on a particular case of holoprosencephaly that will make everyone happy.&lt;br /&gt;
--[[User:Z3389343|z3389343]] 18:40, 11 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey everyone this link from omim might give us better understanding of Friedreich Ataxia..[http://omim.org/entry/229300?search=Friedreich%20Ataxia&amp;amp;highlight=ataxia%20friedreich%20ataxias%20friedreichs]&lt;br /&gt;
If you guys have any other suggestions please let me know soon. As I would like to get start on categorising the aspects of the disease we choose and dividing them among the group.. have a good weekend! z3294943&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
read the link provided - looks good to me! seems pretty interesting in that you only get onset in late childhood to early teens. I'll be happy to do Friedreich ataxia.&lt;br /&gt;
--z3329495 22:20, 13 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Ok great so have we decided on Friereich Ataxia?? DId you all want to meet in the computer room before the next lab in the break we have on thursday. Sorry i missed it last time but i thought we were meeting in the comp room and by the time i went to the lec room you were all gone :( I think we should discuss the aspects we want to research maybe we could all come with a few ideas that we each find interesting for thursday? What do you guys think? --Karmen Magi 11:09, 14 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
I came across Rubinstein-Taybi syndrome and thought that seemed quite interesting so I thought I'd suggest it: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002229/. Though if we're all happy with Friedreich's Ataxia let's go ahead with that. Aren't we missing somebody's opinion still?&lt;br /&gt;
--[[User:Z3389343|z3389343]] 15:02, 14 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
[[File:Oxidative Stress Response in Friedreich Ataxia.jpg|thumb|Oxidative Stress Response in Friedreich Ataxia]]&lt;br /&gt;
--Karmen Magi 11:43, 14 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
---&lt;br /&gt;
&lt;br /&gt;
i think that's everyone? So we're settled on Friedreich's Ataxia?&lt;br /&gt;
--[[User:Z3329495|z3329495]] 10:17, 15 August 2011 (EST)&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
[[File:Gene expression responses of Friedreich's ataxia.jpg|thumb|Gene expression responses of Friedreich's ataxia]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Im ok with with Friedreich Ataxia it looks interesting I got nothing wrong with it.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--z3332250 23:48, 15 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
[[File:Pathogenesis of Friedreich Ataxia.jpg|thumb|Pathogenesis of Friedreich Ataxia]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3329495|Amanda Tan]] 11:30, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
Ok great so i think we have finally decided! Are we still ok to meet between the lecture and lab this thursday? I think we should started working out what aspects of the disease we are interested in and what should be included on the wed page.. &lt;br /&gt;
Could we all come with some ideas like pathogensis etc&lt;br /&gt;
let me know if you guys want to meet.. if so i think the computer room would be best. --Karmen Magi 20:20, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Yes that sounds good to me. And meeting in the computer room is fine, provided it is free, which I assume as it seemed to be last week? --[[User:Z3389343|z3389343]] 22:10, 16 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
[[File:Frataxin mRNA levels and histone modifications on chromatin in the first intron of the frataxin gene in KIKI and WT mice.png|thumb|Frataxin mRNA levels and histone modifications in KIKI and WT mice]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Suggested Outline:&lt;br /&gt;
&lt;br /&gt;
#Background: &lt;br /&gt;
##History&lt;br /&gt;
##Epidemiology&lt;br /&gt;
#Genetics: &lt;br /&gt;
##Inheritance&lt;br /&gt;
##genetic expression (pre- and postnatally)&lt;br /&gt;
#Pathogenesis: &lt;br /&gt;
##first genetics aspect&lt;br /&gt;
##lead into physiology&lt;br /&gt;
#Pathophysiology &amp;amp; Clinical Symptoms - link them together&lt;br /&gt;
#Clinical aspect - split it into symptoms and complications&lt;br /&gt;
#Diagnosis (in table)&lt;br /&gt;
#Treatment (include genetic sreening)&lt;br /&gt;
#Current Research&lt;br /&gt;
#Glossary&lt;br /&gt;
&lt;br /&gt;
*Amanda: pathpart of cardio &amp;amp; musculature, pathpart of pathogenesis, diagnosis&lt;br /&gt;
*Elina: Genetics, molecular &amp;amp; cellular parts of neurophysio aspect, current research&lt;br /&gt;
*Karmen: Neurophysiology aspect, background&lt;br /&gt;
*Ryan: Treatment, physiopart of pathogenesis, physiopart of cardio and musculature&lt;br /&gt;
everyone: make drawing, decide at the end which one we think is best, find video of possible&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Karmen, i think this might be of interest to you. It includes historical information on Friedreich's ataxia: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062632/?tool=pmcentrez Friedreich’s ataxia: Pathology, pathogenesis, and molecular genetics]&lt;br /&gt;
&lt;br /&gt;
Elina, this might be of use to you? [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2373517/?tool=pmcentrez HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Model] I tried reading through it but too much vital information about genetics just went right over my head. It looks promising in terms of research into treatment. Also: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859089/?tool=pmcentrez The Structure and Function of Frataxin] Possibly useful in genetics component when describing frataxin?&lt;br /&gt;
&lt;br /&gt;
Novel treatment: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694693/?tool=pmcentrez Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich’s ataxia]&lt;br /&gt;
&lt;br /&gt;
--Z3329495 19:31, 19 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi all, i'm having trouble locating information on the muscular effects of Friedreich's Ataxia. I've found much more information on the cardiac aspect of Friedreich's Ataxia but if anyone has found anything even mentioning muscular effects please let me know! all the papers i've located only mentions it in one or two lines.&lt;br /&gt;
&lt;br /&gt;
--Z3329495 19:03, 22 August 2011 (EST)&lt;br /&gt;
Antioxidant treatment:&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/15824263&lt;br /&gt;
&lt;br /&gt;
Prenatal detection of Friedreich: http://onlinelibrary.wiley.com/doi/10.1002/ajmg.1320340327/abstract&lt;br /&gt;
&lt;br /&gt;
Pathology and pathogenesis of sensory neuropathy in Friedreich's ataxia.&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/20339857&lt;br /&gt;
The dorsal root ganglion in Friedreich's ataxia.&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/19727777&lt;br /&gt;
--z3294943 10:32, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Mitochondrial impairment of human muscle in Friedreich ataxia in vivo: http://www.sciencedirect.com/science/article/pii/S0960896600001085&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Elina, if you could find this article it'd be a great help - A preliminary study of dynamic muscle function in hereditary ataxia.: http://www.ncbi.nlm.nih.gov/pubmed/7214252&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389343|z3389343]] 17:23, 25 August 2011 (EST) so I can get access to this journal via Edinburgh Uni, but for some strange reason, there is no full text..? it's really weird. sorry :/&lt;br /&gt;
&lt;br /&gt;
I found some things as well on Signs and a bit on heart:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC484058/?tool=pmcentrez Chest pain during exercise as first manifestation of Friedreich's ataxia.]'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;484058&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC482403/?tool=pmcentrez Left ventricular function in Friedreich's ataxia. An echocardiographic study.]'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;482403&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1277199/?tool=pmcentrez Coronary disease, cardioneuropathy, and conduction system abnormalities in the cardiomyopathy of Friedreich's ataxia.]'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1277199&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
'''[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894724/?tool=pmcentrez Friedreich's Ataxia as a Cause of Premature Coronary Artery Disease]'''&amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;1894724&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
Ryan Tran 10:55, 25 August 2011 (EST)&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Carnitine therapy and muscular biopsies&lt;br /&gt;
http://jcn.sagepub.com/content/17/6/453.full.pdf+html&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/12174969&lt;br /&gt;
--z3294943 10:59, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Cognitive impairment in spinocerebellar degeneration. it could be interesting to talk about cognitive elements of FRDA&lt;br /&gt;
http://www.ncbi.nlm.nih.gov/pubmed/19295212&lt;br /&gt;
&lt;br /&gt;
[[File:Chelator and vehicle effect on hematological indices.png|thumb|Chelator and vehicle effect on hematological indices. This is of note for using Chelator as a treatment option for FA (in particular cardiomyopathy).]]&lt;br /&gt;
&lt;br /&gt;
For the glossary, i think we should bold the words we've put in the glossary for easy reference. what do you guys think? i've done two words in that style so see if you think it'll be a good idea to do.&lt;br /&gt;
--Amanda Tan 16:32, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For the current research: http://www.future-science.com/doi/abs/10.4155/cli.11.93?journalCode=cli&lt;br /&gt;
--[[User:Z3389343|z3389343]] 22:18, 25 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Also, I think there will be different genetic factors that will have influences on the severity of the syndrome, I'll mention that in my genetics bit but won't go into detail about what the actual pathophysiology is, I'll just introduce it and then somehow mention that the pathophysiology will be dealt with in subsequent sections. Does that sound alright?&lt;br /&gt;
Here's an example: http://www.ncbi.nlm.nih.gov/pubmed/11269509&lt;br /&gt;
Also, if you find there's a genetic component mentionned, just let me know about that article and I'll make sure I cover the genetic explanation, so you can just mention that for details on the genetics, refer to the genetics section. Do you think that makes sense?&lt;br /&gt;
&lt;br /&gt;
I think you could just add it into the pathophysiology part since you already read it? Right now i've just been reading all articles related to cardio and adding them into the relevant sections. Not that you should do other sections, but i think if you come across something relevant to another section it'd be easier if you just added it in rather than have the person doing that section read it all again to add it in?&lt;br /&gt;
&lt;br /&gt;
Hey elina this might be helpful in understanding the frataxin gene. http://www.springerlink.com.wwwproxy0.library.unsw.edu.au/content/237n26h5wj083865/&lt;br /&gt;
-z3294943&lt;br /&gt;
&lt;br /&gt;
Prenatal diagnosis FRDA http://www.ncbi.nlm.nih.gov.wwwproxy0.library.unsw.edu.au/pubmed/9742572&lt;br /&gt;
-z3294943&lt;br /&gt;
&lt;br /&gt;
what is the intron-1 of the frataxin gene? the paper &amp;quot;The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich’s ataxia&amp;quot; mentions it as an important part for ventricular hypertophy in relating GAA repeats in the intron-1 of the frataxin gene.&lt;br /&gt;
&lt;br /&gt;
[http://www.ncbi.nlm.nih.gov/pubmed/21055653 Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment.] can someone please help me find this article? the UNSW database seems to have it but it won't allow me access to the full article even after opening it from Sirius.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
explanation of an intron:&lt;br /&gt;
&lt;br /&gt;
I guess you know how the coding bit of a gene is transcribed from DNA to mRNA (messenger RNA), which then gets translated into protein? basically, the preliminary RNA transcript you get is hardly ever translated into protein as such, there are a few modifications that happen first. one of these is that parts of the mRNA get cut out - this is called splicing. the bits that are cut out and not used for the translation are called introns. why exactly this mutation that sits in the intron, hence the part that is cut out, has such a big effect is quite interesting; haven't had the time to read thoroughly through the papers yet to find out why exactly that has an effect. but does this explanation help so far?&lt;br /&gt;
so intron-1 would be the first bit that is cut out of the mRNA molecule you get from the frataxin gene.&lt;br /&gt;
&lt;br /&gt;
Hey guys!&lt;br /&gt;
here are some ways of diagnosis/characterising the progression of FRDA&lt;br /&gt;
&lt;br /&gt;
*	electromyogram (EMG), which measures the electrical activity of muscle cells,&lt;br /&gt;
*	nerve conduction studies, which measure the speed with which nerves transmit impulses,&lt;br /&gt;
*	electrocardiogram (ECG), which gives a graphic presentation of the electrical activity or beat pattern of the heart,&lt;br /&gt;
*	echocardiogram, which records the position and motion of the heart muscle,&lt;br /&gt;
*	blood tests to check for elevated glucose levels and vitamin E levels, and&lt;br /&gt;
*	magnetic resonance imaging (MRI) or computed tomography (CT) scans, tests which provide brain and spinal cord images that are useful for ruling out other neurological conditions.&lt;br /&gt;
and i have been seeing this come up alot for treatment [http://www.ncbi.nlm.nih.gov/pubmed/21392622]&lt;br /&gt;
&amp;lt;ref name=&amp;quot;PMID 21392622&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt; 21392622&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
--z3294943 19:39, 29 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
guys, you scare me with the amount of info you've already put up, but it's looking good! I really don't want to be lagging behind but I'm really stressing out with what I need to do this week, I'll try to put some stuff up but it won't be much. I promiss I'll work intensively on it the week it's due, cause before that I just won't have much time. sorry!&lt;br /&gt;
I do have a couple more genetics related references, they're on my own student page at the mo as I didn't wanna keep adding them randomly into the discussion, but thought it would be better to just put them here once I have a reasonable pool together that I've gone through and checked for relevance.&lt;br /&gt;
&lt;br /&gt;
A possible teratogen? Taurine.. http://www.ncbi.nlm.nih.gov/pubmed?term=friedreich%20ataxia/embryology&amp;amp;cmd=correctspelling&lt;br /&gt;
&lt;br /&gt;
Hi guys just with in text referencing eg... Tsou ''et al'', (2011) &amp;lt;ref name=&amp;quot;PMID21652007&amp;quot;&amp;gt;&amp;lt;pubmed&amp;gt;21652007&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
lets just do the last name of first author et al and date + ref after!&lt;br /&gt;
&lt;br /&gt;
Hey Ryan, could you do the table up (about the stuff carmen mentioned today) in diagnosis?&lt;br /&gt;
&lt;br /&gt;
Hi guys! hope your enjoying you time off! I came across this book on pubmed it has PMID [http://www.ncbi.nlm.nih.gov/pubmed/20301458] i think we all should have a look it has alot of info!! hope you find it helpful! --z3294943 11:10, 5 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Looks great! thanks! it'll help with the treatment section! --z3329495 22:09, 5 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
I've edited the treatment section but the person who filled in information on antioxidants please go through it and rewrite some of it. I didn't know all the information so i was hesitant to edit anything. Also include a sentence or two explaining why antioxidant treatment will work.&lt;br /&gt;
--z3329495 18:03, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Our references are missing?! i just noticed it! i fixed up some strange references, but it didn't fix it! if it doesn't reappear by next week we should talk to Mark.&lt;br /&gt;
&lt;br /&gt;
--z3329495 19:51, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
Hi guys,&lt;br /&gt;
Are we able to meet on the wednesday of next week?? I think we really need to go over this project.&lt;br /&gt;
We also need to add in more picture. So please if you find anything related to your subject please add it in. I am having trouble finding any picture that i am able to reuse so im having to draw alot of mine. so even if you cant find something please add a drawing or video. &lt;br /&gt;
just to reiterate what sections everyone is meant to be working on:&lt;br /&gt;
&lt;br /&gt;
*Amanda: pathpart of cardio &amp;amp; musculature, pathpart of pathogenesis, diagnosis&lt;br /&gt;
*Elina: Genetics, molecular &amp;amp; cellular parts of neurophysio aspect, current research&lt;br /&gt;
*Karmen: Neurophysiology aspect, background, history&lt;br /&gt;
*Ryan: Treatment, physiopart of pathogenesis, physiopart of cardio and musculature&lt;br /&gt;
everyone: make drawing, decide at the end which one we think is best, find video of possible&lt;br /&gt;
&lt;br /&gt;
 Amanda are you doing diagnosis?? I think there is a few other ways that can be used like MRI/ECG. It might be interesting to add these in with pictures??&lt;br /&gt;
What do you think?&lt;br /&gt;
And Ryan I thought maybe we could add in some treatment option for the deformities like scoliosis? Ie surgery.. Is there anything to aid with pes cavus? &lt;br /&gt;
Have patient been able to survive heart transplantations? as this is the main cause of death would it help if they received a transplant?&lt;br /&gt;
I have also read some info about 5-hydroxytryptophan being used as an option of treatment. &lt;br /&gt;
Anyway let me know what you guys think?&lt;br /&gt;
--z3294943, 9 September, 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi, yes i'm working on the table of stuff for diagnosis - its on my student page since i'm not done with it yet i didn't want to post it on the main page. Wednesday of next week is fine for me.&lt;br /&gt;
&lt;br /&gt;
--z3329495 22:41, 9 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Well for treatment i could only find clinical tested treatments for mainly cardiac related, but i think its a good idea for treatment for scoliosis. One more question has anyone done a hand drawing yet?.&lt;br /&gt;
&lt;br /&gt;
----Ryan Tran 10:44, 10 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
I've put up the scoliosis one for the drawn image. also, there is new research into a different kind of iron chelation drug called deferiprone http://www.ncbi.nlm.nih.gov/pubmed/21791473 I've used a bit of this in the diagnosis for MRI (since this paper used MRI technology) but i think it'd worthwhile to put it into the current research.&lt;br /&gt;
--z3329495 14:18, 10 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Is Elina working on prenatal diagnosis? I've included prenatal and genetic testing in the table i'm working on but i have no information on either. I'm just about finished with the table so i'll just post it on the main page to see how it looks like and what you guys think of it.&lt;br /&gt;
--z3329495 17:26, 10 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
What time we all meeting on Wednesday? and where?&lt;br /&gt;
&lt;br /&gt;
Ryan Tran 23:42, 12 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi guys,&lt;br /&gt;
unfortunately I am unable to come tomorrow i have some family issues. sorry!&lt;br /&gt;
but i think that thurs will be ok just for final lay out decisions. We need more pics.. so maybe we could all find 2/3 each i think think that would brighten up the page!!&lt;br /&gt;
If you guys still want to meet tomorrow you can. &lt;br /&gt;
z3294943&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hi guys, yes I (Elina) am working on prenatal diagnosis - do you want me to simply do it in the same kind of table format, and not have a subsequent section about it beneath? I think the table looks good, and I'd probably just be repeating myself.&lt;br /&gt;
--[[User:Z3389343|Elina Jacobs]] 19:14, 13 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Elina, could you just post a link to that paper with the muscular info here? I can get something knocked out as soon as.&lt;br /&gt;
--z3329495 13:26, 16 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hi guys, I heard today that monday maybe the last day we can upload something for the peer review. So if you have anything else you would like to add please get it done before then just incase!&lt;br /&gt;
I hope everyone has a great weekend! --Karmen Magi 20:16, 16 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Amanda, here's the reference I was telling you about: Massimo Pandolfo Friedreich ataxia. Handb Clin Neurol: 2011, 103();275-94 PMID:21827895&lt;br /&gt;
It's a 20 pages review on what is known about FRDA so far, hopefully you'll find some useful stuff about the muscular aspect in it!&lt;br /&gt;
&lt;br /&gt;
Ryan: here's the genetics treatment article I was talking about: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001958&lt;br /&gt;
let me know if you're struggling with the genetic &amp;quot;jargon&amp;quot; and I'll help you out.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3389343|z3389343]] 11:44, 17 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Elina, there isn't anything much on the muscular system in that review but i found a paper which i cannot get access to on the UNSW database. If you could access it through your university it would help me a ton! [http://www.ncbi.nlm.nih.gov/pubmed/7634585 | Natural history of muscle weakness in Friedreich's Ataxia and its relation to loss of ambulation.]&lt;br /&gt;
&lt;br /&gt;
Oh no, sorry about that! Also, your link doesn't work for me :/&lt;br /&gt;
&lt;br /&gt;
Should work now - must be because i didn't put a space somewhere...&lt;br /&gt;
&lt;br /&gt;
Sorry, but I can't get access to it either...&lt;br /&gt;
&lt;br /&gt;
==Peer Assessments==&lt;br /&gt;
* Epidemiology was a bit brief and perhaps could be expanded on or supported with statistics from multiple nations etc.&lt;br /&gt;
* Aetiology section was really detailed and had a great span of information. Your image of the Friedreich’s pedigree could perhaps be slightly bigger on the page because I missed it the first time viewing your page.&lt;br /&gt;
* The neuropathology section was extremely ‘full’. The amount of text in heavy paragraphs may be off putting to some readers. A suggestion would be to break it down with the inclusion of tables and maybe dot-pointing the information that can be summarised.&lt;br /&gt;
* Maybe include a glossary so you can accommodate for all readers.&lt;br /&gt;
* It was good to see that you grouped your references :) &lt;br /&gt;
--[[User:Z3332629|z3332629]] 15:29, 22 September 2011 (EST)&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_7&amp;diff=72531</id>
		<title>Talk:2011 Group Project 7</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_7&amp;diff=72531"/>
		<updated>2011-09-27T13:23:20Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Peer review */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[2011_Group_Project_7|'''Group 7''']]: [[User:z3291622]] | [[User:z3291643]] | [[User:z3387190]] | [[User:z3293267]]&lt;br /&gt;
&lt;br /&gt;
{{2011GroupDiscussionMH}}&lt;br /&gt;
&lt;br /&gt;
==Peer review==&lt;br /&gt;
&lt;br /&gt;
'''Group 7'''&lt;br /&gt;
&lt;br /&gt;
*Firstly, you don’t have a very good image/text ratio&lt;br /&gt;
*Introduction would grab my attention a little more with an image&lt;br /&gt;
*Try combining the text that you have for history in the timeline&lt;br /&gt;
*Epidemiology is not very extensive. You need to give more of a worldwide overview- also try and find information regarding Australia as a whole rather than just WA&lt;br /&gt;
*Obviously a lot of research has been put into pathogenesis- although there is a lot of information presented at once, try to break this up using bullet points etc&lt;br /&gt;
*Why have you included ‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95 Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8 ‘ in the text? This should be in your references&lt;br /&gt;
*Differential diagnosis and related diseases should be combined&lt;br /&gt;
*Genetic counselling has not been explained so makes little sense &lt;br /&gt;
*Current and future research should have subheadings&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Comments on Group Project 7===&lt;br /&gt;
'''Strengths:'''&lt;br /&gt;
*The history section was very well done. The block of text above the timeline provided just enough information and captured my interest. The timeline provided adequate summary of the major milestones in research of Angelman Syndrome.&lt;br /&gt;
*The glossary section seems decent.&lt;br /&gt;
*The student images are really good, especially the mechanism illustrations.&lt;br /&gt;
'''Weaknesses:'''&lt;br /&gt;
*Lack of use of subheadings. More subheadings can be used to break some of the sections up. It would not look so overwhelming then.&lt;br /&gt;
*Format of the overall page is not the best as it can be.&lt;br /&gt;
*There is some duplication in references.&lt;br /&gt;
'''Specific corrections:'''&lt;br /&gt;
*Just curious, why are males more predisposed to early developmental delay?&lt;br /&gt;
*It would be good to make the format of the stats under epidemiology consistent. Either fraction or ratio (I prefer ratio :D).&lt;br /&gt;
*Maybe for some of the tables, it will look better with an outline border so it is easier to see when the text in the table ends and when text in paragraphs starts.&lt;br /&gt;
*Use more subheadings e.g. Under Signs &amp;amp; Symptoms, the subheadings would be “Behavioural Characteristics”, “Communication Skills”, “Clinical &amp;amp; External Characteristics”, etc. &lt;br /&gt;
*Section under genetic counselling should come with an explanation or a paragraph of text. It will be good to elaborate further than just a table.&lt;br /&gt;
&lt;br /&gt;
--Z3389806 05:53, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 7 assessment'''&lt;br /&gt;
*Introduction well established and clear though image can’t hurt&lt;br /&gt;
*History of angelmans would be lighten up with the image of the founder&lt;br /&gt;
*Epidemiology could be expanded a little more and even a map would make this section lively&lt;br /&gt;
*Aetiology description of the classes could have a paragraph explaining the table relating to the  cause of angelmans&lt;br /&gt;
* Pathogenesis was a bit confusing with mostly genetic terms that were not found in the glossary. Otherwise structure is proper and well integrated with images&lt;br /&gt;
*Signs and symptoms table is confusing were addition of dot points in the table would be helpful&lt;br /&gt;
*Complications heading seems rather odd to be placed separately form the signs and symptoms, would be better added as a subheading.&lt;br /&gt;
*Diagnosis could introduce the diagnosis types in small paragraph, type are clearly expanded though image of the child could be made smaller&lt;br /&gt;
*Related diseases would be better in the symptoms with the complications as another sub heading instead of small niece headings&lt;br /&gt;
*Genetic council would be suited under the prognosis as chances of risks &lt;br /&gt;
*Research should be sub divided in to current and future research &lt;br /&gt;
*Referencing needs to remove repeats and link needs to be manually referenced. Glossary needs the addition of some genetic terms and method of indicating the glossary words to the web page.&lt;br /&gt;
z3332250 23:55, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 7 Critique'''&lt;br /&gt;
&lt;br /&gt;
#•	Introduction is good&lt;br /&gt;
#•	History is really good. I like how you explain your table and introduce it&lt;br /&gt;
#•	Epidemiology is too short. More statistics need to be included&lt;br /&gt;
#•	Aetiology is ok&lt;br /&gt;
#•	Pathogenesis is complicated. Maybe explain what the genes are and their function&lt;br /&gt;
#•	Pathophysiology has the same problems as pathogenesis&lt;br /&gt;
#•	The remaining sections are done pretty well. I wouldn’t really change anything&lt;br /&gt;
#•	Great use of images throughout the project&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289991|Robert Klein]] 08:54, 25 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Angelman Syndrome'''&lt;br /&gt;
&lt;br /&gt;
*You need to add an image in 'Introduction' or 'History', something to get the reader interested&lt;br /&gt;
*You kind of repeat yourself in 'History'.  Try putting more information into the timeline, as opposed to the text.  &lt;br /&gt;
*Epidemiology' looks a bit bare, is there a graph you can add or something? Also a bit more information can't hurt&lt;br /&gt;
*Pathogenesis is HUGE, looks like you've put a lot of work into it.  But, it needs to be broken up a bit. Also, shrink that first image down, it's a bit out of place. Maybe try to use proper subheadings to break it up, not just bold.  Are you able to make a table out of 'Animal Models'? Ie type (mice), advantages, disadvantages, diagram (if present).  &lt;br /&gt;
*In 'Signs and Symptoms', you don't need the &amp;quot;Adapted from&amp;quot; you can just reference that.  Or at least move it out of the table.  I got confused and thought they were meant to be some of the symptoms&lt;br /&gt;
*But you've got some good information in the rest of the section, nicely arranged with the images&lt;br /&gt;
*Try shrinking the flow chart in 'Diagnosis', also reference it.  It you made it yourself, say so&lt;br /&gt;
*Nice table for 'Treatments'&lt;br /&gt;
*Can you give a bit of an introduction to the table in 'Genetic Counselling', don't just jump straight into it&lt;br /&gt;
*Make sure you reference that first paragraph in 'Current Research', you can't just make statements without justifying them with articles&lt;br /&gt;
*Quite a good project, just need some more images and a bit of formatting&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 7-&lt;br /&gt;
* Very text heavy!&lt;br /&gt;
* The introduction would benefit from an image&lt;br /&gt;
* You can probably put all of the history into the table. Having text then summarised in a table is a bit redundant&lt;br /&gt;
* Epidemiology is a little bland sorry. Table? Graph? Image? There is also not that much information there. And only including western Australia? I think you could find data for Australia as a whole&lt;br /&gt;
* There is A LOT of text in pathogenesis. It is good but could be improved by breaking it up a bit. Maybe bullet points?&lt;br /&gt;
* Animal models should be a new subheading&lt;br /&gt;
* ‘pathophysiology’ subheading is not needed. The information in it could be included in pathogenesis&lt;br /&gt;
‘Adapted from Smith JC, et al. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003;40:87-95&lt;br /&gt;
Adapted from Williams CA, et al Angelman syndrome: consensus for diagnostic criteria. J Med Genet 1995;56:237–8’ &lt;br /&gt;
doesn’t need to be here. Just reference it normally. If this is your student drawn image I’m not sure it is enough. Making a table isn’t an “image”.&lt;br /&gt;
* Other than that I like the signs and symptoms section. Although I believe that the table is a little out of place&lt;br /&gt;
* Diagnosis section could be better formatted&lt;br /&gt;
* Differential diagnosis and related diseases would work well together under one subheading&lt;br /&gt;
* Referencing such as under the table in treatment is wrong. It isn’t done like this. You format it like everything else you reference. There is no place for the actual reference in the text. There should be a link for the reference in the reference section&lt;br /&gt;
* What is the genetic counselling section? It makes no sense and needs to be explained.&lt;br /&gt;
* Your project has obviously made progress but you need to look over it and make sure that things are formatted so that they are easily accessed, referenced properly and everything is in the right order.&lt;br /&gt;
&lt;br /&gt;
'''Group 7'''&lt;br /&gt;
* Good use of headings, maybe you could add sub headings into beak up the text and make the page easy to follow. &lt;br /&gt;
* Intro section- maybe you could dot point the clinical features to make it easier to read.&lt;br /&gt;
* Some of your intro and history dates dont correlate but this might be a typing mistake? 1956 and 1965??&lt;br /&gt;
* Nice use of time line. &lt;br /&gt;
* The epidemiology looks a little bare. Is there anymore info that could be added. &lt;br /&gt;
* In the aetiology table make sure all your stats are referenced. &lt;br /&gt;
* UBE3A Ubiquitylation Pathway picture is extremely large, maybe you could resize this. &lt;br /&gt;
* I like the addition of animal models. With an amazing picture!&lt;br /&gt;
* Sings and symptoms section is very well put together structurally- good use of subheadings, pictures and tables. &lt;br /&gt;
* Are there anymore complication you could add for AS? &lt;br /&gt;
* Maybe you could tabulate your diagnosis section. I like the flow chart! &lt;br /&gt;
* Could have a common heading Related syndromes and differential diagnosis then use subheadings to split them up. &lt;br /&gt;
* Genetic Counselling unsure of what this section is and what the table relates to? &lt;br /&gt;
* I like that you colour scheme/tables are continuous through out the page. &lt;br /&gt;
* Just make sure you reference list isn't doubled for some references.&lt;br /&gt;
* make sure all acronyms are added to the glossary. &lt;br /&gt;
* Nice student illustrations.  &lt;br /&gt;
&lt;br /&gt;
'''Group 7 Assessment''' &lt;br /&gt;
*History section has almost no referencing at all.  The information here definitely needs to be referenced.  Pictures would also be helpful here. &lt;br /&gt;
*There is not nearly enough information in the Epidemiology section… This definitely needs some major work done on it.  More information and pictures are needed.  &lt;br /&gt;
*The student drawing for Chromosome 15 looks good, but where did you get this information from?  Surely there’s a source you found the information from as to how to draw this figure.  Shouldn’t you include that as well? &lt;br /&gt;
*The Aetiology section could also use more work as far as amount of information goes.  Think about what else is important that you could add to this part.  Also, more of the information in the chart should be cited, unless the whole chart is cited from one article, which should be shown. &lt;br /&gt;
*GREAT information given in the pathogenesis and Pathophysiology sections.  Very well organized with superb supporting pictures and diagrams.  &lt;br /&gt;
*The signs and symptoms chart seems a bit confusing… maybe because it’s too close to the information given below it, so they seem to run together.  It would be helpful to space this out more.  Also, not all the information given in the chart is referenced…&lt;br /&gt;
*Angelman Syndrome jpg needs correct referencing and also a descriptive sentence summarizing the information.  &lt;br /&gt;
*Postnatal diagnosis needs referencing as well. &lt;br /&gt;
*The glossary would look more appealing if it used bullet points. &lt;br /&gt;
*It would be a good idea also to have the glossary terms linked with the words in the wiki page, so that the reader can easily get access to the word in the glossary.  &lt;br /&gt;
*Some of the references are repetitive.  Make sure to fix this so they all link to a single reference instead of numerous ones of the same resource.  &lt;br /&gt;
*Overall some sections of this wiki are rather good and near completion, but others need some major work still.  Once the changes are made I'm sure it'll be a great page! &lt;br /&gt;
--[[User:Z3391078|Z3391078]] 16:02, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*'''Introduction''': brief and to the point.&lt;br /&gt;
*'''History''': Very well explained, but references have been forgotten? Also, you mention two dates in the summary table, 1980 &amp;amp; 1982, that you don't seem to explain previously.&lt;br /&gt;
*'''Epidemiology''': Looks a little bit bare. If there simply is not much information about it, I wouldn't split it in three sections with each only containing a sentence, but rather write one short paragraph.&lt;br /&gt;
*'''Aetiology''': I assume the UBE3A gene lies within the 15q11.2-q13 region? You might want to specify that. Also, some terms should be linked to the glossary.&lt;br /&gt;
*'''Pathogenesis''': Watch out with your terminology - you say &amp;quot;its function is vague&amp;quot; - its function most likely isn't vague, but it is only vaguely known. Subtle, but important difference. Why do you mention LTP? Is LTP affected in AS? Otherwise, impressive detail in the mechanisms, well explained.&lt;br /&gt;
Not quite sure it makes sense to have the &amp;quot;animal models&amp;quot; subheading under pathogenesis. Maybe have a separate section, entitled, animal models used in the study of AS?&lt;br /&gt;
I'd also suggest having pathophysiology as a brief, but separate section from pathogenesis, and not have it as a subsection.&lt;br /&gt;
*'''Signs and Symptoms''': Not quite sure what the table is for? Having a table combined with text with subheadings seems a bit odd. The text is well explained. (Just correct obesity, not obeseness.)&lt;br /&gt;
*'''Complications''': A bit brief and out of the blue. How does it link in with the rest? Maybe include in under another section instead of have it as its own.&lt;br /&gt;
*'''Diagnosis''': Prenatal diagnosis looks good, very detailed. Just watch out with the chorionic villus sampling, not chronic villus sampling ;)&lt;br /&gt;
Postnatal: Revise your first sentence, doesn't quite make sense. Also, it seems a bit brief, maybe add a bit more detail?&lt;br /&gt;
Differential Looks fine.&lt;br /&gt;
*'''Related Diseases''': Might make sense to combine this with differential diagnosis? Also, considering pretty much exactly the same region is affected in PWS as in AS, you might want to explain more how this still leads to two separate syndromes.&lt;br /&gt;
*'''Treatment &amp;amp; Management''': Needs a bit more detail.&lt;br /&gt;
*'''Prognosis''': The information provided seems a bit random, thus needs a bit more explanations and how it relates to everything else.&lt;br /&gt;
*'''Genetic counseling''': No explanations provided, simple table. How are people supposed to understand this?&lt;br /&gt;
*'''Current and Future Research''': Fine.&lt;br /&gt;
*'''Glossary''': (Your definition of an allele is not quite right.) Otherwise looks good, though some more terms need explanations.&lt;br /&gt;
*'''References''': The links probably need fixing, and some papers appear several times in the list.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
HELP. I made a flow chart for prenatal diagnosis but it is saved as pdf file. Does anyone know if I can upload a pdf file as an image? I'm too scared to do it in case it mucks up something. --[[User:Z3291622|N Fernando]] 21:51, 18 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
Hey guys, I've deleted the incidence and gender section from the introduction, caus it is outlayed in the epidemiology section anyway, and we would have had different statements.--[[User:Z3387190|Theodora Retzl]] 19:27, 18 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey. I can't find the original article written by H, Angelman but I found a review on that original article published in 2008. It has the same title as the original angelman article. Here's the link:&lt;br /&gt;
http://onlinelibrary.wiley.com.wwwproxy0.library.unsw.edu.au/doi/10.1111/j.1469-8749.2008.03035.x/pdf&lt;br /&gt;
Can I use this?&lt;br /&gt;
It's more of a commentary of the original paper than a review. &lt;br /&gt;
--[[User:Z3291622|N Fernando]] 11:03, 18 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Hey, maybe from now and til peer assessment day, we could work on the glossary? It's really hard to find a suitable image for intro and history. Nimeshi, have you managed to find the original article of Dr Harry's? We should probably ask Dr Hill first if getting a snapshot of the article isn't violating the copyright of the article. --[[User:Z3291643|Sang Lee]] 23:17, 17 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Hey guys, I know the history section is lengthy, don't worry I will shorten it. Julia, is this what you meant? I used information from both the sources. --[[User:Z3291622|N Fernando]] 12:47, 12 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Also, do you guys reckon we should put an image of Harry Angelman in the history section? --[[User:Z3291622|N Fernando]] 22:07, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Hey, Julia, Yes I'll look through the articles and fix up the diagnosis part. &lt;br /&gt;
--[[User:Z3291622|N Fernando]] 20:22, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Hey, Julia, thx for the link. I put up some contant to my section and shifted the AS- PWS image there. I have also added some information to the pheno-genotyp correlation part, and the glossary. It would probably be good to focus on getting the page content we have so far and the sub- headings in order and work on what we have so far, rather than to add new content. Maybe delete the epidemiology section, as there is not enough specific information available that would make senece there (and is in the introduction anyway), what do you think? --[[User:Z3387190|Theodora Retzl]] 19:49, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey, Nimeshi,    http://onlinelibrary.wiley.com.wwwproxy0.library.unsw.edu.au/doi/10.1002/ajmg.c.30278/pdf    ,    http://www.angelman.org/stay-informed/facts-about-angelman-syndrome---7th-edition/harry-angelman-and-the-history-of-as/   , its good for history (like about Ellen Magenis, etc). Maybe we could have a paragraph giving a brief history then a timeline? --[[User:Z3291643|Sang Lee]] 17:28, 10 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Forgot something, Nimeshi, do you think you could take the liberty of breaking down the diagnosis into pre and postnatal, just cos I remember reading about diagnosis and lots of papers have broken them down like so. I also think it won't hurt to have a picture of EEG or graph of AS patients, showing pheno-geno correlations, etc. I also think it'd be good to have more text accompanying the table for Treatment and Management, I knoe there's no treatment as such for AS, so maybe we should write that? Thanks&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 14:06, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Hey, I've added some more info to my section, but need to reupload the image cos I've made a spelling mistake, what do you guys think? Please feel free to make suggestions to refine the image. Also, Theodora, do you think the image of the PWS and AS patients would be better positioned in the signs and symptoms section instead of the intro? I think the intro image could be more general, like a photo of Dr Angelman,etc.. Also, is PWS one of the differential diagnoses of AS? I don't think I put it up there with the other diseases, if so, could the person who added it in also put in the reference for that? This is for Theodora and Nimeshi, PMID 12566516, I think we should lay out the symptoms table like they did here and have a spider diagram style for diagnosis. Just remember to acknowledge them by saying 'Adapted from...', at the bottom of table, etc. Thanks&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 13:46, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Just posted up the pictures. If you're not satisfied about the chromosome 15 pic, just let me know and I can change it up for you.&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3293267|Eugene Chan]] 12:06, 3 September 2011 (EST)&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Hey guys just a quick note, we should refrain from using the words &amp;quot;mental retardation&amp;quot; as this could be deemed offensive. Use &amp;quot;intellectual disability&amp;quot; as that is a more common term now used in Australia. Also use &amp;quot;learning difficulty&amp;quot; or &amp;quot;developmental delay&amp;quot;. We should also encourage the use of person-first language e.g., &amp;quot;a child with an intellectual disability&amp;quot; rather than &amp;quot;intellectually disabled child&amp;quot;. This promotes the idea that a person comes before their disability.&lt;br /&gt;
&lt;br /&gt;
Sorry to be very specific here, but if this is going to be a public-access website we should use the appropriate terminology.&lt;br /&gt;
&lt;br /&gt;
Thanks&lt;br /&gt;
--[[User:Z3293267|Eugene Chan]] 10:41, 3 September 2011 (EST)&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Yeah, sure thing. Nimeshi,I've put your timeline into a table, I've given up on trying to do a graphical timeline. &lt;br /&gt;
*PMID 12566516, I found this to be really good for Clinical features of AS (Theodora), I really liked the table formatting. It's relevant for Differential diagnosis, genetic counselling and phenotype/genotype correlation. It's also got a section on Management as well for Eugene. &lt;br /&gt;
*PMID 20445456, for signs and symptoms, geno/pheno correlation, diagnostic testing methods+prenatal diagnosis, treatment and management&lt;br /&gt;
*PMID 15668046, genetic diagnostic testing and clinical features (again in a table format according to frequency)&lt;br /&gt;
Also, I think we could also add Phenotype/genotype correlation and Animal models as subsections, what do you guys think?&lt;br /&gt;
--[[User:Z3291643|Sang Lee]] 23:12, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Hey, I think it makes more sense to compare the symptoms in adults and children in a table, rather than to draw a timeline. There are no research articles really focusing on the symptoms in every age of the patients, and the changes from year to year.--[[User:Z3387190|Theodora Retzl]] 21:13, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
Hey, I've just typed in some of the information I've collected so far. I'll definitely be writing a lot more on aetiology and pathogenesis, but I thought it won't hurt to contribute to other subsections as well. I'll add the references and glossary words bit later today. Please feel free to make&lt;br /&gt;
&lt;br /&gt;
==Peer Assessments==&lt;br /&gt;
* Your pathogenesis section was good, it was thorough and went into significant depth. The use of animal models and the support of recent studies was also a positive aspect&lt;br /&gt;
* The photo of the ub pathway should be smaller or be placed as a thumb nail as it isn’t something that directly contributes to your defect&lt;br /&gt;
* It is a shame that there is such a large gap in your Aetiology section, but i do realise that this is slightly out of your control due to wiki formatting issues. &lt;br /&gt;
* I personally found the signs and symptoms section to be slightly confusing in format. Perhaps placing this info into a table would make it more concise. &lt;br /&gt;
* Treatment and management section had lots of detail and highlighted a few different methods which gave a good insight of the current technologies and strategies out there in the market. &lt;br /&gt;
--[[User:Z3332629|z3332629]] 15:27, 22 September 2011 (EST)&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_6&amp;diff=72529</id>
		<title>Talk:2011 Group Project 6</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2011_Group_Project_6&amp;diff=72529"/>
		<updated>2011-09-27T13:22:26Z</updated>

		<summary type="html">&lt;p&gt;Z3290379: /* Peer Review */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[2011_Group_Project_6|'''Group 6''']]: [[User:z3290841]] | [[User:z3291317]] | [[User:z3291324]] | [[User:z3291423]]&lt;br /&gt;
&lt;br /&gt;
{{2011GroupDiscussionMH}}&lt;br /&gt;
&lt;br /&gt;
==Peer Review==&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
&lt;br /&gt;
*My first impression is that this project is lacking images. There is way too much text in comparison to images. &lt;br /&gt;
*An image would nicely complement the introduction &lt;br /&gt;
*I feel that history would work better in a timeline&lt;br /&gt;
*Epidemiology needs a table/graph&lt;br /&gt;
*Good links in signs/symptoms although another image would be nice&lt;br /&gt;
*Genetics needs to be explained a little better&lt;br /&gt;
*Student drawn images were great- obviously a lot of effort has been put into these&lt;br /&gt;
*Diagnostic test table needs an image and needs to be referenced properly&lt;br /&gt;
*Again, an image is needed for prognosis&lt;br /&gt;
*Glossary needs to be extended&lt;br /&gt;
*Overall a good project but you need to fix a few things&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
&lt;br /&gt;
*Introduction: the contend is ok, but the structure could be clearer&lt;br /&gt;
&lt;br /&gt;
*History: too text heavy, a timeline would be nice&lt;br /&gt;
&lt;br /&gt;
*Epidemiology: more content would be good&lt;br /&gt;
&lt;br /&gt;
*Symptoms: the picture could be more general&lt;br /&gt;
&lt;br /&gt;
*Genetics/ Aetiology: the structure could be better, maybe use some more subheadings, and put the gene profile in tables&lt;br /&gt;
&lt;br /&gt;
*Pathophysiology: you need references&lt;br /&gt;
&lt;br /&gt;
*Diagnostic tests: why does it say “insert images”, that should be fixed&lt;br /&gt;
&lt;br /&gt;
*Treatment/ management: looks like there are some references missing? Deleate “Want to learn about more surgery and treatment methods?”, the contend is good, types of shunt would look better as a table&lt;br /&gt;
&lt;br /&gt;
*Prognosis: references missing? good use of subheadings, &lt;br /&gt;
&lt;br /&gt;
*Glossary: incomplete&lt;br /&gt;
--[[User:Z3387190|Z3387190]] 21:52, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Group 6 peer assessment'''&lt;br /&gt;
*Introduction is clear though lack images where a image of example of a blue baby would suffice&lt;br /&gt;
*History begins clearly though becomes about surgical history instead of the disease, where time line is not even present of how understanding of this disease improved.&lt;br /&gt;
*Epidemiology should be expanded either the genetics of the disease, in general have more information of the causes, incidence and distribution of the disease.&lt;br /&gt;
*Signs and symptoms poorly structured and requires more images also doesn’t have an introduction to the signs and symptoms. Although the extra links to comparison of the heart is useful and nicely used.&lt;br /&gt;
*Pathophysiology should add supplementary information to back up all the information.&lt;br /&gt;
*Diagnosis please add the images, while there is the content though no image following also first box has “insert text” very confusing.&lt;br /&gt;
*Treatment/management indicate the separation of surgery and other treatment types in the introduction which is lacking otherwise all is A ok&lt;br /&gt;
*Glossary needs to be referenced to other sections of the web page also expanded as most language used is unknown without a dictionary.&lt;br /&gt;
*Referencing needs to be fixed as links is not proper referencing also the repeats need to be removed&lt;br /&gt;
z3332250 23:53, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Comments on Group Project 6===&lt;br /&gt;
'''Strengths:'''&lt;br /&gt;
*The flow between sections and sub-sections is good with appropriate placements of headings and sub-headings.&lt;br /&gt;
*Some of the references have good use of multiple referencing so as to avoid duplication.&lt;br /&gt;
*The external links under signs and symptoms is very apt and will interest readers.&lt;br /&gt;
'''Weaknesses:'''&lt;br /&gt;
*Almost half of the references are not properly formatted.&lt;br /&gt;
*Some of the words that should be in the glossary are not under that section e.g. Velocardiofacial, Conotruncal, Hypothyroidism, nengoitrous, embryotoxon.&lt;br /&gt;
*Punctuation in some sections can be better.&lt;br /&gt;
'''Specific corrections:'''&lt;br /&gt;
*”muattional” under 22q11.21 sub-heading is spelt incorrectly.&lt;br /&gt;
*”cyamnosis” under signs and symptoms is spelt incorrectly.&lt;br /&gt;
*”enlargenemt&amp;quot; under clubbing is spelt incorrectly.&lt;br /&gt;
*Insert a timeline under history to provide a summary.&lt;br /&gt;
*It might be better to have genetics section before signs and symptoms.&lt;br /&gt;
*Under Treatment/Management, it will be good to put “medical therapy”, “palliative procedures” and “surgery” as sub-headings.&lt;br /&gt;
&lt;br /&gt;
--Z3389806 08:03, 26 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 6 Critique'''&lt;br /&gt;
&lt;br /&gt;
#•	Introduction is ok, however it needs to be structured a lot better than what it is&lt;br /&gt;
#•	History is interesting&lt;br /&gt;
#•	Epidemiology needs a lot more detail. A few lines is not good enough&lt;br /&gt;
#•	Signs and Symptoms is ok&lt;br /&gt;
#•	Genetics needs to be explained a lot more clearly than what it is&lt;br /&gt;
#•	Abnormalities is ok&lt;br /&gt;
#•	Diagnostic tests table is impressive&lt;br /&gt;
#•	Treatment/management section is very good&lt;br /&gt;
#•	Prognosis and future directions section is great&lt;br /&gt;
#•	Glossary is incomplete. Check the first term and fix this&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3289991|Robert Klein]] 19:05, 24 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
'''Tetralogy of Fallot'''&lt;br /&gt;
&lt;br /&gt;
*An image in the 'Introduction' to introduce the topic would not go astray&lt;br /&gt;
*&amp;quot;...Infants turning blue when crying...&amp;quot; middle of sentence, no capital is required.  What is tet spells?&lt;br /&gt;
*History might work better as a timeline, otherwise at least '''bold''' the dates so I know whats going on&lt;br /&gt;
*Surgical history has been covered through most of 'Contemporary History', there's not a whole lot of point having two subheadings here&lt;br /&gt;
*The 'Epidemiology' is a bit sparce? Are there no other stats to add to this section?&lt;br /&gt;
*There is a lot of good in information in 'Genetics', but I think you need something to break it up, you've got the images of the chromosomes (which are very good), but can you find other images? Maybe put some of the information into a table?&lt;br /&gt;
*The 'Abnormalities' section looks really good.  The information is clear, succinct, with good illustrative images&lt;br /&gt;
*Though in number 4 under 'abnormalities' can you give a quick definition on what hypertrophy actually is?&lt;br /&gt;
*Diagnosis is poor, it isn't referenced and clearly isn't finished (&amp;quot;insert text here&amp;quot;).  This does not flow on from the rest of the page at all. It looks a bit dry with no colour or images&lt;br /&gt;
*There are minimal references in 'Treatment', surely you didn't all that information out of only a few papers?&lt;br /&gt;
*I like the table in 'Treatment'&lt;br /&gt;
*Can you make the subheadings in 'Treatment' as actually subheadings as opposed to just bold?&lt;br /&gt;
*It's coming along, but you need more images! It starts off well, but there aren't many toward the end.  &lt;br /&gt;
*Make sure you finish the project off!&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Group 6- &lt;br /&gt;
* No way near enough images. As I scrolled through there was HEAPS of text and only a few images, all of which are on the right hand side. It would be better if they were scattered around&lt;br /&gt;
* An image in the introduction would be helpful&lt;br /&gt;
* What are ‘tet spells’? mentioned in the introduction (described later but when seen in the introduction it looks like a typo)&lt;br /&gt;
* History would work better as a list of dates rather than paragraphs. I do like the section at the top with the quote though&lt;br /&gt;
* Epidemiology needs an image- perhaps a table or a graph.&lt;br /&gt;
* Signs and symptoms could do with another image to visualise the clinical manifestations&lt;br /&gt;
* I really liked the audio clips but the first one didn’t work on my computer? I couldn’t hear anything. Not sure if it was just me&lt;br /&gt;
* I think you can come up with a better way of formatting the genetics section. Maybe a table? The information is good it just looks a bit funny&lt;br /&gt;
* The pathogenesis doesn’t actually say HOW is happens in infants. Is this a condition formed during embryonic development or after?&lt;br /&gt;
* The diagnosis section is far from complete. This needs to be corrected&lt;br /&gt;
* Diagnosis section is also not referenced properly&lt;br /&gt;
* Why is there a reference at the bottom of the diagnosis section?&lt;br /&gt;
* As funny as this was: ‘Want to learn about more surgery and treatment methods? Check here!’…. maybe not appropriate sorry. It should be a little more formal. If you want the reader’s attention- try colour. &lt;br /&gt;
* Prognosis- image needed please. Maybe a graph?&lt;br /&gt;
* The glossary also needs to be extended&lt;br /&gt;
* The references need to be tidied up- there are also not many?&lt;br /&gt;
* You need to reference your images properly. ‘normal fetal blood flow and tetralogy of fallot’ is an example. You have but the copyright but not the reference. The web address is not a reference&lt;br /&gt;
* You are clearly on your way with the project but more work is required. You need to FINISH the content and format it a little better with more images.&lt;br /&gt;
&lt;br /&gt;
''Group 6 Assessment'''&lt;br /&gt;
*First, I’d like to note good job on using a reference more than once in the correct way instead of referencing the same thing multiple times.  At least this is done in the first few sections.  First time I’ve seen this done correctly! &lt;br /&gt;
*The introduction, however, has no references whatsoever.  Where did this information come from? &lt;br /&gt;
*It might also be good to add a simple picture in the introduction section so it looks more appealing.  &lt;br /&gt;
*Good information included in the history section.  It might look better if this were laid out in a bullet format though.&lt;br /&gt;
*The epidemiology section looks rather bland.  Not only is there not a picture, but there also isn’t very much information included.  Think about what else you could include here or what you could go into depth about.&lt;br /&gt;
*The signs and symptoms section has good information, but it might be a good idea to represent this information in a better format, possibly in a chart, with pictures of each symptom included in the chart. &lt;br /&gt;
*Finger-clubbing.jpg also needs a detailed description still. &lt;br /&gt;
*Good organization and format under the Genetics section.&lt;br /&gt;
*Under the pathyphysiology and Abnormalities section there are no references made.  Where did this information come from?  Diagnostic Tests and Treatment also needs more referencing. &lt;br /&gt;
*Pictures still haven’t been inserted into the Diagnostic Tests chart.  &lt;br /&gt;
*More referencing is needed for the Prognosis section.  Also, does the glossary terms need to be referenced? &lt;br /&gt;
*It would be a good idea also to have the glossary terms linked with the words in the wiki page, so that the reader can easily get access to the word in the glossary.  References 7-14 are the same reference.  Fix these so they are under one single reference number.  &lt;br /&gt;
*For the references given throughout the wiki, there isn’t any consistency in how the [#] is given.  The [#] is sometimes right after the sentence, sometimes a space is given between the sentence and citation number, and the end of the sentence (period or comma) is sometimes before or after the reference #...&lt;br /&gt;
*Overall, there is a substantial amount of information given within this page, which is good.  I like the basic format of everything and most of the pictures which are included.  Just work on weaving everything together better and referencing things correctly.  Good job! &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3391078|Z3391078]] 15:32, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Group 6'''&lt;br /&gt;
* Nice overall structure and good use of headings and subheading. It gives the page a nice flow. &lt;br /&gt;
* INtroduction is nice and straight to the point and gives the reader a good overview of your topic. &lt;br /&gt;
* I like the historical section with interesting subheadings used, maybe you could add a timeline just to simplify the info. &lt;br /&gt;
* Signs and symptoms nicely arranged. could you add some more pictures here?&lt;br /&gt;
* Pathophysiology and Abnormalities section need to have the references accompanying the information. Just so the read can identify where all the info is from.&lt;br /&gt;
* The diagnostic tests table would be nice with some colour and when the images are it will look complete. It's a little text heavy for a table maybe try bullet points. also the referencing system has changed in this table? and a little unsure of the reference at the bottom of the section? &lt;br /&gt;
* Treatment/Management section is nicely arranged.. could you add another picture here just to compensate for the amount of text. the table really brightens up the page! &lt;br /&gt;
* Future directions section is nicely summarised and I like the tone of voice used here. just make sure the referencing is correct as it is a little confusing and interrupts the flow of the section. &lt;br /&gt;
* Maybe the use of similar tables and colour scheme will increase the continuity of the page. &lt;br /&gt;
* Make sure your references are not doubled in the list. &lt;br /&gt;
* Ensure all of your pictures are correctly referenced. &lt;br /&gt;
* Make sure all acronyms and scientific wording is in the glossary.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*'''Intro''': What's a tet spell?&lt;br /&gt;
*'''History''': Very good in general. Not sure it makes sense to split it into 2 parts, with surgical being separate? I think it would work just as well combining the two.&lt;br /&gt;
*'''Edidemiology''': Looks fine&lt;br /&gt;
*'''Signs and Symptoms''': Otherwise good, but considering you have a whole subsection entitled clubbing, I'd suggest explaining what it is right there, and not just in the glossary.&lt;br /&gt;
*'''Genetics/Aetiology''': Love the detail and depth, though the more technical terms should be explained in the glossary. Tiny comment: &amp;quot;there is only a single copy of the gene in one allele&amp;quot; - I know what you're trying to say, only one allele is functioning, but saying it like this kinda means, this allele only has one copy of the gene, whereas usually there are multiple copies of a gene in one allele, which is, as far as I know, not the case (that would just be contradictory, as an allele is a copy/varient of a gene).&lt;br /&gt;
*'''Pathophysiology and Abnormalities''': Very good, nice use of figures.&lt;br /&gt;
*'''Diagnostic Tests''': Not sure I like the table. It is just a hell of a lot of text... in a table. It doesn't really help give an overview, maybe just have subheadings, with (once you have an image) a picture on the side? Also, referencing needs fixing.&lt;br /&gt;
*'''Treatment/Management''': Very good, nice amount of detail. Again not sure a table is required. Also, the colour is a bit in your face, but that might just be me. I like the links at the end.&lt;br /&gt;
*'''Prognosis''': Content seems fine. A bit odd there's only one reference?&lt;br /&gt;
*'''Future directions''': Otherwise seems fine, though referencing needs fixing.&lt;br /&gt;
*'''Glossary''': A bit poor. More technical terms need to be explained.&lt;br /&gt;
*General: The last few sections lack some figures, it is just a lot of text. The content in general (as in of the whole project) was really good, so well done!&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''Peer Assessment: Group Project 6'''&lt;br /&gt;
*The introduction and the section on pathophysiology and abnormalities have no references. This needs to be rectified.&lt;br /&gt;
*The introduction and some of the history section have short paragraphs that are only one sentence long and would be improved, both for formatting and information purposes, by incorporating them into the rest of the information.&lt;br /&gt;
*Inserting a small timeline in the history section would make the sequence of events more accessible to the reader.&lt;br /&gt;
*Some sentences are too long such as, 'Children with TOF don’t grow at the rate of normal children as whilst breastfeeding in infancy, the babies would get tired quicker and during the growth of the infant, normal functionability of the heart and oxygen saturated blood is needed for proper growth'. This sentence could be broken up and also improved by a greater explanation of why the process of growth is abnormal in TOF.&lt;br /&gt;
*Maybe explain more about what 'clubbing' is.&lt;br /&gt;
*In the diagnostic tests section the images need to be inserted and needs to be properly referenced. The information is good but as noted one section is totally void of text.&lt;br /&gt;
*The section on prognoses needs proper referencing.&lt;br /&gt;
*The section on future directions is well written, however the referencing needs to be adapted to the wiki format.&lt;br /&gt;
*Under the information in some of the images you have uploaded such as in the portait of A. Fallot, you still need to add &amp;lt;nowiki&amp;gt;{{Template:2011 Student Image}}&amp;lt;/nowiki&amp;gt;.&lt;br /&gt;
*The project is informative, however formatting and referencing are issues that need to be addressed.&lt;br /&gt;
--[[User:Z3217345|z3217345]] 22:23, 27 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Test: &lt;br /&gt;
&lt;br /&gt;
{| style=&amp;quot;color:black; background-color:#ffffcc;&amp;quot; width=&amp;quot;85%&amp;quot; cellpadding=&amp;quot;10%&amp;quot; cellpadding=&amp;quot;15%&amp;quot; cellspacing=&amp;quot;0&amp;quot; border=&amp;quot;1&amp;quot;&lt;br /&gt;
| colspan=&amp;quot;2&amp;quot; | '''Diagnosis'''&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291423|z3291423]] 11:57, 22 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Jaz, thanks for letting me know...my english can fail me at times.....lol...fixed it up... regards--[[User:Z3291317|Z3291317]] 18:49, 18 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys! i just realised that the caption of helen taussig and ballot say portraight....not PORTRAIT!?!! i tried to change it but it don't really know how..anyone have any ideas to this?! :S thanks --[[User:Z3291423|z3291423]] 00:06, 17 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Table Test! --[[User:Z3291423|z3291423]] 22:16, 16 September 2011 (EST)&lt;br /&gt;
{|&lt;br /&gt;
|-bgcolor=&amp;quot;# 99FFFF&amp;quot; &lt;br /&gt;
| '''Type of Shunt'''&lt;br /&gt;
| '''Description'''&lt;br /&gt;
| '''Reasons for it not being used'''&lt;br /&gt;
| '''Image'''&lt;br /&gt;
|-&lt;br /&gt;
| Pott’s Shunt &lt;br /&gt;
| This shunt is a connection that is established between the lower part of the Aorta (on the left side of chest) to the left branch of the Pulmonary artery. &lt;br /&gt;
| The shunt has a tendency to increase the pulmonary blood flow and it is also very hard to close when complete repair is undertaken &lt;br /&gt;
| Insert image&lt;br /&gt;
|-&lt;br /&gt;
| Waterston Shunt&lt;br /&gt;
|  This shunt was placed between the back of the Aorta, to the right branch of the pulmonary. &lt;br /&gt;
| This shunt’s use is more suited to those with pulmonary artery stenosis and also the procedure is quite difficult to perform.&lt;br /&gt;
| Insert Image&lt;br /&gt;
|-&lt;br /&gt;
| Glenn Shunt&lt;br /&gt;
| The Super Vena Cava is anastomosed via a shunt to the right pulmonary artery.&lt;br /&gt;
| This procedure is very complicated and difficult to perform, also complete repair becomes a laborious task.  &lt;br /&gt;
| Insert image&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Table test (fingers crossed!) --[[User:Z3291324|Jacqueline Ellero]] 10:49, 15 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
==TOF diagnostic techniques==&lt;br /&gt;
&lt;br /&gt;
{|border=&amp;quot;1px&amp;quot; cellspacing=&amp;quot;1&amp;quot; align=&amp;quot;center&amp;quot; cellpadding=&amp;quot;5&amp;quot; style=&amp;quot;background:seashell&amp;quot;&lt;br /&gt;
&lt;br /&gt;
|+ This table describes different diagnostic tests for TOF&lt;br /&gt;
! Diagnostic technique !! How the procedure works  !! Presentation in TOF patient !! Image&lt;br /&gt;
&lt;br /&gt;
|-&lt;br /&gt;
|Physical examination&lt;br /&gt;
|TOF is often diagnosed during fetal life by echocardiography (Apitz, Webb, &amp;amp; Redington, 2009). If TOF is not detected during fetal life, certain signs and symptoms at birth may alert the need for further investigation. These signs and symptoms include mild to moderate cyanosis, which worsens when the baby cries, difficulty feeding and difficulty gaining weight. However, TOF often goes undiagnosed until adult life. Most adult patients will appear normal, however, some may present with cyanosis and clubbing of the fingers. The jugular venous pressure is usually normally (raised jugular venous pressure often indicates right ventricular failure). If the aorta is pushed to the right (so it is continuous with both the left and right ventricle), a lift below the right sternoclavicular joint may be noted. (Somerville, 1993) &lt;br /&gt;
&lt;br /&gt;
|Insert text here&lt;br /&gt;
|Insert physical examination image&lt;br /&gt;
|-&lt;br /&gt;
|Heart murmurs&lt;br /&gt;
|Heart murmurs are sounds caused by the turbulent flow of blood. They are heard using a stethoscope. They are often the result of problems including valvular stenosis (narrowing of valves), valvular regurgitation (leakage of valves due to incomplete closure) or defects in the heart wall allowing blood to flow in unusual directions.&lt;br /&gt;
|Examination of the heart of a patient with TOF may reveal a loud second heart sound (produced by the closure of the pulmonary valve). A harsh systolic ejection murmur may be heard and a palpable thrill may be felt along the left sternal border. These sounds occur because the pulmonary outflow tract is obstructed. Although this murmur is often present, sometimes it may be short or difficult to hear and is often missed on physical examination. A pansystolic (occurring throughout the whole of systole) murmur may also be heard. This type of murmur occurs due to the ventricular septal defect between the left and right ventricles. The increased pressure in the left ventricle forces blood back into the right ventricle, causing a murmur, which lasts the whole of systole (contraction phase). http://ccjm.org/content/77/11/821.full &lt;br /&gt;
 |Insert heart murmur image&lt;br /&gt;
|-&lt;br /&gt;
|Electrocardiogram&lt;br /&gt;
|Once TOF is suspected, electrocardiogram and chest radiographs are performed. Electrocardiography is used to assess the electrical activity of the heart. The electrical activity is detected by electrodes, which are placed on the skin of the patient and recorded by an external device.&lt;br /&gt;
|The electrocardiogram is extremely important in detecting a right bundle branch block (a block in the electrical conducting system of the heart), which is common in patients with TOF. An electrocardiogram will also reveal a heart that is deviated slightly to the right and an enlarged right ventricle due to the ventricular hypertrophy.(Somerville, 1993)&lt;br /&gt;
|Insert electrocardiogram image here&lt;br /&gt;
|-&lt;br /&gt;
|Chest radiograph&lt;br /&gt;
|A chest radiograph (or chest x-ray) uses ionising radiation to develop an image of the patient’s chest. It is used to diagnoses many conditions including the thorax and structures within the thoracic cavity including the heart, lungs and major blood vessels entering and leaving the heart. Chest radiographs are often used to screen for certain diseases but further tests are required for a definitive diagnosis.&lt;br /&gt;
|In a patient with TOF, a chest radiograph will demonstrate a prominent right ventricular shadow, giving the heart a boot-like appearance, which is typical of patients with TOF. The right ventricular hypertrophy causes the apex of the right ventricle to rise on top of the relatively unfilled left ventricle, giving the heart its boot-shaped appearance on examination. (Bailliard &amp;amp; Anderson, 2009) The radiograph will also show a right-sided aorta in approximately one-quarter of patients. (Somerville, 1993)&lt;br /&gt;
|Insert CXR image here&lt;br /&gt;
 |-&lt;br /&gt;
|Echocardiogram&lt;br /&gt;
|An echocardiogram (also called a cardiac ultrasound) is performed to confirm the above findings. Echocardiography uses ultrasound to produce two-dimensional (and now also three-dimensional) images of the heart. It assesses cardiac tissue, valve function, the velocity of blood flow and any abnormal communications within the heart.&lt;br /&gt;
|The echocardiogram identifies important abnormalities of the heart including obstruction of the pulmonary outflow tract, the size of the pulmonary arteries, the degree of aortic override and the size of the defect in the interventricular septum. (Bailliard &amp;amp; Anderson, 2009)&lt;br /&gt;
|Insert echo image here&lt;br /&gt;
 |-&lt;br /&gt;
|Magnetic resonance imaging&lt;br /&gt;
|Magnetic resonance imaging (MRI) is evolving as the most important technique for evaluating the size and functioning of the right ventricle. An MRI machine uses a magnetic field to produce a detailed image of the scanned area of the body. It is especially useful in viewing soft tissues as it provides greater contrast than techniques such as x-ray.&lt;br /&gt;
|MRI’s are important in assessing pulmonary valve competence and the severity of regurgitation (the amount of blood that flows back into the right ventricle due to the incomplete closure of the pulmonary valves) in patients with TOF. It can measure the volume and mass of the right and left ventricles and can assess the degree of pulmonary outflow tract obstruction. Finally, MRIs are important in measuring the degree of ventricular septal defect. (Somerville, 1993)&lt;br /&gt;
|Insert MRI image here&lt;br /&gt;
 |-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey peeps just put a intro just as a draft...tell me what you guys think of it. Edit it as you may wish.... And Jaq, if you describe briefly how each test works it would be good, regards --[[User:Z3291317|Z3291317]] 23:16, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
hey jaz, ive fixed up the diagnosis, but feel free to add anything! or let me know if you think i should add anything. --[[User:Z3291324|z3291324]] 10:06, 14 September 2011 (EST) should i describe each diagnostic test!!??--[[User:Z3291324|z3291324]] 10:07, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Guys! just added a very few changes, links etc to treatment. I've begun to add make a bit of notes on diagnosis that could just add a bit of detail to the diagnosis section. just wondered if any of you guys know what particular section of the ECG indicates...Left Ventricular Hypertrophy etc maybe ill call up a cardiologist :P nonetheless ill add references and some things to diagnosis tmrw night. regards, --[[User:Z3291423|z3291423]] 00:15, 14 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey jaq. no particular order, the referencing system in the wiki automatically arranges it according to the order it is found in the text. In text referencing is NEEDED, lol. Type in the text title into Pubmed and when the article is found, the pmid code will be found at the bottom of the abstract for that article. if you cant figure out how to reference, put in the pubmed ids as intext citations then ill fix it for you...Make pathophys a bit more simpler, but do not compromise the anatomical words, i.e. write the anatomical word, then write in brackets what it means, eg. ''...anterolaterally (at the top away from the midline)'' is just an example (a crap one to lol). Also did you find any new info for diagnostic tests? and Rom, why did you remove info from the 22q section???? regards --[[User:Z3291317|Z3291317]] 22:02, 13 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
hey guys, quick question about the referencing. are they in any particular order? or should i just add mine to the end of the list? and do we need to do in-text referencing?? and how do you find the pmid code? also, any suggestions on how i should improve pathophys? ie make it more anatomical based or reword it so its simpler? thanks --[[User:Z3291324|z3291324]] 21:30, 13 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey Rom, looking good thus far. if you need help with referencing even after trying so much i can help you during the 1 hour we have afta the lecture tomorrow to go through and help you fix em up... its a bit tricky but can get a handle of it... --[[User:Z3291317|Z3291317]] 20:37, 12 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
Hey guys sorry for the delay, but I'm slowly uploading all my stuff up. I'm just a bit confused about how I do the reference tag thing, as you can see there is a massive red thing on our reference list. I tried copying how you guys did it but I failed at it. I'll be posting some more in the next couple of hours, I just need to get a hang of this coding thing gah!&lt;br /&gt;
--[[User:Z3290841|z3290841]] 19:36, 12 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
hey rommel, we really need to see your part of the project and get your suggestions on parts we have done because its due on thursday --[[User:Z3291324|z3291324]] 19:16, 12 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Peeps, Just reconstucted the referencing so they are done exactly as it should be... Also just uploaded a pic of Mr fallot Himself without any copyright restrictions ( aha ow ye ow ye, took me long before i found it lol). I left the intext references jac and jaz put in their sections for future reference. Thats about it for now... Jaz i hope u liked the pics i showed you, and i hope rom is going well in his section... See yous soon... Regards --[[User:Z3291317|Z3291317]] 17:36, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
update: uploaded the drawn images, took ages but its finally done :) and I've just finished the future directions :) so it should be fine to edit and look over in the next couple of days! &lt;br /&gt;
regards --[[User:Z3291423|z3291423]] 13:16, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
looking good jaz. thanks for the articles fru. ive had a quick look at them but will need to fix it up after work this arvo! --[[User:Z3291324|z3291324]] 11:59, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Jac, ive got 2 articles that i will send to your email, both talk about Cardiac Magnetic Resonance, one some detail about electrocardiography. Also, Jaz i have an article that has a section based on 'Future Innovations' for TOF, have a read and i reckon it will help out with the future directions part... i will send these articles to your emails so look at them when yous can... and rom, you breathing my friend?... regards --[[User:Z3291317|Z3291317]] 01:29, 11 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
hey guys, just reworded diagnosis so it makes sense. can anyone suggest any good articles to read for diagnosis? im having trouble accessing a lot of articles (they keep asking for passwords) and a lot of the articles dont discuss diagnosis in much detail at all. help is much appreciated!! thanks :) --[[User:Z3291324|z3291324]] 21:12, 10 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
hey rom, this might be helpful for genetics. not sure what youve got already though http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747103/&lt;br /&gt;
--[[User:Z3291324|z3291324]] 20:50, 10 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
also what should i do about the symptoms-pathophys overlap. should i alter the pathophys so its more anatomical like in the below article??--[[User:Z3291324|z3291324]] 20:10, 10 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
On to it now fru. thanks for the article. should i reword pathophys too so its easier to read/understand?--[[User:Z3291324|z3291324]] 20:08, 10 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey Fru: in regards to the below comments, im working on future directions now :) also i read through the history section and it seems a lot more better :) just one mistake is the&lt;br /&gt;
&amp;quot;durng such operations there need&amp;quot;. Ill have my edited prognosis and futures up by tonight! :) ohh and the heart! regards --[[User:Z3291423|z3291423]] 11:03, 10 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey Jac i was reading the article: Review - Tetralogy of Fallot by Frederique Bailliard and Robert H Anderson ( im sure you have this one) and theres a section absed on &amp;quot; Anatomical variants of Tetralogy of Fallot, and associated anomalies&amp;quot;. i believe if you could also include this section into the Pathophysiology section it would be great! Furthermore would you please do the things Mark said in regards to your sections it would be good, especially the diagnostic tests part :). Also to everyone we need to get Future Directions and especially Genetics up ASAP! thus respective people have them completed asap. --[[User:Z3291317|Z3291317]] 22:49, 9 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey jaz, the prognosis sounds pretty good. maybe expand/explain how the hypoxic spells, brain abscesses etc cause death. i think in general we could expand upon most sections. off to work now guys but ill fix up my couple of sections tonight/tomorrow morn! --[[User:Z3291324|z3291324]] 08:30, 9 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Thanks Fru! I will definitely crack onto those suggestions, I'm going to first email the owner of the children's hospital video on youtube to get permission for using the video, and then ill put it up in my section. &lt;br /&gt;
ALSO, I've nearly done the picture! I've got an outline and as your reading this, i should have it coloured, labelled and ready for upload! :D &lt;br /&gt;
&lt;br /&gt;
have a great weekend guys! &lt;br /&gt;
&lt;br /&gt;
Reagards&lt;br /&gt;
--[[User:Z3291423|z3291423]] 23:29, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey jaz just read your prognosis section. You made it well, however,i picked up 2 things you could do and it woould be good if you do them: 1. The causes of death after no surgery has done; if you can explain how these 'causes of death' occur due to TOF, it will portray the role TOF has in these problems. 2. You should talk about any complications that could arise in both patients that dont have corrected TOF and the ones who do have the surgery (i.e. any conditions that could develop after having the surgery or not, not just the death of the patient if they dont correct their heart). Other than that great work! :) --[[User:Z3291317|Z3291317]] 23:17, 8 September 2011 (EST) &lt;br /&gt;
&lt;br /&gt;
Ye Jaz, thanks for the pic. Aswell ive attached a reviewed file of the treatment section on an email i sent to you. Maybe the youtube cideo based on the TOF fix up can now be put under this section as an embedded video... --[[User:Z3291317|Z3291317]] 22:19, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
hey jaz, the treatment section is much better, much easier to read. thanks for the heart pic! im pretty sure my section is he one that is too &amp;quot;verbose&amp;quot; so anyone feel free to fix it up--[[User:Z3291324|z3291324]] 19:47, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Guys! sorry prognosis took me a bit longer to do, but It will be up by tonight :) and ill upload the heart pic as well :) which took forever to make! &lt;br /&gt;
regards --[[User:Z3291423|z3291423]] 16:05, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
hey guys just put up some diagnosis, let me know if you want me to add anything to it. furkan, glossary looks good! rommel, how are you going with the genetics do you need any help? and jaz are you able to post up the prognosis? once they are all up we should go through and edit them all together and fix up the wording. --[[User:Z3291324|z3291324]] 15:50, 8 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey peoples...im going to start constucting the glossary wordbank as i read the entire document. Please add words yous think i missed out on... Also i found a pic of Mr Fallot but i think theres copyright rights on it. i think i gotta clear it somehow...--[[User:Z3291317|Z3291317]] 19:19, 7 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
hey jaz, i think the treamtment section is alright. maybe reword the first bit into sentences (i think it was the bit on how severe the cyanosis is) so its a bit clearer. but otherwise good :) what do you think about pathophys?--[[User:Z3291324|z3291324]] 12:40, 7 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
hey guys, i cant tell if this pic has copyright or not. can someone please have a look for me? http://www.nhlbi.nih.gov/health/health-topics/topics/tof/ thanks!--[[User:Z3291324|z3291324]] 09:49, 6 September 2011 (EST)&lt;br /&gt;
--&amp;gt; REPLY: I looked at the pic and looks great. however, i couldnt see if it was copyright or not. HOWEVER, it is found on a public government website, and from what i remember Mark said we can use these materials. To make sure just please check it with him aswell. Also, im going to format your pathophysioligy section now so it looks prettier :)--[[User:Z3291317|Z3291317]] 19:19, 7 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys, i Just finished the Treatment part, I've got palliative in this heading to still complete but Its very brief so i thought id get cracking on getting that drawing done and also the prognosis will be up by tomorrow! also check this out! http://www.nemours.org/content/dam/nemours/www/filebox/service/medical/cardiology/defect/tof.swf&lt;br /&gt;
--[[User:Z3291423|z3291423]] 23:57, 5 September 2011 (EST) &lt;br /&gt;
--&amp;gt;REPLY: Cool animation. Would we use an external link to this animation due to copyright restrictions?--[[User:Z3291317|Z3291317]] 19:19, 7 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Peepz&lt;br /&gt;
&lt;br /&gt;
I just finished the sections of History, Signs and symptoms and Epidemiology&lt;br /&gt;
&lt;br /&gt;
just please check these sections, especially the epidemiology one, do yous want it more detailed or is it enough?&lt;br /&gt;
&lt;br /&gt;
z3291324 your section seems alright so far, show us your edited version so we can fully critic it then.&lt;br /&gt;
&lt;br /&gt;
p.s. the post below my one i dont really understand itl who is speking to who and what are yous refering to? lol&lt;br /&gt;
&lt;br /&gt;
Regards --[[User:Z3291317|Z3291317]] 23:44, 4 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
j: the article on future treatment directions sounds good. i might add some of the info in to the pathophysiology section because it links in well with the pulmonary stenosis and right ventricular hypertrophy. --[[User:Z3291324|z3291324]] 13:47, 2 September 2011 (EST)&lt;br /&gt;
I think this article makes some good points which could be added into the treatment section (eg discuss treatment/surgery after birth and also follow up treatments in adulthood- pulmonary valve replacement etc due to valvular incompetence and regurgitation because of the growing heart)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=pathophysiology=&lt;br /&gt;
hey guys. ive written some basic notes (UNEDITED) for pathophysiology. Just want to get an idea of how much detail i should go into before i start adding links to journal articles etc. can someone please have a quick look through and give me an idea of how much more detail is needed. thanks :)&lt;br /&gt;
&lt;br /&gt;
The four features of tetralogy of fallot are pulmonary stenosis, overriding aorta, ventricular spetal defect and right ventricular hypertrophy. These features result from the anterosuperior displacement of the infundibular septum. The severity of symtpoms is determined by the extent of right ventricular outflow obstruction. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;br /&gt;
'''Pulmonary stenosis'''&lt;br /&gt;
(Symptoms include cyanosis,  right ventricular hypertrophy, hepatomegaly and peripheral oedema (of the legs). More mild symptoms include sudden fainting and dizziness from exercise. )&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;br /&gt;
Valvular or infundibular stenosis (narrowing of the outflow tract of the right ventricle). Obstructs the outflow of blood from the right ventricle reducing pulmonary flow. If the pulmonary stenosis is mild, a left to right shunt (with no cyanosis) will form, due to the higher pressure in the left ventricle. However, significant pulmonary stenosis can raise right ventricular pressure above the left ventricular pressure and cause a right to left shunt (cyanosis etc).  The pathophysiology of pulmonary stenosis usually worsens with age because the pulmonary orifice stays the same size despite an increase in the size of the heart. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;br /&gt;
'''Overriding aorta'''&lt;br /&gt;
The aortic valve has a biventricular connection. Instead of being positioned over the left ventricle, the aortic valve is located above the interventricular spetal defect allowing blood from both the right and left ventricles to pass through the aortic valve.  The degree to which the overriding aorta is continuous with the right ventricle determines the severity of symptoms. Because the right ventricle receieves deoxygenated blood from the systemic circulation, the percent oxygenation of bloood entering the aorta and hence back into the systemic circulation is decreased. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;br /&gt;
'''Ventricular septal defect'''&lt;br /&gt;
The interventricular septum dividing the left and right ventricles is incomplete at its superior, membranous end.  During ventricular contraction, blood from the left ventricle passes into the right ventricle and then re-enters the pulmonary circulation. Leakage of blood from the left to right ventricle raises the right ventricular volume and pressure resulting in pulmonary hypertension. (Shortness of breath, dizziness and fainting) If the right ventricular pressure exceeds that of the left, the left to right shunt is reversed and the patient will experience cyanosis and deoxygenated blood is by-passing the lungs and entring the systemic circulation. (also breathlessness, poor feeding and failure to thrive in infancy.)&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&lt;br /&gt;
'''Rigth ventricular hypertrophy'''&lt;br /&gt;
Compensatory response to pulmonary stenosis ...to be contined. &lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291324|z3291324]] 13:38, 2 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
=link to pathology textbook=&lt;br /&gt;
&lt;br /&gt;
hey guys, this is the link to tetralogy of fallot in robbins pathology&lt;br /&gt;
--[[User:Z3291324|z3291324]] 13:05, 2 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
=More genetics and Surgery=&lt;br /&gt;
&lt;br /&gt;
Hey Peeps, i forund another article in regards to Genetics as it does an genotype-phenotype anaylis os TOF Patients. Have a read and see if it can help in the assignment subsection. if you cant get the full article tell me and ill give you the pdf of it.&lt;br /&gt;
&lt;br /&gt;
Article: PMID: 19948535&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
And Regards to surgery and its prognosis post-operation i found these articles that may be helpful for 3291423. Again if yous cant find the pdf tell me and i'll send yous the pdf articles of these.&lt;br /&gt;
&lt;br /&gt;
Articles: PMID: 20091166 ; PMID: 21769263 ; PMID: 21566339 (hey 3291423 this is the article i showed you in the lab and you wanted it from me)&lt;br /&gt;
&lt;br /&gt;
Anyways peeps i hope all the assignments are coming along well&lt;br /&gt;
&lt;br /&gt;
Regards --[[User:Z3291317|Z3291317]] 19:03, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
REPLY: Thanks z3291317, I had a look through the files and am using them now for summarising :) also, can you send through the picture of what you want the abnormal TOF heart to look like and ill get cracking on it to produce/draw it :)&lt;br /&gt;
&lt;br /&gt;
regards --[[User:Z3291423|z3291423]] 22:15, 1 September 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
=Genetics=&lt;br /&gt;
Hey guys, found some articles relating to genetics and the deletion of the 22q11 gene. take a look :) &lt;br /&gt;
--[[User:Z3291423|z3291423]] 21:09, 27 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
AS Bassett, EWC Chow and J Husted et al., Clinical features of 78 adults with 22q11 deletion syndrome, Am J Med Genet 138 (2005), pp. 307–313. http://pediatrics.aappublications.org.wwwproxy0.library.unsw.edu.au/content/112/1/101&lt;br /&gt;
&lt;br /&gt;
http://www.sciencedirect.com.wwwproxy0.library.unsw.edu.au/science?_ob=MiamiImageURL&amp;amp;_imagekey=B6T18-3V8RDDJ-11-1&amp;amp;_cdi=4884&amp;amp;_user=37161&amp;amp;_pii=S0735109798002599&amp;amp;_check=y&amp;amp;_origin=&amp;amp;_coverDate=08%2F31%2F1998&amp;amp;view=c&amp;amp;wchp=dGLbVlW-zSkWz&amp;amp;md5=0a4f32c3b75ebff2513309081ac0468f&amp;amp;ie=/sdarticle.pdf &lt;br /&gt;
&lt;br /&gt;
http://pediatrics.aappublications.org.wwwproxy0.library.unsw.edu.au/content/112/1/101&lt;br /&gt;
&lt;br /&gt;
=Treatment and future directions info/readings=&lt;br /&gt;
&lt;br /&gt;
Hey guys, found this really amazing article about treatments and their repercussions http://www.ccjm.org/content/77/11/821.long#abstract-3&lt;br /&gt;
--[[User:Z3291423|z3291423]] 21:09, 27 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
=Online lab 4 info=&lt;br /&gt;
I my friends , colleagues and countrymen am going to be undertaking the research of the subsection Genetics/Aetiology in the topics that have been discussed. --[[User:Z3290841|z3290841]] 10:18, 25 August 2011 (EST)  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Im going to be researching Treatment/Management, Prognosis &amp;amp; Future directions. - z3291423&lt;br /&gt;
&lt;br /&gt;
regards, --[[User:Z3291423|z3291423]] 23:30, 24 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Thanks for typing them up. I'm going to research Pathophysiology and abnormalities and diagnostic tests.&lt;br /&gt;
--[[User:Z3291324|z3291324]] 15:40, 24 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Group 6&lt;br /&gt;
&lt;br /&gt;
From the Meeting on Tuesday after the Embryo lecture, we had concluded that we are going to divide the group project of TOF into the following sub-sections (if i am not mistaken):&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
* Introduction&lt;br /&gt;
* History&lt;br /&gt;
* Epidemiology&lt;br /&gt;
* Signs and Symptoms&lt;br /&gt;
* Genetics/Aetiology&lt;br /&gt;
* Pathopgysiology and Abnormalities&lt;br /&gt;
* Diagnostic Tests&lt;br /&gt;
* Treatment/Management&lt;br /&gt;
* Prognosis&lt;br /&gt;
* Future Directions&lt;br /&gt;
* Glossary&lt;br /&gt;
* References&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
From these subsections, I (z3291317) will research the History, Epidemiology and Signs &amp;amp; Symptoms subsections of the group Project.&lt;br /&gt;
&lt;br /&gt;
Just wanted to put forward my part for the group project :)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Regards --[[User:Z3291317|Z3291317]] 15:01, 24 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
=Resources=&lt;br /&gt;
Hey Group 6&lt;br /&gt;
&lt;br /&gt;
When i was looking around for info in regards to TOF, i found some videos on youtube made by an american hospital which we could use on our page in the &amp;quot;more info&amp;quot; section. Check them out and tell me what yous think...&lt;br /&gt;
&lt;br /&gt;
- http://www.youtube.com/watch?v=ACRfFkxow7w&lt;br /&gt;
- http://www.youtube.com/watch?v=jgLC2QABcxo&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
So what you guys think? --[[User:Z3291317|Z3291317]] 22:54, 21 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
COMMENT: great stuff! that really is a great tool, maybe we can incorporate that in as a link, or something to really explain it! without all the mumbo jumbo :) --[[User:Z3291423|z3291423]] 22:22, 22 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
=Articles=&lt;br /&gt;
&lt;br /&gt;
Found really good article detailing some clinical aspects http://journals.cambridge.org.wwwproxy0.library.unsw.edu.au/action/displayAbstract?fromPage=online&amp;amp;aid=331031 its called: The clinical anatomy of tetralogy of Fallot, http://www.sciencedirect.com.wwwproxy0.library.unsw.edu.au/science/article/pii/S0140673609606577 - Tetraology of ballot by christian apitz,  just google scholar it via unsw or use the link I've given you :) --[[User:Z3291423|z3291423]] 19:10, 20 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
=Images=&lt;br /&gt;
Hey guys, this is an image of tetralogy of fallot with pulmonary atresia&lt;br /&gt;
&lt;br /&gt;
[[File: Tetralogy of Fallot with pulmonary atresia.jpg]]&lt;br /&gt;
--[[User:Z3291324|z3291324]] 22:07, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys, just found this still frame showing large ventricular septal defect, aortic override, and right ventricular hypertrophy which are all very common to patients with ToF&lt;br /&gt;
[[File:Some common effects for patients with Tetralogy of Fallot.jpg]]&lt;br /&gt;
--[[User:Z3291423|z3291423]] 21:43, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys this is my image of our disease, it is just outlining some of the basic changes that happens to the heart, mainly the right ventricle. &lt;br /&gt;
&lt;br /&gt;
[[File:Right ventricle of heart with Tetralogy of Fallot.jpg]]&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290841|z3290841]] 13:42, 17 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey Group 6, its z3291317&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
I just wanted to make it clear that we add all new entries into our discussion page at the top of the page and not at the bottom of it. Thats how we are told to edit this discussion page.&lt;br /&gt;
&lt;br /&gt;
Anyways this is my Image for Lab 3 Question 2:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[File:Normal fetal blood flow and Tetralogy of Fallot.jpg]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
I hope it would be beneficial for our page...&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291317|Z3291317]] 12:05, 17 August 2011 (EST)&lt;br /&gt;
 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291317|Z3291317]] 17:00, 7 August 2011 (EST)&lt;br /&gt;
Hey Group 6&lt;br /&gt;
&lt;br /&gt;
i just done some research on a possible group project subject. It is quite detailed and interesting (to me) disease to write on.What do you guys think? Here is the review and research article for it:&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The Disease:'''Tetralogy of Fallot'''&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Review Article:&lt;br /&gt;
&lt;br /&gt;
Orphanet J Rare Dis. 2009 Jan 13;4:2.&lt;br /&gt;
&lt;br /&gt;
'''''Tetralogy of Fallot.'''''&lt;br /&gt;
&lt;br /&gt;
Bailliard F, Anderson RH.&lt;br /&gt;
&lt;br /&gt;
North Carolina Children's Heart Center, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. frederique_bailliard@med.unc.edu&lt;br /&gt;
&lt;br /&gt;
Link: &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19144126&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Description: This paper gives an overview about the disease, how it happens, and clinical manifestations. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Research Article:&lt;br /&gt;
&lt;br /&gt;
J Med Genet. 2010 May;47(5):321-31. Epub 2009 Nov 30.&lt;br /&gt;
&lt;br /&gt;
'''''Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot.'''''&lt;br /&gt;
&lt;br /&gt;
Rauch R, Hofbeck M, Zweier C, Koch A, Zink S, Trautmann U, Hoyer J, Kaulitz R, Singer H, Rauch A.&lt;br /&gt;
&lt;br /&gt;
Institute of Medical Genetics, Schorenstrasse 16, CH-8603 Zurich-Schwerzenbach, Switzerland. anita.rauch@medgen.uzh.ch&lt;br /&gt;
&lt;br /&gt;
Link: &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;19948535&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Description: A study was done to see the prevalent phenotype for Tetralogy of fallot, and it was found that the 22q11.2 deletion was the most common type in Tetralogy of Fallot. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
'''''References:'''''&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291317|Z3291317]] 17:00, 7 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290841|z3290841]] 09:36, 8 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey Guys, &lt;br /&gt;
&lt;br /&gt;
I did research on Cystic fibrosis and these are the 2 articles that I found that explains a lot about the disease, and the genetic research on it. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Review Article:&lt;br /&gt;
&lt;br /&gt;
'''Cystic Fibrosis: Seminar'''&lt;br /&gt;
&lt;br /&gt;
Description: This is basically outlining the pathophysiology of the disease, disease manifestation,current treatments diagnostic tool.  &lt;br /&gt;
&lt;br /&gt;
Ratjen F &amp;amp; Doring G.(2003).Cystic Fibrosis: Seminar.''The Lancet'', 361, 681-9. Retrieved from http://www.sciencedirect.com/science/article/pii/S0140673603125676 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Research Article:&lt;br /&gt;
&lt;br /&gt;
'''Gene expression profile study in CFTR mutated bronchial cell lines'''&lt;br /&gt;
&lt;br /&gt;
Description: This article provides information about the severity of gene expression in relation of the extent or type of mutation.&lt;br /&gt;
&lt;br /&gt;
Gambardella S, Biancolella M, D'Apice M, Amati F, Sangiuolo F, Farcomenti A, Chillemi G, Bueno S, Desideri A &amp;amp; Novelli G.(2006).Gene expression profile study in CFTR mutated bronchial cell lines.''Clinical and Experimental Medicine '', 6, 157-65. Retrieved from http://proquest.umi.com/pqdlink?Ver=1&amp;amp;Exp=08-05-2016&amp;amp;FMT=7&amp;amp;DID=1187181501&amp;amp;RQT=309&amp;amp;cfc=1&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3290841|z3290841]] 09:36, 8 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
--[[User:Z3291324|z3291324]] 20:48, 10 August 2011 (EST)&lt;br /&gt;
&lt;br /&gt;
Hey guys, I like the disease that Furkan found (tetralogy of fallot)! What does everyone think?&lt;br /&gt;
&lt;br /&gt;
These are the two articles I found. The review article gives a pretty good description of the disease, symptoms, treatment and complications etc. The research article looks at some of the genetic causes. &lt;br /&gt;
&lt;br /&gt;
Goldmuntz, E., Geiger, E., &amp;amp; Benson, D. W. (2001). NKX2.5 mutations in patients with tetralogy of fallot. Circulation, 104(21), 2565-2568.&lt;br /&gt;
&lt;br /&gt;
Apitz, C., Webb, G. D., &amp;amp; Redington, A. N. (2009). Tetralogy of Fallot. Lancet, 374(9699), 1462-1471.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hey kiddes just done some research! check it out, its about Hypoplastic left heart syndrome&lt;br /&gt;
&lt;br /&gt;
Review article: &lt;br /&gt;
&lt;br /&gt;
2001 May-Jun;21(3):705-17.&lt;br /&gt;
'''Hypoplastic left heart syndrome.'''&lt;br /&gt;
Bardo DM, Frankel DG, Applegate KE, Murphy DJ, Saneto RP.&lt;br /&gt;
&lt;br /&gt;
Link: [http://www.ncbi.nlm.nih.gov/pubmed/11353117]&lt;br /&gt;
&lt;br /&gt;
Research:&lt;br /&gt;
&lt;br /&gt;
2011 Aug 1;108(3):421-7. Epub 2011 May 31.&lt;br /&gt;
'''Prenatal diagnosis of hypoplastic left heart syndrome in current era.'''&lt;br /&gt;
Kipps AK, Feuille C, Azakie A, Hoffman JI, Tabbutt S, Brook MM, Moon-Grady AJ.&lt;br /&gt;
Link: [http://www.ncbi.nlm.nih.gov/pubmed/21624547]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
References&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
1. Bardo DM, Frankel DG, Applegate KE, Murphy DJ, Saneto RP &amp;quot;&amp;quot;Hypoplastic left heart syndrome.&amp;quot;&amp;quot;Radiographics. 2001 May-Jun;21(3):705-17 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;11353117&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2. Kipps AK, Feuille C, Azakie A, Hoffman JI, Tabbutt S, Brook MM, Moon-Grady AJ &amp;quot;&amp;quot;Prenatal diagnosis of hypoplastic left heart syndrome in current era.&amp;quot;&amp;quot; Am J Cardiol. 2011 Aug 1;108(3):421-7. Epub 2011 May 31 &amp;lt;ref&amp;gt;&amp;lt;pubmed&amp;gt;21624547&amp;lt;/pubmed&amp;gt;&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Peer Assessments==&lt;br /&gt;
* I would suggest placing the history section into a timeline or table format just so that significant dates are more clear and emphasised. &lt;br /&gt;
* The gene profile section was great. It was in detail, it was coherent and the inclusion of gene images enhanced my understanding of this particular section. &lt;br /&gt;
* Maybe for the “how the procedure works” section of the diagnostics table could have been summarised into a flow diagram or through images, rather than having a chunk of text. This could make it more straight forward to the reader.&lt;br /&gt;
* Your website was generally well-written and to the point. You varied your formatting regularly which made your page entertaining. &lt;br /&gt;
* My last suggestion would to only use the image of the shunt once and finding a different image as the repetitiveness of this is slightly disengaging &lt;br /&gt;
--[[User:Z3332629|z3332629]] 15:26, 22 September 2011 (EST)&lt;/div&gt;</summary>
		<author><name>Z3290379</name></author>
	</entry>
</feed>